<SEC-DOCUMENT>0001641489-24-000075.txt : 20241112
<SEC-HEADER>0001641489-24-000075.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112164306
ACCESSION NUMBER:		0001641489-24-000075
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			vTv Therapeutics Inc.
		CENTRAL INDEX KEY:			0001641489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473916571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37524
		FILM NUMBER:		241449220

	BUSINESS ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265
		BUSINESS PHONE:		336-841-0300

	MAIL ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VTV Therapeutics Inc.
		DATE OF NAME CHANGE:	20150506
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtvt-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99,d:3e01e6945c6f4edc9cd6cef8ee05dd63-->
<html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:vtvt="http://vtvtherapeutics.com/20240930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtvt-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001641489</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" scale="0" id="f-374">0.333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones" scale="0" id="f-416">0.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-151" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-548">0.025</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-152" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-549">0.025</ix:nonFraction><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</span></div></ix:footnote><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)</span></div></ix:footnote><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</span></div></ix:footnote></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtvt-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-23</xbrli:startDate><xbrli:endDate>2024-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-22</xbrli:startDate><xbrli:endDate>2022-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-20</xbrli:startDate><xbrli:endDate>2023-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-20</xbrli:startDate><xbrli:endDate>2023-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-160 f-161 f-162 f-163 f-164 f-165 f-166 f-167 f-168 f-169 f-170 f-171 f-172 f-173 f-174 f-175" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-244" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-208 f-209 f-210 f-211 f-212 f-218 f-224 f-225 f-226 f-227 f-228" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/></ix:resources></ix:header></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_1"></div><div style="min-height:14.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2024</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37524</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">vTv Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-3916571</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3980 Premier Dr</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 310</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">High Point</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">27265</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">336</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">841-0300</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Class A common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">VTVT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-18">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Class of Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Outstanding as of November&#160;12, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">2,612,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">577,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.265%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:7.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv THERAPEUTICS INC. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED SEPTEMBER&#160;30, 2024</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_13">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_13">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_13"> 30, 2024 (Unaudited) and December 31, 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_13">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16">Unaudited Condensed Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16"> 30, 2024 and 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_16">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22">Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22"> 30, 2024 and 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31">Unaudited Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31"> 30, 2024 and 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_34">Notes to Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_34">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_85">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_85">24</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_124">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_127">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_130">PART II &#8211; OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_133">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_133">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_136">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_136">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_136">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_139">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_139">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_139">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_142">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_142">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_142">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_145">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_145">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_145">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_148">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_148">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_151">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_151">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_151">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_154">35</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (&#8220;we&#8221;, the &#8220;Company&#8221; or the &#8220;Registrant&#8221;), which is the registrant, and those of vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to vTv Therapeutics Inc. and its consolidated subsidiaries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.363%"><tr><td style="width:1.0%"/><td style="width:71.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">41,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">9,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-34">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-35">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-38">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-39">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">42,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">10,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-42">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-43">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-44">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-45">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">43,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">11,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">6,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">10,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-50">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-51">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-52">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-53">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-55">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">6,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">10,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-60">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-61">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-62">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-63">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-64">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="vtvt:WarrantyLiability" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-66">25,251</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-67">29,567</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-68"/></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-69"/></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-71">6,131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-72"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-73">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-76">2,612,257</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77">2,084,973</ix:nonFraction> shares outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-78">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-79">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85">577,349</ix:nonFraction></ix:nonFraction> outstanding as of September&#160;30, 2024 and December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-88">311,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-89">256,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-90">296,084</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-91">281,042</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit) attributable to vTv Therapeutics Inc.</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">15,008</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">24,680</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-94">2,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit) </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-96">17,913</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-97">24,680</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">43,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">11,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">3,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">9,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">11,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">10,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">9,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">6,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-113">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">20,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">20,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">6,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">5,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">19,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">20,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-120">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">3,640</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-122">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">1,514</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense) &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-124">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-125">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-126">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-127">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-128">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-129">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-130">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-131">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseOperating" scale="3" id="f-133">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpenseOperating" scale="3" id="f-135">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">5,840</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">8,540</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-138">18,168</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-139">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-142">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">5,840</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">8,540</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">18,268</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-148">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">1,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">3,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">4,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">4,783</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">6,654</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">14,828</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">16,772</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-156">4,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-157">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-158">14,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-159">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-160"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-161">0.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-163">3.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-165">2.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-167">8.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-169">5,456,307</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">2,084,973</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-172"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-173">5,498,479</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-175">2,084,973</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.479%"><tr><td style="width:1.0%"/><td style="width:22.041%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.287%"/><td style="width:0.1%"/></tr><tr><td colspan="54" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders'  <br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">2,432,857</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-177">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-178">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-179">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">307,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-181">291,301</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">16,475</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">3,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-184">20,437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">4,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">4,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">4,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-188">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-189">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-190">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Class A Common Stock under ATM offering</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares" format="ixt:num-dot-decimal" scale="0" id="f-191">179,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" scale="3" id="f-192">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-193">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-194">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-195">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-196">1,057</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">1,057</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-198">2,612,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-199">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-200">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-201">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">311,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">296,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">15,008</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">2,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">17,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.182%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the three months ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares(*)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares(*)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances at June 30, 2023</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-207">18,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-208">2,084,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-209">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-210">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-211">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">255,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">280,809</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">25,283</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">1,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-218">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-219">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-220">6,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-221">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-222">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at September 30, 2023</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-223">10,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-224">2,084,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-225">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-226">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-227">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-228">255,932</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-229">281,192</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">25,233</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:26.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.586%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.491%"/><td style="width:0.1%"/></tr><tr><td colspan="63" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'  <br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at December 31, 2023</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-231">6,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">2,084,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-233">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-234">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-235">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-236">256,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-237">281,042</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-238">24,680</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-240">24,680</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">14,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">14,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">14,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to redeemable noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-244">1,085</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of redeemable noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="3" id="f-245">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" scale="3" id="f-246">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" scale="3" id="f-247">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" scale="3" id="f-248">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reclassification of redeemable noncontrolling interest to permanent equity (See Note 7)</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">5,260</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">5,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">5,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-253">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-254">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock and pre-funded warrants, net offering costs</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-255">347,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-256">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-257">50,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-258">50,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-259">50,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A Common Stock under ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares" format="ixt:num-dot-decimal" scale="0" id="f-260">179,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" scale="3" id="f-261">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-262">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-263">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:IssuanceOfClassACommonStockUnderATMOffering" format="ixt:num-dot-decimal" scale="3" id="f-264">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">2,355</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-266">2,355</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-268">2,612,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-269">26</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-270">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-271">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-272">311,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-273">296,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-274">15,008</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-275">2,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-276">17,913</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.817%"><tr><td style="width:1.0%"/><td style="width:26.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.733%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares(*)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares(*)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital(*)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit </span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balances at December 31, 2022</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-277">16,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-278">2,084,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-279">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-280">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-281">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-282">254,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-283">265,524</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-284">10,740</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-285">4,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-286">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-287">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-288">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-289">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-290">1,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-291">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="vtvt:ChangeInRedemptionValueOfNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-292">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2023</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-293">10,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-294">2,084,973</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-295">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-296">577,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-297">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">255,932</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-299">281,192</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-300">25,233</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-301">18,268</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-302">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-303">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-304">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from G42 promissory note early redemption</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-306">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest income </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-308">100</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-309">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-310">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of investments</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-312">3,044</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of investments in Anteris Bio, Inc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-314">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants, related party</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-315">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-316">406</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-317">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-319">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-320">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-321">36</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-322">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-323">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-325">4,016</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-326">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-327">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-329">20,482</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">16,167</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-331">50,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Class A common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-333">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:ProceedsFromSaleOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="vtvt:ProceedsFromSaleOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-336">12,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt issuance</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-338">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-339">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-340">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-341">52,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-342">12,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-343">32,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-344">3,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-345">9,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-346">12,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-347">41,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-348">8,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"/><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="3" id="f-349">214</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-350">1,104</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of noncontrolling interest to additional paid-in capital</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-351">5,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements &#8211; Unaudited</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollar amounts are in thousands, unless otherwise noted)</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_37"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-353" continuedAt="f-353-1" escape="true">Description of Business and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="f-353-1" continuedAt="f-353-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-354">28.9</ix:nonFraction> million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various holders own non-voting interests in vTv LLC, representing a <ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="f-355">18.1</ix:nonFraction>% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to <ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterestByParent" scale="-2" id="f-356">81.9</ix:nonFraction>% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#8217;s Class B common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-357">0.01</ix:nonFraction> (&#8220;Class B common stock&#8221;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#8220;Letter Agreement&#8221; and collectively, the &#8220;Letter Agreements&#8221;). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#8220;CinRx Purchase Agreement&#8221;). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (&#8220;TD Cowen&#8221;) (&#8220;TD Cowen Sales Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-358">296.1</ix:nonFraction>&#160;million and has generated net losses in each year of its existence. As of September&#160;30, 2024, the Company&#8217;s liquidity sources included cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-359">41.6</ix:nonFraction> million. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-353-2" continuedAt="f-353-3"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional accredited investors (the &#8220;Private Placement Investors&#8221;), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the &#8220;Private Placement&#8221;) (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-360">464,377</ix:nonFraction> shares (the &#8220;Private Placement Shares&#8221;) of our Class A common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-361">11.81</ix:nonFraction> per share, and (ii) pre-funded warrants (the &#8220;Private Placement Pre-Funded Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-362">3,853,997</ix:nonFraction> shares of our Class A common stock (the &#8220;Private Placement Warrant Shares&#8221;) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-363">11.80</ix:nonFraction> per Private Placement Pre-Funded Warrant (representing the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-364">11.81</ix:nonFraction> per Private Placement Share purchase price less the exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-365">0.01</ix:nonFraction> per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="f-366">51.0</ix:nonFraction> million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares" format="ixt:num-dot-decimal" scale="0" id="f-367">116,493</ix:nonFraction> Private Placement Shares for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-368">116,590</ix:nonFraction> Private Placement Pre-Funded Warrants.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-353-3">On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="vtvt:SaleOfStockAggregateOfferingPrice" scale="6" id="f-369">50.0</ix:nonFraction> million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="vtvt:EntityPublicFloatThreshold" scale="6" id="f-370">75.0</ix:nonFraction> million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of <ix:nonFraction unitRef="rate" contextRef="c-96" decimals="3" name="vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" scale="-2" id="f-371">3.0</ix:nonFraction>% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-372">179,400</ix:nonFraction> shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-373">2.5</ix:nonFraction> million.</ix:continuation> </span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_43"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-375" continuedAt="f-375-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-375-1" continuedAt="f-375-2"><ix:nonNumeric contextRef="c-1" name="vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock" id="f-376" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2024, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) for the three and nine months ended September&#160;30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2023, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2024, the results of operations for the three and nine months ended September&#160;30, 2024 and 2023 and cash flows for the nine months ended September&#160;30, 2024 and 2023. The December&#160;31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-377" continuedAt="f-377-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-375-2" continuedAt="f-375-3"><ix:continuation id="f-377-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-378" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One collaboration partner represented <ix:nonFraction unitRef="number" contextRef="c-98" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-379">100</ix:nonFraction>% of the revenue earned during the nine months ended September&#160;30, 2024. The Company did not have any revenue during the nine months ended September&#160;30, 2023 or during the three months ended September&#160;30, 2024 and 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-380" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-381" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company has no investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-382" continuedAt="f-382-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-375-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-382-1">Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-383" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-384" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, the FASB issued ASU 2023-09: &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (&#8220;ASU 2023-09&#8221;). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_46"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-385" continuedAt="f-385-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="f-385-1" continuedAt="f-385-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), pursuant to which the Company sold to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-386">259,657</ix:nonFraction> shares of the Company&#8217;s Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-387">96.40</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="f-388">25.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-389">12.5</ix:nonFraction> million in cash at the closing and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="6" id="f-390">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="6" id="f-391">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-104" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-392">3.75</ix:nonFraction>% discount, in full satisfaction of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-385-2" continuedAt="f-385-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the note, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-393">0.3</ix:nonFraction> million and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The Company may combine the results of each party&#8217;s clinical trials to seek FDA approval in the United States for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#8220;G42 Healthcare&#8221;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" scale="6" id="f-394">30.0</ix:nonFraction> million or (b) the payment by the Company of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vtvt:CollaborateArrangementContingentConsiderationTransferredCash" scale="6" id="f-395">30.0</ix:nonFraction> million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least <ix:nonNumeric contextRef="c-105" name="vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod" format="ixt-sec:durwordsen" id="f-396">ten years</ix:nonNumeric> after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-397">18.7</ix:nonFraction> million, net of a note receivable discount of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="vtvt:CollaborativeArrangementNoteReceivableDiscountPaid" scale="6" id="f-398">0.6</ix:nonFraction> million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-385-3" continuedAt="f-385-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2024, the clinical trials had not commenced. Accordingly, <ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-399"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-400">no</ix:nonFraction></ix:nonFraction> collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#8217;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-401"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-402">no</ix:nonFraction></ix:nonFraction>t recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="6" id="f-403">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-110" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-404">3.75</ix:nonFraction>% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-405">0.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables&#8220; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 310&#8221;) and was initially measured at its fair value of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ReceivablesFairValueDisclosure" scale="6" id="f-406">11.9</ix:nonFraction> million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-407">18.7</ix:nonFraction> million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#8220;First Newsoara Amendment&#8221;). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the &#8220;Second Newsoara Amendment&#8221;) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the &#8220;Upfront Fees&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="vtvt:LicenseFeeReceived" scale="6" id="f-408">20.0</ix:nonFraction> million. Newsoara has up to <ix:nonNumeric contextRef="c-111" name="vtvt:LicenseFeeReceivedTerm" format="ixt-sec:durwordsen" id="f-409">one year</ix:nonNumeric> from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" scale="6" id="f-410">76.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="vtvt:LicenseFeePriceIncrease" format="ixt:num-dot-decimal" scale="6" id="f-411">20.0</ix:nonFraction>&#160;million. If the Company receives the Upfront Fees, $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="vtvt:LicenseFeeReceived" format="ixt:num-dot-decimal" scale="6" id="f-412">20.0</ix:nonFraction>&#160;million of revenue will be recognized at a point in time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-385-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue for this performance obligation has been fully recognized as of September&#160;30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="f-413">1.0</ix:nonFraction> million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the nine months ended September&#160;30, 2024, as the related performance obligation was fully satisfied. <ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-414"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-415">No</ix:nonFraction></ix:nonFraction> revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and nine months ended September&#160;30, 2023.</span></div></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_52"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-417" continuedAt="f-417-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-417-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a <ix:nonNumeric contextRef="c-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-418">four-year</ix:nonNumeric> period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a <ix:nonNumeric contextRef="c-117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-419">three-year</ix:nonNumeric> period. The option awards expire after a term of <ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-420">ten years</ix:nonNumeric> from the date of grant. As of September&#160;30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-421">4.7</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-116" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-422">2.5</ix:nonNumeric> years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-423">14.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-424">30.59</ix:nonFraction> per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2024 was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company&#8217;s Board of Directors, effective on the closing of the Private Placement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of their resignations, <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-425">14,340</ix:nonFraction> stock options to purchase shares of common stock were modified to increase the time period to exercise the options and <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="f-426">7,590</ix:nonFraction> stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="vtvt:ShareBasedPaymentArrangementExpenseReductionAmount" scale="6" id="f-427">0.1</ix:nonFraction> million reduction in stock compensation expense for the modifications for the nine months ended September&#160;30, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-428" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-429">249,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-430">77.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-431">447,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-432">13.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-433">5,153</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-434">18.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-435">691,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-436">36.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-437">237,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-438">75.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-439">6.9</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-440">551,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-441">41.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-442">8.2</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-443" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-444">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-445">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-446">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-447">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-448">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-449">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-450">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-451">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-452">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-453">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-454">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-455">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_55"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-456" continuedAt="f-456-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-456-1" continuedAt="f-456-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-456-2" continuedAt="f-456-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><ix:continuation id="f-456-3" continuedAt="f-456-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-456-4">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-457">9.0</ix:nonFraction> million for approval of a product for the treatment of type 1 diabetes, $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-458">50.5</ix:nonFraction> million for approval of a product for the treatment of type 2 diabetes, or $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-459">115.0</ix:nonFraction> million for approval of a product in any other indication. The Company may also be obligated to pay an additional $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="vtvt:PotentialMilestonePayment" scale="6" id="f-460">75.0</ix:nonFraction> million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.</ix:continuation> </span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_58"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6:  <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-461-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease included an option to renew for a <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-462">five-year</ix:nonNumeric> term as well as an option to terminate after <ix:nonNumeric contextRef="c-4" name="vtvt:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durwordsen" id="f-463">three years</ix:nonNumeric>, neither of which was recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September&#160;30, 2024 and December&#160;31, 2023, the weighted average incremental borrowing rate for the operating lease held by the Company was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-464"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-465">9.5</ix:nonFraction></ix:nonFraction>%. At September&#160;30, 2024 and December&#160;31, 2023, the weighted average remaining lease terms for the operating lease held by the Company were <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-466">1.2</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-467">1.9</ix:nonNumeric> years, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-468" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating lease as of September&#160;30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-469">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-470">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-475">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:OperatingLeasesImputedInterest" scale="3" id="f-476">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-477">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-478"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-479">0.2</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_61"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7:  <ix:nonNumeric contextRef="c-1" name="us-gaap:MinorityInterestDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true">Noncontrolling Interest</ix:nonNumeric></span></div><ix:continuation id="f-480-1" continuedAt="f-480-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the <ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="f-481">18.1</ix:nonFraction>% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a <ix:nonFraction unitRef="number" contextRef="c-134" decimals="0" name="vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-482">one</ix:nonFraction>-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a <ix:nonNumeric contextRef="c-27" name="vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" format="ixt-sec:durday" id="f-483">20</ix:nonNumeric>-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-480-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;) governance rights such that directors designated by M&amp;F no longer comprised a majority of the Company&#8217;s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company&#8217;s independent Board of Directors. As a result, $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="f-484">5.3</ix:nonFraction> million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December&#160;31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="f-485">6.1</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" id="f-486" continuedAt="f-486-1" escape="true">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</ix:nonNumeric></span></div><ix:continuation id="f-486-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-487">4,783</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-488">6,654</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-489">14,828</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-490">16,772</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-491">1,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-492">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-493">7,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-494">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-495">6,755</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-496">5,062</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-497">7,236</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-498">12,560</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_64"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8:  <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-499" continuedAt="f-499-1" escape="true">Stockholders&#8217; Equity (Deficit)</ix:nonNumeric></span></div><ix:continuation id="f-499-1" continuedAt="f-499-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="vtvt:IncreaseInCommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-500">100,000,000</ix:nonFraction> shares of Class A common stock to <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-501">200,000,000</ix:nonFraction> shares of Class A common stock, representing an increase of <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="vtvt:IncreaseInCommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-502">100,000,000</ix:nonFraction> shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-503">200,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-504">300,000,000</ix:nonFraction>, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-505">250,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-506">350,000,000</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company&#8217;s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company&#8217;s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-507">200,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-508">100,000,000</ix:nonFraction> respectively and did not change the par value of the common stock, which remained at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-509"><ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-510">0.01</ix:nonFraction></ix:nonFraction> per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company&#8217;s preferred stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-511">0.01</ix:nonFraction> per share, which would remain at <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-512">50,000,000</ix:nonFraction> shares. Currently no shares of preferred stock are outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Pre-funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-513">464,377</ix:nonFraction> shares of our Class A common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-514">11.81</ix:nonFraction> per share and (ii) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued pre-funded warrants to purchase an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-515">3,853,997</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of the Company&#8217;s Class A common stock at a price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-516">11.80</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-517">0.01</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" scale="-2" id="f-518">9.99</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the number of shares of the Company&#8217;s common </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-499-2" continuedAt="f-499-3"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="4" name="vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" scale="-2" id="f-519">19.99</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by providing at least 61 days&#8217; prior notice to the Company. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were pre-funded warrants to purchase an aggregate o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-520">3,970,587</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company&#8217;s common stock that remained available for exercise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares" format="ixt:num-dot-decimal" scale="0" id="f-521">116,493</ix:nonFraction> Private Placement Shares for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-522">116,590</ix:nonFraction> Private Placement Pre-Funded Warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-523">259,657</ix:nonFraction> shares of the Company's Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-524">96.40</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="f-525">25.0</ix:nonFraction> million, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-526">12.5</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="6" id="f-527">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at the <ix:nonNumeric contextRef="c-99" name="vtvt:SaleOfStockConsiderationReceivableTerm" format="ixt-sec:durwordsen" id="f-528">one-year</ix:nonNumeric> anniversary of the execution of the G42 Purchase Agreement (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="6" id="f-529">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-104" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-530">3.75</ix:nonFraction>% discount, in full satisfaction of the note, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-531">0.3</ix:nonFraction> million and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the &#8220;Transaction Date&#8221;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#8220;CinPax&#8221;) and CinRx-Pharma, LLC (&#8220;CinRx&#8221;), pursuant to which the Company agreed to sell to CinPax <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-532">103,864</ix:nonFraction> shares of the Company&#8217;s Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-533">96.40</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="f-534">10.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-535">6.0</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="6" id="f-536">4.0</ix:nonFraction> million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-537">30,000</ix:nonFraction> shares of common stock at an initial exercise of price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-538">28.80</ix:nonFraction> per share (the &#8220;CinRx Warrants&#8221;). The CinRx Warrants were initially measured at fair value of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="f-539">0.4</ix:nonFraction> million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#8220;FDA Approval&#8221;) to market and distribute the pharmaceutical product containing the Company&#8217;s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within <ix:nonNumeric contextRef="c-147" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-540">five years</ix:nonNumeric> of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#8220;CinRx MSA&#8221;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-499-3" continuedAt="f-499-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company&#8217;s board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the &#8220;TD Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="vtvt:SaleOfStockAggregateOfferingPrice" scale="6" id="f-541">50.0</ix:nonFraction> million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="vtvt:EntityPublicFloatThreshold" scale="6" id="f-542">75.0</ix:nonFraction> million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of <ix:nonFraction unitRef="rate" contextRef="c-96" decimals="3" name="vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" scale="-2" id="f-543">3.0</ix:nonFraction>% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-499-4">During the three and nine months ended September&#160;30, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-544"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-545">179,400</ix:nonFraction></ix:nonFraction> shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-546"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-547">2.5</ix:nonFraction></ix:nonFraction> million.</ix:continuation> </span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_70"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9:  <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-550" continuedAt="f-550-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-550-1" continuedAt="f-550-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-551">577,108</ix:nonFraction> shares of Class B common stock. Further, as of September&#160;30, 2024, MacAndrews directly or indirectly holds <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-552">912,982</ix:nonFraction> shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately <ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="vtvt:OwnershipPercentageOfMajorityOwner" scale="-2" id="f-553">46.7</ix:nonFraction>% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-155" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-554">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-550-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&amp;F governance rights that now entitles M&amp;F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.</span></div></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_73"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10:  <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-555-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company&#8217;s income tax provision for the nine months ended September&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-556">0.1</ix:nonFraction> million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-557"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-558">not</ix:nonFraction></ix:nonFraction> record an income tax provision for the three months ended September&#160;30, 2024 and 2023. The Company did <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-559">not</ix:nonFraction> record an income tax provision for the nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2024, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-156" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-560">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2024.</span></div></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_76"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11:  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-561" continuedAt="f-561-1" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="f-561-1" continuedAt="f-561-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-561-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-562" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-563">5,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-564">8,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-565">18,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-566">21,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-567">1,057</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-568">1,886</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-569">3,440</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-570">4,753</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-571"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-572">4,783</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-573"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-574">6,654</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-575"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-576">14,828</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-577"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-578">16,772</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-579"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-580">5,456,307</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-581"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-582">2,084,973</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-583"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-584">5,498,479</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-585"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-586">2,084,973</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-587"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-588">0.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-589"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-590">3.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-591"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-592">2.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-593"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-594">8.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended September&#160;30, 2024.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-595" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-596">577,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-597">577,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-598">691,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-599">238,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-600">75,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-601">80,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-602">1,344,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-603">896,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_79"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12:  <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-604" continuedAt="f-604-1" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-604-1" continuedAt="f-604-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-605" continuedAt="f-605-1" escape="true">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-604-2" continuedAt="f-604-3"><ix:continuation id="f-605-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-606">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-609">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-610">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-613">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-614">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-617">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-618">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-621">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-622">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-625">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the nine months ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclass</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-626">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-627">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" sign="-" name="vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" scale="3" id="f-630">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-631">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability </span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-633">157</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" scale="3" id="f-636">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-637">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-638">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-639">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-643">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-644">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-645">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-649">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-650">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-651">406</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-655">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><ix:continuation id="f-604-3" continuedAt="f-604-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the time of valuation. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-656" continuedAt="f-656-1" escape="true">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2024 and December&#160;31, 2023, were:</ix:nonNumeric></span></div><ix:continuation id="f-656-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:30.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-657">95.13</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-195" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-658">124.70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-659">109.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-660">79.96</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-198" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-661">89.61</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-199" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-662">81.55</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-200" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-663">3.64</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-664">4.85</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-665">3.79</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-666">4.01</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-204" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-667">4.87</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-205" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-668">4.15</ix:nonFraction>%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2024, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-206" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-669">98.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-207" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-670">2.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-208" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-671">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-604-4">Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</ix:continuation> </span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_82"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-673" continuedAt="f-673-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-673-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events through November 12, 2024, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws regarding, among other things, our intentions, plans, estimates, assumptions, predictions and beliefs. Although we believe that these forward-looking statements are based upon reasonable assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances, our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under &#8220;Part II, Other Information&#8212;Item 1A, Risk Factors&#8221; and under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. Given the numerous uncertainties and factors to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, you should not place undue reliance on these forward-looking statements and understand that these statements are not guarantees of performance or results. Also, forward-looking statements represent our management&#8217;s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an orally administered, small molecule, liver-selective glucokinase activator (&#8220;GKA&#8221;) in development as an adjunctive therapy to insulin for the treatment of type 1 diabetes (&#8220;T1D&#8221;).</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2024, the Company, received notice from OnKure Therapeutics, formerly Reneo Pharmaceuticals, Inc. ("OnKure"), of its intent to terminate the License Agreement between vTv LLC and Reneo Pharmaceuticals, Inc., dated December 21, 2017, as amended December 20, 2021 (the &#8220;Agreement&#8221;). Under the Agreement, the Company had granted OnKure an exclusive, worldwide license to intellectual property pertaining to the Company's peroxisome proliferator-activated receptor delta (ppar-&#948;) agonist program. In its notice, OnKure indicated that it had decided to discontinue development of the program.  Under the Agreement, the termination will become effective as of January 20, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our drug candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, their partnership status and their respective stages of development:</span></div><div style="text-align:justify"><img src="vtvt-20240930_g1.jpg" alt="vTv_grayscale pipeline for 10-Q_3Q2024_FINAL_11-11-2024.jpg" style="height:396px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These product candidates are under investigation and their safety and efficacy have not been established. There is no guarantee that these products will receive health authority approval or become commercially available for the uses being investigated.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_94"></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Type 1 Diabetes Program &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cadisegliatin (TTP399)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation in 2021 for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunctive therapy to insulin for the treatment of type 1 diabetes. The Breakthrough Therapy designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine. The Breakthrough Therapy designation for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in T1D was supported by the positive results from the Phase 2 SimpliciT-1 Study, a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an adjunct to insulin therapy in adults with T1D. In this trial, treatment with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulted in a statistically significant improvement in HbA1c relative to placebo and a clinically meaningful decrease (40%) in the frequency of severe and symptomatic hypoglycemia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> demonstrated a favorable safety profile, in which abnormal levels of serum or urine ketones were detected less frequently in patients taking </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> than those taking placebo. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May of 2023, the FDA issued new draft guidance on "Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products" which, for the first time, permitted the use of hypoglycemia as an endpoint to support a label claim. Consistent with this guidance and with input from the FDA, we initiated our CATT1 trial to assess the effect of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on reducing the frequency of Level 2 hypoglycemia (blood glucose levels are less than 54 mg/dL or 3 mmol/L, regardless of symptoms) and Level 3 hypoglycemia ("severe" hypoglycemia e.g., requiring assistance of another person) in 150 patients with type 1 diabetes. On July 26, 2024, the FDA issued a clinical hold for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program, including the CATT1 trial, based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that could not be resolved by standard mass spectroscopy. The FDA will require a single in vitro study to characterize this signal before the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program, including the CATT1 trial, can resume. At the time of the clinical hold, no patient had been dosed in the CATT1 trial and past clinical studies did not reveal any clinically concerning safety issues. The Company has conducted activities to address the issue identified by FDA and restart clinical trial activities.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to work on the design for two international registrational studies for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in type 1 diabetes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we expect to start in 2026. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to work with our partner, G42 Investments AI Holding RSC Ltd. (&#8220;G42&#8221;), to initiate a double-blind, randomized, controlled Phase 2 trial in the Middle East region in 450 insulin-using patients with type 2 diabetes. We expect that trial to begin in 2025.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holding Company Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results under the VIE accounting model in its consolidated financial statements.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from milestone payments, up-front proceeds and research fees under collaboration and license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses by project for the three and nine months ended September&#160;30, 2024 and 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other projects*</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">azeliragon</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and further advance the development of our other drug candidates, subject to the availability of additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the uncertainty of the duration of the clinical hold placed on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program and the scope, rate of progress and expense of our clinical trials once resumed as well as any additional, clinical trials and other research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential benefits of our candidates over other therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">future clinical trial results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of any regulatory approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to secure sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">legislation and regulatory actions and changes in laws or regulations; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income represents noncash interest income related to the imputed interest from the G42 Promissory Note receivable using the effective interest method, which ended in 2023, and cash interest income from dividends and interest from our money market account, all of which are recognized in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investments in OnKure, the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock, the loss from the G42 promissory note early redemption on February 28, 2023 and the impairment charge from Anteris Bio, Inc. (&#8220;Anteris&#8221;) liquidation and dissolution..</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended September&#160;30, 2024 and 2023</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,506)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,840)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,840)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,783)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue for the three months ended September&#160;30, 2024 and 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $3.2 million and $2.8 million for the three months ended September&#160;30, 2024 and 2023, respectively. The increase in research and development expenses during this period of $0.4 million or 14.2%, was primarily driven by i) an increase in indirect costs and other projects of $0.7 million and offset by ii) lower spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $0.3 million, due to decreases in toxicity study costs and drug manufacturing related costs partially offset by increases in clinical trial start-up costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $3.3 million and $2.5 million for the three months ended September&#160;30, 2024 and 2023, respectively. The increase in general and administrative expenses during this period of $0.7&#160;million, or 29.0%, was primarily driven by i) increases of $0.3 million in share-based expense, ii) increases of $0.2 million in legal expenses and iii) increases of $0.2 million in payroll related costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended September&#160;30, 2024, of $0.5 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is related to dividend income from our money market accounts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest income for the three months ended September&#160;30, 2023, of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is related to dividend income from our money market account.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $0.2 million for the three months ended September&#160;30, 2024, and was driven by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gains rel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ated to the change in the fair value of the warrants to purchase shares of our own stock. Other expense was $3.3 million for the three months ended September&#160;30, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was driven by an impairment charge on a cost-method investment of $4.2 million. This was partially offset by an unrealized gain from the Company&#8217;s investment in OnKure and gains from changes in the fair value of warrants to purchase shares of our own stock issued to related parties.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the nine months ended September&#160;30, 2024 and 2023</span></div><div style="margin-top:6pt;text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:58.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,145)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,976</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,338</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,288</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,795</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,288)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,795)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,108)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,168)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,268)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,440)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,828)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the nine months ended September&#160;30, 2024 includes a $1.0 million increase to the transaction price for the license performance obligation under the Newsoara License Agreement due to the satisfaction of a development milestone. There was no revenue for the nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $9.3 million and $11.5 million for the nine months ended September&#160;30, 2024 and 2023, respectively. The decrease in research and development expenses during the period of $2.1 million, or 18.7%, was primarily driven by i) lower spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $3.8 million due to decreases in toxicity study costs and drug manufacturing related costs, partially offset by increases in clinical trial start-up costs, and ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases in indirect costs and other projects of $1.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $11.0 million and $9.3 million for the nine months ended September&#160;30, 2024 and 2023, respectively. The increase of $1.6 million or 17.5%, was primarily driven by i) increases of $1.0 million in payroll costs, ii) increases of $0.7 million in legal expense, iii) increases of $0.5 million in share-based expense, partially offset by iv)  decreases of $0.6 million in other general and administrative costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the nine months ended September&#160;30, 2024, of $1.1 million, is related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividend income from our money market accounts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest income for the nine months ended September&#160;30, 2023 of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is related to imputed interest on the G42 Promissory Note and dividend income from our money market account.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense for the nine months ended September&#160;30, 2024 was immaterial. Other expense was $1.1 million for the nine months ended September&#160;30, 2023, and was driven by an impairment charge on a cost-method investment of $4.2 million. This was partially offset by an unrealized gain from the Company&#8217;s investment in OnKure and gains from changes in the fair value of warrants to purchase shares of our own stock issued to related parties.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we had an accumulated deficit of $296.1 million. Since our inception, we have experienced a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses and negative cash flow from operations for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of September&#160;30, 2024, we had cash and cash equivalents of $41.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, the Company closed a private placement financing of up to $51.0 million and additionally granting investors the right to purchase up to an additional $30.0 million of common stock 18 months following the closing of the private placement financing. The financing raised will allow the Company to further advance its lead program for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to available cash and cash equivalents and available funds discussed above, we are seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We are evaluating several financing strategies to fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The timing and availability of such additional financing are not yet known. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TD Cowen Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the "TD Cowen Sales Agreement") with Cowen and Company, LLC (&#8220;TD Cowen&#8221;) pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $50.0 million, although we may only offer and sell under the TD Cowen ATM Offering up to one-third of the aggregate market value of our Class A common stock held by non-affiliates during any 12 calendar month period pursuant to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General Instruction I.B.6 of Form S-3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are not obligated to sell any shares under the TD Cowen Sales Agreement. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of September&#160;30, 2024, we have sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million, leaving $47.5 million available to be sold. The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. In no event will we sell Class A common stock under this registration statement with a value exceeding more than one-third of the &#8220;public float&#8221; (the market value of our Class A common stock and any other equity securities that we may issue in the future that are held by non-affiliates) in any 12-calendar month period so long as our public float remains below $75 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,482)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,167)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,125&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"/><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2024, our net cash used in operating activities increased by $4.3 million from the nine months ended September&#160;30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The significant contributor to the change in cash used during the year was working capital changes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash flows from investing activities for the nine months ended September&#160;30, 2024 and 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2024, net cash provided by financing activities was driven by sales of our Class A common stock and proceeds from pre-funded warrants of $51.0 million from the Private Placement financing and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the TD Cowen ATM Offering of $2.5 million. For the nine months ended September&#160;30, 2023, net cash provided by financing activities was driven by the receipt of proceeds of $12.0 million from the G42 promissory note early redemption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months. We plan to finance our operations through the use of our cash and cash equivalents, including funding activities needed to lift the clinical hold and resume the CATT1 trial. We continue to evaluate financing strategies to fund future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including direct equity investments and the potential licensing and monetization of other Company programs. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, they may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering. However, the ability to use this source of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, results and timing needed to lift the clinical hold on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs, results and timing of restarting our trials to evaluate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a potential adjunctive therapy for the treatment of type 1 diabetes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the FDA to lift the clinical hold and to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain control over our costs in line with our budget for our lead product candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability of our drug candidates to progress through clinical development successfully;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to expand our research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with securing, establishing and maintaining commercialization capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need and ability to hire additional management, scientific, and medical personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of any payments we are required to make to M&amp;F TTP Holdings Two LLC in the future under the Tax Receivable Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we did not have outstanding any off-balance sheet arrangements as defined under SEC rules. </span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. There have been no material changes to our critical accounting policies and estimates in 2024.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management&#8217;s intentions, plans, beliefs, expectations, or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties, and assumptions, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of recent accounting pronouncements in Note 2, &#8220;Summary of Significant Accounting Policies&#8221;, to the Condensed Consolidated Financial Statements in this Form 10-Q.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any material interest rate exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain cash and cash equivalents with multiple financial institutions that management believes to be of high credit quality. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any material foreign currency exposure.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_127"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of September&#160;30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September&#160;30, 2024, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website Availability of Reports and other Corporate Governance Information</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC&#8217;s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_133"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_136"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are set forth under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_139"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_142"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_145"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_148"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third fiscal quarter ended September&#160;30, 2024, none of our directors or executive officers <ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-674"><ix:nonNumeric contextRef="c-14" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-675">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-14" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-676"><ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-677">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_151"></div><div style="-sec-extract:summary;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20240930xexx311.htm">Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20240930xexx312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20240930xexx321.htm">Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20240930xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i3e01e6945c6f4edc9cd6cef8ee05dd63_154"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3e01e6945c6f4edc9cd6cef8ee05dd63_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;12, 2024</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:58.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTV THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steven Tuch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Tuch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>vtvt-20240930xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i00a11ba7111c469eb8e9cf7f35357c35_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Sekhri, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2024</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>vtvt-20240930xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i008f534ccb5242cdbdd03abcf8349557_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steven Tuch, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2024</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>vtvt-20240930xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id86c0849b3d748a594b5337281819999_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2024</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Executive Chairperson</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>vtvt-20240930xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i72d4ae80c6d94c5d93e233ee379a2ef4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Steven Tuch, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2024</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vtvt-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtvt="http://vtvtherapeutics.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vtvtherapeutics.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://vtvtherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited">
        <link:definition>9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements">
        <link:definition>9952158 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation">
        <link:definition>9952159 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>9952160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://vtvtherapeutics.com/role/Leases">
        <link:definition>9952161 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterest" roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterest">
        <link:definition>9952162 - Disclosure - Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://vtvtherapeutics.com/role/StockholdersEquityDeficit">
        <link:definition>9952163 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>9952164 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://vtvtherapeutics.com/role/IncomeTaxes">
        <link:definition>9952165 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://vtvtherapeutics.com/role/NetLossperShare">
        <link:definition>9952166 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments">
        <link:definition>9952167 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vtvtherapeutics.com/role/SubsequentEvents">
        <link:definition>9952168 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>9954472 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://vtvtherapeutics.com/role/LeasesTables">
        <link:definition>9954473 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestTables" roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestTables">
        <link:definition>9954474 - Disclosure - Noncontrolling Interest (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables">
        <link:definition>9954475 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>9954476 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDetail" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail">
        <link:definition>9954477 - Disclosure - Description of Business and Basis of Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail">
        <link:definition>9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail">
        <link:definition>9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail">
        <link:definition>9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail">
        <link:definition>9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954484 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail">
        <link:definition>9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1">
        <link:definition>9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail">
        <link:definition>9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail">
        <link:definition>9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail">
        <link:definition>9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>9954490 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail">
        <link:definition>9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail">
        <link:definition>9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail">
        <link:definition>9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail">
        <link:definition>9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtvt_WarrantyLiability" abstract="false" name="WarrantyLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_RedeemableNoncontrollingInterestsMember" abstract="true" name="RedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" abstract="false" name="ChangeInRedemptionValueOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" abstract="false" name="IssuanceOfClassACommonStockUnderATMOfferingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_IssuanceOfClassACommonStockUnderATMOffering" abstract="false" name="IssuanceOfClassACommonStockUnderATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ProceedsFromSaleOfCommonStock" abstract="false" name="ProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" abstract="false" name="NoncontrollingInterestReclassificationToAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_VTvLLCMember" abstract="true" name="VTvLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_TDCowenSalesAgreementMember" abstract="true" name="TDCowenSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_PrivatePlacementPreFundedWarrantsMember" abstract="true" name="PrivatePlacementPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterest" abstract="false" name="PercentageOfNonVotingEconomicInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterestByParent" abstract="false" name="PercentageOfNonVotingEconomicInterestByParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" abstract="false" name="CommonStockParOrStatedValueOfPrivatePlacementShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" abstract="false" name="CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_EntityPublicFloatThreshold" abstract="false" name="EntityPublicFloatThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" abstract="false" name="SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_OneCustomerMember" abstract="true" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" abstract="true" name="G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_NewsoaraBiopharmaCoLtdMember" abstract="true" name="NewsoaraBiopharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_JDRFInternationalMember" abstract="true" name="JDRFInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_G42InvestmentsMember" abstract="true" name="G42InvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CognaMember" abstract="true" name="CognaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_LicenseAndTechnologyTransferServicesMember" abstract="true" name="LicenseAndTechnologyTransferServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_NotesReceivableDiscountRate" abstract="false" name="NotesReceivableDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" abstract="false" name="CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborateArrangementContingentConsiderationTransferredCash" abstract="false" name="CollaborateArrangementContingentConsiderationTransferredCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" abstract="false" name="CollaborativeArrangementRoyaltiesReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" abstract="false" name="CollaborativeArrangementNoteReceivableDiscountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseFeeReceived" abstract="false" name="LicenseFeeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseFeeReceivedTerm" abstract="false" name="LicenseFeeReceivedTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseFeePriceIncrease" abstract="false" name="LicenseFeePriceIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" abstract="false" name="MaximumFundingPercentageOfResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" abstract="false" name="ShareBasedPaymentArrangementExpenseReductionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" abstract="true" name="DevelopmentalAndRegulatoryMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SalesBasedMilestonesPaymentMember" abstract="true" name="SalesBasedMilestonesPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_NovoLicenseAgreementMember" abstract="true" name="NovoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_TypeOneDiabetesMember" abstract="true" name="TypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_TypeTwoDiabetesMember" abstract="true" name="TypeTwoDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_OtherIndicationMember" abstract="true" name="OtherIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PotentialMilestonePayment" abstract="false" name="PotentialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_OperatingLeasesImputedInterest" abstract="false" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" abstract="true" name="ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" abstract="false" name="RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" abstract="false" name="PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" abstract="false" name="ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CinRxInvestmentMember" abstract="true" name="CinRxInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_IncreaseInCommonStockSharesAuthorized" abstract="false" name="IncreaseInCommonStockSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_CommonStockAndPreferredStockSharesAuthorized" abstract="false" name="CommonStockAndPreferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivableTerm" abstract="false" name="SaleOfStockConsiderationReceivableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_MacAndrewsAndForbesIncorporatedMember" abstract="true" name="MacAndrewsAndForbesIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_OwnershipPercentageOfMajorityOwner" abstract="false" name="OwnershipPercentageOfMajorityOwner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_PercentageOfAmountOfCashSavings" abstract="false" name="PercentageOfAmountOfCashSavings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_MFTTPHoldingsLLCMember" abstract="true" name="MFTTPHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareTable" abstract="true" name="ScheduleOfEarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareLineItems" abstract="true" name="ScheduleOfEarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LetterAgreementWarrantsMember" abstract="true" name="LetterAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CinRxWarrantsMember" abstract="true" name="CinRxWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vtvt-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e56dae60-2336-4dc6-977f-bc91682306ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_129ab599-4d4c-460b-b15c-33c9be767fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e56dae60-2336-4dc6-977f-bc91682306ef" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_129ab599-4d4c-460b-b15c-33c9be767fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_63a13d9c-dad2-4e68-8c6d-0f52059a8764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e56dae60-2336-4dc6-977f-bc91682306ef" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_63a13d9c-dad2-4e68-8c6d-0f52059a8764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bfd531e2-b821-443b-b9fe-492d951f910b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e56dae60-2336-4dc6-977f-bc91682306ef" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bfd531e2-b821-443b-b9fe-492d951f910b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_09b5e810-3cac-40c9-a95b-bc1d6ce8d52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e56dae60-2336-4dc6-977f-bc91682306ef" xlink:to="loc_us-gaap_Liabilities_09b5e810-3cac-40c9-a95b-bc1d6ce8d52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc2e0cfa-05ac-41db-b2ed-4a5d09d5197c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94fcb270-6a36-4ee3-a987-96af27f51ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc2e0cfa-05ac-41db-b2ed-4a5d09d5197c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94fcb270-6a36-4ee3-a987-96af27f51ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_893ba379-8a54-4f6a-9c76-c96df744a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc2e0cfa-05ac-41db-b2ed-4a5d09d5197c" xlink:to="loc_us-gaap_CommonStockValue_893ba379-8a54-4f6a-9c76-c96df744a2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eb795d85-87cf-4f1b-8237-c2f5680aec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bc2e0cfa-05ac-41db-b2ed-4a5d09d5197c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eb795d85-87cf-4f1b-8237-c2f5680aec5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b4286194-c604-4ac9-b509-31a5736bec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_74e054d5-eaf6-4ae7-9036-8dedbb3a58db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4286194-c604-4ac9-b509-31a5736bec4d" xlink:to="loc_us-gaap_AssetsCurrent_74e054d5-eaf6-4ae7-9036-8dedbb3a58db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_606603f9-1a11-441f-b96e-169ec7ff6561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4286194-c604-4ac9-b509-31a5736bec4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_606603f9-1a11-441f-b96e-169ec7ff6561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_73fe8858-73c3-4c87-9e45-ed491ce10cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4286194-c604-4ac9-b509-31a5736bec4d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_73fe8858-73c3-4c87-9e45-ed491ce10cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c83731c2-972e-4a39-8d3e-52b8d7ce2269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_25b89426-3a40-4634-adaf-ab81f53120ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c83731c2-972e-4a39-8d3e-52b8d7ce2269" xlink:to="loc_us-gaap_DepositsAssetsCurrent_25b89426-3a40-4634-adaf-ab81f53120ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1f434ce1-4634-4dce-806e-0bb8d4e97c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c83731c2-972e-4a39-8d3e-52b8d7ce2269" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1f434ce1-4634-4dce-806e-0bb8d4e97c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e1d4fe3-be84-4506-b8ea-74f611119c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c83731c2-972e-4a39-8d3e-52b8d7ce2269" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5e1d4fe3-be84-4506-b8ea-74f611119c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bc529047-04aa-4e9e-869c-8b1afb48fa87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c83731c2-972e-4a39-8d3e-52b8d7ce2269" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bc529047-04aa-4e9e-869c-8b1afb48fa87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_419bdc9e-beb2-407b-9a28-df533b8269ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_771a0f89-ef86-4abf-a385-77f84b19ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_419bdc9e-beb2-407b-9a28-df533b8269ff" xlink:to="loc_us-gaap_MinorityInterest_771a0f89-ef86-4abf-a385-77f84b19ca81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90d71779-056c-4060-a153-62415f3de904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_419bdc9e-beb2-407b-9a28-df533b8269ff" xlink:to="loc_us-gaap_StockholdersEquity_90d71779-056c-4060-a153-62415f3de904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cbecf440-9094-486a-bc1d-8683be7f26cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5b3188e9-15c3-484a-a08c-229adb657a65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbecf440-9094-486a-bc1d-8683be7f26cc" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5b3188e9-15c3-484a-a08c-229adb657a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe7ba593-aa52-45ca-a55c-16edec0bdce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbecf440-9094-486a-bc1d-8683be7f26cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe7ba593-aa52-45ca-a55c-16edec0bdce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a342aad1-b57c-4c7d-8cd0-3661c9de65dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbecf440-9094-486a-bc1d-8683be7f26cc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a342aad1-b57c-4c7d-8cd0-3661c9de65dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_e87922e5-ae15-4bfa-af6b-85e90374f9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbecf440-9094-486a-bc1d-8683be7f26cc" xlink:to="loc_us-gaap_NotesPayableCurrent_e87922e5-ae15-4bfa-af6b-85e90374f9cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_48e7c020-d6f6-43f2-a74a-c0943f2cdeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc7d531c-7752-4538-9a89-d5ce468a65cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48e7c020-d6f6-43f2-a74a-c0943f2cdeed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc7d531c-7752-4538-9a89-d5ce468a65cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4e705aee-6f13-43d3-83d4-c14005a85d28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48e7c020-d6f6-43f2-a74a-c0943f2cdeed" xlink:to="loc_us-gaap_LiabilitiesCurrent_4e705aee-6f13-43d3-83d4-c14005a85d28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_f0776058-ed8f-4df2-8b42-19e5d6733fc3" xlink:href="vtvt-20240930.xsd#vtvt_WarrantyLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48e7c020-d6f6-43f2-a74a-c0943f2cdeed" xlink:to="loc_vtvt_WarrantyLiability_f0776058-ed8f-4df2-8b42-19e5d6733fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337e56f8-30e9-4760-ad33-39e677331a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_48e7c020-d6f6-43f2-a74a-c0943f2cdeed" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337e56f8-30e9-4760-ad33-39e677331a1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d1c792fb-774e-4ff9-b045-ae0326a49314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6d8765a2-0b1a-4a9d-9c33-84635e347b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1c792fb-774e-4ff9-b045-ae0326a49314" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6d8765a2-0b1a-4a9d-9c33-84635e347b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b0d68ca6-0ce8-4822-9ead-73ec546b045d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1c792fb-774e-4ff9-b045-ae0326a49314" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b0d68ca6-0ce8-4822-9ead-73ec546b045d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b33248b7-9cfd-4673-a854-b4c781d03c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_929f98cf-3f59-47e8-9f0e-d43d02f825e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b33248b7-9cfd-4673-a854-b4c781d03c67" xlink:to="loc_us-gaap_ProfitLoss_929f98cf-3f59-47e8-9f0e-d43d02f825e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3e50ca8-d72b-4f85-9191-bd693bd686d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b33248b7-9cfd-4673-a854-b4c781d03c67" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3e50ca8-d72b-4f85-9191-bd693bd686d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af85cc27-269b-4aee-9916-b0b8f2d34c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_80e7a04c-ade0-4d04-89a1-45502fd11144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af85cc27-269b-4aee-9916-b0b8f2d34c62" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_80e7a04c-ade0-4d04-89a1-45502fd11144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_651352b6-6195-413b-b338-ab8e77f72efb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af85cc27-269b-4aee-9916-b0b8f2d34c62" xlink:to="loc_us-gaap_InterestExpenseOperating_651352b6-6195-413b-b338-ab8e77f72efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4159e38a-43f0-447d-a2d7-3ced642a2ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af85cc27-269b-4aee-9916-b0b8f2d34c62" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4159e38a-43f0-447d-a2d7-3ced642a2ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6386b25e-688d-4315-bb50-4baa6bd31017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af85cc27-269b-4aee-9916-b0b8f2d34c62" xlink:to="loc_us-gaap_OperatingIncomeLoss_6386b25e-688d-4315-bb50-4baa6bd31017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9273e4c2-5a83-4b9d-8b4d-54d4e80cd052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdc1614f-7d29-4e73-a590-9b64c6ab41c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9273e4c2-5a83-4b9d-8b4d-54d4e80cd052" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdc1614f-7d29-4e73-a590-9b64c6ab41c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a0811b41-528f-4c3b-8644-f4a3e8a6745e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9273e4c2-5a83-4b9d-8b4d-54d4e80cd052" xlink:to="loc_us-gaap_OperatingExpenses_a0811b41-528f-4c3b-8644-f4a3e8a6745e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3fc2af5f-7d21-4ba7-a65e-baf67c03f613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5245c5c7-34b9-4c73-9fda-9a0f0deaaa36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3fc2af5f-7d21-4ba7-a65e-baf67c03f613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5245c5c7-34b9-4c73-9fda-9a0f0deaaa36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6bbe5648-8125-4c99-9f6e-389b8cca322a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3fc2af5f-7d21-4ba7-a65e-baf67c03f613" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6bbe5648-8125-4c99-9f6e-389b8cca322a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_331f72da-1637-4e42-a841-d6d478777019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_331f72da-1637-4e42-a841-d6d478777019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c80ef597-b080-429f-a7fe-4619f5703f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_Depreciation_c80ef597-b080-429f-a7fe-4619f5703f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0fad046e-2c43-477c-8364-36bff51a6405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0fad046e-2c43-477c-8364-36bff51a6405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2b5235bf-4428-48a7-a5f9-7762d705c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_ProfitLoss_2b5235bf-4428-48a7-a5f9-7762d705c41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0e3e2885-2afd-4744-a0f0-a4f2170429d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_ShareBasedCompensation_0e3e2885-2afd-4744-a0f0-a4f2170429d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11e85fa9-989a-48cd-a6bb-6450ed74137b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11e85fa9-989a-48cd-a6bb-6450ed74137b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8cb424c7-bfa5-43fa-86b2-f3e0c31fd5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8cb424c7-bfa5-43fa-86b2-f3e0c31fd5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_a3efdbb2-5485-4d4a-8637-6b2b4ba52006" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_a3efdbb2-5485-4d4a-8637-6b2b4ba52006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfdbdd5a-f5b9-4586-a6e3-f83c1acd3f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfdbdd5a-f5b9-4586-a6e3-f83c1acd3f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9133968f-4e4c-4da6-851a-5b248cdbe501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9133968f-4e4c-4da6-851a-5b248cdbe501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_daa501f3-a28f-4f52-8125-f2f830d19c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_InterestIncomeOperating_daa501f3-a28f-4f52-8125-f2f830d19c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48b5ce6a-4dbd-463d-8a78-72cbbd8526b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_48b5ce6a-4dbd-463d-8a78-72cbbd8526b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a4425517-73b5-4dd8-a22e-cd25e1b4a0af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b462f265-c08a-48a8-bb69-9fb5cd722d10" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a4425517-73b5-4dd8-a22e-cd25e1b4a0af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f189b908-1fb9-4223-b9f1-324bd463f3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad20fea9-3cbe-4a2d-8520-f9acfa0350d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f189b908-1fb9-4223-b9f1-324bd463f3ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad20fea9-3cbe-4a2d-8520-f9acfa0350d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cbfed1b-b3c8-4850-89d7-f4875f5b5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f189b908-1fb9-4223-b9f1-324bd463f3ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cbfed1b-b3c8-4850-89d7-f4875f5b5e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_4781e617-b151-4709-aff3-b992adb3d24e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_4781e617-b151-4709-aff3-b992adb3d24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5b83f5e0-1410-4336-8a47-641a1faf524d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5b83f5e0-1410-4336-8a47-641a1faf524d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_97b9a15b-4856-470a-bdd0-c03674fc1186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_97b9a15b-4856-470a-bdd0-c03674fc1186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_13af59fd-3ec4-46a6-928c-b30ec9ff5a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_13af59fd-3ec4-46a6-928c-b30ec9ff5a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock_2859f05c-e362-4e5a-9a40-c4045c9129ea" xlink:href="vtvt-20240930.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca761c64-53e9-4bd2-aa4e-1b391163fd92" xlink:to="loc_vtvt_ProceedsFromSaleOfCommonStock_2859f05c-e362-4e5a-9a40-c4045c9129ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12c813ae-598c-4603-841e-81fb134a24b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_438765ad-b309-43c3-a642-d2f361cb0342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12c813ae-598c-4603-841e-81fb134a24b9" xlink:to="loc_us-gaap_OperatingLeaseLiability_438765ad-b309-43c3-a642-d2f361cb0342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_c6279fd8-9f77-4dbe-97e9-6f22b5cc74ac" xlink:href="vtvt-20240930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12c813ae-598c-4603-841e-81fb134a24b9" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_c6279fd8-9f77-4dbe-97e9-6f22b5cc74ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="vtvt-20240930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b366c547-54e0-495a-9025-9bfbc6ac5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b366c547-54e0-495a-9025-9bfbc6ac5bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_73483c39-6799-41f6-8ba1-8bc1633b4e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_73483c39-6799-41f6-8ba1-8bc1633b4e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e93ebddb-f26c-4191-b35c-a0337e9c5038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e93ebddb-f26c-4191-b35c-a0337e9c5038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b86c35d7-7f27-4dae-a778-a73ddca39352" xlink:href="vtvt-20240930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b86c35d7-7f27-4dae-a778-a73ddca39352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc1dace5-305a-497b-a896-70965ba50790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc1dace5-305a-497b-a896-70965ba50790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7aeb7daa-d0c7-4bb3-924d-787301df7070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_201b305b-7f28-473f-9f89-dc6afb2944cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7aeb7daa-d0c7-4bb3-924d-787301df7070" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_f8cb755b-a9ff-4c5a-a787-64aa40cc8330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_af377ad3-4d6e-454d-b74b-e3549b719445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_f8cb755b-a9ff-4c5a-a787-64aa40cc8330" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_af377ad3-4d6e-454d-b74b-e3549b719445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_e8bc83ec-d043-4d3b-9a4c-ef4a0b13087a" xlink:href="vtvt-20240930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_f8cb755b-a9ff-4c5a-a787-64aa40cc8330" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_e8bc83ec-d043-4d3b-9a4c-ef4a0b13087a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad16dd9a-a2ac-40ed-bf61-c0c22abdffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_14292f10-9243-435a-b1b7-f84a93611f93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad16dd9a-a2ac-40ed-bf61-c0c22abdffbe" xlink:to="loc_us-gaap_ProfitLoss_14292f10-9243-435a-b1b7-f84a93611f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b024da17-1355-4200-a323-ee611f81edb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ad16dd9a-a2ac-40ed-bf61-c0c22abdffbe" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b024da17-1355-4200-a323-ee611f81edb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fd9f5c6a-dcd3-46a5-ba11-988ad9e034af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5cca2d46-2d62-47c7-ac9b-dc3f787e04e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fd9f5c6a-dcd3-46a5-ba11-988ad9e034af" xlink:to="loc_us-gaap_ProfitLoss_5cca2d46-2d62-47c7-ac9b-dc3f787e04e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ca8839a-cb19-48f8-b853-9baee7b649eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fd9f5c6a-dcd3-46a5-ba11-988ad9e034af" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4ca8839a-cb19-48f8-b853-9baee7b649eb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vtvt-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20240930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_91e6fbf8-024d-411a-832e-46ee4b6d97d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:to="loc_us-gaap_ClassOfStockDomain_91e6fbf8-024d-411a-832e-46ee4b6d97d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:to="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a972fd78-3518-47fa-a8e9-da9fb60cc323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:to="loc_us-gaap_CommonClassAMember_a972fd78-3518-47fa-a8e9-da9fb60cc323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_92f7511c-5628-4711-85e4-8fbee6f7f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:to="loc_us-gaap_CommonClassBMember_92f7511c-5628-4711-85e4-8fbee6f7f8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_754bd501-beba-4713-a362-719fac34ab0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentType_754bd501-beba-4713-a362-719fac34ab0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_08f4edb5-06cd-4fab-bb3f-fed704cf93ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentQuarterlyReport_08f4edb5-06cd-4fab-bb3f-fed704cf93ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_26cd3861-a5a3-4703-9c52-ea3eaaa08e5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentPeriodEndDate_26cd3861-a5a3-4703-9c52-ea3eaaa08e5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a90495f7-e1c3-4057-8e40-f53611eae1fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentTransitionReport_a90495f7-e1c3-4057-8e40-f53611eae1fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fc8debff-c4d0-4ba4-b868-e43381398f73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityFileNumber_fc8debff-c4d0-4ba4-b868-e43381398f73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e646aea0-bfa6-4261-899e-af391ba7d115" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityRegistrantName_e646aea0-bfa6-4261-899e-af391ba7d115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2cc46e31-805c-4c8b-9d59-870a9e486b36" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2cc46e31-805c-4c8b-9d59-870a9e486b36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c1b6d019-8472-4308-8a92-3a8f895806b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityTaxIdentificationNumber_c1b6d019-8472-4308-8a92-3a8f895806b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_90abb726-4930-4183-9ac9-d833361ac2f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressAddressLine1_90abb726-4930-4183-9ac9-d833361ac2f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6592b8ea-9497-43c8-bb4f-12b7e66c4257" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressAddressLine2_6592b8ea-9497-43c8-bb4f-12b7e66c4257" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e976b178-17bc-445b-b672-15390023978a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressCityOrTown_e976b178-17bc-445b-b672-15390023978a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_94049422-6143-4221-98d9-1020c74e0eba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressStateOrProvince_94049422-6143-4221-98d9-1020c74e0eba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c8582da4-4b92-478b-93de-5c03342790ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressPostalZipCode_c8582da4-4b92-478b-93de-5c03342790ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4232ea9f-b74c-4282-a896-51f17e0d8cdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_CityAreaCode_4232ea9f-b74c-4282-a896-51f17e0d8cdc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fa23a4d8-112f-47a1-a7d9-ff96e4dd8498" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_LocalPhoneNumber_fa23a4d8-112f-47a1-a7d9-ff96e4dd8498" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b8df7aa9-80dd-4231-8f34-5a44023a5125" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_Security12bTitle_b8df7aa9-80dd-4231-8f34-5a44023a5125" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22e2c3c7-a1e4-42ac-8b3b-8a19a95c6fea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_TradingSymbol_22e2c3c7-a1e4-42ac-8b3b-8a19a95c6fea" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b6145673-fa09-45b1-8df6-7c90f23dcdf6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_SecurityExchangeName_b6145673-fa09-45b1-8df6-7c90f23dcdf6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_eb957d87-9243-42e1-aaf1-56fde2e532c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCurrentReportingStatus_eb957d87-9243-42e1-aaf1-56fde2e532c0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fb015cd2-3c18-4c6b-9ea4-3d91c4d6dbc4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityInteractiveDataCurrent_fb015cd2-3c18-4c6b-9ea4-3d91c4d6dbc4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2d763e3c-3f2e-481e-a3ce-8580c28f031e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityFilerCategory_2d763e3c-3f2e-481e-a3ce-8580c28f031e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_347a9652-c1ca-4085-8553-c67e6be68727" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntitySmallBusiness_347a9652-c1ca-4085-8553-c67e6be68727" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c16bb11-c8f3-4a9f-94c6-c06ad1f9093f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c16bb11-c8f3-4a9f-94c6-c06ad1f9093f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1d7a6c4e-3201-40ee-8780-15274e32cb76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityShellCompany_1d7a6c4e-3201-40ee-8780-15274e32cb76" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b4aa1b21-5cef-4a4d-99f8-b363d5eeaf6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b4aa1b21-5cef-4a4d-99f8-b363d5eeaf6c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b2138f5-8925-4165-87ea-9aaf975897da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCentralIndexKey_5b2138f5-8925-4165-87ea-9aaf975897da" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_506e7deb-624c-4790-b5f9-e0f917d7a3dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_CurrentFiscalYearEndDate_506e7deb-624c-4790-b5f9-e0f917d7a3dd" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3910c637-4ac4-4ba2-a6be-1bf388b4ce22" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentFiscalYearFocus_3910c637-4ac4-4ba2-a6be-1bf388b4ce22" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_55edb27c-19bf-4fd3-a80d-48e0556861f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentFiscalPeriodFocus_55edb27c-19bf-4fd3-a80d-48e0556861f8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2328f708-425a-4007-bdb0-7a7a005a6886" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_AmendmentFlag_2328f708-425a-4007-bdb0-7a7a005a6886" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:to="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c8b90ebd-994a-495c-8571-f2bdfea2b5f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:to="loc_us-gaap_ClassOfStockDomain_c8b90ebd-994a-495c-8571-f2bdfea2b5f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:to="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94e72cb6-5012-41d5-81f9-3a646a57cfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:to="loc_us-gaap_CommonClassAMember_94e72cb6-5012-41d5-81f9-3a646a57cfcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7a040394-aedf-4db7-8a24-a24c6ab3ff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:to="loc_us-gaap_CommonClassBMember_7a040394-aedf-4db7-8a24-a24c6ab3ff1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f606b220-75ec-44af-90ee-992b710cdee9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:to="loc_us-gaap_RelatedPartyDomain_f606b220-75ec-44af-90ee-992b710cdee9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:to="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1b7328e8-6226-4115-958e-98644c957a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:to="loc_us-gaap_RelatedPartyMember_1b7328e8-6226-4115-958e-98644c957a44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_2c1898ff-30e4-4760-b122-b8a820203599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:to="loc_us-gaap_NonrelatedPartyMember_2c1898ff-30e4-4760-b122-b8a820203599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:to="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eb2cbd7-74c0-48bd-a418-4ded9b76c13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eb2cbd7-74c0-48bd-a418-4ded9b76c13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2d216855-de8d-47a5-9545-3998278a2197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2d216855-de8d-47a5-9545-3998278a2197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cd379c1-f48a-410f-a1ec-b96eab871f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cd379c1-f48a-410f-a1ec-b96eab871f3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_a50b7255-f6dc-4862-8114-f4198746e341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_DepositsAssetsCurrent_a50b7255-f6dc-4862-8114-f4198746e341" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf70d2db-c4f4-42b6-9758-ad7312e4cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_AssetsCurrent_bf70d2db-c4f4-42b6-9758-ad7312e4cf6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a4e1a3e8-0dfb-40c2-b241-3c9f39893d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a4e1a3e8-0dfb-40c2-b241-3c9f39893d77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7fd4c5e-6aad-418e-a11e-cdadac9abbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7fd4c5e-6aad-418e-a11e-cdadac9abbd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eb00daa4-5a09-4a0a-893d-16babc84f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_Assets_eb00daa4-5a09-4a0a-893d-16babc84f55a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_553ca042-a726-4e18-a140-7bd84cca770d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_553ca042-a726-4e18-a140-7bd84cca770d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96243af0-fbab-4674-a953-f706f3902b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96243af0-fbab-4674-a953-f706f3902b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212b7996-32e9-4733-aebd-f52f2001f713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212b7996-32e9-4733-aebd-f52f2001f713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_dca4662c-1e16-4c82-af4e-66a8677db2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_NotesPayableCurrent_dca4662c-1e16-4c82-af4e-66a8677db2b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a08e095-27cc-4e50-985e-1712549f44a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a08e095-27cc-4e50-985e-1712549f44a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d4e852eb-5fc4-4a4c-b754-a96954ca6b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d4e852eb-5fc4-4a4c-b754-a96954ca6b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2753e07f-c297-4cf4-b71e-c8e9de85afc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2753e07f-c297-4cf4-b71e-c8e9de85afc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_6e255b54-bd96-4c6c-ac18-d1c573656f9f" xlink:href="vtvt-20240930.xsd#vtvt_WarrantyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_vtvt_WarrantyLiability_6e255b54-bd96-4c6c-ac18-d1c573656f9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ab522da-7729-4b8e-b435-6b836f7a2c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_Liabilities_6ab522da-7729-4b8e-b435-6b836f7a2c02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ca4fbefd-d431-4f8d-af3e-503b0afbdec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ca4fbefd-d431-4f8d-af3e-503b0afbdec1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_598343d4-cbae-4d5d-871a-f5e9216d11e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_598343d4-cbae-4d5d-871a-f5e9216d11e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_81e996ea-8d5d-4185-8159-3c4803bf0149" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_CommonStockValue_81e996ea-8d5d-4185-8159-3c4803bf0149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6454e708-2d58-4a65-b9eb-8b960f6e4752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6454e708-2d58-4a65-b9eb-8b960f6e4752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a0d58db-5fb5-4730-8d1a-f35a518687b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a0d58db-5fb5-4730-8d1a-f35a518687b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_740b0881-8a2d-47fe-ad65-bb5ce9e6fdab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_StockholdersEquity_740b0881-8a2d-47fe-ad65-bb5ce9e6fdab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4a2fcba4-021d-494e-a87a-068465d3a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_MinorityInterest_4a2fcba4-021d-494e-a87a-068465d3a1c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44b0bb64-494f-4569-bd1d-f78d1ecb2e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44b0bb64-494f-4569-bd1d-f78d1ecb2e9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52e75669-20ff-4cae-825d-7b5a87cd37c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_52e75669-20ff-4cae-825d-7b5a87cd37c5" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3056d389-beeb-4409-8e81-fd52bacee3f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:to="loc_us-gaap_ClassOfStockDomain_3056d389-beeb-4409-8e81-fd52bacee3f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:to="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d7b97aca-df88-4946-a1cd-47306eaf39d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:to="loc_us-gaap_CommonClassAMember_d7b97aca-df88-4946-a1cd-47306eaf39d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_859a2476-1dc2-4b07-88c4-9c6b751a7715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:to="loc_us-gaap_CommonClassBMember_859a2476-1dc2-4b07-88c4-9c6b751a7715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b682bd66-0713-4445-a47a-4813ba9d90d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b682bd66-0713-4445-a47a-4813ba9d90d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c91f2266-2c6a-4d98-8666-cdcf480ea750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c91f2266-2c6a-4d98-8666-cdcf480ea750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_65230ad8-0cf6-49c3-8ef8-5e7b46e654a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_65230ad8-0cf6-49c3-8ef8-5e7b46e654a9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd7a5e6d-c227-4663-9bca-2f6713f239f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:to="loc_us-gaap_ClassOfStockDomain_cd7a5e6d-c227-4663-9bca-2f6713f239f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:to="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_972d2937-2065-4cce-b061-4edb738ce31a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:to="loc_us-gaap_CommonClassAMember_972d2937-2065-4cce-b061-4edb738ce31a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:to="loc_us-gaap_RelatedPartyDomain_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:to="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6d73ff08-7cc6-4bbf-8eb0-6adc70f9b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:to="loc_us-gaap_NonrelatedPartyMember_6d73ff08-7cc6-4bbf-8eb0-6adc70f9b01d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_8d3b058b-1384-41a7-a109-80d07d448370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:to="loc_us-gaap_RelatedPartyMember_8d3b058b-1384-41a7-a109-80d07d448370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3cfca679-2496-448b-92ea-e0de46d4d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3cfca679-2496-448b-92ea-e0de46d4d5b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0139a61e-54e5-43ad-915f-9ee1337cb859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0139a61e-54e5-43ad-915f-9ee1337cb859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_34d2c555-8b87-43c1-a87b-5728c979a744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_34d2c555-8b87-43c1-a87b-5728c979a744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3a949f4-4076-4b05-b0ed-dea8155e316e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_OperatingExpenses_d3a949f4-4076-4b05-b0ed-dea8155e316e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f05e0fbd-c2f5-4124-bb27-676260deec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OperatingIncomeLoss_f05e0fbd-c2f5-4124-bb27-676260deec7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6113b1be-ba7d-495e-8847-20eb74e83231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6113b1be-ba7d-495e-8847-20eb74e83231" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0de25fb2-314b-4fa5-8214-e9e8a929f9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0de25fb2-314b-4fa5-8214-e9e8a929f9aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_b5418482-4322-4e3a-ad4a-19972e2b2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_InterestExpenseOperating_b5418482-4322-4e3a-ad4a-19972e2b2e2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb94a149-68cf-4c46-b129-c69de97a8ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb94a149-68cf-4c46-b129-c69de97a8ad9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6ca03dfb-5fc9-4d43-b2f5-81e939cf3c31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6ca03dfb-5fc9-4d43-b2f5-81e939cf3c31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f576a08-d186-471f-9da0-9e4e8f3cfaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_ProfitLoss_7f576a08-d186-471f-9da0-9e4e8f3cfaf4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e62019f-313a-49fc-887b-25c175b6393c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e62019f-313a-49fc-887b-25c175b6393c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f848c465-c947-44eb-8af3-d5f65829b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLoss_f848c465-c947-44eb-8af3-d5f65829b1c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31d18700-cf12-48df-b8a1-fe603abbe663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31d18700-cf12-48df-b8a1-fe603abbe663" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d7799eb-85bc-4bc8-a684-934364d1cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d7799eb-85bc-4bc8-a684-934364d1cfb9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_28bd3503-a49d-4e5f-9b56-21712171d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_EarningsPerShareDiluted_28bd3503-a49d-4e5f-9b56-21712171d6f7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c41e9266-93f8-4f4f-8de6-3effd3f14b89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c41e9266-93f8-4f4f-8de6-3effd3f14b89" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad82695d-86cd-4c9f-9548-4d93684e9953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad82695d-86cd-4c9f-9548-4d93684e9953" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:to="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a53f6c5b-01f4-464e-b141-f4c63c58d7dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:to="loc_us-gaap_EquityComponentDomain_a53f6c5b-01f4-464e-b141-f4c63c58d7dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:to="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_af640849-78b4-4c75-9355-540273e59bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_CommonStockMember_af640849-78b4-4c75-9355-540273e59bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2c7c84ec-d816-4ba9-ac38-be8bb3d7bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2c7c84ec-d816-4ba9-ac38-be8bb3d7bbb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71963bfb-efac-4b0f-a4ed-0922f7492d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_RetainedEarningsMember_71963bfb-efac-4b0f-a4ed-0922f7492d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_8c9b1755-8124-404d-906b-409a0c9fae3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_ParentMember_8c9b1755-8124-404d-906b-409a0c9fae3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e79f509a-b2e2-4df0-a802-d6bfc2938719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e79f509a-b2e2-4df0-a802-d6bfc2938719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e2ae96f-a0e2-4d98-b760-375ac76ebb12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:to="loc_us-gaap_ClassOfStockDomain_0e2ae96f-a0e2-4d98-b760-375ac76ebb12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:to="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_f74ca073-f96b-42cc-8080-0600df1f7e7e" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_f74ca073-f96b-42cc-8080-0600df1f7e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6f3409f4-40e2-42de-a909-713a7874ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_us-gaap_CommonClassAMember_6f3409f4-40e2-42de-a909-713a7874ec90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2b42aae3-1ff5-4efc-a2f3-43885bfddaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_us-gaap_CommonClassBMember_2b42aae3-1ff5-4efc-a2f3-43885bfddaf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c0a767af-5e17-4943-a66b-9ebb105e8621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c0a767af-5e17-4943-a66b-9ebb105e8621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_34a225bf-b35c-4c0a-8dd6-b5174c30b129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_34a225bf-b35c-4c0a-8dd6-b5174c30b129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_932981bd-9ad1-47e2-aaa0-e1bdd43b10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_932981bd-9ad1-47e2-aaa0-e1bdd43b10c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_186bcac7-7def-45e2-bc99-562f1ce55900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_186bcac7-7def-45e2-bc99-562f1ce55900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f7a9ccd5-07ed-4991-be96-3b670870c1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f7a9ccd5-07ed-4991-be96-3b670870c1cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_11bd3f2b-6fe4-466d-ac74-8b369cbf508c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d57c5647-704f-4f3b-840a-f0449746f391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d57c5647-704f-4f3b-840a-f0449746f391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33bd1ede-951b-41cf-925a-5998503abc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33bd1ede-951b-41cf-925a-5998503abc3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c09d8e86-51e2-406b-b35d-24ec4017242f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_NetIncomeLoss_c09d8e86-51e2-406b-b35d-24ec4017242f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_5e32f309-6162-4c9c-b85c-b9170745961e" xlink:href="vtvt-20240930.xsd#vtvt_ChangeInRedemptionValueOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_5e32f309-6162-4c9c-b85c-b9170745961e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e0897120-2c23-4c6b-9f5e-7236a4bbb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f204a203-319b-4dc6-a329-e52ce5ad8d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f204a203-319b-4dc6-a329-e52ce5ad8d1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_47e9e8f8-2a08-4477-95e1-d7bcb9b45acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_47e9e8f8-2a08-4477-95e1-d7bcb9b45acd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad3f0777-9d30-4c62-84b5-40bb702f5612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad3f0777-9d30-4c62-84b5-40bb702f5612" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_8a695cb1-8c2a-47ef-9a2c-b523b324c1f9" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_8a695cb1-8c2a-47ef-9a2c-b523b324c1f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_c3cb818f-bd94-4eea-96e8-8c3987589957" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_c3cb818f-bd94-4eea-96e8-8c3987589957" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_9f7de77f-b0a7-4265-81b1-39f0b243006b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_9f7de77f-b0a7-4265-81b1-39f0b243006b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b465908b-beb9-479f-9b0e-d011c822e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1dd049b-8f13-4a7f-9fae-15e6994bcc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09e7cb74-e533-4398-9456-048cbee7a935_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:to="loc_us-gaap_RelatedPartyDomain_09e7cb74-e533-4398-9456-048cbee7a935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:to="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_de137738-d0ae-40da-a2a6-6de90c293eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:to="loc_us-gaap_RelatedPartyMember_de137738-d0ae-40da-a2a6-6de90c293eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_676f1b82-77df-4d53-8067-989b25365468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:to="loc_us-gaap_NonrelatedPartyMember_676f1b82-77df-4d53-8067-989b25365468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_66c9f6d1-1c7b-4856-bc15-23400d696ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_ProfitLoss_66c9f6d1-1c7b-4856-bc15-23400d696ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c070616d-20c4-4572-8079-c40b982c311a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_Depreciation_c070616d-20c4-4572-8079-c40b982c311a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_71b41928-a2d1-4118-a55d-61d448c169b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_71b41928-a2d1-4118-a55d-61d448c169b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_51abecb9-8aa8-4078-8105-b54cbac21c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_InterestIncomeOperating_51abecb9-8aa8-4078-8105-b54cbac21c30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_70412938-403f-4634-951a-ef564d31c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_ShareBasedCompensation_70412938-403f-4634-951a-ef564d31c8c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e27c516a-7c79-4d78-bcb5-c57221496255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e27c516a-7c79-4d78-bcb5-c57221496255" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_c6bf43a2-0ee7-4963-b9e7-7406dd047ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_c6bf43a2-0ee7-4963-b9e7-7406dd047ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5e6bebfb-ea17-4ec2-890a-f8035f1afafd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5e6bebfb-ea17-4ec2-890a-f8035f1afafd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2321c2db-58c6-44d2-81cc-84da37b60581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2321c2db-58c6-44d2-81cc-84da37b60581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e89d5908-6bd2-4917-b60a-379bb9ae504b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e89d5908-6bd2-4917-b60a-379bb9ae504b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_920dd1f7-d1f9-4d27-8da0-2d7b1c4b123e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_920dd1f7-d1f9-4d27-8da0-2d7b1c4b123e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24f6ec38-fa6f-4df6-8f04-37d6161d3650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24f6ec38-fa6f-4df6-8f04-37d6161d3650" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1aa6b04c-ee96-4cd3-b1a7-a5a93e86fbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1aa6b04c-ee96-4cd3-b1a7-a5a93e86fbf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1767ece7-7299-472c-92af-79464e1af84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1767ece7-7299-472c-92af-79464e1af84f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5c9bb5f6-bdd9-437b-9428-bcc33be6212c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5c9bb5f6-bdd9-437b-9428-bcc33be6212c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e293318c-a2e4-49c6-8443-ee8a0f2dd5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e293318c-a2e4-49c6-8443-ee8a0f2dd5da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock_5646b234-5cf8-45ae-89de-d703607c0b1f" xlink:href="vtvt-20240930.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_vtvt_ProceedsFromSaleOfCommonStock_5646b234-5cf8-45ae-89de-d703607c0b1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_d21bcf49-ed84-4e31-8699-b11817515156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_d21bcf49-ed84-4e31-8699-b11817515156" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_22cb11c2-0208-4ae5-a126-5a41a309b65f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_22cb11c2-0208-4ae5-a126-5a41a309b65f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e1b54d7-69cf-481d-a357-bb9baa4e2b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e1b54d7-69cf-481d-a357-bb9baa4e2b42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2670e51c-a7e9-4c46-9131-409eec7c618c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2670e51c-a7e9-4c46-9131-409eec7c618c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_032892a8-9af6-47f3-884a-75ca0f9c2ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_032892a8-9af6-47f3-884a-75ca0f9c2ff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b994879f-351f-4728-8c5f-760ca4ae369c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_4824a890-3e7e-4e93-93b5-86e74f866651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_4824a890-3e7e-4e93-93b5-86e74f866651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_ec8486bf-318f-4946-928c-57d3f042638e" xlink:href="vtvt-20240930.xsd#vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:to="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_ec8486bf-318f-4946-928c-57d3f042638e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#DescriptionofBusinessandBasisofPresentationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f824eae-c0dc-4094-ad87-94f5695faa6d_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:to="loc_dei_EntityDomain_2f824eae-c0dc-4094-ad87-94f5695faa6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:to="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_d994c141-3d64-4d76-90d2-4ba1f8e3ddde" xlink:href="vtvt-20240930.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:to="loc_vtvt_VTvLLCMember_d994c141-3d64-4d76-90d2-4ba1f8e3ddde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_015ea579-f4c9-48ae-9792-d46511f5718b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:to="loc_us-gaap_ClassOfStockDomain_015ea579-f4c9-48ae-9792-d46511f5718b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:to="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c73fcc66-a467-4690-aaf9-f2514a2ab089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:to="loc_us-gaap_CommonClassAMember_c73fcc66-a467-4690-aaf9-f2514a2ab089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b758b629-3ca8-47ce-949e-5da00695c24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:to="loc_us-gaap_CommonClassBMember_b758b629-3ca8-47ce-949e-5da00695c24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ff573876-ad58-442c-9950-f3da54cc01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:to="loc_us-gaap_PrivatePlacementMember_ff573876-ad58-442c-9950-f3da54cc01d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_9bb949a7-46af-4af4-8fef-06531f319439" xlink:href="vtvt-20240930.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_9bb949a7-46af-4af4-8fef-06531f319439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_793cc732-b816-404e-8885-2ced944ed588_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_793cc732-b816-404e-8885-2ced944ed588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_63ff8560-09eb-4c18-b3a4-26c0cfb2f0ec" xlink:href="vtvt-20240930.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_63ff8560-09eb-4c18-b3a4-26c0cfb2f0ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a45debe7-fc1a-4237-a76c-7151284e54bf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a45debe7-fc1a-4237-a76c-7151284e54bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_c9323157-e0e6-4259-a983-aa4c1d376bc0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:to="loc_srt_ParentCompanyMember_c9323157-e0e6-4259-a983-aa4c1d376bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5583f5b-a50a-4c15-8a2d-f235f13c4e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5583f5b-a50a-4c15-8a2d-f235f13c4e27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_c44ca471-4107-4d50-82e1-ffab128399c4" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_c44ca471-4107-4d50-82e1-ffab128399c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_4e6ee2c5-65e9-4518-a63d-cd5de3dc84b2" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_4e6ee2c5-65e9-4518-a63d-cd5de3dc84b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9fe1a0-b5d3-4f01-bb4a-458137857f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9fe1a0-b5d3-4f01-bb4a-458137857f5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_951e1e9e-1e3d-4201-aff8-dfdb28a0c592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_951e1e9e-1e3d-4201-aff8-dfdb28a0c592" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_481f3505-8ddf-4957-bcb6-d0d709829e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_481f3505-8ddf-4957-bcb6-d0d709829e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ff1d5352-74ab-45bb-81b9-9eab450d9714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ff1d5352-74ab-45bb-81b9-9eab450d9714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46de5da6-c7df-4841-8dc1-3b6e8870cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46de5da6-c7df-4841-8dc1-3b6e8870cb26" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9d7ade1-3a99-4058-bfcc-6a694b5155ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9d7ade1-3a99-4058-bfcc-6a694b5155ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b9ff8689-e995-4217-962c-16ca64665a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b9ff8689-e995-4217-962c-16ca64665a02" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_6297130b-8e15-4a57-9a1b-8c5ff299a675" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_6297130b-8e15-4a57-9a1b-8c5ff299a675" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_d0509aea-253c-47ef-aa87-492c493fc4cc" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_d0509aea-253c-47ef-aa87-492c493fc4cc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_6240db79-d85c-44e7-a467-f847e9bfbb70" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_6240db79-d85c-44e7-a467-f847e9bfbb70" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_7986ed38-c7c7-49a3-9fb7-d2809f4319a6" xlink:href="vtvt-20240930.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_EntityPublicFloatThreshold_7986ed38-c7c7-49a3-9fb7-d2809f4319a6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_74efb197-79f8-4fe8-bb52-bcc8b8b6b01b" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_74efb197-79f8-4fe8-bb52-bcc8b8b6b01b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_480a4b80-cd9e-4270-bb18-f8caa6330d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_480a4b80-cd9e-4270-bb18-f8caa6330d02" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0faeab4d-492b-40ae-8739-25c5e1f09d10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0faeab4d-492b-40ae-8739-25c5e1f09d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8090058c-49be-44de-9b75-1f2dde0c53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:to="loc_us-gaap_SalesRevenueNetMember_8090058c-49be-44de-9b75-1f2dde0c53d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b43f208c-3af0-417c-bb0d-347dabcb9e6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b43f208c-3af0-417c-bb0d-347dabcb9e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_cb0eb02c-6496-4a02-987a-0f9b771e8015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_cb0eb02c-6496-4a02-987a-0f9b771e8015" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e82930d5-d3f5-429c-adce-e1819545483e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:to="loc_srt_NameOfMajorCustomerDomain_e82930d5-d3f5-429c-adce-e1819545483e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_c4d6c005-610e-4f6d-b313-b3485a300363" xlink:href="vtvt-20240930.xsd#vtvt_OneCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:to="loc_vtvt_OneCustomerMember_c4d6c005-610e-4f6d-b313-b3485a300363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_02a86e97-937d-4783-8206-7f6d861e464a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_02a86e97-937d-4783-8206-7f6d861e464a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9b632a7-2252-42e0-9ac9-0e3de6273bc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9b632a7-2252-42e0-9ac9-0e3de6273bc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_7826182f-d6c3-44c9-af14-d41e2b18d453" xlink:href="vtvt-20240930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_7826182f-d6c3-44c9-af14-d41e2b18d453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c3c858e4-f974-44d8-b87a-7c39db63907f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c3c858e4-f974-44d8-b87a-7c39db63907f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f4eda4e2-0432-49fc-88d0-3be589641784_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:to="loc_dei_EntityDomain_f4eda4e2-0432-49fc-88d0-3be589641784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:to="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_bc970f31-c669-4307-ac5b-e4c75ebdbb0c" xlink:href="vtvt-20240930.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_bc970f31-c669-4307-ac5b-e4c75ebdbb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_3c123664-b29f-4e8b-883f-238d0028eeef" xlink:href="vtvt-20240930.xsd#vtvt_JDRFInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:to="loc_vtvt_JDRFInternationalMember_3c123664-b29f-4e8b-883f-238d0028eeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9a36102-6c53-406b-bd61-9ab2e318c0eb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9a36102-6c53-406b-bd61-9ab2e318c0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_ec563416-77ec-46aa-9922-d805849bed89" xlink:href="vtvt-20240930.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_G42InvestmentsMember_ec563416-77ec-46aa-9922-d805849bed89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_2db2bdc3-55d0-4913-b620-7276984d46e8" xlink:href="vtvt-20240930.xsd#vtvt_CognaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_CognaMember_2db2bdc3-55d0-4913-b620-7276984d46e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_516cf36f-617c-4505-ae8c-062b4bab0241" xlink:href="vtvt-20240930.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_516cf36f-617c-4505-ae8c-062b4bab0241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_151e7457-86b9-4fef-871f-d6a99a1703df_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:to="loc_srt_ProductsAndServicesDomain_151e7457-86b9-4fef-871f-d6a99a1703df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:to="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember_31af2a83-5fc4-403c-aede-44c780252ba1" xlink:href="vtvt-20240930.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesMember_31af2a83-5fc4-403c-aede-44c780252ba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_981a8b07-cd35-415b-a90a-bc68dd78b0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_981a8b07-cd35-415b-a90a-bc68dd78b0c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4de25c2c-c443-43fb-b31c-130abbecc219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4de25c2c-c443-43fb-b31c-130abbecc219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_d5f86eda-1a5b-448c-9085-f4eb4096da31" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_d5f86eda-1a5b-448c-9085-f4eb4096da31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd151a6-f7c4-4476-936e-4a17b041e6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd151a6-f7c4-4476-936e-4a17b041e6c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_5fded3e3-ae3f-4eac-afdf-8306f7e4d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_5fded3e3-ae3f-4eac-afdf-8306f7e4d21f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_a4cf56ef-1768-44a8-82da-b26b0e5c3684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_a4cf56ef-1768-44a8-82da-b26b0e5c3684" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_6b6f82ac-d933-4396-8245-dccce27db933" xlink:href="vtvt-20240930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_NotesReceivableDiscountRate_6b6f82ac-d933-4396-8245-dccce27db933" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48e86c89-9d77-4a5d-ac96-32e78af371ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48e86c89-9d77-4a5d-ac96-32e78af371ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_2abf75a1-ed98-47fe-8257-33213d74a90c" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_2abf75a1-ed98-47fe-8257-33213d74a90c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_d8d38bfc-f0c7-4e11-9d62-60f39ea7bbd7" xlink:href="vtvt-20240930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_d8d38bfc-f0c7-4e11-9d62-60f39ea7bbd7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_5a4e2dff-a664-473d-a308-90659764080d" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_5a4e2dff-a664-473d-a308-90659764080d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_45a122da-04cd-42e3-8930-594b6232a77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_45a122da-04cd-42e3-8930-594b6232a77e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_c5880543-421c-4673-88ca-b2665cef69a3" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_c5880543-421c-4673-88ca-b2665cef69a3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_face3c03-0d59-44d0-8cf5-f449dfbabbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_face3c03-0d59-44d0-8cf5-f449dfbabbee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c14feb1-e6c4-4d6b-b934-889272bd50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c14feb1-e6c4-4d6b-b934-889272bd50b8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_549ed7af-3cfc-4973-a616-c7de0fdf3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_549ed7af-3cfc-4973-a616-c7de0fdf3bf7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_a4e4628d-09b9-4fc2-adfb-c90f61adb714" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeeReceived_a4e4628d-09b9-4fc2-adfb-c90f61adb714" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceivedTerm_9496cef6-f7f2-40e5-a607-27e152b97a0b" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceivedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeeReceivedTerm_9496cef6-f7f2-40e5-a607-27e152b97a0b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_739a740c-133e-4d89-95a2-fb3504708e99" xlink:href="vtvt-20240930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_739a740c-133e-4d89-95a2-fb3504708e99" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeePriceIncrease_1e9ea840-955e-49fb-a98c-e5bc23443d3f" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeePriceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeePriceIncrease_1e9ea840-955e-49fb-a98c-e5bc23443d3f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_d1be3593-ce00-4538-8bae-5d6a775abaea" xlink:href="vtvt-20240930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_d1be3593-ce00-4538-8bae-5d6a775abaea" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_02e853bc-3c91-4e37-b45a-10214909c669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_02e853bc-3c91-4e37-b45a-10214909c669" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1cbf9b01-c0e4-49ba-adb4-d54ff7c0a216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1cbf9b01-c0e4-49ba-adb4-d54ff7c0a216" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:to="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d63eb9db-3ec8-445c-b5a7-b8ea98f5fbce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d63eb9db-3ec8-445c-b5a7-b8ea98f5fbce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6283adf-7a8e-4857-9d67-06e61b42564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6283adf-7a8e-4857-9d67-06e61b42564d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_301f85b0-4db6-43cb-9860-a956a0270b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_301f85b0-4db6-43cb-9860-a956a0270b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f2ac3f8-a47a-488e-9c71-de510e718360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f2ac3f8-a47a-488e-9c71-de510e718360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00eb0d0f-4f36-41ed-a35b-00fefeea031c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00eb0d0f-4f36-41ed-a35b-00fefeea031c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_346cb992-c0b0-4cb3-87d0-8870f49146fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_346cb992-c0b0-4cb3-87d0-8870f49146fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_d151bc74-14bb-4bec-a72d-f2372740d8eb" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_d151bc74-14bb-4bec-a72d-f2372740d8eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a6661b9e-19ce-49d8-8f6f-8dc2c4e4ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a6661b9e-19ce-49d8-8f6f-8dc2c4e4ec7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_9d969e89-48f4-4dba-aaec-b47e264ab602" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedPaymentArrangementExpenseReductionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_9d969e89-48f4-4dba-aaec-b47e264ab602" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eeb21797-808b-4abd-b495-13e42151e5c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eeb21797-808b-4abd-b495-13e42151e5c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1a2d12f8-a6d9-4574-892a-4b3266ae5fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1a2d12f8-a6d9-4574-892a-4b3266ae5fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd3a1f21-93ad-4fa5-a15b-49264ab681db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd3a1f21-93ad-4fa5-a15b-49264ab681db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8d38a309-4f4c-4a9a-9fdc-01fc474576fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8d38a309-4f4c-4a9a-9fdc-01fc474576fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3c0957f8-05bb-4fbe-bec6-816cead1ae21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3c0957f8-05bb-4fbe-bec6-816cead1ae21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:to="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_2c0f4ad3-4a1f-43cf-a8ac-716d598790e1" xlink:href="vtvt-20240930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_2c0f4ad3-4a1f-43cf-a8ac-716d598790e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_aebed7b5-beb5-4e23-ba1d-f8e3feb76c11" xlink:href="vtvt-20240930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_aebed7b5-beb5-4e23-ba1d-f8e3feb76c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_6cc73ac4-02d7-452c-9d54-7214400714c8" xlink:href="vtvt-20240930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:to="loc_vtvt_NovoLicenseAgreementMember_6cc73ac4-02d7-452c-9d54-7214400714c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f98432a1-c562-46da-bfe4-49426cdbfe97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f98432a1-c562-46da-bfe4-49426cdbfe97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_718b2e1f-1fcc-4433-869d-3832c7c1a5c5" xlink:href="vtvt-20240930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_TypeOneDiabetesMember_718b2e1f-1fcc-4433-869d-3832c7c1a5c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_af8af080-0c6e-4052-8dad-d18b82717ba1" xlink:href="vtvt-20240930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_TypeTwoDiabetesMember_af8af080-0c6e-4052-8dad-d18b82717ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_686688ab-6c56-4eaa-bc38-e68e20f1eaa1" xlink:href="vtvt-20240930.xsd#vtvt_OtherIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_OtherIndicationMember_686688ab-6c56-4eaa-bc38-e68e20f1eaa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccdb38a1-8b56-48d4-997f-e12ab2105305_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:to="loc_srt_RangeMember_ccdb38a1-8b56-48d4-997f-e12ab2105305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:to="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769e1d56-f256-4219-b520-ca92d3ad492f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:to="loc_srt_MaximumMember_769e1d56-f256-4219-b520-ca92d3ad492f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_3d4b6060-ad7c-43df-8969-9eb45dc918c0" xlink:href="vtvt-20240930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:to="loc_vtvt_PotentialMilestonePayment_3d4b6060-ad7c-43df-8969-9eb45dc918c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterestAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:to="loc_dei_EntityDomain_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:to="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_2effc8ac-089c-4e6c-8894-f8091a025042" xlink:href="vtvt-20240930.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:to="loc_vtvt_VTvLLCMember_2effc8ac-089c-4e6c-8894-f8091a025042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_881e52f3-06d9-46ea-b783-bff3bff7f463_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:to="loc_us-gaap_ClassOfStockDomain_881e52f3-06d9-46ea-b783-bff3bff7f463_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:to="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1402440b-9cc4-4dfd-882f-5a2fc80f9d22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:to="loc_us-gaap_CommonClassAMember_1402440b-9cc4-4dfd-882f-5a2fc80f9d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_3fc4b4a5-2e12-4a15-b84e-6174df839152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_3fc4b4a5-2e12-4a15-b84e-6174df839152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_1319c3df-427c-479e-940d-98bc3d91dd60" xlink:href="vtvt-20240930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_1319c3df-427c-479e-940d-98bc3d91dd60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_fbfb75e4-488b-4466-b401-491c221248ff" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_fbfb75e4-488b-4466-b401-491c221248ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_599963ac-aaab-4df5-ba95-edfd88408879" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_599963ac-aaab-4df5-ba95-edfd88408879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_f4f7cf62-5424-4e09-995c-2b16e3c81d16" xlink:href="vtvt-20240930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_f4f7cf62-5424-4e09-995c-2b16e3c81d16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_b915f6c2-a734-4de5-8ae5-003fe0107efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_b915f6c2-a734-4de5-8ae5-003fe0107efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_cd1cc06d-0736-47c4-8ef7-7a49ef50436c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_cd1cc06d-0736-47c4-8ef7-7a49ef50436c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#StockholdersEquityDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc44ceac-17eb-432e-b788-c3396eacd1da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:to="loc_us-gaap_ClassOfStockDomain_fc44ceac-17eb-432e-b788-c3396eacd1da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:to="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f49f8a80-8a31-4090-ae14-f5db40d469ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonClassAMember_f49f8a80-8a31-4090-ae14-f5db40d469ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_496003be-fb80-42f5-a882-27b7efb1703e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonClassBMember_496003be-fb80-42f5-a882-27b7efb1703e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7dda25c8-7483-4edd-8003-2a62ce329665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonStockMember_7dda25c8-7483-4edd-8003-2a62ce329665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2daab25-01a8-4d58-907a-308782f6ebd2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f2daab25-01a8-4d58-907a-308782f6ebd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_444da226-9c3e-4684-90a8-ec770c7bd418" xlink:href="vtvt-20240930.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:to="loc_vtvt_G42InvestmentsMember_444da226-9c3e-4684-90a8-ec770c7bd418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember_8b074f83-d85c-45c2-9ba6-02d3f8c20347" xlink:href="vtvt-20240930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:to="loc_vtvt_CinRxInvestmentMember_8b074f83-d85c-45c2-9ba6-02d3f8c20347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06407980-ca03-4603-8b5c-95220ba0a3bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06407980-ca03-4603-8b5c-95220ba0a3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_973385f1-8a9d-48ce-a0a3-193c304b6f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:to="loc_us-gaap_PrivatePlacementMember_973385f1-8a9d-48ce-a0a3-193c304b6f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_c4114e20-bc49-4c53-9d36-5d52fa7b1031" xlink:href="vtvt-20240930.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_c4114e20-bc49-4c53-9d36-5d52fa7b1031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f2c77af8-3e14-47ea-9ad2-c0746a8904e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f2c77af8-3e14-47ea-9ad2-c0746a8904e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_c3a41bbe-3c77-467d-98eb-ca2e7efbd051" xlink:href="vtvt-20240930.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_c3a41bbe-3c77-467d-98eb-ca2e7efbd051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_fdf5d857-8c02-464c-9ee1-eaeb9afe936f" xlink:href="vtvt-20240930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_fdf5d857-8c02-464c-9ee1-eaeb9afe936f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b2bc82b-980b-4112-9882-be308b3eb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b2bc82b-980b-4112-9882-be308b3eb7a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_da7d9f4d-4fed-483d-9e9c-99b1434221e6" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_da7d9f4d-4fed-483d-9e9c-99b1434221e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a0cff298-de65-4199-a404-86331bfe3ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a0cff298-de65-4199-a404-86331bfe3ee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f3d9806-adbf-4e2e-9000-0181aed7d17e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f3d9806-adbf-4e2e-9000-0181aed7d17e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6879cdd4-24fb-4fc4-a692-dcd4bf7ea104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6879cdd4-24fb-4fc4-a692-dcd4bf7ea104" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0520eda1-7c3c-434b-8167-d82a9d89e468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0520eda1-7c3c-434b-8167-d82a9d89e468" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f32310e7-1b63-4e27-b11f-d871ea33ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f32310e7-1b63-4e27-b11f-d871ea33ce98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_667119de-a0e1-481f-874f-a18f6937aaba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_667119de-a0e1-481f-874f-a18f6937aaba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2525a2ba-341d-440e-99f1-59092af1990b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2525a2ba-341d-440e-99f1-59092af1990b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71e72033-ab4d-45ec-b7b8-cafe971e9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71e72033-ab4d-45ec-b7b8-cafe971e9ec1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_cd3f86f4-1200-45aa-ac3d-8509b0019dee" xlink:href="vtvt-20240930.xsd#vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_cd3f86f4-1200-45aa-ac3d-8509b0019dee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_7d339b89-4d07-4fad-bfc7-8fb0d180619e" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_7d339b89-4d07-4fad-bfc7-8fb0d180619e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_904a576b-b69a-4aee-ba09-5081c9bfa98d" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_904a576b-b69a-4aee-ba09-5081c9bfa98d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_fc9a51ad-1675-47f0-9146-d33add291e11" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_fc9a51ad-1675-47f0-9146-d33add291e11" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05857d33-d176-4167-9167-a4d371fe822d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05857d33-d176-4167-9167-a4d371fe822d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2d8a11e3-06db-49fd-8581-c03e1ab2734f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2d8a11e3-06db-49fd-8581-c03e1ab2734f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm_452118b3-a744-4cde-ae94-a136f507a897" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivableTerm_452118b3-a744-4cde-ae94-a136f507a897" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c5531346-aee5-4d21-bb7e-f3264e2196d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c5531346-aee5-4d21-bb7e-f3264e2196d1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_6e1125f9-0fe0-46e6-9e79-a6f92a9f5890" xlink:href="vtvt-20240930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_NotesReceivableDiscountRate_6e1125f9-0fe0-46e6-9e79-a6f92a9f5890" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0414878-d56e-4369-b8b7-1b496373188b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0414878-d56e-4369-b8b7-1b496373188b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_48bad798-80ce-42e9-b0bc-f6e965fab622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_48bad798-80ce-42e9-b0bc-f6e965fab622" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6d1d809d-eb77-4829-ac20-2214b8298d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6d1d809d-eb77-4829-ac20-2214b8298d76" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_ce82059c-3aaf-4a65-bbce-61f456492f12" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_ce82059c-3aaf-4a65-bbce-61f456492f12" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_7b53d340-bdc0-4d82-b1b1-a855a0eafaef" xlink:href="vtvt-20240930.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_EntityPublicFloatThreshold_7b53d340-bdc0-4d82-b1b1-a855a0eafaef" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_bc2532ea-7bcf-4fbc-9fd7-b8e54932c0f4" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_bc2532ea-7bcf-4fbc-9fd7-b8e54932c0f4" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2d2af6f-fd42-457c-93e1-72f96c83f16f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:to="loc_us-gaap_RelatedPartyDomain_e2d2af6f-fd42-457c-93e1-72f96c83f16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:to="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_58d033a5-0857-4d1a-9ded-a272f83a92e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:to="loc_us-gaap_RelatedPartyMember_58d033a5-0857-4d1a-9ded-a272f83a92e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34d70d26-cb9f-494c-897a-87eb1fa86a0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:to="loc_us-gaap_ClassOfStockDomain_34d70d26-cb9f-494c-897a-87eb1fa86a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:to="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ee10d435-ed57-4c1b-8c67-a3ad2f13af08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:to="loc_us-gaap_CommonClassBMember_ee10d435-ed57-4c1b-8c67-a3ad2f13af08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3929dca8-0130-4e00-9661-cea730853812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:to="loc_us-gaap_CommonClassAMember_3929dca8-0130-4e00-9661-cea730853812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_130b84bc-8fa6-46e2-ab3a-32b3f2309410" xlink:href="vtvt-20240930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_130b84bc-8fa6-46e2-ab3a-32b3f2309410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_f6b237fa-c429-4caa-9419-3e06be34a972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_f6b237fa-c429-4caa-9419-3e06be34a972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_3fdc7a2b-84a7-46ee-91b9-88ea29c3fd5a" xlink:href="vtvt-20240930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_3fdc7a2b-84a7-46ee-91b9-88ea29c3fd5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_6d43d21b-acfd-41d6-98eb-b4d7dd47e2b0" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_6d43d21b-acfd-41d6-98eb-b4d7dd47e2b0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:to="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:to="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1bd265a1-1937-44fd-900e-338bb5701a0e_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:to="loc_dei_EntityDomain_1bd265a1-1937-44fd-900e-338bb5701a0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:to="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_311c5c0c-4da3-4875-8b7f-7267d4935b5f" xlink:href="vtvt-20240930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_311c5c0c-4da3-4875-8b7f-7267d4935b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_64cb078c-3d09-4c17-8247-4f4197649b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_64cb078c-3d09-4c17-8247-4f4197649b6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_a4e9e265-0262-40f0-b771-57012332301d" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_a4e9e265-0262-40f0-b771-57012332301d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aaf8f678-9eb0-4341-ab04-8e67a0dab23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:to="loc_us-gaap_ClassOfStockDomain_aaf8f678-9eb0-4341-ab04-8e67a0dab23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:to="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_116b4189-912a-46a6-aa28-898b3e699bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:to="loc_us-gaap_CommonClassAMember_116b4189-912a-46a6-aa28-898b3e699bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:to="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27fe7c6f-2b62-4f76-b674-f200d4f20e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_ProfitLoss_27fe7c6f-2b62-4f76-b674-f200d4f20e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_79b703b6-4bc5-42c0-a78b-2409ea8bc4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_79b703b6-4bc5-42c0-a78b-2409ea8bc4c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9d01923c-e9ec-4c15-b123-4d5159e9afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9d01923c-e9ec-4c15-b123-4d5159e9afdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b9cb0a44-37b1-4ccc-8652-7ddcba6a068a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b9cb0a44-37b1-4ccc-8652-7ddcba6a068a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7d1e0ee-2a9a-4575-b68e-dfd5f9aa062d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7d1e0ee-2a9a-4575-b68e-dfd5f9aa062d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6365e826-69dc-4435-a36e-3c8a1ee67fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6365e826-69dc-4435-a36e-3c8a1ee67fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_866c38e6-3510-438b-95b3-8daeec347cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_EarningsPerShareBasic_866c38e6-3510-438b-95b3-8daeec347cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d5852d60-ddb2-4c80-983d-0f0009a9e8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d5852d60-ddb2-4c80-983d-0f0009a9e8f2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fb7fcb3-1f5b-4246-9dc9-01750829fd39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0fb7fcb3-1f5b-4246-9dc9-01750829fd39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1bbc1c15-b833-4575-ae7d-add013fe31b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_CommonClassBMember_1bbc1c15-b833-4575-ae7d-add013fe31b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96ff3d4d-1f87-4173-9880-c54f977b28cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96ff3d4d-1f87-4173-9880-c54f977b28cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_669f5eb0-7608-4664-8c29-e03e69814895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_WarrantMember_669f5eb0-7608-4664-8c29-e03e69814895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d7acbad-66a5-4fa0-9bfc-c005e71d54f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d7acbad-66a5-4fa0-9bfc-c005e71d54f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a3dc126d-e0de-475c-af09-6e1bb35f8c4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a3dc126d-e0de-475c-af09-6e1bb35f8c4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5d2cc558-3fd7-40bf-9c76-57f189d78cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5d2cc558-3fd7-40bf-9c76-57f189d78cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_694e3dda-084a-43ae-b928-4c04f7757d93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_694e3dda-084a-43ae-b928-4c04f7757d93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4c502b4-e280-4ad4-b8b6-465b9cd2b26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4c502b4-e280-4ad4-b8b6-465b9cd2b26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f45b0b3-def4-4270-9fa4-e7fbf3c1bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f45b0b3-def4-4270-9fa4-e7fbf3c1bfa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e04efe4e-01d7-4c19-aa94-05a79357b8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e04efe4e-01d7-4c19-aa94-05a79357b8b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_284ee2d1-fb40-4ee8-9631-e8f41f669a62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_284ee2d1-fb40-4ee8-9631-e8f41f669a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0960d1ec-16c8-4aa2-9fac-3d256857edc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:to="loc_us-gaap_WarrantMember_0960d1ec-16c8-4aa2-9fac-3d256857edc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4631af8c-7021-4dc9-a57b-e872139807a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:to="loc_us-gaap_RelatedPartyDomain_4631af8c-7021-4dc9-a57b-e872139807a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:to="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_85cc2cfd-9c84-4264-8002-c44e51338f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:to="loc_us-gaap_RelatedPartyMember_85cc2cfd-9c84-4264-8002-c44e51338f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3ffe7801-acee-4076-b38a-1ee019e304d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:to="loc_us-gaap_NonrelatedPartyMember_3ffe7801-acee-4076-b38a-1ee019e304d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_22952bbc-1b32-49e7-9c90-bcdaa98b95fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_22952bbc-1b32-49e7-9c90-bcdaa98b95fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_334620b0-9ae8-40dc-aec2-4fc04256f125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_334620b0-9ae8-40dc-aec2-4fc04256f125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_da08ec88-d4f2-4dda-bdff-9a4eab77ef63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_da08ec88-d4f2-4dda-bdff-9a4eab77ef63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_50e0c97f-2f8a-4ddd-b767-0047d635eb16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_50e0c97f-2f8a-4ddd-b767-0047d635eb16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_6d0aa11c-e68a-4128-adae-25fdf0fb5cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_6d0aa11c-e68a-4128-adae-25fdf0fb5cb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_3c1580e2-0042-448e-9229-d133e9185fde" xlink:href="vtvt-20240930.xsd#vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_3c1580e2-0042-448e-9229-d133e9185fde" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79b62439-523d-42ff-a25f-e3a3d2b542c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbd38283-3496-48f1-9e8d-272b3146db9c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:to="loc_srt_RangeMember_fbd38283-3496-48f1-9e8d-272b3146db9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:to="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6bea950-41e6-418d-b73a-92fefb6fc0dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_MinimumMember_e6bea950-41e6-418d-b73a-92fefb6fc0dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4298958c-038b-40c8-b735-bf7904b12806" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_MaximumMember_4298958c-038b-40c8-b735-bf7904b12806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_6f8a1b74-ed34-4a1c-afc4-60982ba68630" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_WeightedAverageMember_6f8a1b74-ed34-4a1c-afc4-60982ba68630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b6cde24b-2571-452d-88d0-0b3037b35237_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b6cde24b-2571-452d-88d0-0b3037b35237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_571fe2ea-f975-447d-9470-ae2698cfa553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_571fe2ea-f975-447d-9470-ae2698cfa553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_58e72cc6-b355-4332-ab3b-61ca3c142d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_58e72cc6-b355-4332-ab3b-61ca3c142d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_af5ff3c4-7289-4a83-b9d2-bb78bb71641a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_af5ff3c4-7289-4a83-b9d2-bb78bb71641a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c14aec6b-cc0c-466a-ab64-1303c37a0fed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c14aec6b-cc0c-466a-ab64-1303c37a0fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_eb0e71bb-cca3-499e-8f98-ffb10d9e970d" xlink:href="vtvt-20240930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_eb0e71bb-cca3-499e-8f98-ffb10d9e970d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember_c9d5043e-6b16-4610-af50-715f3db6cff7" xlink:href="vtvt-20240930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:to="loc_vtvt_CinRxWarrantsMember_c9d5043e-6b16-4610-af50-715f3db6cff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_623c8022-e2b2-48d8-aef3-6a3376153738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_623c8022-e2b2-48d8-aef3-6a3376153738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f87ab4b1-0a3e-478a-ae99-b9be865f21a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f87ab4b1-0a3e-478a-ae99-b9be865f21a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vtvt-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_9ba7a248-b144-407a-9d10-13a74bdf4337_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of redeemable noncontrolling interest to permanent equity</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_5cb52ffe-e474-4ba4-bcb9-939d92c1b538_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of redeemable noncontrolling interest to permanent equity</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_8d7934d0-99e1-4604-836e-dae840a9e9a0_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_label_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_documentation_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable non controlling interest exchange agreement stock conversion ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:to="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VTvLLCMember_49c40876-ed05-4f65-b457-156b92ba052f_terseLabel_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">vTv Therapeutics LLC</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_label_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">V Tv L L C [Member]</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_documentation_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">vTv LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember" xlink:href="vtvt-20240930.xsd#vtvt_VTvLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VTvLLCMember" xlink:to="lab_vtvt_VTvLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f5fc2da3-248b-4ba9-83a0-d1162daf66ac_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f90f24ba-f75f-4bd1-85cc-5fadbf7d72c8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_20fd7874-012f-49d1-8348-ffc8893c510b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b4983b78-32c2-4ee1-8e2e-220680e1cf82_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ea503f7-6c61-4537-b611-ac4b29061d26_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_ee6c9934-8a9e-4307-a6db-da096e6e1749_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_391dd967-3a6b-43d8-9b8c-995710f2293c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Lease Liabilities for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_07ec06ad-bbc8-458c-99cc-6e7c9c73b654_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collection of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c79a08e9-96ed-416f-97aa-ad3de4109caf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b90d8c51-6585-4496-bf55-651593f8c9c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df9d2e1e-c140-4858-b5f7-1c2a516bde79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-qualified stock option awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_887ab2cd-efdc-4e82-8d03-22a8ae4d7549_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, contingent consideration</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:to="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_a289ad42-13af-4b1a-839c-97000bb54794_terseLabel_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_label_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_documentation_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:href="vtvt-20240930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:to="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_27ea10f7-7bb3-4d7b-b102-952e671b9e2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_ce4b7d06-82ad-492b-8174-4ac5f876aa91_terseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_label_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Discount Rate</link:label>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_documentation_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Receivable, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate" xlink:href="vtvt-20240930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NotesReceivableDiscountRate" xlink:to="lab_vtvt_NotesReceivableDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_78b5ed3e-b773-4ba0-be66-3aead6843e6c_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f13458ce-4450-42fd-acbc-e7565271d817_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_82f9625d-4161-46ec-acb7-38507830bc99_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7dc0a16e-d937-48d1-9596-1e73f8b43b2a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_d6b88324-d21b-487b-b4c5-3c2597732465_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:to="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ee03d1ec-a6cf-4fc4-b5fb-22e02ac659c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_0859abea-5c1e-4fde-ab86-b603890cb18a_terseLabel_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MacAndrews &amp; Forbes Incorporated</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_label_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mac Andrews And Forbes Incorporated [Member]</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_documentation_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MacAndrews and Forbes Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:href="vtvt-20240930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:to="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_3cb0e8d8-7de4-4bb7-a405-af2fda3a6fc7_terseLabel_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type 2 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type Two Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type 2 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember" xlink:href="vtvt-20240930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeTwoDiabetesMember" xlink:to="lab_vtvt_TypeTwoDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3b63cd2c-9fef-4f5f-8663-a230f30c73c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_07615f3c-b698-48e3-993a-48af88c213cd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ae4435ee-2cae-4081-9e89-d9ed89f816e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3277b906-9e71-49f8-9ea9-23ad7d157219_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d89bffd7-bfff-47ce-9fd3-d4a4204c6803_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_6f363bad-c330-4e03-b6a9-b14511b3300f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_8cfbe69c-59ac-4343-bccc-55bb22f76d24_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, termination period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:href="vtvt-20240930.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_def34ead-e1e3-4796-be58-3df7fd58a773_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_dc21bca2-47cc-42ee-8ed5-a76286f25b5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_cafc5513-56d3-4465-ad0c-22434d58b7d6_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_96737024-964b-4b07-bb86-cc45aecba41d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_78cb13b0-5f80-4586-96a9-df0eda8b5254_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_021a19b1-81f6-4f64-b179-8a0430cbc1aa_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life of options in years</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2b8c9b97-8e88-41b0-8227-03edcf7e3aad_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_960ad25d-edc9-49b2-9216-4566ba0dff33_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_861f45af-be0c-4c0c-949e-e996ddc5a478_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_9ea4894c-5690-4ca4-8e9b-52d2a1e8a78d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_3359c26c-1496-49f3-ae46-daf77e47be1c_terseLabel_en-US" xlink:label="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclass</link:label>
    <link:label id="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_label_en-US" xlink:label="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass</link:label>
    <link:label id="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_documentation_en-US" xlink:label="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:href="vtvt-20240930.xsd#vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:to="lab_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d6613246-31ae-467a-ae5d-31af10f4b08d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd31896b-5388-4cfe-8a94-b27d35da25bc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_eaabcdcc-5ada-4c92-af19-6e2cde327e1c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecf8ae07-1156-4862-b7ed-a9171cbacbc4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_4ff78e17-27b9-4b64-abcb-bbb8d5bdec17_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interest, equity, fair value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5ca321e1-d9c8-430e-b280-bf32d37a9c2d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_697a2e65-5eda-4bf2-908e-3edda04db0d6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_463fc928-52c1-41ec-8af9-9f98a1c76c68_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_bc7f0a17-b1ae-4ab1-bab1-98c78cbdced1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_c3b273fb-eca8-4cfd-865a-ba3698a1ae57_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_249cbbe8-2db3-477c-b5ae-10b67a53d3cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a73b71a8-dda2-4063-a083-e7b3fec3b992_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_9344714f-26cf-46ba-a22a-9ace2b17864c_terseLabel_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</link:label>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_vtvt_ProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock" xlink:href="vtvt-20240930.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ProceedsFromSaleOfCommonStock" xlink:to="lab_vtvt_ProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_05f6d0b2-50b9-498f-9442-b751f1b679ab_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_73a50027-5160-439a-bd31-f0742621f610_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_03d42937-4090-43c7-b216-b9d1d6cde990_terseLabel_en-US" xlink:label="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of noncontrolling interest to additional paid-in capital</link:label>
    <link:label id="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_label_en-US" xlink:label="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Reclassification to Additional Paid-in-Capital</link:label>
    <link:label id="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Reclassification to Additional Paid-in-Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:href="vtvt-20240930.xsd#vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:to="lab_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7bf2ffeb-29e4-4d37-86ef-0d17c05420a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2db03f5a-bd43-4b15-8e5e-5fb59fc83229_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_686f9144-d7c0-43c3-8f06-d2eb1effb3ee_terseLabel_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novo License Agreement</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novo License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novo license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember" xlink:href="vtvt-20240930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NovoLicenseAgreementMember" xlink:to="lab_vtvt_NovoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_27c17eb1-cce9-43b2-9e33-60754f82299a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dfdefc8-d5be-4dc2-bc0d-af02b44162bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_61cd91e0-2cd6-4cf6-a5b5-d9cccbfac871_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e54e2115-3040-42f0-8b0d-a2b814ae9cc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ddfac170-757d-473d-875a-29755d983cd5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_961a14ef-3c72-450e-8ff1-70274fd38e92_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_bbeae056-796e-47ce-b98f-6cbe35a3bf28_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:to="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_37243357-38d2-4526-8b11-cc3e15397f1d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_dc32c4ea-3c4d-4089-9afd-d344f0f97254_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Income Attributable to Vtv Therapeutics Inc</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a702af53-42ca-4c46-9e31-fb2bca9820d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb3e394e-86a8-49c3-b7bf-e7d46af0424f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b4780ac8-4030-4bb0-8416-03a1a1f2c781_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c788d68f-707f-430c-872e-bcb9a554dfee_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1a94d4af-2762-4674-b9ca-4f05525d5a28_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_865f8f43-baf0-49ae-a5e0-c14e15e522d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock options granted under the Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a0e68682-e05a-4cab-bfde-df0610774432_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_59ebff70-2844-4200-b1ce-2920cc8f8174_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7cbb2cdd-10c4-46db-9424-65bbbbb799f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5df898b1-32fb-4fb1-a435-bdc77a0c329a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8550039b-3057-486e-a531-96afa88414f2_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_3cf8b57a-c88a-4b96-894f-1f90de6dd7e7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a10f3982-b083-4a9f-9511-e17fc742772c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fa5d716b-8ea2-4384-9cf3-67c72435b902_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_42c7983c-c93b-4c9d-a510-99ab8c56f247_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from change in estimated transaction prices</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_f15c8716-b01b-4d6d-aae1-49178cba3d30_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_d2ef2cd3-d8a9-46b5-9f6a-5362b57563fe_terseLabel_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class A Common Stock under ATM offering (in shares)</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_label_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Class A Common Stock Under A T M Offering Shares</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_documentation_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Class A Common Stock Under A T M Offering Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:to="lab_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_333ec7e5-9ce3-4a00-ba63-23001dbccf57_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ffa7b720-8343-4ecf-bc8a-67c30c8a3c15_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_14df6830-0a5e-449a-b282-8c5959e21848_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c5ae0212-be0a-4130-9ab9-beab59050b77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_403e8731-4a31-4611-bae9-ffbb97c2eb7f_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3300e48e-a952-4664-a126-9fd8abfc64ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f39daff2-2d8d-4d63-bcf1-ce7cfc990dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c5fcfda-d7bd-4734-855e-8d175a6b7ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_5fdde4eb-8818-47be-a9a4-45ad6df5b719_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share held by related party (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_eb852e80-91eb-4a0d-89fc-bc89e60edbdc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d3525013-d6ca-4653-90b9-225d075d21b2_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c174354f-0344-4267-b20c-fd9f59aefee0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9b2eadfe-7671-49a8-a005-20ea13ebc7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0f2b310-9852-49a0-a285-10b6931c0ffe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_82981098-83af-4b08-8a2b-beaa4f7016c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d75c5091-c399-45a4-b01c-45ced2bd39c3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_9939e739-3cc0-4b70-a744-e5aa56616ff9_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:to="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxWarrantsMember_46f2126a-76b4-4b0e-b9f6-6121183e5564_terseLabel_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CinRx Warrants</link:label>
    <link:label id="lab_vtvt_CinRxWarrantsMember_label_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CinRx Warrants [Member]</link:label>
    <link:label id="lab_vtvt_CinRxWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CinRx Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember" xlink:href="vtvt-20240930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxWarrantsMember" xlink:to="lab_vtvt_CinRxWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_bc625c21-0851-43aa-82d2-3186d68e8849_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of public float</link:label>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_label_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</link:label>
    <link:label id="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:to="lab_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_4a634ff4-8e04-433d-a7b9-0d970a36d6d0_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_vtvt_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockAggregateOfferingPrice" xlink:to="lab_vtvt_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f801aa2f-5db1-417f-b919-9ab9b9d0f252_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit) attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_23a7aa09-c567-45a1-af44-0dbbefee50ba_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ff8434ae-39e6-4494-bdaf-f4e86aec1af2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_c0f0dbea-4771-43a1-8a91-55daf497f7a7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_2ec0c980-3d53-46e9-abc1-95b221956117_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_58e62e09-1c24-4041-bbc5-e44d871964dd_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of cash savings percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_label_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Amount Of Cash Savings</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_documentation_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of amount of cash savings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:to="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_3d161aed-2089-4c73-b133-e1d3055994ee_terseLabel_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborate arrangement, contingent consideration transferred, cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_label_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_documentation_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:href="vtvt-20240930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:to="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_d6fa9503-1922-4914-a068-ef37e9ccb485_terseLabel_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type 1 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type One Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type 1 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember" xlink:href="vtvt-20240930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeOneDiabetesMember" xlink:to="lab_vtvt_TypeOneDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6a1ba809-5f49-40a0-b052-95e3592d4415_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f9e38963-3474-400d-b21b-d6190c4f8586_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b0317874-8b79-4578-885a-50d3e19787d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_ba2521ea-c725-43be-a773-7ec3470b4133_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f11cca36-cc80-4a95-a6b4-eb10490a37eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_570ccc3c-4e1b-45a7-bb77-dad23769b163_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G42InvestmentsMember_b8199297-a080-4efb-94b6-ada08c05194f_terseLabel_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">G42 Investments</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_label_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">G42 Investments [Member]</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_documentation_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">G42 Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember" xlink:href="vtvt-20240930.xsd#vtvt_G42InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G42InvestmentsMember" xlink:to="lab_vtvt_G42InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_fb6cad6e-4a29-4c40-bb06-b2fb7bca2ee7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_04299784-a3b5-4315-b8ae-97e8af0841f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3eb8035d-4ebe-40d9-b483-4da62c3398a6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesTable_47ced7d9-c212-435c-8e22-a0f8616cee32_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_label_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesTable" xlink:to="lab_vtvt_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_5443d827-0ef2-4efe-8e67-4379d5840d52_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_eda2029b-6ebc-488b-ab3f-c075dcd160dc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8c606e15-be45-498a-b037-9e5f46053768_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_4ae1433f-0668-4744-b2bf-936095045760_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6ecb3a7d-5245-4e99-ab0c-54b2c1619afe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_a9653efb-132f-4c0c-845d-7d1c0671456f_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3ca820d1-b558-438f-b2df-47514b5f149c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8193c03d-7a1e-45b7-9d83-6fdb973763e5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_65837ac2-b960-4097-8598-b961a5ca7da0_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_df6fc3c9-4b51-4db0-b999-0458f72d7064_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4967cf4-4070-4cfe-aed6-8c7f04263dde_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b4832774-0f83-4acd-bf11-178f8e4f4f22_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6d77e99c-5cb0-4715-933d-c5e9fd39528a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9ed22878-95bd-400a-b43c-84f3f8aaf6b2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4097f203-8d60-4c27-81eb-be7d2ec5faa7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_fadcb2eb-8c5e-4fa2-a1bf-3aef4d052392_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reduction</link:label>
    <link:label id="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_label_en-US" xlink:label="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense Reduction, Amount</link:label>
    <link:label id="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_documentation_en-US" xlink:label="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense Reduction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedPaymentArrangementExpenseReductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:to="lab_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1964340-9c6b-4104-b1df-4be050160278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7afca25-7f24-44fc-b28f-ad55884f8e65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_48da5b69-f0e7-42f3-99d1-e9a753df544c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_ba4e15d1-6a69-4e02-a2d2-a7e4a8352e40_terseLabel_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class A Common Stock under ATM offering</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_label_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Class A Common Stock under ATM offering</link:label>
    <link:label id="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering_documentation_en-US" xlink:label="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Class A Common Stock under ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:to="lab_vtvt_IssuanceOfClassACommonStockUnderATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_d8c23408-17ae-4d2a-8f3e-06e94f9289e4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6de3cd8d-014e-4d6e-a958-832d544e4649_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_e9e5d73f-747d-4880-a86d-af22cfe7775d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aea6ff61-1f01-42e9-ab51-138d4fae492e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_53e89d72-5269-4202-b998-7ddf07618d8d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_23ffcf5b-450d-4384-8add-fffd9128188a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c89cbbec-d7c4-4e11-938c-f9ca1d82e4b0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_154d8afd-b339-46ad-be96-22773a934350_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a32eaa40-3a01-41ef-b92b-c5165b70a27b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_83098eae-b1e5-4f30-8974-dd81bd0db3a1_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_10895815-dfbc-4a63-b6ec-d3ac6f706707_terseLabel_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days used to determine exchange value based on weighted average price of Class A common stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_label_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_documentation_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period used to determine exchange value based on weighted average price of Class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:href="vtvt-20240930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:to="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_370a7488-c9c0-4e1c-9be1-861d8ca37176_terseLabel_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_label_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd [Member]</link:label>
    <link:label id="lab_vtvt_NewsoaraBiopharmaCoLtdMember_documentation_en-US" xlink:label="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Newsoara Biopharma Co Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:href="vtvt-20240930.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:to="lab_vtvt_NewsoaraBiopharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_c0cf6c48-4e8c-4ce5-97f8-f63af8865e11_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_51e045d4-62c0-40ac-b791-19dbf69cda39_terseLabel_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants</link:label>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_label_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtvt_PrivatePlacementPreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:href="vtvt-20240930.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:to="lab_vtvt_PrivatePlacementPreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3f5641b1-797d-44a9-85cb-f321d2b46063_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_ccbdfe72-8953-4e3b-a306-a9f3f835a8b2_negatedLabel_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_label_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Imputed Interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_documentation_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating leases imputed interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest" xlink:href="vtvt-20240930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OperatingLeasesImputedInterest" xlink:to="lab_vtvt_OperatingLeasesImputedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_5c3ba056-f41c-4eed-8277-4fe36f37c444_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ab45fe4d-edc6-4aa5-bb9f-0470810d8836_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarizes the Conclusions Reached Regarding Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3f467d9f-4e14-409c-9fdb-1deb9c095105_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_JDRFInternationalMember_e2c60ffe-319f-452f-a6bd-696c9d7c1eca_terseLabel_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JDRF</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_label_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">J D R F International [Member]</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_documentation_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JDRF international.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember" xlink:href="vtvt-20240930.xsd#vtvt_JDRFInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_JDRFInternationalMember" xlink:to="lab_vtvt_JDRFInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e4edd01e-479a-4e3d-9568-95e525fb2dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeeReceivedTerm_f330354e-434a-49ed-97be-e3109aa65402_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeeReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee received, term</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceivedTerm_label_en-US" xlink:label="lab_vtvt_LicenseFeeReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee Received, Term</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceivedTerm_documentation_en-US" xlink:label="lab_vtvt_LicenseFeeReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee Received, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceivedTerm" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceivedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeeReceivedTerm" xlink:to="lab_vtvt_LicenseFeeReceivedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0ee490da-94bf-4179-b50f-20487a20e76c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_72604ba0-290f-4b43-a80d-ba23b4d31026_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_28c6c62a-2105-4f17-906d-7b948a93cbb0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_38ae48e1-f845-492a-be2d-39073511ed46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Change in fair value included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2e74fdc6-956f-4132-9593-611e1a89dab8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_11639d9d-e5e5-4be5-be79-ed7134f9a4bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases / Issuance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_441854ec-90cb-42b5-97f9-faf71a5b60d0_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bf4716c5-584d-4856-9435-b7acb4479370_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c1ad7005-efb9-453d-b71b-dcf5dc9c07a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period to recognize unrecognized share-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d25759d-8415-45dd-961b-c9d5aa78cd5a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeePriceIncrease_72edc10b-9099-4b25-85ee-0d89cab2fce2_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeePriceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee price increase</link:label>
    <link:label id="lab_vtvt_LicenseFeePriceIncrease_label_en-US" xlink:label="lab_vtvt_LicenseFeePriceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee Price Increase</link:label>
    <link:label id="lab_vtvt_LicenseFeePriceIncrease_documentation_en-US" xlink:label="lab_vtvt_LicenseFeePriceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee Price Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeePriceIncrease" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeePriceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeePriceIncrease" xlink:to="lab_vtvt_LicenseFeePriceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a4fddba0-a097-4864-aaf2-4480d5875d93_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1c45f1eb-f82a-4843-88a6-bfe0d32f2a2f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_f3b758de-f173-4f9e-b721-b4b79b686f23_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_03557573-1134-4fa1-ae8e-62c232c8fcac_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_e7aa000a-f7cd-42de-b1ca-a998d010afb4_terseLabel_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings LLC</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_label_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M F T T P Holdings L L C [Member]</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_documentation_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M&amp;F TTP Holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember" xlink:href="vtvt-20240930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MFTTPHoldingsLLCMember" xlink:to="lab_vtvt_MFTTPHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5b0ad6bb-4db5-46e9-9d47-3fb294221b16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1b80475-c0f1-4088-bb52-ebfe95d759cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19082672-9cb9-4504-aea6-fcd056bfab4d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a852e02-073b-44ba-9449-91a54ce82ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_3a3dbf8d-9b13-4296-af4a-d0157aa2ef26_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a62ff7ee-f4cc-4bf7-a271-92f67b730749_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_38da66f1-01a8-45ad-984b-153dc14c2d6b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3e9deedb-3ed5-4a8e-a159-ecb4f8a534ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialMilestonePayment_ee348a7d-6c85-4320-83cf-347824e55380_terseLabel_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_label_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_documentation_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment" xlink:href="vtvt-20240930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialMilestonePayment" xlink:to="lab_vtvt_PotentialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_32b5df85-ca69-4fb2-b0c1-57ee45fa70ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a669817c-bd60-437c-af69-d005db7cd1ff_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_15e64e63-0499-48c8-84f8-0da1cb5329ac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_73f6ba02-5d4c-47cd-9aa8-295a85e83116_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f7d31067-79db-45aa-8311-9a23a9d9b320_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a8742691-d3a0-42da-bff7-726480ff0ce4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_d3591074-cf6b-42ce-b8db-8b0aeab24793_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d1c6f2b4-72d4-478b-8764-d1defd6e885d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_904af374-d3a4-4b5d-a22e-d1f34ba2ddf1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_3c8e050e-2684-41d7-8833-ea62d7cce6f8_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_938ca022-f36c-4956-b3c4-462fca77e760_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85348757-c50c-441d-bba1-493406553ff4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0be7d591-a0eb-403b-97b1-c3cdc76a8b00_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3f162b5c-5a9c-4e04-b3f2-460056756a0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_484db4f6-7686-4483-b6e4-20a16d35628d_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_ef41cbce-9311-4df2-a97d-b13cfd68a3ad_terseLabel_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_label_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development And Regulatory Milestone Payments Receivable</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:href="vtvt-20240930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:to="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1719903c-9c9a-4aee-8828-f6d760f978de_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_372ec99a-3bbd-4936-9f9d-410600ba695c_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inputs utilized in the valuation of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ae252dcb-e54f-4f89-9b53-87c4734b3d5d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_05a9bd44-e175-4f48-9921-afa193e03616_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_724ab09a-b51e-446e-99ea-1696ad7866d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9bea1f1c-034e-4bbd-8364-ea4eaea1b39f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_96f7e8a6-2f93-4898-a16b-2754338514d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a24e25-996e-4606-a3a1-e43f7439f38c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1074d793-bd4e-4068-a471-433b2fe45775_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_7325d431-ab6f-4883-b889-721ee7498af6_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount on note receivable</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:to="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_248d1b20-8c04-4043-950b-b98f322462d0_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_label_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesLineItems" xlink:to="lab_vtvt_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_81282307-1e92-4735-a821-bf4382f250cf_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_669b98a7-b75c-4194-97bc-ab935de24417_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_18ab3ce8-e7c7-46db-90b8-dd102df328c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantyLiability_02c953b3-31d8-4f28-802e-2364f58c56ae_terseLabel_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_label_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty Liability</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_documentation_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warranty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability" xlink:href="vtvt-20240930.xsd#vtvt_WarrantyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantyLiability" xlink:to="lab_vtvt_WarrantyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_9ee3dc7e-940d-4857-a943-9b87a5229edf_terseLabel_en-US" xlink:label="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of securities called by warrants</link:label>
    <link:label id="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Percent of Securities Called by Warrants or Rights</link:label>
    <link:label id="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_documentation_en-US" xlink:label="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Percent of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:href="vtvt-20240930.xsd#vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_64a2def3-9a5d-46b2-aa68-0613c3595a24_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_98642373-caba-48fd-9608-7c67bbc760a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2ed2d81d-76f7-41bb-bc45-94408d93201f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxInvestmentMember_afab2ba1-d1f8-460c-a4cc-5c58d36dc8d8_terseLabel_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CinRx Investment</link:label>
    <link:label id="lab_vtvt_CinRxInvestmentMember_label_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CinRx Investment [Member]</link:label>
    <link:label id="lab_vtvt_CinRxInvestmentMember_documentation_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CinRx Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember" xlink:href="vtvt-20240930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxInvestmentMember" xlink:to="lab_vtvt_CinRxInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_55c9d9b6-a72d-4e4d-99c4-7aacb02cb4f2_totalLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_30607ea1-cb10-4668-94b4-2e73300d7eb0_terseLabel_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Modified common stock (in shares)</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_label_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock</link:label>
    <link:label id="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_documentation_en-US" xlink:label="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:to="lab_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_92c55c65-4a50-4d3f-8bed-4981545646de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_b355d3b0-9f85-4be4-a562-99db268109ce_terseLabel_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental and Regulatory Milestone Payment</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental And Regulatory Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental and regulatory milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:href="vtvt-20240930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:to="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_3cccbc8b-f9e1-4735-b769-e3ed7429ab17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_0b01ac89-1ed2-402e-8c5d-3c3e593fff30_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_444fa011-1f10-4289-852c-537171f2b041_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ef681732-aff1-43dc-9671-95423e0e50c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_72129626-543f-4e1b-b388-cfcce6015e02_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties receivable, period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:to="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a9e6559-713f-4cf1-8ab6-626aaae0d5f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ff24349f-39dd-4d12-bfce-eded39d45477_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6459e15d-8398-4c53-ae53-b6b358bbf460_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="vtvt-20240930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f912709a-56d1-49a3-aba6-6ac766ef2267_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_ec7c5a09-caea-4d2f-87be-806ab1728a84_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_ee0f013b-d6a4-4210-8f4b-6b921a49e3c9_terseLabel_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity public float, threshold</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_label_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float, Threshold</link:label>
    <link:label id="lab_vtvt_EntityPublicFloatThreshold_documentation_en-US" xlink:label="lab_vtvt_EntityPublicFloatThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity Public Float, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold" xlink:href="vtvt-20240930.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EntityPublicFloatThreshold" xlink:to="lab_vtvt_EntityPublicFloatThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c405c626-9456-4fe0-8624-990bd1bbbaf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0f479a46-53a0-4192-820d-b354438f9905_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efc41594-6477-4312-8c84-048e324adc5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherIndicationMember_93b6113c-e0e7-4144-9d12-977be0e2d3da_terseLabel_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Indication</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_label_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Indication [Member]</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_documentation_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember" xlink:href="vtvt-20240930.xsd#vtvt_OtherIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherIndicationMember" xlink:to="lab_vtvt_OtherIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_8ee06dad-30d3-4391-bd75-62583428f4b6_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital stock, shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock And Preferred Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock and preferred stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:to="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3982d131-5d15-4bb3-838c-bf8694f3636a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_aab94271-84d8-45b7-8223-490ad0e6d2cc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_cbe871d4-e56d-4df2-a56c-4b1737feedee_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Non Voting Economic Interest By Parent</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of non voting economic interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0a8a5bf3-e5b8-4b47-8723-01e69b8df0db_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0b0268e6-41aa-4558-a5e6-fab4a1ec735a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_2915de2e-522b-456e-9753-3b74c63f58dc_terseLabel_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum funding percentage of research and development milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Funding Percentage Of Research And Development Milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum funding percentage of research and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:href="vtvt-20240930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:to="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e841f4dd-97c2-4123-8d1e-5444d39fe302_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8e5d6c81-3a27-4718-be44-163b8ef0f190_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_d9ff920c-0823-4949-9029-b52f52da0583_terseLabel_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:href="vtvt-20240930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:to="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f697b9bc-cb71-42df-83db-7890072206e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class A common stock and prefunded warrants, net offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b3ef0168-c05f-40a3-b49c-ae591c78fffc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5f390b5b-97b2-4823-b940-803984948fae_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1884ce44-4294-4cb2-b194-769ba811a7fd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84e0e333-fcca-4a0c-b413-a134fa22ce8a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ff97c23-58d9-421e-a29d-6cf0eae997d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_123ae195-a480-401d-809d-c85bcfd71fca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_214c7360-2743-4c20-a0bb-515a9267e059_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par or stated value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9150abcf-3fd3-4e19-aa90-dc882ca7c823_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7147e0ba-3da7-409d-a086-666df12cd9cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_706ba22d-9c05-4022-a95d-24bedadbe2b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_a725bc98-9e74-49c8-9f75-b6b925cb06de_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_96c93212-2aaa-4d4b-a62f-b6f0baee3fde_terseLabel_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange of Redeemable Non controlling Interest To Class A Common Stock</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_label_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_documentation_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange of redeemable non controlling interest to class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:href="vtvt-20240930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:to="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cc941f68-ec03-479f-b09a-f3ba703ad52c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a267a108-336b-4ddb-8c2c-2b7180e26bf1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_813dc47c-1db5-417c-8869-f9af3af92c8f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_f28f9edf-63eb-4564-aa3e-dae38f627825_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ab4d7114-31c1-4994-9de6-2a50c39d8947_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_c547a0a2-f095-4e3c-a472-0b79cc681ea2_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_80528fc7-5d80-4625-9d98-09c8c916841c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_93b98355-46b8-4324-beb5-5a04a7e33044_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2fceb46f-75b9-456d-94aa-45194ae48972_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_b1af1654-9c85-4dad-b527-3d43eb0e880d_terseLabel_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-based Milestones Payment</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_label_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestones Payment [Member]</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_documentation_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-based milestones payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:href="vtvt-20240930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:to="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_181a4c63-9dc3-4d19-a03d-c4ea062ddc3d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8412b034-b8bf-4831-97a0-3cd439ca1f15_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_aa8714ff-f342-4fc3-9557-e5f29e5d6d48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeeReceived_053a076d-c902-4481-a0ff-66646f8d6300_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_label_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee Received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_documentation_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeeReceived" xlink:to="lab_vtvt_LicenseFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f3136429-e56d-4cf1-ac1c-97b2ef1a90dd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c1c68562-1224-4fb3-afa2-e14388ddf685_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_48741d7c-9c8f-4fd8-8034-740ba3b8e56b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_9ac74aa1-5317-4063-9013-faaabce77383_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration, receivables, payment term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration, Receivable, Term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Consideration, Receivable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f64fe9f4-f07c-4c7d-ad42-d19a18939166_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_2e336b67-9924-41da-ba25-039564bc3041_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_3bf93923-a85b-4afd-9e68-6b5202378d20_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_aacff707-e23d-4b1a-9bc8-ad4ee7d23dbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b0eefa91-5c10-43b3-9fa2-48504d84a863_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_b77a21e7-e294-42fd-af40-9f18a382ba01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b0fde559-001d-43c9-b65a-966ae33406fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fa0c7d85-dad8-43d3-b77e-7ed14137e8cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_db96a444-7009-4348-b141-65f5efb2d4aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_745105cf-6b5b-441e-8d1a-90a46bb49b88_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_48b99524-4a56-48df-8cf4-9d9a81975ef5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f0f77912-4607-4d78-9830-8c8fe9c7cd9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b51dcc77-b765-4a3d-940c-768e848439f4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_95fa0c03-03ea-4188-9c62-a0d24fb44bcb_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_8477f581-a39f-4478-ba66-1692cb877917_verboseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Non Voting Economic Interest</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of non voting economic interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_88a40531-78cb-43ff-a5a3-29614a64e867_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1344b81-b361-408e-abda-dc6f6276f396_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_66ca1eca-980c-4d31-a277-35c74e419a3f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_4e1e8612-ba0f-4a15-a2dd-2d5a49fb9985_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1efc3c55-63a4-4108-97c6-205a94d0a78f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34aa8ff9-a547-453c-82be-ec6c887b1aa7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3ef7f72c-2258-4f08-b23c-175d8467af30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_9ae9aa0b-d16f-417a-90b1-bb2f390f8847_terseLabel_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Information Policy [Policy Text Block]</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unaudited interim financial information policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="vtvt-20240930.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b88f9d61-2e5c-4b51-96e9-a33f238c0cf8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e696255-1e55-4560-aa41-5967ac5294f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_86693a61-bf77-4ef6-b16c-09de52bd36f7_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7ce01678-c75c-48b9-b216-8a264f5fa965_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a99ce270-f145-42d0-8403-4c52bb2afd83_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0076f988-2b41-4168-98c1-b78097de5648_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_4e301d52-df04-420f-93ca-e9697a3a7b98_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2c0d2a95-e023-4d6a-85a7-f2f06f046020_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_5dd50e1b-4dc9-4e0c-9b3b-0903fd2682a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_02d18669-c171-4da7-9835-aa8570c1327b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ccc2767-e24b-4e9c-8484-3993f0b4015e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7837c383-eebe-49bc-9f9a-863ce5743dbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c5e190b6-7f2f-481d-96a7-7fa658d55e17_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class A common stock and pre-funded warrants, net offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4442f84c-dd03-4593-af05-707cb21dbc42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2ba0875c-c626-4762-8586-3059a847513a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_54d7d673-738d-44ed-8664-b72e84575828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Compensation Expense Related to Grants of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_f9082122-93ca-49d5-aca3-e7a14e97c66b_terseLabel_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter Agreement Warrants</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_label_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter Agreement Warrants [Member]</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Letter agreement warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember" xlink:href="vtvt-20240930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LetterAgreementWarrantsMember" xlink:to="lab_vtvt_LetterAgreementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7fbda594-1371-4091-9e78-25d2aeeee8df_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a41853dc-5943-41f0-8fab-6fa7bfd401ff_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3a65bae8-9ab8-4fc0-b50b-f4fab949cd3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9b10ba70-a08b-4ed7-b03b-051b31e99f79_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_4b2b53ec-67c1-4649-820a-5fa0f07698fc_terseLabel_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Common Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in common stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:href="vtvt-20240930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:to="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c449753-d24f-4b09-a204-7081870a5477_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1aef6514-e97b-49e5-8c3f-7a5946404131_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CognaMember_dbfdc39d-72ba-461a-b67a-8cc88bc5773b_terseLabel_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cogna</link:label>
    <link:label id="lab_vtvt_CognaMember_label_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cogna [Member]</link:label>
    <link:label id="lab_vtvt_CognaMember_documentation_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cogna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember" xlink:href="vtvt-20240930.xsd#vtvt_CognaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CognaMember" xlink:to="lab_vtvt_CognaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b8b1473b-775d-4ea4-abe8-37c4bef674fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from G42 promissory note early redemption</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac8dd9a0-630d-44e5-a687-b3648fa006cb_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_c7459f09-7505-41d2-9b85-903a10bbbb6c_terseLabel_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement</link:label>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_label_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement [Member]</link:label>
    <link:label id="lab_vtvt_TDCowenSalesAgreementMember_documentation_en-US" xlink:label="lab_vtvt_TDCowenSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TD Cowen Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember" xlink:href="vtvt-20240930.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TDCowenSalesAgreementMember" xlink:to="lab_vtvt_TDCowenSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1502fe3b-93de-4806-8261-886fd95b0d97_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6090ebf-39ff-4ff7-afb3-2864b5d1d787_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_74c70ddf-984e-4197-b560-c1a3ea7b07c2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1508cd6d-bcb6-4d7d-907e-136ab8924c69_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_749b8941-360d-415d-8a91-d238511935f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of Class A common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_353d4fdd-6110-4b01-a4b5-43b4ef53776b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-qualified stock option awards expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OneCustomerMember_614bf103-fd38-41d8-8810-839375afa118_terseLabel_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_label_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Customer [Member]</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_documentation_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember" xlink:href="vtvt-20240930.xsd#vtvt_OneCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OneCustomerMember" xlink:to="lab_vtvt_OneCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_b17ae58a-8d6d-47f9-b55c-6bcfbfeec03c_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable" xlink:to="lab_vtvt_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f4a812e7-f442-4ad4-97b1-268d52b2c45d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_dcaff55a-9c9b-4621-8210-4111e25ecdd9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_242c3151-5761-44f2-8110-3c5e3c9a53ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_985f86ee-d0f9-4e09-a682-1497ad1ed15a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f9311ebf-14e0-4499-86f0-39f4666880ef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26a59e02-48f2-428f-bd77-119d3e248656_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_550398f1-c826-4535-861d-e2b99096c14f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_f608d53e-455c-4d02-b2ab-6f18abe8422b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_4c80aabd-f260-4857-9431-d53dd74a2c07_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_c659d181-8021-42b5-8e96-178f1735d851_terseLabel_en-US" xlink:label="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_label_en-US" xlink:label="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Redemption Value Of Noncontrolling Interest</link:label>
    <link:label id="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Redemption Value Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:href="vtvt-20240930.xsd#vtvt_ChangeInRedemptionValueOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:to="lab_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0742a789-c990-4470-83b4-c648caf73cdc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_b90ec3b4-02d9-4b11-a10a-007d4986f0b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_2ef50971-3682-4415-a10d-f6c361439c11_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Technology Transfer Services</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_label_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Technology Transfer Services [Member]</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesMember_documentation_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and technology transfer services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:href="vtvt-20240930.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:to="lab_vtvt_LicenseAndTechnologyTransferServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_7cf9ce26-1481-48ef-b0f9-c099c69b09b5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_83c4a3ea-0780-4083-88b2-1146c0078e16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0bb3c05d-c3b2-4274-bc82-c98937e589af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbab02ba-49ac-4503-898f-7b4597fae57c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c8a01de-c130-487a-8401-64f917aec669_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3b4fff80-db5f-44f6-ae72-b77dba5f6a09_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_4b0a4899-7d64-4b21-9fe7-64ced6defb83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales / Repurchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_982b78fa-47b3-4739-9476-1c3ba7feca40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_38fac55d-c2bc-4471-8cb1-d480e7a26dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Award Activity for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_ac4372fa-a723-4a41-a815-9fc91848c05d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_82b5d03f-e10d-42e1-8190-928fb6155493_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_73fb0093-b225-4f7a-b955-0f348f646238_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5807d148-9b36-4424-b7a6-393c9ffe125a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8f5bb5ce-429b-4720-bdd5-286ea5871ac9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0e099443-51d5-41da-8523-e1cf7a383acd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2b5f3336-4c51-4ed1-8011-45eaa5ba7a45_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b80b9df8-4bfe-4b29-a5b1-ccf235e3a046_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6ba70887-c13b-445d-9677-86b85f1f59ab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9ed54d7b-d6cc-4936-b154-81a66bdc5215_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a4cc5add-c4e2-4d67-85ba-7b64b779866e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d4fcc63a-63c5-4bb8-b688-da4b6ff45b17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_fc29776e-9c90-4d4e-8107-98d3ee3b7400_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1dc289f1-b607-43c6-8d73-4b18db343559_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b2f4b7ec-9dff-4eff-a0dd-bf1c64f84e22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining operating lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_18c00180-118f-4043-858f-36e85356e78c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c553dce8-5429-4129-85d4-e321fab33813_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_af53f36b-e564-4486-a442-78bb7e87dd83_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_4ec709ba-aafc-4c35-b37e-c90f4787f6a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of investments in Anteris Bio, Inc</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a84728f-fe75-4111-aa60-8419b184be5c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6d2557e0-d4a5-491e-90b7-56c9a184cb91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_759bef67-c58a-461f-82be-910b7ed1ae71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_6f79246b-bbd2-4c61-911d-639326506cd2_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement pre-funded warrants, shares (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_label_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_documentation_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:to="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_14aeff6b-4532-4abe-b10e-99f762e8afb9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_f0919a78-d5c6-4b2f-a92d-94f6860245cb_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5801898c-eec4-4df3-af67-b2b6d058331a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_de0ea81d-312f-446d-a333-67032c3ccef8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_18d298dd-dd17-41f5-ab63-d54112beaa49_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts and financing receivable, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b8a5f3f7-00f8-42fd-81b6-8d61671aa9d3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_f503a482-d9b9-46d0-bd5f-5331f753bcde_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement, shares (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_label_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement, Shares</link:label>
    <link:label id="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_documentation_en-US" xlink:label="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value of Private Placement, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:to="lab_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_456b9dfd-4191-4a8d-a9c2-6364bd4a1ac2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOperating_901d20e2-5a5d-4037-85bc-60342cb3c1e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOperating" xlink:to="lab_us-gaap_InterestExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f3888acb-dd74-4085-90b4-798193b0d50e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0b74392a-0030-425d-bca4-ccd00742cde7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8d483bf7-3cae-4c46-9294-5cafab92faa6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0714f90f-6e7c-4caa-b812-fc1c11dc8f75_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14b23cdc-0f68-4b5c-b770-e9e4d973f9eb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_57129f8d-60a5-4d3f-a202-4253af7bcf01_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1bc20c9-5351-470e-9047-49160233a2ac_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd90e611-81a8-4730-8d77-acd2a027952b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53a53479-09f4-42c7-a316-ffbdea8e493b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_59aac81e-2638-4dea-8625-020907892383_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_f8ccca70-c361-4973-851c-8ff1f2a6a0b3_terseLabel_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage of majority owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_label_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage Of Majority Owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_documentation_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership percentage of majority owner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:href="vtvt-20240930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:to="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_a1af625c-a1bd-4c55-bd8b-e0ca08884017_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a05d039d-3754-4ce2-8d99-164a7c12fc2f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e2267d88-a6eb-4312-acf7-92a0fc051508_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0a7eef0a-19da-4657-bc32-ebc8e7513da3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_4c2537b9-6601-46e2-9b54-66bfd32a9878_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vtvt-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f4fb7ba7-beba-4869-a91f-ebf12b463982,g:5fea8a28-3d3c-4a54-a59a-546946171a99-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20240930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ec6ddcbf-2fab-4883-a02f-fa988f3de81d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ec6ddcbf-2fab-4883-a02f-fa988f3de81d" xlink:to="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91e6fbf8-024d-411a-832e-46ee4b6d97d1" xlink:to="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a972fd78-3518-47fa-a8e9-da9fb60cc323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:to="loc_us-gaap_CommonClassAMember_a972fd78-3518-47fa-a8e9-da9fb60cc323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_92f7511c-5628-4711-85e4-8fbee6f7f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e8abd9b-0dbf-41d8-90fd-f077623bb480" xlink:to="loc_us-gaap_CommonClassBMember_92f7511c-5628-4711-85e4-8fbee6f7f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_bd7cd674-cec5-46f2-931f-d8a72ed0f3c5" xlink:to="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_754bd501-beba-4713-a362-719fac34ab0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentType_754bd501-beba-4713-a362-719fac34ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_08f4edb5-06cd-4fab-bb3f-fed704cf93ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentQuarterlyReport_08f4edb5-06cd-4fab-bb3f-fed704cf93ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_26cd3861-a5a3-4703-9c52-ea3eaaa08e5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentPeriodEndDate_26cd3861-a5a3-4703-9c52-ea3eaaa08e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a90495f7-e1c3-4057-8e40-f53611eae1fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentTransitionReport_a90495f7-e1c3-4057-8e40-f53611eae1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fc8debff-c4d0-4ba4-b868-e43381398f73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityFileNumber_fc8debff-c4d0-4ba4-b868-e43381398f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e646aea0-bfa6-4261-899e-af391ba7d115" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityRegistrantName_e646aea0-bfa6-4261-899e-af391ba7d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2cc46e31-805c-4c8b-9d59-870a9e486b36" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2cc46e31-805c-4c8b-9d59-870a9e486b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c1b6d019-8472-4308-8a92-3a8f895806b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityTaxIdentificationNumber_c1b6d019-8472-4308-8a92-3a8f895806b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_90abb726-4930-4183-9ac9-d833361ac2f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressAddressLine1_90abb726-4930-4183-9ac9-d833361ac2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6592b8ea-9497-43c8-bb4f-12b7e66c4257" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressAddressLine2_6592b8ea-9497-43c8-bb4f-12b7e66c4257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e976b178-17bc-445b-b672-15390023978a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressCityOrTown_e976b178-17bc-445b-b672-15390023978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_94049422-6143-4221-98d9-1020c74e0eba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressStateOrProvince_94049422-6143-4221-98d9-1020c74e0eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c8582da4-4b92-478b-93de-5c03342790ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityAddressPostalZipCode_c8582da4-4b92-478b-93de-5c03342790ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4232ea9f-b74c-4282-a896-51f17e0d8cdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_CityAreaCode_4232ea9f-b74c-4282-a896-51f17e0d8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fa23a4d8-112f-47a1-a7d9-ff96e4dd8498" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_LocalPhoneNumber_fa23a4d8-112f-47a1-a7d9-ff96e4dd8498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b8df7aa9-80dd-4231-8f34-5a44023a5125" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_Security12bTitle_b8df7aa9-80dd-4231-8f34-5a44023a5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22e2c3c7-a1e4-42ac-8b3b-8a19a95c6fea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_TradingSymbol_22e2c3c7-a1e4-42ac-8b3b-8a19a95c6fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b6145673-fa09-45b1-8df6-7c90f23dcdf6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_SecurityExchangeName_b6145673-fa09-45b1-8df6-7c90f23dcdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_eb957d87-9243-42e1-aaf1-56fde2e532c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCurrentReportingStatus_eb957d87-9243-42e1-aaf1-56fde2e532c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fb015cd2-3c18-4c6b-9ea4-3d91c4d6dbc4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityInteractiveDataCurrent_fb015cd2-3c18-4c6b-9ea4-3d91c4d6dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2d763e3c-3f2e-481e-a3ce-8580c28f031e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityFilerCategory_2d763e3c-3f2e-481e-a3ce-8580c28f031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_347a9652-c1ca-4085-8553-c67e6be68727" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntitySmallBusiness_347a9652-c1ca-4085-8553-c67e6be68727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c16bb11-c8f3-4a9f-94c6-c06ad1f9093f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c16bb11-c8f3-4a9f-94c6-c06ad1f9093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1d7a6c4e-3201-40ee-8780-15274e32cb76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityShellCompany_1d7a6c4e-3201-40ee-8780-15274e32cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b4aa1b21-5cef-4a4d-99f8-b363d5eeaf6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b4aa1b21-5cef-4a4d-99f8-b363d5eeaf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b2138f5-8925-4165-87ea-9aaf975897da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_EntityCentralIndexKey_5b2138f5-8925-4165-87ea-9aaf975897da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_506e7deb-624c-4790-b5f9-e0f917d7a3dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_CurrentFiscalYearEndDate_506e7deb-624c-4790-b5f9-e0f917d7a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3910c637-4ac4-4ba2-a6be-1bf388b4ce22" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentFiscalYearFocus_3910c637-4ac4-4ba2-a6be-1bf388b4ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_55edb27c-19bf-4fd3-a80d-48e0556861f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_DocumentFiscalPeriodFocus_55edb27c-19bf-4fd3-a80d-48e0556861f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2328f708-425a-4007-bdb0-7a7a005a6886" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ef0f4976-2d1f-4a20-9ad3-c981cb8b4246" xlink:to="loc_dei_AmendmentFlag_2328f708-425a-4007-bdb0-7a7a005a6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9c478139-51e8-4f07-b439-6f0e1884cbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9c478139-51e8-4f07-b439-6f0e1884cbe8" xlink:to="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8b90ebd-994a-495c-8571-f2bdfea2b5f6" xlink:to="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94e72cb6-5012-41d5-81f9-3a646a57cfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:to="loc_us-gaap_CommonClassAMember_94e72cb6-5012-41d5-81f9-3a646a57cfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7a040394-aedf-4db7-8a24-a24c6ab3ff1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_892953c5-8547-439d-be59-dbb6d6f5b792" xlink:to="loc_us-gaap_CommonClassBMember_7a040394-aedf-4db7-8a24-a24c6ab3ff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f606b220-75ec-44af-90ee-992b710cdee9" xlink:to="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1b7328e8-6226-4115-958e-98644c957a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:to="loc_us-gaap_RelatedPartyMember_1b7328e8-6226-4115-958e-98644c957a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_2c1898ff-30e4-4760-b122-b8a820203599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_68275241-49ab-4d4b-b7d3-f19d308b6816" xlink:to="loc_us-gaap_NonrelatedPartyMember_2c1898ff-30e4-4760-b122-b8a820203599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c9b180c2-b060-4f9a-a83f-c9c9d8807aaa" xlink:to="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:to="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eb2cbd7-74c0-48bd-a418-4ded9b76c13c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eb2cbd7-74c0-48bd-a418-4ded9b76c13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2d216855-de8d-47a5-9545-3998278a2197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2d216855-de8d-47a5-9545-3998278a2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cd379c1-f48a-410f-a1ec-b96eab871f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cd379c1-f48a-410f-a1ec-b96eab871f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_a50b7255-f6dc-4862-8114-f4198746e341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_DepositsAssetsCurrent_a50b7255-f6dc-4862-8114-f4198746e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf70d2db-c4f4-42b6-9758-ad7312e4cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6664d8a2-ef21-4b23-82d1-b27fb73bd8b4" xlink:to="loc_us-gaap_AssetsCurrent_bf70d2db-c4f4-42b6-9758-ad7312e4cf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a4e1a3e8-0dfb-40c2-b241-3c9f39893d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a4e1a3e8-0dfb-40c2-b241-3c9f39893d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7fd4c5e-6aad-418e-a11e-cdadac9abbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7fd4c5e-6aad-418e-a11e-cdadac9abbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eb00daa4-5a09-4a0a-893d-16babc84f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_38a15e40-3229-4433-91dd-03c88e2c77dc" xlink:to="loc_us-gaap_Assets_eb00daa4-5a09-4a0a-893d-16babc84f55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4c49072c-7688-461f-b51c-dc7d32bd83ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_553ca042-a726-4e18-a140-7bd84cca770d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_553ca042-a726-4e18-a140-7bd84cca770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96243af0-fbab-4674-a953-f706f3902b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96243af0-fbab-4674-a953-f706f3902b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212b7996-32e9-4733-aebd-f52f2001f713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212b7996-32e9-4733-aebd-f52f2001f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_dca4662c-1e16-4c82-af4e-66a8677db2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_NotesPayableCurrent_dca4662c-1e16-4c82-af4e-66a8677db2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a08e095-27cc-4e50-985e-1712549f44a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56f79f26-073d-422a-96de-5722e06c3f62" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a08e095-27cc-4e50-985e-1712549f44a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d4e852eb-5fc4-4a4c-b754-a96954ca6b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d4e852eb-5fc4-4a4c-b754-a96954ca6b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2753e07f-c297-4cf4-b71e-c8e9de85afc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2753e07f-c297-4cf4-b71e-c8e9de85afc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_6e255b54-bd96-4c6c-ac18-d1c573656f9f" xlink:href="vtvt-20240930.xsd#vtvt_WarrantyLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_vtvt_WarrantyLiability_6e255b54-bd96-4c6c-ac18-d1c573656f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ab522da-7729-4b8e-b435-6b836f7a2c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_Liabilities_6ab522da-7729-4b8e-b435-6b836f7a2c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ca4fbefd-d431-4f8d-af3e-503b0afbdec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ca4fbefd-d431-4f8d-af3e-503b0afbdec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_598343d4-cbae-4d5d-871a-f5e9216d11e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_598343d4-cbae-4d5d-871a-f5e9216d11e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_81e996ea-8d5d-4185-8159-3c4803bf0149" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_CommonStockValue_81e996ea-8d5d-4185-8159-3c4803bf0149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6454e708-2d58-4a65-b9eb-8b960f6e4752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6454e708-2d58-4a65-b9eb-8b960f6e4752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a0d58db-5fb5-4730-8d1a-f35a518687b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0a0d58db-5fb5-4730-8d1a-f35a518687b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_740b0881-8a2d-47fe-ad65-bb5ce9e6fdab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_StockholdersEquity_740b0881-8a2d-47fe-ad65-bb5ce9e6fdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4a2fcba4-021d-494e-a87a-068465d3a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_MinorityInterest_4a2fcba4-021d-494e-a87a-068465d3a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44b0bb64-494f-4569-bd1d-f78d1ecb2e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f45c79dc-efc4-4c83-b17c-33be51d70292" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44b0bb64-494f-4569-bd1d-f78d1ecb2e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52e75669-20ff-4cae-825d-7b5a87cd37c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6cae56bd-e71f-4626-a1db-a8bcecb5797e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_52e75669-20ff-4cae-825d-7b5a87cd37c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_afa3e8cd-07de-4e76-8d67-215e878b4803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_afa3e8cd-07de-4e76-8d67-215e878b4803" xlink:to="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3056d389-beeb-4409-8e81-fd52bacee3f1" xlink:to="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d7b97aca-df88-4946-a1cd-47306eaf39d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:to="loc_us-gaap_CommonClassAMember_d7b97aca-df88-4946-a1cd-47306eaf39d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_859a2476-1dc2-4b07-88c4-9c6b751a7715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ad61e7ec-b7f4-49e2-a6f9-cbc3dcae8d7b" xlink:to="loc_us-gaap_CommonClassBMember_859a2476-1dc2-4b07-88c4-9c6b751a7715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_135d9ca5-0471-423a-8ecf-c00c78e4a16d" xlink:to="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b682bd66-0713-4445-a47a-4813ba9d90d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b682bd66-0713-4445-a47a-4813ba9d90d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c91f2266-2c6a-4d98-8666-cdcf480ea750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c91f2266-2c6a-4d98-8666-cdcf480ea750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_65230ad8-0cf6-49c3-8ef8-5e7b46e654a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48c02f73-8a7d-47be-a1fc-1545bf22385e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_65230ad8-0cf6-49c3-8ef8-5e7b46e654a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2184ae92-486d-4122-9c10-fda1ff7dbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2184ae92-486d-4122-9c10-fda1ff7dbd45" xlink:to="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd7a5e6d-c227-4663-9bca-2f6713f239f0" xlink:to="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_972d2937-2065-4cce-b061-4edb738ce31a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_70525632-42f3-4187-8532-63041eaab89d" xlink:to="loc_us-gaap_CommonClassAMember_972d2937-2065-4cce-b061-4edb738ce31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fcdb4d4c-4cad-4ebe-a30b-76896f6bea13" xlink:to="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6d73ff08-7cc6-4bbf-8eb0-6adc70f9b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:to="loc_us-gaap_NonrelatedPartyMember_6d73ff08-7cc6-4bbf-8eb0-6adc70f9b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_8d3b058b-1384-41a7-a109-80d07d448370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2cc41d47-e5d6-4206-8605-72c6a3f8364f" xlink:to="loc_us-gaap_RelatedPartyMember_8d3b058b-1384-41a7-a109-80d07d448370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_47bc50ee-4bf0-483a-b355-5b0031bf5dc9" xlink:to="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3cfca679-2496-448b-92ea-e0de46d4d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3cfca679-2496-448b-92ea-e0de46d4d5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0139a61e-54e5-43ad-915f-9ee1337cb859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0139a61e-54e5-43ad-915f-9ee1337cb859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_34d2c555-8b87-43c1-a87b-5728c979a744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_34d2c555-8b87-43c1-a87b-5728c979a744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3a949f4-4076-4b05-b0ed-dea8155e316e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_10d29238-6276-4d00-8000-d09d6d835c91" xlink:to="loc_us-gaap_OperatingExpenses_d3a949f4-4076-4b05-b0ed-dea8155e316e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f05e0fbd-c2f5-4124-bb27-676260deec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OperatingIncomeLoss_f05e0fbd-c2f5-4124-bb27-676260deec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6113b1be-ba7d-495e-8847-20eb74e83231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6113b1be-ba7d-495e-8847-20eb74e83231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0de25fb2-314b-4fa5-8214-e9e8a929f9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0de25fb2-314b-4fa5-8214-e9e8a929f9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_b5418482-4322-4e3a-ad4a-19972e2b2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_InterestExpenseOperating_b5418482-4322-4e3a-ad4a-19972e2b2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb94a149-68cf-4c46-b129-c69de97a8ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb94a149-68cf-4c46-b129-c69de97a8ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6ca03dfb-5fc9-4d43-b2f5-81e939cf3c31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6ca03dfb-5fc9-4d43-b2f5-81e939cf3c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f576a08-d186-471f-9da0-9e4e8f3cfaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_ProfitLoss_7f576a08-d186-471f-9da0-9e4e8f3cfaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e62019f-313a-49fc-887b-25c175b6393c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e62019f-313a-49fc-887b-25c175b6393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f848c465-c947-44eb-8af3-d5f65829b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLoss_f848c465-c947-44eb-8af3-d5f65829b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31d18700-cf12-48df-b8a1-fe603abbe663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_31d18700-cf12-48df-b8a1-fe603abbe663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1d7799eb-85bc-4bc8-a684-934364d1cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_EarningsPerShareBasic_1d7799eb-85bc-4bc8-a684-934364d1cfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_28bd3503-a49d-4e5f-9b56-21712171d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_EarningsPerShareDiluted_28bd3503-a49d-4e5f-9b56-21712171d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c41e9266-93f8-4f4f-8de6-3effd3f14b89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c41e9266-93f8-4f4f-8de6-3effd3f14b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad82695d-86cd-4c9f-9548-4d93684e9953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e1e8900e-92cc-4bc1-a0c2-583886b46126" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad82695d-86cd-4c9f-9548-4d93684e9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_86da4ee0-3372-41a8-aa8c-7fbc23398873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_86da4ee0-3372-41a8-aa8c-7fbc23398873" xlink:to="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53f6c5b-01f4-464e-b141-f4c63c58d7dd" xlink:to="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_af640849-78b4-4c75-9355-540273e59bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_CommonStockMember_af640849-78b4-4c75-9355-540273e59bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2c7c84ec-d816-4ba9-ac38-be8bb3d7bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2c7c84ec-d816-4ba9-ac38-be8bb3d7bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71963bfb-efac-4b0f-a4ed-0922f7492d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_RetainedEarningsMember_71963bfb-efac-4b0f-a4ed-0922f7492d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_8c9b1755-8124-404d-906b-409a0c9fae3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_ParentMember_8c9b1755-8124-404d-906b-409a0c9fae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e79f509a-b2e2-4df0-a802-d6bfc2938719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3993b4b-5ab4-4d34-aff8-ec94a18e9b8f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e79f509a-b2e2-4df0-a802-d6bfc2938719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0e2ae96f-a0e2-4d98-b760-375ac76ebb12" xlink:to="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_f74ca073-f96b-42cc-8080-0600df1f7e7e" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_f74ca073-f96b-42cc-8080-0600df1f7e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6f3409f4-40e2-42de-a909-713a7874ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_us-gaap_CommonClassAMember_6f3409f4-40e2-42de-a909-713a7874ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_2b42aae3-1ff5-4efc-a2f3-43885bfddaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0ab3ef6a-1bd5-4ffb-8f88-d78b57f34e58" xlink:to="loc_us-gaap_CommonClassBMember_2b42aae3-1ff5-4efc-a2f3-43885bfddaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8c4785a3-906a-4103-9710-3dd66441746f" xlink:to="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c0a767af-5e17-4943-a66b-9ebb105e8621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c0a767af-5e17-4943-a66b-9ebb105e8621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_34a225bf-b35c-4c0a-8dd6-b5174c30b129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_34a225bf-b35c-4c0a-8dd6-b5174c30b129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_932981bd-9ad1-47e2-aaa0-e1bdd43b10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_932981bd-9ad1-47e2-aaa0-e1bdd43b10c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_186bcac7-7def-45e2-bc99-562f1ce55900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_186bcac7-7def-45e2-bc99-562f1ce55900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f7a9ccd5-07ed-4991-be96-3b670870c1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f7a9ccd5-07ed-4991-be96-3b670870c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_11bd3f2b-6fe4-466d-ac74-8b369cbf508c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28b0e5c3-4c98-4296-b57a-c7582ea6279a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_11bd3f2b-6fe4-466d-ac74-8b369cbf508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1e586f-0a8f-40a2-be58-fd18d1570250" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d57c5647-704f-4f3b-840a-f0449746f391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d57c5647-704f-4f3b-840a-f0449746f391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33bd1ede-951b-41cf-925a-5998503abc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33bd1ede-951b-41cf-925a-5998503abc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c09d8e86-51e2-406b-b35d-24ec4017242f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_NetIncomeLoss_c09d8e86-51e2-406b-b35d-24ec4017242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_5e32f309-6162-4c9c-b85c-b9170745961e" xlink:href="vtvt-20240930.xsd#vtvt_ChangeInRedemptionValueOfNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest_5e32f309-6162-4c9c-b85c-b9170745961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e0897120-2c23-4c6b-9f5e-7236a4bbb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e0897120-2c23-4c6b-9f5e-7236a4bbb25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f204a203-319b-4dc6-a329-e52ce5ad8d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f204a203-319b-4dc6-a329-e52ce5ad8d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_47e9e8f8-2a08-4477-95e1-d7bcb9b45acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_47e9e8f8-2a08-4477-95e1-d7bcb9b45acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad3f0777-9d30-4c62-84b5-40bb702f5612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ad3f0777-9d30-4c62-84b5-40bb702f5612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_8a695cb1-8c2a-47ef-9a2c-b523b324c1f9" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares_8a695cb1-8c2a-47ef-9a2c-b523b324c1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_c3cb818f-bd94-4eea-96e8-8c3987589957" xlink:href="vtvt-20240930.xsd#vtvt_IssuanceOfClassACommonStockUnderATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_vtvt_IssuanceOfClassACommonStockUnderATMOffering_c3cb818f-bd94-4eea-96e8-8c3987589957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_9f7de77f-b0a7-4265-81b1-39f0b243006b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_9f7de77f-b0a7-4265-81b1-39f0b243006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b465908b-beb9-479f-9b0e-d011c822e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b465908b-beb9-479f-9b0e-d011c822e01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1dd049b-8f13-4a7f-9fae-15e6994bcc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d2ed965c-aa77-4003-82b8-640409f0067e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f1dd049b-8f13-4a7f-9fae-15e6994bcc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_30c4e7fa-2aff-4280-951b-4719ddfd6c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_30c4e7fa-2aff-4280-951b-4719ddfd6c55" xlink:to="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09e7cb74-e533-4398-9456-048cbee7a935" xlink:to="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_de137738-d0ae-40da-a2a6-6de90c293eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:to="loc_us-gaap_RelatedPartyMember_de137738-d0ae-40da-a2a6-6de90c293eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_676f1b82-77df-4d53-8067-989b25365468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_52132e38-d4c4-4118-ae50-661c739970ab" xlink:to="loc_us-gaap_NonrelatedPartyMember_676f1b82-77df-4d53-8067-989b25365468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8f863c74-57eb-4086-9237-e01fc53fa357" xlink:to="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_66c9f6d1-1c7b-4856-bc15-23400d696ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_ProfitLoss_66c9f6d1-1c7b-4856-bc15-23400d696ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c070616d-20c4-4572-8079-c40b982c311a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_Depreciation_c070616d-20c4-4572-8079-c40b982c311a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_71b41928-a2d1-4118-a55d-61d448c169b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_71b41928-a2d1-4118-a55d-61d448c169b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_51abecb9-8aa8-4078-8105-b54cbac21c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_InterestIncomeOperating_51abecb9-8aa8-4078-8105-b54cbac21c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_70412938-403f-4634-951a-ef564d31c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_ShareBasedCompensation_70412938-403f-4634-951a-ef564d31c8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e27c516a-7c79-4d78-bcb5-c57221496255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e27c516a-7c79-4d78-bcb5-c57221496255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_c6bf43a2-0ee7-4963-b9e7-7406dd047ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_c6bf43a2-0ee7-4963-b9e7-7406dd047ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5e6bebfb-ea17-4ec2-890a-f8035f1afafd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5e6bebfb-ea17-4ec2-890a-f8035f1afafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fa92c14b-aa15-490e-b33c-55c88219d115" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2321c2db-58c6-44d2-81cc-84da37b60581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2321c2db-58c6-44d2-81cc-84da37b60581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e89d5908-6bd2-4917-b60a-379bb9ae504b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e89d5908-6bd2-4917-b60a-379bb9ae504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_920dd1f7-d1f9-4d27-8da0-2d7b1c4b123e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_920dd1f7-d1f9-4d27-8da0-2d7b1c4b123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24f6ec38-fa6f-4df6-8f04-37d6161d3650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24f6ec38-fa6f-4df6-8f04-37d6161d3650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1aa6b04c-ee96-4cd3-b1a7-a5a93e86fbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f017003-3999-4aa6-b172-69394cd1ac12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1aa6b04c-ee96-4cd3-b1a7-a5a93e86fbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1767ece7-7299-472c-92af-79464e1af84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_14e32cb3-06b8-4738-a08b-e3ee81d67c50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1767ece7-7299-472c-92af-79464e1af84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5c9bb5f6-bdd9-437b-9428-bcc33be6212c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_5c9bb5f6-bdd9-437b-9428-bcc33be6212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e293318c-a2e4-49c6-8443-ee8a0f2dd5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e293318c-a2e4-49c6-8443-ee8a0f2dd5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ProceedsFromSaleOfCommonStock_5646b234-5cf8-45ae-89de-d703607c0b1f" xlink:href="vtvt-20240930.xsd#vtvt_ProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_vtvt_ProceedsFromSaleOfCommonStock_5646b234-5cf8-45ae-89de-d703607c0b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_d21bcf49-ed84-4e31-8699-b11817515156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_d21bcf49-ed84-4e31-8699-b11817515156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_22cb11c2-0208-4ae5-a126-5a41a309b65f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_22cb11c2-0208-4ae5-a126-5a41a309b65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e1b54d7-69cf-481d-a357-bb9baa4e2b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1ed2894e-71fb-4569-ae06-59454dff56d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e1b54d7-69cf-481d-a357-bb9baa4e2b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2670e51c-a7e9-4c46-9131-409eec7c618c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2670e51c-a7e9-4c46-9131-409eec7c618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_032892a8-9af6-47f3-884a-75ca0f9c2ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_032892a8-9af6-47f3-884a-75ca0f9c2ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b994879f-351f-4728-8c5f-760ca4ae369c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b994879f-351f-4728-8c5f-760ca4ae369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c10dc26-81e1-4fa9-a6c6-4b05370050c3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_4824a890-3e7e-4e93-93b5-86e74f866651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_4824a890-3e7e-4e93-93b5-86e74f866651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_ec8486bf-318f-4946-928c-57d3f042638e" xlink:href="vtvt-20240930.xsd#vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7ff911fe-90aa-45c9-b74d-3942f6fcba0c" xlink:to="loc_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital_ec8486bf-318f-4946-928c-57d3f042638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="vtvt-20240930.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d4015706-209d-4d1d-a7c3-cdff49b7ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c2d4f30b-549e-4545-8038-57388cc7609b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d4015706-209d-4d1d-a7c3-cdff49b7ecb8" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c2d4f30b-549e-4545-8038-57388cc7609b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtvt-20240930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d96274b-3707-4acf-9150-ad8deac4423c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c43b3f8a-9041-4412-b4bd-f73386ac82a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d96274b-3707-4acf-9150-ad8deac4423c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c43b3f8a-9041-4412-b4bd-f73386ac82a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95c83d96-8db3-4be6-997f-0245a9c53727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_98e5b896-71dd-4fab-9494-cadca982339c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95c83d96-8db3-4be6-997f-0245a9c53727" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_98e5b896-71dd-4fab-9494-cadca982339c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1f3e37d-2cb7-4d21-9f13-b7a66d7692f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e46a70f6-39d9-4586-ac41-315436a2b858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1f3e37d-2cb7-4d21-9f13-b7a66d7692f7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e46a70f6-39d9-4586-ac41-315436a2b858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dede2b8c-25c2-4194-ab02-bd27165e42f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_555814ec-041d-4771-9810-d270fa3608c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dede2b8c-25c2-4194-ab02-bd27165e42f9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_555814ec-041d-4771-9810-d270fa3608c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Leases" xlink:type="simple" xlink:href="vtvt-20240930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d9a50e9d-bc93-4f63-b839-877b478681cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5c5fa48b-2b1f-46c0-93b4-7a87f6aaa628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d9a50e9d-bc93-4f63-b839-877b478681cd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5c5fa48b-2b1f-46c0-93b4-7a87f6aaa628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterest" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterest"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_6c220098-fee2-4664-a086-f5e075146bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_2c7b31af-bec9-4730-923b-86ae4c2897fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_6c220098-fee2-4664-a086-f5e075146bcb" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_2c7b31af-bec9-4730-923b-86ae4c2897fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="vtvt-20240930.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_20823dec-dfe4-49f5-9445-42da0958a4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7d312ae0-496b-47a4-ba53-1b48da544891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_20823dec-dfe4-49f5-9445-42da0958a4c5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7d312ae0-496b-47a4-ba53-1b48da544891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtvt-20240930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a7619b92-4dac-4e5a-9cce-f4ccafd5b30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b27c4add-5b1e-4c45-bcc7-460a768d2718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a7619b92-4dac-4e5a-9cce-f4ccafd5b30f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b27c4add-5b1e-4c45-bcc7-460a768d2718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vtvt-20240930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5716db73-b6f3-497d-befe-e092a6273b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_18cba251-4ef1-4219-a5ec-5b5d5092a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5716db73-b6f3-497d-befe-e092a6273b37" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_18cba251-4ef1-4219-a5ec-5b5d5092a0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_96b3682a-3160-4df6-a5cc-60a647696eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d29bc6fc-8933-4965-aa97-49a3c0ce27f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96b3682a-3160-4df6-a5cc-60a647696eb0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d29bc6fc-8933-4965-aa97-49a3c0ce27f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f8ceeb6-08a4-48b1-9162-754bbb1f8617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_830e9376-fd59-4b43-a6f9-3b4bbf5d2adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f8ceeb6-08a4-48b1-9162-754bbb1f8617" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_830e9376-fd59-4b43-a6f9-3b4bbf5d2adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtvt-20240930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ed17ff00-7ff6-4f76-acc9-edb1c3d9a909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_620288c2-d2ae-49a4-8bcc-43c800018699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ed17ff00-7ff6-4f76-acc9-edb1c3d9a909" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_620288c2-d2ae-49a4-8bcc-43c800018699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtvt-20240930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_4ae1cf16-a84f-4de0-84eb-2875857f1f94" xlink:href="vtvt-20240930.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_4ae1cf16-a84f-4de0-84eb-2875857f1f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dd3ab93a-70ef-4be8-ba9c-434cbfd3e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_UseOfEstimates_dd3ab93a-70ef-4be8-ba9c-434cbfd3e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_473262f9-e5c7-4b1a-a455-a30410276113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_473262f9-e5c7-4b1a-a455-a30410276113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_25e4bf9d-fce8-4f58-8a53-e463f978b29d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_25e4bf9d-fce8-4f58-8a53-e463f978b29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_fccf9487-cdbb-4905-97cc-77994601b197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_fccf9487-cdbb-4905-97cc-77994601b197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ce664652-722e-4e22-918b-552a750114a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ce664652-722e-4e22-918b-552a750114a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b63f5241-c45e-4272-87f0-54449d3d3114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b63f5241-c45e-4272-87f0-54449d3d3114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_effe21ee-9675-4c20-8658-9794098f97bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1c21906-7f02-4fcf-a309-3dd3e3bfbee2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_effe21ee-9675-4c20-8658-9794098f97bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f65e9f1d-23b8-430e-bc02-19522cb9c4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3fb13e43-d421-4c5b-bdc6-740096ed33ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f65e9f1d-23b8-430e-bc02-19522cb9c4ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3fb13e43-d421-4c5b-bdc6-740096ed33ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52e046dd-2393-47d7-b6d4-17c98cc61dea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f65e9f1d-23b8-430e-bc02-19522cb9c4ea" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_52e046dd-2393-47d7-b6d4-17c98cc61dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="vtvt-20240930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_107d6c61-02b1-418b-88c2-d0c79a0c7d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0a9cbaea-62c3-40fe-b08d-c98183741041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_107d6c61-02b1-418b-88c2-d0c79a0c7d7d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0a9cbaea-62c3-40fe-b08d-c98183741041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestTables" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterestTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterestTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_48e665d1-26f2-4120-a12e-a0a3c6ae022b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_4f3b7fc7-09d2-43d8-986e-729d927215b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_48e665d1-26f2-4120-a12e-a0a3c6ae022b" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_4f3b7fc7-09d2-43d8-986e-729d927215b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f17c4a9-8d0d-4c5e-a5f4-810ccf1d2339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_28274eae-eaa0-4ae8-86ae-7de07faab963" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f17c4a9-8d0d-4c5e-a5f4-810ccf1d2339" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_28274eae-eaa0-4ae8-86ae-7de07faab963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_10424039-e9a4-44c6-b88d-0c8155c63472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f17c4a9-8d0d-4c5e-a5f4-810ccf1d2339" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_10424039-e9a4-44c6-b88d-0c8155c63472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_65c47812-420a-4da2-9cf3-c5bef47a88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0b247dd3-c8de-4227-835e-614e4433650a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65c47812-420a-4da2-9cf3-c5bef47a88ca" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0b247dd3-c8de-4227-835e-614e4433650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3d272538-ce41-485d-b760-b13d6c885fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65c47812-420a-4da2-9cf3-c5bef47a88ca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3d272538-ce41-485d-b760-b13d6c885fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#DescriptionofBusinessandBasisofPresentationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d59f9bf9-2244-4ced-a9fa-730a5be22b78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d59f9bf9-2244-4ced-a9fa-730a5be22b78" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2f824eae-c0dc-4094-ad87-94f5695faa6d" xlink:to="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_d994c141-3d64-4d76-90d2-4ba1f8e3ddde" xlink:href="vtvt-20240930.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fd85ab29-7111-4e49-8e7e-4c279d48daf4" xlink:to="loc_vtvt_VTvLLCMember_d994c141-3d64-4d76-90d2-4ba1f8e3ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_015ea579-f4c9-48ae-9792-d46511f5718b" xlink:to="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c73fcc66-a467-4690-aaf9-f2514a2ab089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:to="loc_us-gaap_CommonClassAMember_c73fcc66-a467-4690-aaf9-f2514a2ab089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b758b629-3ca8-47ce-949e-5da00695c24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4760706c-35c3-4273-94de-0850d93713b9" xlink:to="loc_us-gaap_CommonClassBMember_b758b629-3ca8-47ce-949e-5da00695c24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6057cda4-41b8-4ec6-9f12-f8db9e3e2dc0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ff573876-ad58-442c-9950-f3da54cc01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:to="loc_us-gaap_PrivatePlacementMember_ff573876-ad58-442c-9950-f3da54cc01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_9bb949a7-46af-4af4-8fef-06531f319439" xlink:href="vtvt-20240930.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492119fd-9d99-4d79-ae4a-11f848f68dec" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_9bb949a7-46af-4af4-8fef-06531f319439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_793cc732-b816-404e-8885-2ced944ed588" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_63ff8560-09eb-4c18-b3a4-26c0cfb2f0ec" xlink:href="vtvt-20240930.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_06695a9c-382c-4c95-8651-862e334b9140" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_63ff8560-09eb-4c18-b3a4-26c0cfb2f0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a45debe7-fc1a-4237-a76c-7151284e54bf" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_c9323157-e0e6-4259-a983-aa4c1d376bc0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b82bd70d-7aa0-4824-b882-d8a000385ee2" xlink:to="loc_srt_ParentCompanyMember_c9323157-e0e6-4259-a983-aa4c1d376bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:href="vtvt-20240930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_cae2dbf2-1289-4f1d-b89b-8bcd76bc2fbf" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5583f5b-a50a-4c15-8a2d-f235f13c4e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5583f5b-a50a-4c15-8a2d-f235f13c4e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_c44ca471-4107-4d50-82e1-ffab128399c4" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_c44ca471-4107-4d50-82e1-ffab128399c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_4e6ee2c5-65e9-4518-a63d-cd5de3dc84b2" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_4e6ee2c5-65e9-4518-a63d-cd5de3dc84b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9fe1a0-b5d3-4f01-bb4a-458137857f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b9fe1a0-b5d3-4f01-bb4a-458137857f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_951e1e9e-1e3d-4201-aff8-dfdb28a0c592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_951e1e9e-1e3d-4201-aff8-dfdb28a0c592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_481f3505-8ddf-4957-bcb6-d0d709829e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_481f3505-8ddf-4957-bcb6-d0d709829e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ff1d5352-74ab-45bb-81b9-9eab450d9714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ff1d5352-74ab-45bb-81b9-9eab450d9714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46de5da6-c7df-4841-8dc1-3b6e8870cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46de5da6-c7df-4841-8dc1-3b6e8870cb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9d7ade1-3a99-4058-bfcc-6a694b5155ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f9d7ade1-3a99-4058-bfcc-6a694b5155ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b9ff8689-e995-4217-962c-16ca64665a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b9ff8689-e995-4217-962c-16ca64665a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_6297130b-8e15-4a57-9a1b-8c5ff299a675" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_6297130b-8e15-4a57-9a1b-8c5ff299a675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_d0509aea-253c-47ef-aa87-492c493fc4cc" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_d0509aea-253c-47ef-aa87-492c493fc4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_6240db79-d85c-44e7-a467-f847e9bfbb70" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_6240db79-d85c-44e7-a467-f847e9bfbb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_7986ed38-c7c7-49a3-9fb7-d2809f4319a6" xlink:href="vtvt-20240930.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_EntityPublicFloatThreshold_7986ed38-c7c7-49a3-9fb7-d2809f4319a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_74efb197-79f8-4fe8-bb52-bcc8b8b6b01b" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_74efb197-79f8-4fe8-bb52-bcc8b8b6b01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_480a4b80-cd9e-4270-bb18-f8caa6330d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_ba6e68dd-33c6-4c49-966e-564dcea35fc6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_480a4b80-cd9e-4270-bb18-f8caa6330d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8c471514-e096-4b27-a457-06106ef57375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c471514-e096-4b27-a457-06106ef57375" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0faeab4d-492b-40ae-8739-25c5e1f09d10" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8090058c-49be-44de-9b75-1f2dde0c53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f21c701-d8e9-4810-81b2-4e2a88323e77" xlink:to="loc_us-gaap_SalesRevenueNetMember_8090058c-49be-44de-9b75-1f2dde0c53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b43f208c-3af0-417c-bb0d-347dabcb9e6e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_cb0eb02c-6496-4a02-987a-0f9b771e8015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_675d243f-34bd-4aa3-9bd3-db053b290df6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_cb0eb02c-6496-4a02-987a-0f9b771e8015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e82930d5-d3f5-429c-adce-e1819545483e" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_c4d6c005-610e-4f6d-b313-b3485a300363" xlink:href="vtvt-20240930.xsd#vtvt_OneCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b273772-f640-44b4-a75f-e62dda218b00" xlink:to="loc_vtvt_OneCustomerMember_c4d6c005-610e-4f6d-b313-b3485a300363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:href="vtvt-20240930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ce1e7fa2-8804-4ecd-ba29-f372813ff94c" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_02a86e97-937d-4783-8206-7f6d861e464a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_e1582d37-f023-424a-9515-77497e5f856e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_02a86e97-937d-4783-8206-7f6d861e464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6324ba99-8d9b-49fb-bfe0-6c77ed8f9a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6324ba99-8d9b-49fb-bfe0-6c77ed8f9a44" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d9b632a7-2252-42e0-9ac9-0e3de6273bc3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_7826182f-d6c3-44c9-af14-d41e2b18d453" xlink:href="vtvt-20240930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_7826182f-d6c3-44c9-af14-d41e2b18d453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c3c858e4-f974-44d8-b87a-7c39db63907f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f48b33c-6292-47cf-aa53-9cf3bfa58e2c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c3c858e4-f974-44d8-b87a-7c39db63907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f4eda4e2-0432-49fc-88d0-3be589641784" xlink:to="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_bc970f31-c669-4307-ac5b-e4c75ebdbb0c" xlink:href="vtvt-20240930.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_bc970f31-c669-4307-ac5b-e4c75ebdbb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_3c123664-b29f-4e8b-883f-238d0028eeef" xlink:href="vtvt-20240930.xsd#vtvt_JDRFInternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d19f35a-a953-441d-a1d4-7e262cfde7b9" xlink:to="loc_vtvt_JDRFInternationalMember_3c123664-b29f-4e8b-883f-238d0028eeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c9a36102-6c53-406b-bd61-9ab2e318c0eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_ec563416-77ec-46aa-9922-d805849bed89" xlink:href="vtvt-20240930.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_G42InvestmentsMember_ec563416-77ec-46aa-9922-d805849bed89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_2db2bdc3-55d0-4913-b620-7276984d46e8" xlink:href="vtvt-20240930.xsd#vtvt_CognaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_CognaMember_2db2bdc3-55d0-4913-b620-7276984d46e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NewsoaraBiopharmaCoLtdMember_516cf36f-617c-4505-ae8c-062b4bab0241" xlink:href="vtvt-20240930.xsd#vtvt_NewsoaraBiopharmaCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3159ae7c-8610-4b38-b2c6-d40b2518007c" xlink:to="loc_vtvt_NewsoaraBiopharmaCoLtdMember_516cf36f-617c-4505-ae8c-062b4bab0241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_151e7457-86b9-4fef-871f-d6a99a1703df" xlink:to="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesMember_31af2a83-5fc4-403c-aede-44c780252ba1" xlink:href="vtvt-20240930.xsd#vtvt_LicenseAndTechnologyTransferServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b676309-01b2-4b05-a8ae-5f9f3665cb6a" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesMember_31af2a83-5fc4-403c-aede-44c780252ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96d58b42-4d19-4cba-9ab3-cc0738d30406" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_981a8b07-cd35-415b-a90a-bc68dd78b0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_981a8b07-cd35-415b-a90a-bc68dd78b0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4de25c2c-c443-43fb-b31c-130abbecc219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4de25c2c-c443-43fb-b31c-130abbecc219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_d5f86eda-1a5b-448c-9085-f4eb4096da31" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_d5f86eda-1a5b-448c-9085-f4eb4096da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd151a6-f7c4-4476-936e-4a17b041e6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd151a6-f7c4-4476-936e-4a17b041e6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_5fded3e3-ae3f-4eac-afdf-8306f7e4d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_5fded3e3-ae3f-4eac-afdf-8306f7e4d21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_a4cf56ef-1768-44a8-82da-b26b0e5c3684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_a4cf56ef-1768-44a8-82da-b26b0e5c3684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_6b6f82ac-d933-4396-8245-dccce27db933" xlink:href="vtvt-20240930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_NotesReceivableDiscountRate_6b6f82ac-d933-4396-8245-dccce27db933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48e86c89-9d77-4a5d-ac96-32e78af371ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48e86c89-9d77-4a5d-ac96-32e78af371ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_2abf75a1-ed98-47fe-8257-33213d74a90c" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_2abf75a1-ed98-47fe-8257-33213d74a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_d8d38bfc-f0c7-4e11-9d62-60f39ea7bbd7" xlink:href="vtvt-20240930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_d8d38bfc-f0c7-4e11-9d62-60f39ea7bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_5a4e2dff-a664-473d-a308-90659764080d" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_5a4e2dff-a664-473d-a308-90659764080d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_45a122da-04cd-42e3-8930-594b6232a77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_45a122da-04cd-42e3-8930-594b6232a77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_c5880543-421c-4673-88ca-b2665cef69a3" xlink:href="vtvt-20240930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_c5880543-421c-4673-88ca-b2665cef69a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_face3c03-0d59-44d0-8cf5-f449dfbabbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_face3c03-0d59-44d0-8cf5-f449dfbabbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c14feb1-e6c4-4d6b-b934-889272bd50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c14feb1-e6c4-4d6b-b934-889272bd50b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_549ed7af-3cfc-4973-a616-c7de0fdf3bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_549ed7af-3cfc-4973-a616-c7de0fdf3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_a4e4628d-09b9-4fc2-adfb-c90f61adb714" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeeReceived_a4e4628d-09b9-4fc2-adfb-c90f61adb714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceivedTerm_9496cef6-f7f2-40e5-a607-27e152b97a0b" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeeReceivedTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeeReceivedTerm_9496cef6-f7f2-40e5-a607-27e152b97a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_739a740c-133e-4d89-95a2-fb3504708e99" xlink:href="vtvt-20240930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_739a740c-133e-4d89-95a2-fb3504708e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeePriceIncrease_1e9ea840-955e-49fb-a98c-e5bc23443d3f" xlink:href="vtvt-20240930.xsd#vtvt_LicenseFeePriceIncrease"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_LicenseFeePriceIncrease_1e9ea840-955e-49fb-a98c-e5bc23443d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_d1be3593-ce00-4538-8bae-5d6a775abaea" xlink:href="vtvt-20240930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_d1be3593-ce00-4538-8bae-5d6a775abaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_02e853bc-3c91-4e37-b45a-10214909c669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_02e853bc-3c91-4e37-b45a-10214909c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1cbf9b01-c0e4-49ba-adb4-d54ff7c0a216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1253b2e1-2cac-43db-a29b-a7fbb0f70ae4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1cbf9b01-c0e4-49ba-adb4-d54ff7c0a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3dcfbb17-356b-4227-9d7e-9eed9234f0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3dcfbb17-356b-4227-9d7e-9eed9234f0f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:to="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5b475ad-2fca-4069-b1e9-8e1b7c14edd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d63eb9db-3ec8-445c-b5a7-b8ea98f5fbce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ef48eeb-41a1-4270-93ad-097b5f6731eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d63eb9db-3ec8-445c-b5a7-b8ea98f5fbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d90c12a-71ed-4ba1-add1-8b8b388987a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6283adf-7a8e-4857-9d67-06e61b42564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6283adf-7a8e-4857-9d67-06e61b42564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_301f85b0-4db6-43cb-9860-a956a0270b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_301f85b0-4db6-43cb-9860-a956a0270b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f2ac3f8-a47a-488e-9c71-de510e718360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f2ac3f8-a47a-488e-9c71-de510e718360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00eb0d0f-4f36-41ed-a35b-00fefeea031c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00eb0d0f-4f36-41ed-a35b-00fefeea031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_346cb992-c0b0-4cb3-87d0-8870f49146fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_346cb992-c0b0-4cb3-87d0-8870f49146fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_d151bc74-14bb-4bec-a72d-f2372740d8eb" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock_d151bc74-14bb-4bec-a72d-f2372740d8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a6661b9e-19ce-49d8-8f6f-8dc2c4e4ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a6661b9e-19ce-49d8-8f6f-8dc2c4e4ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_9d969e89-48f4-4dba-aaec-b47e264ab602" xlink:href="vtvt-20240930.xsd#vtvt_ShareBasedPaymentArrangementExpenseReductionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6c3dfd3-6bb9-4f7b-8a93-47d51c67ec11" xlink:to="loc_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount_9d969e89-48f4-4dba-aaec-b47e264ab602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a94453bf-b6fc-40b5-a297-cd5a61e6f78a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a94453bf-b6fc-40b5-a297-cd5a61e6f78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4a9c9fa0-a26a-4680-a7d3-0259189a3106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4a9c9fa0-a26a-4680-a7d3-0259189a3106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ab74d15b-457f-4d43-a513-9f58653ea26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ab74d15b-457f-4d43-a513-9f58653ea26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3ffde86-6984-4fba-b296-7d2b7ea00704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25f2f7c6-73da-4c0f-832f-7ce9c1a7c1ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3ffde86-6984-4fba-b296-7d2b7ea00704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9b093db6-10e2-413b-ac33-5050fa214935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9b093db6-10e2-413b-ac33-5050fa214935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4dd8c34e-2dad-49c0-b2c8-a22f9c639608" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4dd8c34e-2dad-49c0-b2c8-a22f9c639608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7e1a069-2821-451a-99b7-9be6a83c679b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f7e1a069-2821-451a-99b7-9be6a83c679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3c9b6e77-d3e0-407f-90f9-e632d07d868d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3c9b6e77-d3e0-407f-90f9-e632d07d868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df1840e6-4baa-4c39-b8e8-bd4192b671d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df1840e6-4baa-4c39-b8e8-bd4192b671d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e89e74c1-b87c-4fb8-a97d-dcb8496e507c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e89e74c1-b87c-4fb8-a97d-dcb8496e507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9d201433-e172-44c4-a3f1-9202797b7a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9d201433-e172-44c4-a3f1-9202797b7a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d59c2e2-e6f2-44e7-b886-bb4bae789ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_839cdef5-5239-42de-8d9a-afd87de3c1b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d59c2e2-e6f2-44e7-b886-bb4bae789ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f0055421-9245-450f-b6c9-e82c1ed345e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f0055421-9245-450f-b6c9-e82c1ed345e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cc04e8df-2e58-4eb4-a5ef-51953f848cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49bff21e-377f-45d8-8295-dba27f47acef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cc04e8df-2e58-4eb4-a5ef-51953f848cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71573a7f-4fa9-40d6-b1f8-8b3d78335e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71573a7f-4fa9-40d6-b1f8-8b3d78335e0c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eeb21797-808b-4abd-b495-13e42151e5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1a2d12f8-a6d9-4574-892a-4b3266ae5fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1a2d12f8-a6d9-4574-892a-4b3266ae5fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd3a1f21-93ad-4fa5-a15b-49264ab681db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ae26112-1934-4277-a77b-71556e1d70b3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dd3a1f21-93ad-4fa5-a15b-49264ab681db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0a291e1-0bdd-4699-8f7e-14e48246b6ea" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8d38a309-4f4c-4a9a-9fdc-01fc474576fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_21e10f67-b5e4-4d72-96f4-28e0ff690357" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8d38a309-4f4c-4a9a-9fdc-01fc474576fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_418ece7b-ae42-4d32-8f5b-78e1bf71b560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_418ece7b-ae42-4d32-8f5b-78e1bf71b560" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3c0957f8-05bb-4fbe-bec6-816cead1ae21" xlink:to="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_2c0f4ad3-4a1f-43cf-a8ac-716d598790e1" xlink:href="vtvt-20240930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_2c0f4ad3-4a1f-43cf-a8ac-716d598790e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_aebed7b5-beb5-4e23-ba1d-f8e3feb76c11" xlink:href="vtvt-20240930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_38d08713-11d0-4de7-a2e0-cf2e1fac7ff3" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_aebed7b5-beb5-4e23-ba1d-f8e3feb76c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44c2c6c7-3cb9-43f9-a61f-9616d9ffc201" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_6cc73ac4-02d7-452c-9d54-7214400714c8" xlink:href="vtvt-20240930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16f23709-4fd5-4130-a200-015e1855fe31" xlink:to="loc_vtvt_NovoLicenseAgreementMember_6cc73ac4-02d7-452c-9d54-7214400714c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f98432a1-c562-46da-bfe4-49426cdbfe97" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_718b2e1f-1fcc-4433-869d-3832c7c1a5c5" xlink:href="vtvt-20240930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_TypeOneDiabetesMember_718b2e1f-1fcc-4433-869d-3832c7c1a5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_af8af080-0c6e-4052-8dad-d18b82717ba1" xlink:href="vtvt-20240930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_TypeTwoDiabetesMember_af8af080-0c6e-4052-8dad-d18b82717ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_686688ab-6c56-4eaa-bc38-e68e20f1eaa1" xlink:href="vtvt-20240930.xsd#vtvt_OtherIndicationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_11000565-3821-415a-818a-e14c1481f536" xlink:to="loc_vtvt_OtherIndicationMember_686688ab-6c56-4eaa-bc38-e68e20f1eaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ccdb38a1-8b56-48d4-997f-e12ab2105305" xlink:to="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769e1d56-f256-4219-b520-ca92d3ad492f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f5fce1e-dbc0-4d70-8fc7-513cb845ae1b" xlink:to="loc_srt_MaximumMember_769e1d56-f256-4219-b520-ca92d3ad492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:href="vtvt-20240930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_47d18337-b5fd-456a-88a5-f4aa8f15de66" xlink:to="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_3d4b6060-ad7c-43df-8969-9eb45dc918c0" xlink:href="vtvt-20240930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_35d01d8f-d763-4e8c-97a3-2e9221a7fc31" xlink:to="loc_vtvt_PotentialMilestonePayment_3d4b6060-ad7c-43df-8969-9eb45dc918c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20240930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b0c97a9d-a331-47ca-880f-ac6dc1af23ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b0c97a9d-a331-47ca-880f-ac6dc1af23ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_04c559a4-2176-4afc-8a66-81daa60ace7c" xlink:href="vtvt-20240930.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:to="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_04c559a4-2176-4afc-8a66-81daa60ace7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8440fab6-b024-4527-b535-7a48e79f0019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8440fab6-b024-4527-b535-7a48e79f0019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_31319a85-6470-4349-9f6c-cad570c0fcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_31319a85-6470-4349-9f6c-cad570c0fcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_fa53375c-4210-4b70-8a64-f08be2935867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90e48778-4412-4187-84d5-31bbb133e3c1" xlink:to="loc_us-gaap_OperatingLeaseCost_fa53375c-4210-4b70-8a64-f08be2935867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5fdf46ee-36a6-45c8-b0ce-2c63ce5c25d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5fdf46ee-36a6-45c8-b0ce-2c63ce5c25d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2913195-9e83-4070-8ed1-09d1aabfbea5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2913195-9e83-4070-8ed1-09d1aabfbea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2bbaec56-de52-4558-914c-42b4ce38ba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2bbaec56-de52-4558-914c-42b4ce38ba4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66d90515-0c33-4eb6-b52b-53d338649326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66d90515-0c33-4eb6-b52b-53d338649326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ea34442-1f3d-4446-86fa-5248746a58a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ea34442-1f3d-4446-86fa-5248746a58a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_921081cf-85e7-4e95-907f-0907038e386b" xlink:href="vtvt-20240930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_921081cf-85e7-4e95-907f-0907038e386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_855f9965-c24c-410e-896a-612a4f23b92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_855f9965-c24c-410e-896a-612a4f23b92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_bc5ea3fb-43ba-46b9-b60b-207fb795d2c3" xlink:href="vtvt-20240930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_bc5ea3fb-43ba-46b9-b60b-207fb795d2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e2794dcf-be3e-45a0-aa21-9b2fe0bfb464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f5feece-99aa-48c6-b21c-8c4ce5add1c1" xlink:to="loc_us-gaap_OperatingLeaseLiability_e2794dcf-be3e-45a0-aa21-9b2fe0bfb464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterestAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_37e8110d-c482-45f1-9724-26b89bf075d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_37e8110d-c482-45f1-9724-26b89bf075d1" xlink:to="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5ac0d0d6-fbe9-4aad-aa3c-2742b1a747f5" xlink:to="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_2effc8ac-089c-4e6c-8894-f8091a025042" xlink:href="vtvt-20240930.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2b3f8ec5-4f63-4544-82d1-e293d97cb61d" xlink:to="loc_vtvt_VTvLLCMember_2effc8ac-089c-4e6c-8894-f8091a025042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_881e52f3-06d9-46ea-b783-bff3bff7f463" xlink:to="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1402440b-9cc4-4dfd-882f-5a2fc80f9d22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca69962f-3d24-4c4c-9d84-3ab819eaa54f" xlink:to="loc_us-gaap_CommonClassAMember_1402440b-9cc4-4dfd-882f-5a2fc80f9d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_3fc4b4a5-2e12-4a15-b84e-6174df839152" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_1319c3df-427c-479e-940d-98bc3d91dd60" xlink:href="vtvt-20240930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c660ace6-d810-4fec-8830-c64f30f7c64f" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_1319c3df-427c-479e-940d-98bc3d91dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1d34aa1b-7e9f-4b9e-bc82-35cc178fdd6c" xlink:to="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_fbfb75e4-488b-4466-b401-491c221248ff" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_fbfb75e4-488b-4466-b401-491c221248ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_599963ac-aaab-4df5-ba95-edfd88408879" xlink:href="vtvt-20240930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_599963ac-aaab-4df5-ba95-edfd88408879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_f4f7cf62-5424-4e09-995c-2b16e3c81d16" xlink:href="vtvt-20240930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_f4f7cf62-5424-4e09-995c-2b16e3c81d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_b915f6c2-a734-4de5-8ae5-003fe0107efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_b915f6c2-a734-4de5-8ae5-003fe0107efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_cd1cc06d-0736-47c4-8ef7-7a49ef50436c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_812518ab-12f1-4a03-842d-3daef6ae71b1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_cd1cc06d-0736-47c4-8ef7-7a49ef50436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_f1fd837f-00eb-41a4-b7bb-d2ec2f157059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fb27d290-4f16-47e9-b4cb-7f26ed39e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f1fd837f-00eb-41a4-b7bb-d2ec2f157059" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fb27d290-4f16-47e9-b4cb-7f26ed39e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_6997a67f-723e-472c-b2cb-30de3bf6d195" xlink:href="vtvt-20240930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f1fd837f-00eb-41a4-b7bb-d2ec2f157059" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_6997a67f-723e-472c-b2cb-30de3bf6d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_47ede977-036b-4018-a1be-17625f8cbded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f1fd837f-00eb-41a4-b7bb-d2ec2f157059" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_47ede977-036b-4018-a1be-17625f8cbded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#StockholdersEquityDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7e187657-750e-4f50-8c0b-491918b45590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7e187657-750e-4f50-8c0b-491918b45590" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc44ceac-17eb-432e-b788-c3396eacd1da" xlink:to="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f49f8a80-8a31-4090-ae14-f5db40d469ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonClassAMember_f49f8a80-8a31-4090-ae14-f5db40d469ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_496003be-fb80-42f5-a882-27b7efb1703e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonClassBMember_496003be-fb80-42f5-a882-27b7efb1703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7dda25c8-7483-4edd-8003-2a62ce329665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0e0665f9-d41a-4c89-9ffb-726e2298b567" xlink:to="loc_us-gaap_CommonStockMember_7dda25c8-7483-4edd-8003-2a62ce329665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f2daab25-01a8-4d58-907a-308782f6ebd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_444da226-9c3e-4684-90a8-ec770c7bd418" xlink:href="vtvt-20240930.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:to="loc_vtvt_G42InvestmentsMember_444da226-9c3e-4684-90a8-ec770c7bd418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember_8b074f83-d85c-45c2-9ba6-02d3f8c20347" xlink:href="vtvt-20240930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ac3ff122-a0b4-4921-bd9e-2e07374d7c47" xlink:to="loc_vtvt_CinRxInvestmentMember_8b074f83-d85c-45c2-9ba6-02d3f8c20347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06407980-ca03-4603-8b5c-95220ba0a3bc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_973385f1-8a9d-48ce-a0a3-193c304b6f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:to="loc_us-gaap_PrivatePlacementMember_973385f1-8a9d-48ce-a0a3-193c304b6f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TDCowenSalesAgreementMember_c4114e20-bc49-4c53-9d36-5d52fa7b1031" xlink:href="vtvt-20240930.xsd#vtvt_TDCowenSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fcdf4e76-5e6a-4d8c-880e-4e055202f01f" xlink:to="loc_vtvt_TDCowenSalesAgreementMember_c4114e20-bc49-4c53-9d36-5d52fa7b1031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f2c77af8-3e14-47ea-9ad2-c0746a8904e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_c3a41bbe-3c77-467d-98eb-ca2e7efbd051" xlink:href="vtvt-20240930.xsd#vtvt_PrivatePlacementPreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aa350011-29ad-49d0-b9a5-1e6682d0ccc2" xlink:to="loc_vtvt_PrivatePlacementPreFundedWarrantsMember_c3a41bbe-3c77-467d-98eb-ca2e7efbd051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da1dc938-432d-4976-8255-8f61a816713d" xlink:to="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_fdf5d857-8c02-464c-9ee1-eaeb9afe936f" xlink:href="vtvt-20240930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_fdf5d857-8c02-464c-9ee1-eaeb9afe936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b2bc82b-980b-4112-9882-be308b3eb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b2bc82b-980b-4112-9882-be308b3eb7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_da7d9f4d-4fed-483d-9e9c-99b1434221e6" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_da7d9f4d-4fed-483d-9e9c-99b1434221e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a0cff298-de65-4199-a404-86331bfe3ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a0cff298-de65-4199-a404-86331bfe3ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f3d9806-adbf-4e2e-9000-0181aed7d17e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f3d9806-adbf-4e2e-9000-0181aed7d17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6879cdd4-24fb-4fc4-a692-dcd4bf7ea104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6879cdd4-24fb-4fc4-a692-dcd4bf7ea104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0520eda1-7c3c-434b-8167-d82a9d89e468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0520eda1-7c3c-434b-8167-d82a9d89e468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f32310e7-1b63-4e27-b11f-d871ea33ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f32310e7-1b63-4e27-b11f-d871ea33ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_667119de-a0e1-481f-874f-a18f6937aaba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_667119de-a0e1-481f-874f-a18f6937aaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2525a2ba-341d-440e-99f1-59092af1990b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2525a2ba-341d-440e-99f1-59092af1990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71e72033-ab4d-45ec-b7b8-cafe971e9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71e72033-ab4d-45ec-b7b8-cafe971e9ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_cd3f86f4-1200-45aa-ac3d-8509b0019dee" xlink:href="vtvt-20240930.xsd#vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights_cd3f86f4-1200-45aa-ac3d-8509b0019dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_7d339b89-4d07-4fad-bfc7-8fb0d180619e" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares_7d339b89-4d07-4fad-bfc7-8fb0d180619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_904a576b-b69a-4aee-ba09-5081c9bfa98d" xlink:href="vtvt-20240930.xsd#vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares_904a576b-b69a-4aee-ba09-5081c9bfa98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_fc9a51ad-1675-47f0-9146-d33add291e11" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_fc9a51ad-1675-47f0-9146-d33add291e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05857d33-d176-4167-9167-a4d371fe822d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05857d33-d176-4167-9167-a4d371fe822d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2d8a11e3-06db-49fd-8581-c03e1ab2734f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2d8a11e3-06db-49fd-8581-c03e1ab2734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm_452118b3-a744-4cde-ae94-a136f507a897" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivableTerm_452118b3-a744-4cde-ae94-a136f507a897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c5531346-aee5-4d21-bb7e-f3264e2196d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c5531346-aee5-4d21-bb7e-f3264e2196d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_6e1125f9-0fe0-46e6-9e79-a6f92a9f5890" xlink:href="vtvt-20240930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_NotesReceivableDiscountRate_6e1125f9-0fe0-46e6-9e79-a6f92a9f5890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0414878-d56e-4369-b8b7-1b496373188b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0414878-d56e-4369-b8b7-1b496373188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_48bad798-80ce-42e9-b0bc-f6e965fab622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_48bad798-80ce-42e9-b0bc-f6e965fab622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6d1d809d-eb77-4829-ac20-2214b8298d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6d1d809d-eb77-4829-ac20-2214b8298d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockAggregateOfferingPrice_ce82059c-3aaf-4a65-bbce-61f456492f12" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockAggregateOfferingPrice_ce82059c-3aaf-4a65-bbce-61f456492f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EntityPublicFloatThreshold_7b53d340-bdc0-4d82-b1b1-a855a0eafaef" xlink:href="vtvt-20240930.xsd#vtvt_EntityPublicFloatThreshold"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_EntityPublicFloatThreshold_7b53d340-bdc0-4d82-b1b1-a855a0eafaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_bc2532ea-7bcf-4fbc-9fd7-b8e54932c0f4" xlink:href="vtvt-20240930.xsd#vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_02069bf2-4497-448e-9f47-f62750942576" xlink:to="loc_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat_bc2532ea-7bcf-4fbc-9fd7-b8e54932c0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f7830e4b-61aa-43bc-84d0-3ccdca41c341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f7830e4b-61aa-43bc-84d0-3ccdca41c341" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e2d2af6f-fd42-457c-93e1-72f96c83f16f" xlink:to="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_58d033a5-0857-4d1a-9ded-a272f83a92e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f373356b-6c6d-4cfb-b2f3-7ba68934b164" xlink:to="loc_us-gaap_RelatedPartyMember_58d033a5-0857-4d1a-9ded-a272f83a92e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34d70d26-cb9f-494c-897a-87eb1fa86a0a" xlink:to="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ee10d435-ed57-4c1b-8c67-a3ad2f13af08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:to="loc_us-gaap_CommonClassBMember_ee10d435-ed57-4c1b-8c67-a3ad2f13af08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3929dca8-0130-4e00-9661-cea730853812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e6090796-b5df-417e-b368-5056bd6bab8b" xlink:to="loc_us-gaap_CommonClassAMember_3929dca8-0130-4e00-9661-cea730853812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b4c21a5f-9a6b-4a8e-8766-ec29231e2b90" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_130b84bc-8fa6-46e2-ab3a-32b3f2309410" xlink:href="vtvt-20240930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5e0ecbb2-5bc5-4f20-b3ec-638b12675eb6" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_130b84bc-8fa6-46e2-ab3a-32b3f2309410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dfb1e52f-de9b-4a0a-81f3-8039170e0eb5" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_f6b237fa-c429-4caa-9419-3e06be34a972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_f6b237fa-c429-4caa-9419-3e06be34a972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_3fdc7a2b-84a7-46ee-91b9-88ea29c3fd5a" xlink:href="vtvt-20240930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_3fdc7a2b-84a7-46ee-91b9-88ea29c3fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_6d43d21b-acfd-41d6-98eb-b4d7dd47e2b0" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8e025543-eb0f-44b6-bf64-6576f3857df9" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_6d43d21b-acfd-41d6-98eb-b4d7dd47e2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3b6ec9fa-f033-4216-b511-69fa6d0caf57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b6ec9fa-f033-4216-b511-69fa6d0caf57" xlink:to="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:to="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1bd265a1-1937-44fd-900e-338bb5701a0e" xlink:to="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_311c5c0c-4da3-4875-8b7f-7267d4935b5f" xlink:href="vtvt-20240930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4bfa9fc5-3f21-41ec-b106-824e9c0e779a" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_311c5c0c-4da3-4875-8b7f-7267d4935b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:href="vtvt-20240930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_a9698c1a-a3cd-47c9-b454-78674e6c381a" xlink:to="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_64cb078c-3d09-4c17-8247-4f4197649b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_64cb078c-3d09-4c17-8247-4f4197649b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_a4e9e265-0262-40f0-b771-57012332301d" xlink:href="vtvt-20240930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_e76056b4-58cf-4551-9889-4dbe1b5b2328" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_a4e9e265-0262-40f0-b771-57012332301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6364858b-c877-46f4-b7cc-0b9fce835d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6364858b-c877-46f4-b7cc-0b9fce835d3c" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aaf8f678-9eb0-4341-ab04-8e67a0dab23d" xlink:to="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_116b4189-912a-46a6-aa28-898b3e699bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e5f2e16b-26a6-4669-b51d-81176e653171" xlink:to="loc_us-gaap_CommonClassAMember_116b4189-912a-46a6-aa28-898b3e699bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:href="vtvt-20240930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_0408fb76-7d3c-46e9-ae76-d1f9d713c397" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:to="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27fe7c6f-2b62-4f76-b674-f200d4f20e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_ProfitLoss_27fe7c6f-2b62-4f76-b674-f200d4f20e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_79b703b6-4bc5-42c0-a78b-2409ea8bc4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_79b703b6-4bc5-42c0-a78b-2409ea8bc4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9d01923c-e9ec-4c15-b123-4d5159e9afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9d01923c-e9ec-4c15-b123-4d5159e9afdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b9cb0a44-37b1-4ccc-8652-7ddcba6a068a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_70cf9e9d-2144-420d-8fe3-9bd0914296d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b9cb0a44-37b1-4ccc-8652-7ddcba6a068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_7bc3f8f7-40e8-434a-b018-4a44a58d0a00" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7d1e0ee-2a9a-4575-b68e-dfd5f9aa062d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7d1e0ee-2a9a-4575-b68e-dfd5f9aa062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6365e826-69dc-4435-a36e-3c8a1ee67fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6365e826-69dc-4435-a36e-3c8a1ee67fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_866c38e6-3510-438b-95b3-8daeec347cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_EarningsPerShareBasic_866c38e6-3510-438b-95b3-8daeec347cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d5852d60-ddb2-4c80-983d-0f0009a9e8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26b11512-dd1f-4e1c-b5bf-9f51115a7665" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d5852d60-ddb2-4c80-983d-0f0009a9e8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e87b188c-537b-478d-aad5-611a12cac224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e87b188c-537b-478d-aad5-611a12cac224" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0fb7fcb3-1f5b-4246-9dc9-01750829fd39" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1bbc1c15-b833-4575-ae7d-add013fe31b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_CommonClassBMember_1bbc1c15-b833-4575-ae7d-add013fe31b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96ff3d4d-1f87-4173-9880-c54f977b28cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96ff3d4d-1f87-4173-9880-c54f977b28cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_669f5eb0-7608-4664-8c29-e03e69814895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2deefc94-eeff-4aad-8c2d-ffbfe743b924" xlink:to="loc_us-gaap_WarrantMember_669f5eb0-7608-4664-8c29-e03e69814895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8d13b65a-d8eb-4281-94e2-476482f2a3f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d7acbad-66a5-4fa0-9bfc-c005e71d54f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ce1425e6-cdd0-49b4-bc0e-ea04028dbf18" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d7acbad-66a5-4fa0-9bfc-c005e71d54f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5fc99983-a252-4b62-a6f3-634724dbe72c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5fc99983-a252-4b62-a6f3-634724dbe72c" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a3dc126d-e0de-475c-af09-6e1bb35f8c4f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5d2cc558-3fd7-40bf-9c76-57f189d78cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8d1b102c-efca-477c-af56-2d55bc2e43b7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5d2cc558-3fd7-40bf-9c76-57f189d78cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_694e3dda-084a-43ae-b928-4c04f7757d93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4c502b4-e280-4ad4-b8b6-465b9cd2b26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4c502b4-e280-4ad4-b8b6-465b9cd2b26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f45b0b3-def4-4270-9fa4-e7fbf3c1bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f45b0b3-def4-4270-9fa4-e7fbf3c1bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e04efe4e-01d7-4c19-aa94-05a79357b8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3215da6f-34b6-430b-b17b-04bff54fa332" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e04efe4e-01d7-4c19-aa94-05a79357b8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_284ee2d1-fb40-4ee8-9631-e8f41f669a62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0960d1ec-16c8-4aa2-9fac-3d256857edc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3003aab-293d-449d-afed-2a5bf0ea6c55" xlink:to="loc_us-gaap_WarrantMember_0960d1ec-16c8-4aa2-9fac-3d256857edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4631af8c-7021-4dc9-a57b-e872139807a9" xlink:to="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_85cc2cfd-9c84-4264-8002-c44e51338f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:to="loc_us-gaap_RelatedPartyMember_85cc2cfd-9c84-4264-8002-c44e51338f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3ffe7801-acee-4076-b38a-1ee019e304d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f9cf598c-4e89-4de4-9552-ee5cb8179873" xlink:to="loc_us-gaap_NonrelatedPartyMember_3ffe7801-acee-4076-b38a-1ee019e304d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:href="vtvt-20240930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_c52759b9-3af2-42b6-8c5d-60f152ee3b54" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_22952bbc-1b32-49e7-9c90-bcdaa98b95fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_22952bbc-1b32-49e7-9c90-bcdaa98b95fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_2e155304-0251-4ab0-bfe4-a38dffe9ded1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_334620b0-9ae8-40dc-aec2-4fc04256f125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_334620b0-9ae8-40dc-aec2-4fc04256f125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_da08ec88-d4f2-4dda-bdff-9a4eab77ef63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_da08ec88-d4f2-4dda-bdff-9a4eab77ef63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_50e0c97f-2f8a-4ddd-b767-0047d635eb16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_50e0c97f-2f8a-4ddd-b767-0047d635eb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_6d0aa11c-e68a-4128-adae-25fdf0fb5cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_6d0aa11c-e68a-4128-adae-25fdf0fb5cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_3c1580e2-0042-448e-9229-d133e9185fde" xlink:href="vtvt-20240930.xsd#vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass_3c1580e2-0042-448e-9229-d133e9185fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79b62439-523d-42ff-a25f-e3a3d2b542c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01a795f2-04fa-458f-84d1-bb0e03d20d6b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_79b62439-523d-42ff-a25f-e3a3d2b542c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="simple" xlink:href="vtvt-20240930.xsd#FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e93d0fa3-d660-4e73-83b2-075c6f0d29af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e93d0fa3-d660-4e73-83b2-075c6f0d29af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fbd38283-3496-48f1-9e8d-272b3146db9c" xlink:to="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6bea950-41e6-418d-b73a-92fefb6fc0dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_MinimumMember_e6bea950-41e6-418d-b73a-92fefb6fc0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4298958c-038b-40c8-b735-bf7904b12806" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_MaximumMember_4298958c-038b-40c8-b735-bf7904b12806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_6f8a1b74-ed34-4a1c-afc4-60982ba68630" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_070d8067-357b-4ec7-a91d-e5688af2b3cd" xlink:to="loc_srt_WeightedAverageMember_6f8a1b74-ed34-4a1c-afc4-60982ba68630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6cde24b-2571-452d-88d0-0b3037b35237" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_571fe2ea-f975-447d-9470-ae2698cfa553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_571fe2ea-f975-447d-9470-ae2698cfa553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_58e72cc6-b355-4332-ab3b-61ca3c142d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_58e72cc6-b355-4332-ab3b-61ca3c142d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_af5ff3c4-7289-4a83-b9d2-bb78bb71641a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_27635235-a461-4c43-bd99-c18bed9bf499" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_af5ff3c4-7289-4a83-b9d2-bb78bb71641a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c14aec6b-cc0c-466a-ab64-1303c37a0fed" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_eb0e71bb-cca3-499e-8f98-ffb10d9e970d" xlink:href="vtvt-20240930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_eb0e71bb-cca3-499e-8f98-ffb10d9e970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember_c9d5043e-6b16-4610-af50-715f3db6cff7" xlink:href="vtvt-20240930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d4657900-fd10-414b-9ee4-5f8903fe7783" xlink:to="loc_vtvt_CinRxWarrantsMember_c9d5043e-6b16-4610-af50-715f3db6cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d0520e38-c2bc-4ed1-a356-7d432b4a1c6b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_623c8022-e2b2-48d8-aef3-6a3376153738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_623c8022-e2b2-48d8-aef3-6a3376153738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f87ab4b1-0a3e-478a-ae99-b9be865f21a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d2e1902e-8548-4c0e-b984-5e5fcfde322c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f87ab4b1-0a3e-478a-ae99-b9be865f21a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vtvt-20240930_g1.jpg
<DESCRIPTION>GRAHPIC
<TEXT>
begin 644 vtvt-20240930_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@'824-#7U!23T9)3$4  0$   '(
M  0P  !M;G1R4D="(%A96B 'X  !  $       !A8W-P
M                     0  ]M8  0    #3+0
M                                              ED97-C    \
M "1R6%E:   !%    !1G6%E:   !*    !1B6%E:   !/    !1W='!T   !
M4    !1R5%)#   !9    "AG5%)#   !9    "AB5%)#   !9    "AC<')T
M   !C    #QM;'5C          $    ,96Y54P    @    < ', 4@!' $)8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]865H@        ]M8  0    #3+7!A<F$       0
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M)$-E@J,E)CAC9(/P)T1%1H0H1W72\2G#_\0 %P$! 0$!
M  $" __$ !P1 0$! 0$! 0$!           1 1(A D$Q$__:  P# 0 "$0,1
M #\ ZI@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        "!G8
M1$BCL F)1&'E(2*4G1V W?1\H#T         !"_%<+VWF);I,[W$FFE2[$ ]
M=O*(CR*Q;;B<CXK )@
M
M
M
M
M
M
M                                           !#;<#V<=@^02N:/&
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MT&1DHC*^\@'V@
M
M
M
M
M
M
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M)9*YHUH1+#*4N(O>QV(82S*86XCS2IY16N%TN.)CT$XW%M)62=)*BT;F9\A
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M&9GOWC(C:C/VU[[@'H
M
M
M
M
M
M
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M8C.UB*XE+2)!)T;"9)'I'<[@/0
M
M
M
M
M
M
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M9:UM*C296LHRVES@*B
M
M
M
M
M
M
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M:]M@"S\ON7RCLN=&D^^XP[-7&M;,9BZ1)-1D5[;=UMI;-XU>S"YA*RS)UFG
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MQ6*UA[I/2VWV )P
M
M
M
M
M
M
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MWU;J%_%,C 14C2(125BL8F$"5<[ (@
M
M
M
M
M
M
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MH65R,P'V
M
M
M
M
M
M
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MA64P[#1);05B(A[<?<ENWD G
M
M
M
M
M
M
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MQ #7?MXYC?T=?K5 =O',;^CK]:H ;$ -=^WCF-_1U^M4!V\<QOZ.OUJ@!L0
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MCF-_1U^M4!V\<QOZ.OUJ@$K8<B^@+C7)C';,6X\XG[G;=_Q5 ]BQQS%V+_\
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M<Z\?C5(#8X!KJG'+,6:2,LNN\O&J!'MY9C/T=?K5 L2MB0&N_;QS&_HZ_6J
M[>&8W]'7ZU0$*V( :[]O',;^CK]:H#MXYC?T=?K5 BMB &N_;QS&_HZ_6J [
M>.8W]'7ZU0 V( :[]O',;^CK]:H#MXYC?T=?K5 #8@!KOV\<QOZ.OUJ@.WCF
M-_1U^M4 -B &N_;QS&_HZ_6J [>.8W]'7ZU0 V( :[]O',;^CK]:H#MXYC?T
M=?K5 #8@!KOV\<QOZ.OUJ@.WCF-_1U^M4 -B &N_;QS&_HZ_6J [>.8W]'7Z
MU0 V( :[]O',;^CK]:H#MXYC?T=?K5 #8@!KOV\<QOZ.OUJ@.WCF-_1U^M4
M-B &N_;PS&_HZ_6J [>.8W]'7ZU0 V( :[]O',;^CK]:H#MXYC?T=?K5 #8@
M!KOV\<QOZ.OUJ@.WCF-_1U^M4 -B &N_;QS&_HZ_6J [>&8W]'7ZU0 V( :[
M]O',;^CK]:H#MXYC?T=?K5 #8@!KOV\<QOZ.OUJ@.WCF-_1U^M4 -B &N_;Q
MS&_HZ_6J [>.8W]'7ZU0 V( :[]O',;^CK]:H#MXYC?T=?K5 #8@!KOV\<QO
MZ.OUJ@.WCF-_1U^M4 -B &N_;QS&_HZ_6J [>.8W]'7ZU0 V( :[]O',;^CK
M]:H#MXYC?T=?K5 #8@!KOV\<QOZ.OUJ@.WCF-_1U^M4 -B &N_;QS&_HZ_6J
M [>.8W]'7ZU0 V'([@9D7&->.WAF-X\NOUJ@2JQOS%*/_P .WUHD!L*2MER/
M:)O(9W(]PU:FN9/&^3U'*Y9/,#^QZ8YS0(^R*5:17*Y_(-GH-Y3\*PZXUH&M
MM*U%?O3,KV ?4   "50B>P"W +?K4C32LS21_P#VSFW_ )3&(LK.S!V6EH7_
M -IBMM]_WPQE^MB/@I,U'[V<_P )C$&5D]'!V6J-S_[F)V6W_?3 9;N9F1I,
M1)1&1$A0%IV+13Y@)*"01I+: A97?"/ZPAW7>B-R[TP$       (S/<!W3M,
MQ&_$6P2]R1]V8!I'HDHBWB8S/3));@,SLE2D:5^/=8#OW25*TN0@$   $;F%
MS$MSY N?( 7/>(]UO(#4@E:&W:&X[$>P
M                  !,VI$L07WJZN(C'Q2,S['HL7ME>L?9$G]Y6?(1CY)&
M:CEZ-$BM=7K%(^XU&6PU7 C,^].P@E2"7W*;B)J,U=[8%   $;F6[<"CMM(0
M+85A"UC(!&YE91'8O:D!Z25&DMIGO(0,B.^N+23[0"N2"9TM-7N;6^D!,1^U
MMM/<(7XK;#W"-EV)7'Q"!:2D).P    C<Q#2/C(0MR"):SD -+98C$;[.Z(2
MFE*CND1/2/8 B1^UMM/<(7XK;#W"-EF1+X^(0+2-"3MR@
M
M     ![2L![K$!;3L!;S(!39HHR?A[<IBI(N6B?D%,FG]+#GY3%221J21\A
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MI;#]L(WN7>W(_; (]T6TS#2/E$N[>8=SO,!,1D>\0O8#+2VD!\A@
M               "/M@+>( 6\P&$\=/RSHWRNN>LAL/!?@</^Z3ZAKQCI^6=
M&?O7/60V(@?P)C]TGU /<   $J1,)4@*)6]SI69EQ=;.?X3&'<K%E8.RU/\
MZF)_S3&8:W,^"DS/_P!,Y_A,8?RL$2<'):O_ -3$_P":8)JE9J<R7W-5#*K
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MFVAY5FS)2;Z6PO, Z#E<S,C/N2$.4SXA*JQ-:LCVW$Z[$O1*UB(!
M
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M[L649I?[-K=.UCMO&7T[2,M_DY!J!U, S/+5)M$^Z^^?XQN!?CM<
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MEM/B^0;5J,U*TS/2MLORCE3U)(RX=USQ?[2FY_\ ,H=5C,[D24[" 0
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M)62.O&$IT4;-_<7'1&'?ZYA68@F]%+J$K(^6Y7 >GF
M   ]P >X!A/'/\LZ,_>N?Z#8>"_ X?\ =)]0UXQS_+.C/WKG^@V'@OP.'_=)
M]0#Z    2I$PE2 HE;E_W5F9_P#IG/\ "8P]E:_J=ENW_P"YB?\ -,9AKC\E
M)G_#.?X3&'LK?]34MY>N8G_-,$UK[U5HE=HXV];?1W%;?W1#4;*MU/2<Y@,+
MX*NX3%R,D;<3I6A&T*,D65;B,=)\U>6Q.9:B2HKA)V"UF]_5:R]CON'W98,
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MYBFFS6:[%8MQ[!FG+3@;$X X=0="1-6O3]4+I6BG4F1JN=^,S 9:
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ME8^4$6)O8G1(]R/Y@1G8E<G$
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M_P#G&W]RN9%L(AA[+!@!]SGAG"8>E4?98X6]HC5:%[G?<,QV41F1E8R^D!
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MK-98R.U^+<,\3;"Y<UPL7APN<Z"%PA0W76KY$VO8!SHZDF=J\KA1[NN4[?\
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M:=83=3ADM(UJSB#B)6[M91["B4A3K:F]$R\EQN<RTQ#M-L,(T664DA"?(16
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MSDY0N9'W>WR\HCHG:^[D"QD6S:%TZ #1\@:'D"Z= !H>0-#R!=.@ T/(&AY
MNG0 :'D#0\@73H -#R!H>0+IT &AY T/(%TZ #0\@:'D"Z= !H>0-#R!=.@
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M%TZ #0\@:'D"Z= !H>0-#R!=.@ T/(&AY NG0 :'D#0\@73H -#R!H>0+IT
M&AY T/(%TZ #0\@:'D"Z= !H>0-#R!=.@ T/(&AY NG0 :'D#0\@73H -#R!
MH>0+IT &AY T/(%TZ #0\@:'D"Z= !H>0-#R!=.@ T/(&AY NG0 :'D#0\@7
M3H -#R!H>0+IT")6XQ+HB8DGN"Z=*9-;&ZQLXS%22HT)*W(0ITVT=8P1<HJ"
M2422V<1!4J9-DK5I[;[A*DB)-TW(3$2MAVO<#)1W*U@*A?:L0(]B1'0VGY1
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M+#[+5%\'U=,.RU1?!]73%^:!>"+F#0+P1<P=D6'V6J+Q KIAV6J+Q KIB_-
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MN-FX"_64.HRL9M(OS$,&YAFRX944:2(C)URVSRD,YP23*#9N?^[3ZB$3'T
M T"5(F$J0%$K;\EYE_#.?X3&-\I)?_1.5?Q,5_FF,D5M^2TR_AG/\)C'&4G^
MI*5?Q,5_FF##,@  -@
M                              F#PC/P=SXI^H?!3'XI;^,KUC[XS\'<
M^*?J'P4Q^*6_C*]8K"K   V
M
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MM54K&M*6^B[L-I=TT?)RC*31WV;[<8#V
M           !"VVXI53?B=SXR?6*L*34WXG<^,GU@/NA/P9'Q2'LH>,)^#(^
M*0]E )@
M                             &!<P_Y945^\=]9#.<'^!L_ND>HA@S,,
M7_?&B_WCOK(9S@OP1C]TCU /<   $J1,)4@*)6WY+3+^&<_PF,<92?ZDI5_$
MQ7^:8R/6WY+3+^&<_P )C'&4G^I*5?Q,5_FF##,@  -@
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MD76%7Q?6<J@"(WG]$U:-_(0IV&6*U"XQTRBKJ#FG9"61!F2'= T7,CL>P_*
MO6Y=Z07(]O()-+1*_*(IL6R^\!/L/:(&LB$A*/1'SO3" 963+\=#MN'N0MU)
M*/Y#,!]>D5["-RW7'DA:'4Z21$TF1:1 /0K<0%;B'F5TE8Q"QI.YF ]=(+W'
MF=U%L$Z>Y+: F
M             $BBN)Q"UP&HO50O_"555_\ R?\ &0X*J/=8OE'>GJHVS*95
M!?N?\8X*JW )0                                       !,1W$H
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M[GQD^L584FIOQ.Y\9/K ?="?@R/BD/917L/&$_!D?%(>Y[R 1
M
M            8%S#_EE17[UWUD,YP7X(S^Z1ZA@S,/\ EE17[UWUD,YP7X(S
M^Z1Z@'N   "5(F$J0%$K;\EIE_#.?X3&.,I/]24J_B8K_-,9'K;\EIE_#.?X
M3&.,I/\ 4E*OXF*_S3!AF0  &P
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M4T I*7XMDD))U6W>22L.@J-NP]A@/4
M                                !J)U4;_PF51_[/\ C(<$CWCO;U4;
M_P )E4?^S_C(<$CW@
M
M                                      B1V$  3J4)T.D6RP\1%(#-
MN67,W6F7*MX:?2*-=5+E.)Z[@]/N7$[N/=8=XLOF8*B<P%%0E5TM,&ENK;2;
M[)*[I"MQ[#V[[C\VB3,CL:M$B\@VXZG7.<;X+%^!A,,VHN(ESKA=?M7/5J3Q
M;3V%Q@.]5R$1\T*;JX5DX@M%W5IUA<BK;?I'N1D96(!,
M                 "DU-^)W/C)]8JPI-3?B=SXR?6 ^^#_!V_BEZA['O(>,
M'^#M_%+U#V/>0"(
M                                     # N8?\ +*BOWKOK(9S@OP1G
M]TCU#!F8?\LJ*_>N^LAG."_!&?W2/4 ]P   2I$PE2 HE;?DM,OX9S_"8QQE
M)_J2E7\3%?YIC(];?DM,OX9S_"8QQE)_J2E7\3%?YI@PS(  #8 "51@!K(@-
M1$);$>T#L>P@$Q'?O@^,)+^Z$;^Z 3Z1<8$8\S-)F6EO$34=K*W (Z1<OT";
M2+E$A*_5$Q&?N0$P    "0SY0$=(M(R!)WN)"[XS$R+%<P$X
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M#8A*5H5:^DD_H$QZ*K$?&(DFQ$1;N0!,
M                                   U$ZJ-_P"$RJ/_ &?\9#@D>\=[
M>JC?^$RJ/_9_QD."1[P
M
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MW/C)]8#[X/\ !V_BEZA['O(>,'^#M_%+U#V/>0"(
M
M  # N8?\LJ*_>N^LAG."_!&?W2/4,&9A_P LJ*_>N^LAG."_!&?W2/4 ]P
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MF)KV#?N 1
M                                                ! K'M#>6TA$>
M3FF?>[ &I/50TWRFU0>_^AMTR'!4[6W[2'Z.,U^"_P!T'A7'X7=FNQ?930+K
MK5Z>KT3ONXQHNGJ)&D@S[=UB/_AW\P'*P!U4]A#_ &W_ %=_,/80_P!M_P!7
M_P P'*L!U4]A#_;?]7_S#V$/]M_U?_,!RK =5/80_P!M_P!7_P P]A#_ &W_
M %?_ # <JP'53V$/]M_U?_,/80_VW_5_\P'*L!U4]A#_ &W_ %?_ ##V$/\
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M$/\ ;?\ 5_\ ,!RK =5/80_VW_5_\P]A#_;?]7_S <JP'53V$/\ ;?\ 5_\
M,/80_P!M_P!7_P P'*L!U4]A#_;?]7_S#V$/]M_U?_,!RK =5/80_P!M_P!7
M_P P]A#_ &W_ %?_ # <JP'53V$/]M_U?_,/80_VW_5_\P'*L!U4]A#_ &W_
M %?_ ##V$/\ ;?\ 5_\ ,!RK =5/80_VW_5_\P]A#_;?]7_S <JP'53V$/\
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M:%RVTBW(*<A67XY1$41'&BRG3+=OW#,Z5:1F6XR "2)P
M                     !- 4FIOQ.Y\9/K%6%)J;\3N?&3ZQ1]\'^#M_%+U
M#V/>0\8/\';^*7J'L>\@3 CN(B5(F!0
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MR#Y7:XF;D\J/#]#\2ZK24;;ZFR,_,0R=A;@AAI@W+"E= 4U#R]DBY-)?2/:
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M )P$FN:\*CI$&N:\*CI$ G 2:YKPJ.D0:YKPJ.D0"<!)KFO"HZ1!KFO"HZ1
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ML0AH^42ZQKPJ.<A#6->%1TB 3;=,42Q<(/\ YR"M:YJ]]8GG%$TV^SU]8GG
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MTC#@S!^Z7TC%9 !1N#,'[I?2,.#,'[I?2,5D %&X,P?NE](PX,P?NE](Q60
M4;@S!^Z7TC#@S!^Z7TC%9 !1N#,'[I?2,.#,'[I?2,5D %&X,P?NE](PX,P?
MNE](Q60 4;@S!^Z7TC#@S!^Z7TC%9 !1N#,'[I?2,.#,'[I?2,5D %&X,P?N
ME](PX,P?NE](Q60 4;@W"<JND8*IN$(C.ZMWNC%9$JKZ)[>(!:<JD<.N-C",
MU;R]L8JB::A-MU+V_K&)9,?_ &C';=QI%;ON%T4?@S!^Z7TC#@S!^Z7TC%9
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MEOXRO6*PJP  -@
M
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MOS.6P[9OQ,?#,-(WN./)2DOE,Q)"3R2Q]S@)Q!1!)[[51"%V\]C'%W,#F-Q
MS)5FC _ V(C'94X]JXJ+:<4GKFQ[3O[71V\>T;58"8/RW+[1"SC9]%1DP>9)
MR8S"(BED2M$KVLH[%;:6S> W[?F<MAVS?B8^&8:1O<<>2E)?*9B2$GDEC[G
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M1;M)7K'W1=^MUI+?HF/@I=.C*FR/?I*]8U^,*P  ,M@
M                       I-3?B=SXR?6*L*34WXG<^,GU@/NA/P9'Q2'N>
M\AX0GX,CXI#W/>0NLX$?$%R+>8EN?&0\8B(AX9I3T0ZEM""TE*4=B(AG&GMI
M<1;1&YEM,K#4#,=U1S";!!YZ42IYJ?S=BZ5P[:]$D'Q=T6PQH_6/5=L7YS$J
M72\K[%-W/13II7<N84=GMNTB,-,CW;;;QQ7I3JMV-4HBB?G\$<S82?=MFI*+
M_0-RLNW5/\+,78N'D56LHIR:O&2&VEK-9+5Y]Q -W24E1$:3V"-S.YGLY!\4
M+&PD9#HC8>);?86C3)Q"B-.C:^\ASISS]4:FV%-8IP]PGB4'&P)F4:^A1*(C
M,KEO =(B,C,R,]J>,"6G995[\8YGY#\\>,./&)O!FLICUS"$E1F6BDO:F?$+
M(S3]4%Q\PMQNG]$4E$/IEL I!-))@C+:5SVV =:#45K7W F^TE%\HXHTQU6#
M'N23)$14[+L?"FLKM+03=RX]MATWRL9K:/S-TEV9D:D0TSATIZ\@M*YM&>[;
MQW 9YTB/C"]Q(5A,D!,               @H[$ D):3,SO:V\>41'0<,1=<1
MC+-]VL62;\XB^X;#*W;:6BDU:/F&OTEI]G&K$2HEU;%//R:6*;3 PJ'%-ZNY
M=UM([GM 9^AYA!19_P"R13#Q\>K<)5N8?1I%WM]I#%U-X+RN@ZI1.J4FST'
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MM0>EM,!@G,/^65%?O7?60SG!?@C/[I'J&#,P_P"65%?O7?60SG!?@C/[I'J
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M9"1J">@8EI]'NFEDHC^4A[H-5^ZX]P#T
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M-XU?S!9@ZTS*5HG _!%+[LG6[JHB*:NDH@B/:9G[71V^<1S!9@ZSS)5HG _
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MF\!+E]R^45EUHQ3\6;+LT<:ULPF+MDF9D5[;=UMI;-XU@S Y@ZTS*5HG _!
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M31FDHDB/:9G[71V^<;09?,OE&Y<Z+4_$NL+FKK6MF4P=(B-1D5[%?=;:6S>
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M65%?O'?60SG!?@C/[I'J&#,P_P"65%?O7?60SG!?@C/[I'J >X   )4B82I
M42MOR6F7\,Y_A,8XRD_U)2K^)BO\TQD>MOR6F7\,Y_A,8XRD_P!24J_B8K_-
M,&&9   ;
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M,WJ;6%M8RS$FH*RDTHC)11<0XDX1EY:C)2=I;E;2'3)!$1;#V$ ]
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M?$9K:[@[7W"<BVWYAYFV5DIOHV*Q"+!]SOV<0RT]@
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M)_J2E7\3%?YIC(];?DM,OX9S_"8QQE)_J2E7\3%?YI@PS(  #8
M
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MIOQDE@(AP]ZW89"SYS(50 'RPL!"0*-5!0C$.CW+3:4%S$/H(C+C$P
M                                                        E5O$
MPD5Q@,>XS1\)+*2B)C,'FV&6$FMQQ:B(DD6WC'(W,'F#K7,G6*,#\$$ONRAU
MW51,0U=)1)$>TS/VNCMX]HZ09]Z(J?$++W.J5I1#BIG&K92TVA>@>CIEI'?R
M$-?<OF7RC,N-&+>B5L.35UHG9E,W;$9F17L5]UMI;-X".7[+[1>72C#B'7&%
MS5QK6S*9.D1&9D5[%?=;:6S>-8,P68*L\RM:(P.P/0^]*G'=5%131FDHHB/:
M9G[31V^<0S YA*RS)5HG _!-M]R3NNZJ)BFKD421'M,S]KH[?.-H<OV7RB\N
M-&+?B5L/39UHG9E,G;)-1D5[%?O;;2V;P$,OV7RB\NE&'$/.,.35;6MF4R=(
MB,S(KV*^ZVTMF\:P9@LP59YE:T1@=@>A]Z5..ZJ*BFC-)11$>TS/VFCM\XAF
M!S"5EF2K1.!^";;ZY.Z[JHF):N77)$>TS/VNCM\XVAR_9?*+RXT8M^)6P]-G
M6B=F4R=LDU&17L5^]MM+9O 0R_9?*+RZ48<0\XPY-5M:V93)TB(S,BO8K[K;
M2V;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*:,TE%$1[3,_::.WSB&8',)669*M$X
M'X)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:'+]E\HO+C1BWXE;#TV=:)V93)VR34
M9%>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU6UK9E,G2(C,R*]BONMM+9O&L&8+,%
M6>96M$8'8'H?>E3CNJBHIHS2441'M,S]IH[?.(9@<PE99DJT3@?@FV^N3NNZ
MJ)B6KEUR1'M,S]KH[?.-H<OV7RB\N-&+?B5L/39UHG9E,G;)-1D5[%?O;;2V
M;P$,OV7RB\NE&'$/.,.35;6MF4R=(B,S(KV*^ZVTMF\:P9@LP59YE:T1@=@>
MA]Z5..ZJ*BFC-)11$>TS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z[JHF):N77)$>
MTS/VNCM\XVAR_9?*+RXT8M^)6P]-G6B=F4R=LDU&17L5^]MM+9O 0R_9?*+R
MZ48<0\XPY-5M:V93)TB(S,BO8K[K;2V;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*
M:,TE%$1[3,_::.WSB&8',)669*M$X'X)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:
M'+]E\HO+C1BWXE;#TV=:)V93)VR349%>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU
M6UK9E,G2(C,R*]BONMM+9O&L&8+,%6>96M$8'8'H?>E3CNJBHIHS2441'M,S
M]IH[?.(9@<PE99DJT3@?@FV^N3NNZJ)B6KEUR1'M,S]KH[?.-H<OV7RB\N-&
M+?B5L/39UHG9E,G;)-1D5[%?O;;2V;P$,OV7RB\NE&'$/.,.35;6MF4R=(B,
MS(KV*^ZVTMF\:P9@LP59YE:T1@=@>A]Z5..ZJ*BFC-)11$>TS/VFCM\XAF!S
M"5EF2K1.!^";;ZY.Z[JHF):N77)$>TS/VNCM\XVAR_9?*+RXT8M^)6P]-G6B
M=F4R=LDU&17L5^]MM+9O 0R_9?*+RZ48<0\XPY-5M:V93)TB(S,BO8K[K;2V
M;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*:,TE%$1[3,_::.WSB&8',)669*M$X'X
M)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:'+]E\HO+C1BWXE;#TV=:)V93)VR349%
M>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU6UK9E,G2(C,R*]BONMM+9O&L&8+,%6>
M96M$8'8'H?>E3CNJBHIHS2441'M,S]IH[?.(9@<PE99DJT3@?@FV^N3NNZJ)
MB6KEUR1'M,S]KH[?.-H<OV7RB\N-&+?B5L/39UHG9E,G;)-1D5[%?O;;2V;P
M$,OV7RB\NE&'$/.,.35;6MF4R=(B,S(KV*^ZVTMF\:P9@LP59YE:T1@=@>A]
MZ5..ZJ*BFC-)11$>TS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z[JHF):N77)$>TS
M/VNCM\XVAR_9?*+RXT8M^)6P]-G6B=F4R=LDU&17L5^]MM+9O 0R_9?*+RZ4
M8<0\XPY-5M:V93)TB(S,BO8K[K;2V;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*:,
MTE%$1[3,_::.WSB&8',)669*M$X'X)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:'+
M]E\HO+C1BWXE;#TV=:)V93)VR349%>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU6U
MK9E,G2(C,R*]BONMM+9O&L&8+,%6>96M$8'8'H?>E3CNJBHIHS2441'M,S]I
MH[?.(9@<PE99DJT3@?@FV^N3NNZJ)B6C,NN2(]IF?M=';YQM#E^R^47EQHQ;
M\4MAV;.M$[,ID[9)J,BO8K[K;2V;P$,OV7RB\NE&'$/.,.35;6MF4R=(B,S(
MKV*^ZVTMF\:P9@LP59YE:T1@=@>A]Z5..ZJ*BFC-)11$>TS/VFCM\XAF!S"5
MGF2K1.!^";;[DG==U43$M7+KDB/:9G[71V^<;0Y?LOE%Y<:,6_$K8=FSK1.S
M*9.V2:C(KV*_>VVELW@(9?LOE%Y=*,.(><8<FJVM;,IDZ1$9F17L5]UMI;-X
MU@S!9@JSS*UHC [ ]#[TJ<=U45%-&:2BB(]IF?M-';YQ#,#F$K/,E6B<$,$V
MWUR=UW51,4U<BB2(]IF?M=';YQM#E^R^47EQHQ;\2MAV;.M$[,ID[9)J,BO8
MK][;:6S> AE^R^47ETHPXAYQAR:K:ULRF3I$1F9%>Q7W6VELWC6#,%F"K/,K
M6B,#L#T/O2IQW5144T9I**(CVF9^TT=OG$,P.82LLR5:)P/P3;?7)W7=5$Q+
M5RZY(CVF9^UT=OG&T.7[+Y1>7&C%OQ*V'ILZT3LRF3MDFHR*]BOWMMI;-X"&
M7[+Y1>72C#B'G&')JMK6S*9.D1&9D5[%?=;:6S>-8,P68*L\RM:(P.P/0^]*
MG'=5%131FDHHB/:9G[31V^<0S YA*RS)5HG _!-M]<G==U43$M7+KDB/:9G[
M71V^<;0Y?LOE%Y<:,6_$K8>FSK1.S*9.V2:C(KV*_>VVELW@(9?LOE%Y=*,.
M(><8<FJVM;,IDZ1$9F17L5]UMI;-XU@S!9@JSS*UHC [ ]#[TJ<=U45%-&:2
MBB(]IF?M-';YQ#,#F$K+,E6B<#\$VWUR=UW51,2U<NN2(]IF?M=';YQM#E^R
M^47EQHQ;\2MAZ;.M$[,ID[9)J,BO8K][;:6S> AE^R^47ETHPXAYQAR:K:UL
MRF3I$1F9%>Q7W6VELWC6#,%F"K/,K6B,#L#T/O2IQW5144T9I**(CVF9^TT=
MOG$,P.82LLR5:)P/P3;?7)W7=5$Q+5RZY(CVF9^UT=OG&T.7[+Y1>7&C%OQ*
MV'ILZT3LRF3MDFHR*]BOWMMI;-X"&7[+Y1>72C#B'G&')JMK6S*9.D1&9D5[
M%?=;:6S>-8,P68*L\RM:(P.P/0^]*G'=5%131FDHHB/:9G[31V^<0S YA*RS
M)5HG _!-M]<G==U43$M7+KDB/:9G[71V^<;0Y?LOE%Y<:,6_$K8>FSK1.S*9
M.V2:C(KV*_>VVELW@(9?LOE%Y=*,.(><8<FJVM;,IDZ1$9F17L5]UMI;-XU@
MS!9@JSS*UHC [ ]#[TJ<=U45%-&:2BB(]IF?M-';YQ#,#F$K+,E6B<#\$VWU
MR=UW51,2U<NN2(]IF?M=';YQM#E^R^47EQHQ;\2MAZ;.M$[,ID[9)J,BO8K]
M[;:6S> AE^R^47ETHPXAYQAR:K:ULRF3I$1F9%>Q7W6VELWC6#,%F"K/,K6B
M,#L#T/O2IQW5144T9I**(CVF9^TT=OG$,P.82LLR5:)P/P3;?7)W7=5$Q+5R
MZY(CVF9^UT=OG&T.7[+Y1>7&C%OQ*V'ILZT3LRF3MDFHR*]BOWMMI;-X"&7[
M+Y1>72C#B'G&')JMK6S*9.D1&9D5[%?=;:6S>-8,P68*L\RM:(P.P/0^]*G'
M=5%131FDHHB/:9G[31V^<0S YA*RS)5HG _!-M]<G==U43$M7+KDB/:9G[71
MV^<;0Y?LOE%Y<:,6_$K8>FSK1.S*9.V2:C(KV*_>VVELW@(9?LOE%Y=*,.(>
M<8<FJVM;,IDZ1$9F17L5]UMI;-XU@S!9@JSS*UHC [ ]#[TJ<=U45%-&:2BB
M(]IF?M-';YQ#,#F$K+,E6B<#\$VWUR=UW51,2U<NN2(]IF?M=';YQM#E^R^4
M7EQHQ;\2MAZ;.M$[,ID[9)J,BO8K][;:6S> AE^R^47ETHPXAYQAR:K:ULRF
M3I$1F9%>Q7W6VELWC6#,%F"K/,K6B,#L#T/O2IQW5144T9I**(CVF9^TT=OG
M$,P.82LLR5:)P/P3;?7)W7=5$Q+5RZY(CVF9^UT=OG&T.7[+Y1>7&C%OQ*V'
MILZT3LRF3MDFHR*]BOWMMI;-X"&7[+Y1>72C#B'G&')JMK6S*9.D1&9D5[%?
M=;:6S>-8,P68*L\RM:(P.P/0^]*G'=5%131FDHHB/:9G[31V^<0S YA*RS)5
MHG _!-M]<G==U43$M7+KDB/:9G[71V^<;0Y?LOE%Y<:,6_$K8>FSK1.S*9.V
M2:C(KV*_>VVELW@(9?LOE%Y=*,.(><8<FJVM;,IDZ1$9F17L5]UMI;-XU@S!
M9@JSS*UHC [ ]#[TJ<=U45%-&:2BB(]IF?M-';YQ#,#F$K+,E6B<#\$VWUR=
MUW51,2U<NN2(]IF?M=';YQM#E^R^47EQHQ;\2MAZ;.M$[,ID[9)J,BO8K][;
M:6S> AE^R^47ETHPXAYQAR:K:ULRF3I$1F9%>Q7W6VELWC6#,%F"K/,K6B,#
ML#T/O2IQW5144T9I**(CVF9^TT=OG$,P.82L\R5:)P/P3;?7*'7=5$Q+5RZY
M(CVF9^UT=OG&T.7[+Y1>7&C5OQ2V'9LZT3LRF+MDFHR*]BOWMMI;-X"&7[+Y
M1>72C#B'G&')JMK6S*9.D1&9D5[%?=;:6S>-8,P68*L\RM:(P.P/0^]*G'=5
M%131FDHHB/:9G[31V^<0S YA*SS)5HG!#!-M]R3NNZJ)BFKD421'M,S]KH[>
M/:-H<OV7RB\N-&+?B5L.S9UHG9E,G;)-1D5[%?O;;2V;P$,OV7RB\NE&'$/.
M,.35;6MF4R=(B,S(KV*^ZVTMF\:P9@LP59YE:T1@=@>A]Z5..ZJ*BFC-)11$
M>TS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z[JHF):N77)$>TS/VNCM\XVAR_9?*+
MRXT8M^)6P]-G6B=F4R=LDU&17L5^]MM+9O 0R_9?*+RZ48<0\XPY-5M:V93)
MTB(S,BO8K[K;2V;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*:,TE%$1[3,_::.WSB
M&8',)669*M$X'X)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:'+]E\HO+C1BWXE;#T
MV=:)V93)VR349%>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU6UK9E,G2(C,R*]BON
MMM+9O&L&8+,%6>96M$8'8'H?>E3CNJBHIHS2441'M,S]IH[?.(9@<PE99DJT
M3@?@FV^N3NNZJ)B6KEUR1'M,S]KH[?.-H<OV7RB\N-&+?B5L/39UHG9E,G;)
M-1D5[%?O;;2V;P$,OV7RB\NE&'$/.,.35;6MF4R=(B,S(KV*^ZVTMF\:P9@L
MP59YE:T1@=@>A]Z5..ZJ*BFC-)11$>TS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z
M[JHF):N77)$>TS/VNCM\XVAR_9?*+RXT8M^)6P]-G6B=F4R=LDU&17L5^]MM
M+9O 0R_9?*+RZ48<0\XPY-5M:V93)TB(S,BO8K[K;2V;QK!F"S!5GF5K1&!V
M!Z'WI4X[JHJ*:,TE%$1[3,_::.WSB&8',)669*M$X'X)MOKD[KNJB8EJY=<D
M1[3,_:Z.WSC:'+]E\HO+C1BWXE;#TV=:)V93)VR349%>Q7[VVTMF\!#+]E\H
MO+I1AQ#SC#DU6UK9E,G2(C,R*]BONMM+9O&L&8+,%6>96M$8'8'H?>E3CNJB
MHIHS2441'M,S]IH[?.(9@<PE99DJT3@?@FV^N3NNZJ)B6KEUR1'M,S]KH[?.
M-H<OV7RB\N-&+?B5L/39UHG9E,G;)-1D5[%?O;;2V;P$,OV7RB\NE&'$/.,.
M35;6MF4R=(B,S(KV*^ZVTMF\:P9@LP59YE:T1@=@>A]Z5..ZJ*BFC-)11$>T
MS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z[JHF):N77)$>TS/VNCM\XVAR_9?*+RX
MT8M^)6P]-G6B=F4R=LDU&17L5^]MM+9O 0R_9?*+RZ48<0\XPY-5M:V93)TB
M(S,BO8K[K;2V;QK!F"S!5GF5K1&!V!Z'WI4X[JHJ*:,TE%$1[3,_::.WSB&8
M',)669*M$X'X)MOKD[KNJB8EJY=<D1[3,_:Z.WSC:'+]E\HO+C1BWXE;#TV=
M:)V93)VR349%>Q7[VVTMF\!#+]E\HO+I1AQ#SC#DU6UK9E,G2(C,R*]BONMM
M+9O&L&8+,%6>96M$8'8'H?>E3CNJBHIHS2441'M,S]IH[?.(9@<PE99DJT3@
M?@FV^N3NNZJ)B6KEUR1'M,S]KH[?.-H<OV7RB\N-&+?B5L/39UHG9E,G;)-1
MD5[%?O;;2V;P$,OV7RB\NE&'$/.,.35;6MF4R=(B,S(KV*^ZVTMF\:P9@LP5
M9YE:T1@=@>A]Z5..ZJ*BFC-)11$>TS/VFCM\XAF!S"5EF2K1.!^";;ZY.Z[J
MHF):N77)$>TS/VNCM\XVAR_9?*+RXT8M^)6P]-G6B=F4R=LDU&17L5^]MM+9
MO 0R_9?*+RZ48<0\XPY-5M:V93)TB(S,BO8K[K;2V;QK!F"S!5GF6K1&!V!Z
M'WI6X[JHJ*:,TE%$1[3,_::.WSB&8',)669*M$X'X)MOKD[KNJB8EJY=<D1[
M3,_:Z.WSC:'+]E\HO+C1BWXE;#TV=:)V93)VR349%>Q7[VVTMF\!+E]R^4;E
MUHPWGW6')JMK6S*9.D1&HR*]BONMM+9O&K^83,)6>9.LT8(X(-/N2M;NJBHI
MHS(HDB/:9G[71V^<1S!9A:SS)5FG [!%#[DH<=U45$M7(HDB/:9G[71V^<;0
M9>\OU%Y<*,4_$J8<FSK6MF4S=L1J,BO8K[K;2V;P$,OV7VCLNE'F^\IAR:O-
M:V8S%ZR3,R*]BONMM+9O&L6/^/\ 6F9>M6\"\#&XA^6//:J)BF;I*)L>TS/V
MNCM\XAF Q^K?,O6K>!F!Y/ORQQ[51$4S=)11$>VY^UT=OG&^>3/)=3. ]*LQ
MTRA41$[B4I7&QJT=TXK>1$7%;=LW@//)KDMIC JD$Q\?"HCIS&MDN+BUILI:
MBVV(CW6W;-XVMIAIM,F;;9[TC41<X^YQ#76NBR9)(D'HV+BL/DIH[RMO1+12
M2E?+M!-56UM@)3H;1,=N,1!0
M    4FIOQ.Y\9/K%6%)J;\3N?&3ZP'W0GX,CXI#V5M'C"?@R/BD/<]Y /!UD
MWD+:<3=*DFE7E(]XXY]4\RBS6C:T?QAHJ4K5)Y@K3BB93^#F6PCL6^YCLD9;
M;GL%&JNE)%6<FB:?J* :BX.+0:%MN)(RL9 ..^1?JBT=@U#,8:XH/KBJ>0HD
M0\0X9WA2OM\IW'5*ALQ6$.(DM9F5.5?!/,/)(R-;A(/F,QSVS.=2:C%1\34F
M![VFEU2G>Q9%;0/?WQC2Z?97\SN';AMQM.S:#)LS+[S$+,O[)@.\U78TX64C
M!KCZDJB6I8;2:KZQ#AF7F(QSISH=4QDL;*XN@\#39-;Q&TY,DMEL(]Y:)EQ[
M2&E4ERZYFJ_B4PT'(9S%K=.Q$[$+27TF-LLN/4FZQF\VA)]C.\<OA&E$MR!,
MB7K?)I%N 8SZGYE,J#'/$UBOJM@'52"7O=</J=29$ZLSN1E?]8=BL4L0J;P5
MP\75$\91V.ENIAS2:=A7,D)%6P]PZI?#"F(.DZ1E;4' PB-%)(+;YS/>8Q!G
MQD$TJ7+=/Y1*81<7$O/0R4H06W^D+;\@"]:LQLH:CL,58G1;D&<%9H]%*DW/
M3,B+86WC'U(Q?PVAZ>ET_FL?!0K,R3I-$I"=(_DW\8T7Q,RAXA2[+RW."KJ+
MF#K:H5:97J5;>[3<K^06AB!A]7$+6,IBL041\)3SD*2((VDK62#U9$?<I\H#
MI=-Z\P_D,I9GD?,8!,'$%=#I$E1*+Y!8.)69*@L/I;)YY"-0L="359I0XU;N
M;'8S.PTRJ"!C*2PMI"E(JF)E/82.**)N/UCB50VVY73O.]^,8_HG#[$M,"N1
M3221JI<W$(.':<TE62I=SL9@.B-/YL,(*EG4VD$OJ%#D;*F$.N-:)EO1I6N/
M##'-?AY7J7SBX]B7+:=-IM+CG?'I6XQJ)25 4EAOC_6TMJ&@XQYR9P;'8AQ+
MCFB2B9[O:6S?RBVY3EM5,\'ZUJZ8R".54"(QAR7$AU:#;+7<1%OV .E%3XFT
M52"8=<^GL.QUR5VRTR,S^2X^:;8M4#(I=#S295 RW#1?]$N]](<\)=)H^35L
MQ.\Q=.3*;RJ+;;1)U(<<(F=%)$JY(^3>+DQPC9/-6Z8IZGL-9BQ*WV8G4QI1
M#BM4>CLNGRF WV/$FBD0<+'N5!")8C$J4PLW4V41;^,?(K%R@$2-51*J*'*"
M([$YI%<SO;87&.7% X38C57#4/1U50TT:EK43$FXDW%D:4&NY7/?M(95S48)
M32@ZIHQ$AA(Z&H:&:=*+U2UN:)J25C,BVGW0#H?3]422J9>W,Y%,&HJ'=[U:
M%$?/R"I),K6([WW$-6\C-)%3M.3.)@YC%1,OBS2;"7TJ2:+'MV*VC:5*]*]D
M["W& E-"SVCQ5 PSKI/N0C)NEN6;9&KGWCZRW!>^XP'B4*RC24AEM*U]\9)(
MC5YQ*F"AB:-KK9G05O3H%8_D'T;>4#V[ 'R,RV7PKNLAX"&;5[I#22/G(A[N
ML,NEH.M(6@_:J21D/2Q;P >1MD6PBL7()=3#M:2M2V1N=\>B5U>?E'OL,2.$
M2B >)0D,3)L)AVM6>]O0+1/Y!Y(E\K8/33+H9"N(TLI(_4/GGT^E=-2QR;S=
M\V6&"NM1$9V^06M3&-5 UC-$RF231QV(<OHH<84WNWVOO 7BY+9;$+/7P4.Z
MKB-;23,OE,A.F7P1LG#G!L:![T$V1)/Y!8T^QRPZIF-B9=-IRZA^"MKT-PZE
MZ-]VXA4X/%2B8^DN'4--M*3^&4@TGOMWN_>$2KE5+X%ULH=R#AS0C<DVDF1?
M)83P\'"0:33"PC+!'OU:"3?F& ZNS$RR;U1(Y)0<[?(HA:BBDKA5)(RXK&HA
MD/%G$!^@:+.<0C!Q,P<)M##5[:1J,B,_DO<6%7K$04'%]U&P;#^AWFL;)5O-
M<&I7+6#-;,OAVC/?H-)*_,0PRFCL>XF!;GD/BG=;J2>1 ]9)W'MT=+Z!?LNJ
M^-D=%(J#$5HI3$,D9/EI:>X[$>SE$*N<I3*=)1G+(4CWW)E-S^@>SL#!Q!(*
M)A&7=#O=-LCT?-<632F-F'U93#L;))JZM\^\2XPIO2Y;7WCSG^.>'5,3"*EL
MVF[J8F$MKD-L*7HWW;@*OI$# (;U*(1A*%;T$V1$?R"ESZE)34$G5)8J$93#
M.*2I39-D1&9'<MA#&V(.9:AZ.H!G$&!4Y,(=]9)AT$VI)K[K149\EA<TMQFH
MB/HYBMW(];<N6@E+<6TI)I,^*Q[=XL*O-N7P3$*F#ZV0IM"222#26CL\@]S0
M9()MHB07&1%L(A9\#BW1$RD,34T),7%0$-;6+4RI)E?D(]ICYZ9QIH&KH],I
MD4V=7%.$K00XPIO2,N32"%7F4!")-"DPK.DF]E:LKEYA.F'9;6XXVPV2UVTC
M))$9^<8\H.JYY.*\JF43&(UK$N-HH9NUM#2+;M'W8R57,:1HF,F4C<),R/11
M#EQFHSML((5>B89AI2W&F&TFOOS))75YS'@<IE2%DZ<OAB/EU*;W\]AC+ ZM
MZCF$CBI7B#,">G<I3K8MPR)-TJVIV%R$*E+\?<-YU-4R.73MU42XI2$&<.HD
MW+?MM8(5?JY;+GEZYR AEK/<:FDF?/8?%4-*RBHI0N1QL(T<*XI*C;))$1&1
MWW"VZ5J-F/JNH85VK.R"(%+:^M-3H=:$97[[VUQ\B,?L,^O^Q_9MW6DO5F9P
MRR2:KV[ZUA"L@PL&S!PS<'#))M#:22DB+B(>Y;"NHK6$C+C;S274*TDJ(E$9
M<9'M$R5:6TCOY 5@G,/^65%?O7?60SG!?@C/[I'J&#,P_P"65%?O7?60SG!?
M@C/[I'J >X   )4B82I 42MOR6F7\,Y_A,8XRD_U)2K^)BO\TQD>MOR6F7\,
MY_A,8XRD_P!24J_B8K_-,&&9   ;
M                                    0N7* "(  F#PC/P=SXI^H?!3
M'XI;^,KUC[XS\'<^*8^"F/Q2W\97K%858  &P
M
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M?46ZQ;0/=MV /GAH*%@T:J%A6F4GQ-H))?0/9""2=RXQ$[F!&=]H"8
M  0 1$I[Q&Y<HE48#%686:1,LHEY4.PLDFI&F^E)KU7=;]'C&%Z=FL9.\4Z-
MB8*KW)O#L(>)Y"9:<.2+IW&=BN-M7X:'B6S9BFD.)7O):2,C^0QYE+I<PHE,
MR^&0:=RD-)(RYB 81PZER7L2L1E1<M)31M-:LG6M(N\/<9EM&.W9=/'</HI7
M6CKD# Q6F[#$@TZ2=9?=Y!MRS#LMJ6I+39*7WRB21&KSCS5+X(TK;ZS:T%]\
MG1*RA:D:R536]&UO4%*P](0ZW(B!+1?64$IO5G8ME[;1DG':F)U/:$:C*<AC
MB9A :I;;>ZZ2,C5O\A#)[<IEC*R6W+X9L_U64D?J'U*01]R1$1'LM:Y&%(PR
MC,A0L')V88GHOLJAI+76_6KEC<(K6O:V\4#%MBMJYPGAIG'M.2IPG"<?;26L
M,DDNZ3L6_8,\KE$K4=U2J$4J][ZE-_4/H-AI;1L+90INW>FDC(_D$(U8HZ(@
MZJKFGHB"KUR.=E:%I4R4K-@KFFUC.Q7%XX>RS78G8BKBX$EH)EK1-UJY*/0/
M=<AG!N70,.HEPTNAD+XU(:2DRYB'LVPPE:EMMMI4O^D,D$1J\_*!&H\ZE4TF
M6"-0P:Y<;RX>,:6V@VMJ$D]<[%;D%WXD3:45/@;!\'TK>;)4.A1)AS0=R6DC
M+1L-A2@((D+9*&:-*N^3H%90AUE!(8U2)>Q;B;)!:/,+2,0XNQ3DBPTA4PLN
M)E*F637$-MWU5K;321;1BRG)K$U!BK1KT'5CDWAVDO$ZE,M.')!Z.PC.Q7&V
M2V(>(;)A]IMQ/&A2",OI!F60+%G&9?#(6G=H-)(R^4B"D8=P]G4'*<7JHDLP
M6ZB*F!L];_>E:*M%.WNMPI&+\CJ3%3$&6TS2<^<E/80U*BGS8TTEI%=.P]AC
M/A0;.N**ZW9)WC5H%I<^\1*&9)Y3VI02U^V))$?.%(U@=H>M,+\02FE15*[4
MT-4C2DQ"40^J)DFT6+=ON+;9G<.P[#-4U.'8EEQ]6C).QYH,^ZV_?C*_E&X2
MF&72^^MH=<1N-22.P\#ELM94EQ$##)-/(RF_/8*1K_0[TQ@ZRQ"B"E#JE];P
MQMH.Y7[C;8^.PQ3/I_%3>BGI5"5<ZB).,0?8XI69*1]]V_?+;1NXAEA"UKZV
M;(UEM42"(U><>*I1*SVJED+>]S,F4_8(<O&F4FF00).$9**';O?ET2%4222,
MU$8\VDI0C5IVD6XMP]$%LMHV!6",P_Y945^]=]9#.<%^",_ND>H8,S#_ )94
M5^]=]9#.<%^",_ND>H![@   E2)A*D!1*V_)>9%_Z9S_  F,;92#/M)RO9MZ
MYBO\TQD.O7SAZ3FCFCI6AW-G_*8PYE;JE<%@_+FDRY2[1,3N,_"&##86Y\@7
M/D%J\-GO%:N<PX;/>*U<Y@VNJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!
M:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-
MGO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5
MJYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,
M.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/
M>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5
MSF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"
MZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?
M(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/
MD%J\-GO%:N<PX;/>*U<Y@+I,C/B"QBUN&SWBM7.8<-GO%:N<P%TZ/E#1%K<-
MGO%:N<PX;/>*U<Y@+J$+F6\6MPV=\5KYS#AJ]XK7SF&8E\7)%?T+GQ3]0IU+
M'I2=L[>V5ZQ1WZQ=6TK_ +-7M(RWF/BD-6N0\N2V4M4=E*XSY1J>,9OJ_+GR
M!<^06KPV>\5JYS#AL]XK5SF,NBZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7
M/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06
MKPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9
M[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:
MN<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#
MAL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SW
MBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<
MY@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF N
MJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR
M!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY
M!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\
M-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\
M5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+JN?(%SY!:O#9[Q6KG
M,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK5SF NJY\@7/D%J\-GO%:N<PX;
M/>*U<Y@+JN?(%SY!:O#9[Q6KG,.&SWBM7.8"ZKGR!<^06KPV>\5JYS#AL]XK
M5SF NJY\@7/D%J\-GO%:N<PX;/>*U<Y@+J^0#Y+"U>&SWBM7.8<-GO%:N<P'
MW3Q!)B86Q<9BKH3=*=G$0L>;U<ZI^%,Y8K>?&*D5:.IL78Q>XN46)5T:*^4#
M)7&8M?AJZ6Z5KYS$>&K_ (J7SF$*N?17R@9*XS%K\-72W2M?.8CPU?\ %2^<
MQ%7/HKY0,E<9BU^&KI;I6OG,1X:O^*E\Y@+GT5\H&2N,Q:_#5TMTK7SF(\-7
M_%2^<P%SZ*^4#)7&8M?AJZ6Z5KYS$>&K_BI?.8"Y]%?*!DKC,6OPU=+=*U\Y
MB/#5_P 5+YS 7/HKY0,E<9BU^&KI;I6OG,1X:O\ BI?.8"Y]%?*!DKC,6OPU
M=+=*U\YB/#5_Q4OG,!<^BOE R5QF+7X:NENE:^<Q'AJ_XJ7SF N?17R@9*XS
M%K\-72W2M?.8CPU?\5+YS 7/HKY0,E<9BU^&KI;I6OG,1X:O^*E\Y@+GT5\H
M&2K;Q:_#5TMTK7SF(\-7_%2^<P%SI0HB+3.X*0H[Z!V%L<-72,[2M?.8APU>
M,R(Y6O;Y3 7.:3(["BZ%I_>W_P L/B.M'358Y8OG,4HZN=[-W[&*YSY!K,8^
MM7Y96X1LKD%K\-7>*6+YS#AJ]XL7SB:OSJZ-%?&8&2N,Q:_#5TMTK7SF(\-7
M_%2^<Q&ESZ*^4#)7&8M?AJZ6Z5KYS$>&K_BI?.8"Y]%?*!DKC,6OPU=+=*U\
MYB/#5_Q4OG,!<^BOE R5QF+7X:NENE:^<Q'AJ_XJ7SF N?17R@9*XS%K\-72
MW2M?.8CPU?\ %2^<P%SZ*^4#)7&8M?AJZ6Z5KYS$>&K_ (J7SF N?17R@9*X
MS%K\-72W2M?.8CPU?\5+YS 7/HKY0,E<9BU^&KI;I6OG,1X:O^*E\Y@+GT5\
MH&2N,Q:_#5TMTK7SF(\-7_%2^<P%SZ*^4#)7&8M?AJZ6Z5KYS$>&K_BI?.8"
MY]%?*!DKC,6OPU=+=*U\YB/#5_Q4OG,!<^BOE R/C,6OPU=+=*U\YB/#5_Q4
MOG,!<Y)5QF"TJT3V\0MCAJ^7_P"+7SF(*K5XTF78M>[E%FI50DR"[(1Q\II%
M8,E%8B%ARRKG&XR*,I8O:9<9BJE6CNG;L8OZ0W"KGT5\9@9*XS%L'6KI'LE:
M^<PX:O\ BI?.8BKGT5\H&2N,Q:_#5TMTK7SF(\-7_%2^<P%SZ*^4#)7&8M?A
MJZ6Z5KYS$>&K_BI?.8"Y]%?*!DKC,6OPU=+=*U\YB/#5_P 5+YS 7/HKY0,E
M<9BU^&KI;I6OG,1X:O\ BI?.8"Y]%?*!DKC,6OPU=+=*U\YB/#5_Q4OG,!<^
MBOE R5QF+7X:NENE:^<Q'AJ_XJ7SF N?17R@9*XS%K\-72W2M?.8CPU?\5+Y
MS 7/HKY0,E<9BU^&KI;I6OG,1X:O^*E\Y@+GT5\H&2N,Q:_#5TMTK7SF(\-7
M_%2^<P%SZ"]]P-*N,6OPU=+=*U\YB/#9_P 5+YS 7,E"^,Q,;9GO,6OPV?\
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MK(9S@S_V1C9_NT^H:W8]5&N-K*CDG!J3]]<W^<AL? D2H*',RM=I'J(1M](
M  )4B82I 4.MD).EIG?CAG/\)C&V4MII>"TK6IM)FJ)BMY?^:8R76WY*S/\
MAG/\)C&V4G^I.5_Q,5_FF##,6I9\$CHD&I9\$CHD)P!M)J6?!(Z)!J6?!(Z)
M"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z)"
M< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z)"<
M $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z)"<
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M DU+/@D=$@U+/@D=$A. "34L^"1T2#4L^"1T2$X )-2SX)'1(-2SX)'1(3@
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M$5G$PER><2\I@DV*Y[RMQ&+LRU9Y9!CC4T50524RJEJH9/13+UN&X:SX]O$
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M>B5X)RQF?EL,2]5J0A_#>3MO(NTIXDF=^(UE<4RA,HF5F=Y9(>HIU*)>4T5
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MP
M                                               !*9<8F !A/-;C
M5]S]A9'8I=@^RIRG1^\:S0TM)5MXT53U;<T;\$=O_P#4-_T#9OJHE_N3:IVW
M(]3_ (QP4,_)Y@'5+V;S]B'UA_(/9O/V(?6'\ARKL86,!U4]F\_8A]8?R#V;
MS]B'UA_(<J[&%C =5/9O/V(?6'\@]F\_8A]8?R'*NQA8P'53V;S]B'UA_(/9
MO/V(?6'\ARKL86,!U4]F\_8A]8?R#V;S]B'UA_(<J[&%C =5/9O/V(?6'\@]
MF\_8A]8?R'*NQA8P'53V;S]B'UA_(/9O/V(?6'\ARKL86,!U4]F\_8A]8?R#
MV;S]B'UA_(<J[&%C =5/9O/V(?6'\@]F\_8A]8?R'*NQA8P'53V;S]B'UA_(
M/9O/V(?6'\ARKL86,!U4]F\_8A]8?R#V;S]B'UA_(<J[&%C =5/9O/V(?6'\
M@]F\_8A]8?R'*NQA8P'53V;S]B'UA_(/9O/V(?6'\ARKL86,!U3]FZ*Y?_1'
MZP_D/E]FI9Z^Z\[26[_B'\ARV$?( ZI^S>?L0^L/Y![-Y^Q#ZP_D.5=S"Y@.
MJGLWG[$/K#^0>S>?L0^L/Y#E78PL8#JI[-Y^Q#ZP_D'LWG[$/K#^0Y5V,+&
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MB)J"C75?TA<GDXB'3J&?;BF&XF&B$K9<22DJ3M(R,!].D07(2G>PBD!,
M        )@\(S\'<^*8^"F/Q2W\97K'WQGX.Y\4_4/@IC\4M_&5ZQ6%6  !L
M                                        %)J;\3N?&3ZQ5A2:F_$[
MGQD^L!]\'^#H^*0]CWD/&#_!V_BEZA['O(!$
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M+*PTQ<H+%R2)J*A)\U,H!S:DR[E2?.D]I"]$*N1JO<CW /0
M                                                 !J)U4;_ ,)E
M4?\ L_XR'!(]X[V]5&_\)E4?^S_C(<$CW@
M
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MQ5A2:F_$[GQD^L!]\'^#M_%+U#V/>0\8/\';^*7J'L>\@$0
M
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M8K#Z$$9;; )Q*HN,3  \S0KE$4I41><3@ \M%24Z*NZ$30>C9!V$^XN0-_E
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M^2<=-%DM^(>B&G5&KR&JYEO&_F42.S91;DZ5F5E76:6]7V/[M"K^Z[T!>F<
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M(!Z
M      -1.JC?^$RJ/_9_QD."1[QWMZJ-_P"$RJ/_ &?\9#@D>\
M
M                                                +7 3)(K7 0/D
ML(I,R[FP%OTK#WAV'HI]#$.TIQQQ1)2E)7,S,![2M<Q9CX5V4K>*+2X1M:JY
M*)5]F[RCO;U/.<8RS?!J$=Q:@W4&39%!/.F6DXF_&6\MEMXU%ZGOU/9^;.0V
M+&+,O-,&1I=@H-U/]+]G$.K4M@(670K<+!0Z(=IM)(2V@B(B(BL6X!]@
M        F#PC/P=SXI^H?!3'XI;^,KUC[XS\'<^*?J'P4Q^*6_C*]8K"K
MV                                        "DU-^)W/C)]8JPI-3?B
M=SXR?6 ^^#_!V_BEZA['O(>,'^#M_%+U#V/>0"(
M
M # N8?\ +*BOWKOK(9S@OP1G]TCU#!F8?\LJ*_>N^LAG."_!&?W2/4 ]P
M2I$PE2 HE;?DM,OX9S_"8QQE)_J2E7\3%?YIC(];?DM,OX9S_"8QQE)_J2E7
M\3%?YI@PS(  #:4B,KW%.J2W!^9?PCW^ Q4N,QY1,.S%PSL,^6DVZA2%%RD9
M6,!J/D#+_8JK42+$<6KC_P#,4-J*D,TR*8G>Q%"/6Z!B@8?83T-A>B-31TI.
M"3'+TW_OAJTU7OQ[MIBZWFFXN'=AH@KH=0:%E^J96,!J7D$3HP=5.)+N51:K
M'?\ \Q0MKJFDLA9Q3]+RV-9-;$1$DAPB5HF9&XDCVC:_#_"BAL+T1:*-E76*
M(U>F^6F:M)5[WV^4Q\^)F#>'^+;,)#US)NR*8!9.,)UAHT5$9'?9Y2 86I#(
M)EF3*Y9-N"$<MXV&7N[F;RDFK1(^],[;QFNI:@H7 V@'YS,EL2V32IKN22DB
M(N0MG*8NZ&A&82'9AFBT40R$MMD7$DBL1<PM;%+"BB,8Z8?I"OY:N.E,1;6,
MI=4WI6.Y;2 :8TW,6LW]<(KG$NI(65T)+'C5+)6J*277=CVF9D9&5C(CVC>"
MDIG2T1+D0%*QL(]#P2$MDB'6DR25K%N&!(?J<^56&1JH>BHYI!;D(FCR2+Y"
M,94PEP!PUP2AHJ%P\E<1!-1FCKB=BEO7MN[XS 8(SNU<Y5S\CR\2",4F8U4^
M2GEM[3:2THE&1D7*0V8P\I&6T'1<LIR5L$VQ!PZ2T2+>K1*_TBD.X)X<NXC-
MXI.2'65$B^C%*=,R3LML2>PM@ODE;-$BL?$7( P(>:&2P6,TVP?K>2)DR&=
MH*.?5I-1A&FZM^PK# 6<F:8>158T@[ABTR]5K\5=AR6G8DD2BTM(D;#V<HVU
MQ3P PPQIA40]?T]UWH;EM.FTYTD[1;V&N4[ _""<]F*)I=;4:>Y43$+?MYM.
M]@&5:?)]4AEZHI)ZXX5K67WZ6@5Q4F_+QB2YJ7H)V)3O(A,C?WV[> ]0
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M-;;<+;;@)"191JY0))F6B8]! ]NT@$O=>Y$+*Y!Z  \]68F2DB$;D(@
M                                                        A>PB
M)%GQ -1^JBE?*75!I/9]Y_QD."BBMLM8=Z^JA)4>4RI] ]A:G_&0X+.&DC,B
MX@'F                                           'LV (E8O.!%;:
M8" ;MP6ON(-V\                                           (K@
M")%RD('L                     !%/?$(#VA(9Z+?1#P[2G'7%$E*4E<S,
M]P#T8AGHN(2Q#LJ<6M1)2E)7,S/R#IOU/;J>JYRY!XLXLRPR@D&3L%!NI_I?
M*?);8)NI[=3U<FKD)BSBW*S3"D9.P4$Z7])Y3Y.(]HZM0$!#2Z';A(.'0RRT
MDD(0@B(DD16+80",%+X:70K4%!,(98922$(0DB(B(K#Z2*PB
M  )@\(S\'<^*?J'P4Q^*6_C*]8^^,_!W/BGZA\%,?BEOXRO6*PJP  -@
M                                    I-3?B=SXR?6*L*34WXG<^,GU
M@/O@_P ';^*7J'L>\AXP?X.W\4O4/8]Y (@
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M9^#N?%/U#X*8_%+?QE>L??&?@[GQ3'P4Q^*6_C*]8OXPJP  C8
M
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M %?_ ##V$/\ ;?\ 5_\ ,=5  <J_80_VW_5_\P]A#_;?]7_S'50 '*OV$/\
M;?\ 5_\ ,/80_P!M_P!7_P QU4 !RK]A#_;?]7_S#V$/]M_U?_,=5  <J_80
M_P!M_P!7_P P]A#_ &W_ %?_ #'50 '*OV$/]M_U?_,/80_VW_5_\QU4 !RK
M]A#_ &W_ %?_ ##V$/\ ;?\ 5_\ ,=5  <J_80_VW_5_\P]A#_;?]7_S'50
M'*OV$/\ ;?\ 5_\ ,/80_P!M_P!7_P QU4 !RK]A#_;?]7_S#V$/]M_U?_,=
M5  <J_80_P!M_P!7_P P]A#_ &W_ %?_ #'50 '*H^HB&9_UW?5_\Q$NHBZ-
MS[=WU?\ S'5.VVX@H[7\P#E' ]17*)?>8[=EC:V'_P!G_P Q])=1$,[_ /UO
M^KOYCIS)]LQCCMO-(K9 .5GL(?[;_J_^8>PA_MO^K_YCJH #E7["'^V_ZO\
MYA["'^V_ZO\ YCJH #E7["'^V_ZO_F'L(?[;_J_^8ZJ  Y5^PA_MO^K_ .8>
MPA_MO^K_ .8ZJ  Y5^PA_MO^K_YA["'^V_ZO_F.J@ .5?L(?[;_J_P#F'L(?
M[;_J[^8ZJ  Y5IZB,1;\;K^3L?\ S&3,!>I(T;A76L/558UFFJ6891+1"JAM
M41&6[;YQT'\EQ#=Y0'SP4OAI="M04$PAEAE)(0A!$1$1%8A])%81
M          'A&?@[GQ3]0^"F/Q2W\97K'WQGX.Y\4Q\%,?BEOXRO6+^,*L
M(V                                      "4SX@$PI-3?B=SXR?6*J
MD4JIOQ.Y\9/K!-??!_@[?Q2]0]CWD/&#_!V_BD/8]Y!NIB(  -
M
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M;<9#9&!*T##W\$B_,0C3Z    2*V[1,>X0(K@*)6OY,3(^2&<_PF,;Y2B_\
MHI*_XF*_S3&2*U_)>9'R0SG^$QC?*27_ -$Y5MW1,5_FF##,H  -@
M                                                           "
M%B$0 !*H3 )@^>+_  9?Q3'PTQME+?QE>L??&;(9?Q3%/IC9*$?&5ZQIA5P
M!&P
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M !*H3 )@^>+_  9?Q3'PTQME+?QE>L??&;(9?Q3%/IC9*$?&5ZQIA5P !&P
M                                     !- 4FI]DI<^,GUBK"DU/^*7
M/C)]8H^Z#+_9D?%(>R"L0\H/\'1\4O4/8MP)@1WWB(E2)@4
M
M      !@3,.7_?*B_P!XY_H,Z0.R$9_=H]0P9F'+_OE1?D<<]9#.<%^",?ND
M^H![@   E2)A*D!1*V_):9?PSG^$QCC*3_4E*OXF*_S3&1ZV_):9?PSG^$QC
MC*3_ %)2K^)BO\TP89D  !L
M                                   $P>$9^#N?%/U"GTQ^*6_C*]8J
M$9^#N?%/U"G4U^*6_C*]8UC"K$9'<N(-(C*XET;IL1[2 U%8C+B$;37VD5]H
M$>TRXQ+?<7%RB)'>Y<7* G       0,["(E4>W: CI 1W'F9W$2.X#T >9W(
MQ,FX"80,["(E48")[+@1W'EI;+GQ 1F2=^X!ZW+>%[[AYJ(]$3-]Z G   !#
M?O(1'FX>S8 G)21 MICS(RL)D&9[0'H
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M),S-5KV(OI CY"V<HH5'U9(*UD$+45.Q[47!139+;4A1'O(5Q!J,BO\ * ]
M                $%=Z?F$1!7>GY@%#D_XRCO\ E%;]J*))_P 91W_**W[4
M!,                                          )@\(S\'<^*?J'P4Q
M^*6_C*]8^^,_!W/BGZA\%,?BEOXRO6*PJP  -@
M                ": I-3?B=SXR?6*L*34WXG<^,GUBC[X/\';^*7J'L>\A
MXP?X.W\4O4/8]Y F()$P@16$04
M                                             !@7,/\ EE17[UWU
MD,YP7X(S^Z1ZA@S,/^65%?O7?60SG!?@C/[I'J >X   )4B82I 42MOR6F7\
M,Y_A,8XRD_U)2K^)BO\ -,9'K;\EIE_#.?X3&.,I/]24J_B8K_-,&&9   ;
M
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M$$V,A*1D1[1,DR,@$P
M              U$ZJ-_X3*H_P#9_P 9#@D>\=[>JC?^$RJ/_9_QD."1[P
M
M  $2.P@ "<G-$K) E&D])!F1EQB2U]PF;2:E6(!NQD/SWSW J>PM%5M&N15*
MQ:TMD;BC/K?;SG<S';"CZLD-:2.%J&GH]J+@XILG&U(41[R'Y>T[-MS2:#V&
M-ULB.>V?8&SZ%HFMH]V)I>*6EM"G%&?6USYSN9@.Y&G<]]N012=[W+8*/2U2
M2BL9#"5%)HHHB"C6R6THO*0J[:-%)6*U@'H             ""N]/S"(@KO3
M\P"AR?\ &4=_RBM^U%$D_P",H[_E%;]J F
M                $P>$9^#N?%/U#X*8_%+?QE>L??&?@[GQ3]0^"F/Q2W\9
M7K%858  &P                                        4FIOQ.Y\9/
MK%6%)J;\3N?&3ZP'WP?X.W\4O4/8]Y#Q@_P=OXI>H>Q[R 1
M
M          8%S#_EE17[UWUD,YP7X(S^Z1ZA@S,/^65%?O7?60SG!?@C/[I'
MJ >X   )4B82I 42MOR6F7\,Y_A,8XRD_P!24J_B8K_-,9'K;\EIE_#.?X3&
M.,I/]24J_B8K_-,&&9   ;
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M/24?G4>TP%[H+B/<0G3Y2VD(&5RT2$4[>Z+< G
M                                  &HG51O_"95'_L_XR'!(]X[V]5&
M_P#"95'_ +/^,AP2/>
M                          )D^<2B=!<6\!,1F1&V1:5QMQDCR0U/F%JB
M'GL[A78.F(-Q+CSZT&6LY"+CWD),DN2*ILP]2L3Z=0CL#2\&XE;SZT'9PK["
M(OD'<7#S#ZF<-*8@Z5I65M0<%!MDA*4$5S.VTS/CV@/6AJ*DN'],P-)4^P;$
M% -DAHC4:N+:>T7"5^6_D#1/2(]'?O,1(SON^4!,             ""N]/S"
M(@KO3\P"AR?\91W_ "BM^U%$D_XRCO\ E%;]J F
M                     $P>$9^#N?%/U#X*8_%+?QE>L??&?@[GQ3]0^"F/
MQ2W\97K%858  &P                                        4FIOQ
M.Y\9/K%6%)J;\3N?&3ZP'WP?X.W\4O4/8]Y#Q@_P=OXI>H>Q[R 1
M
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M]MP/;L 2Z'D#0\@G !YIV;R$Q6Y+".WD P$0
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ME*RQJ"@X-LD)2@BN9VVF9\8N5"5$>W:?+R@1;3V[3XQ-HV*Q;+ )@
M         $%=Z?F$1!7>GY@%#D_XRCO^45OVHHDG_&4=_P HK?M0$P
M                                    F#PC/P=SXI^H?!3'XI;^,KUC
M[XS\'<^*?J'P4Q^*6_C*]8K"K   V
M         "DU-^)W/C)]8JPI-3?B=SXR?6 ^^#_!V_BEZA['O(>,'^#M_%+U
M#V/>0"(
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MH?!3'XI;^,KUC[XS\'7\4Q\%,?BEOXRO6*PJP  -@
M
M                           AMOY!*;1*5<S$Q7XP.W& MZIH2&C%,0\9
M#-/M*/:AQ!*2?G(]@^I%)TJ:4WIJ5;B_^S;^P23XCZXAO.8K".]+S$ IG!.E
M?@S*OF3?V!P3I7X,RKYDW]@JP *3P3I7X,RKYDW]@<$Z5^#,J^9-_8*L "D\
M$Z5^#,J^9-_8'!.E?@S*OF3?V"K  I/!.E?@S*OF3?V!P3I7X,RKYDW]@JP
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M"=*_!F5?,F_L#@G2OP9E7S)O[!5@ 4G@G2OP9E7S)O[ X)TMQ4U*OF3?V"K
M ^&#E4OE]DP,!#PI'O2RTE!'S$/J0E6DHU%O$^P]Y;@XMH"(
M        @KO3\PB(*[T_, H<G_&4=_RBM^U%$D_XRCO^45OVH"8
M                                 3!X1GX.Y\4_4/@IC\4M_&5ZQ]\9
M^#N?%/U"GTQ^*6_C*]8K"K@  V
M      "DU-^)W/C)]8JPI-2_B=SXR?6 ^^#_  =OXI>H>Q[R'C!_@[?Q2]0]
MCWD B
M                            P+F'_+*BOWKOK(9S@OP1G]TCU#!F8?\
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MAU^C,5/40_@4=$-1#^!1T0%,X52;PZ_1F'"J3>'7Z,Q4]1#^!1T0U$/X%'1
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M%'1 4SA5)O#K]&8<*I-X=?HS%3U$/X%'1#40_@4=$!3.%4F\.OT9@=528_\
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M3>'7Z,PX52;PZ_1F*GJ(?P*.B&HA_ HZ("F<*I-X=?HS#A5)O#K]&8J>HA_
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M#K]&8J>HA_ HZ(:B'\"CH@*9PJDWAU^C,.%4F\.OT9BIZB'\"CHAJ(?P*.B
MIG"J3>'7Z,P.JI-[X7Z,Q4M2QX!'1(#8A_ (Z) ->L?I[+HFLJ,2RXJYNN;T
M'RD-@H(R5!,*3M^](]1#!>8AEI-84;HMI+[XYN+RD,Z0-C@V+;?O2/4 ^D
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MO9;NE>L5",_!W/BF/@IC\4M_&5ZQ?QA5@ !&P
M
M                       0WEM RV6$1Y.+,E6L HT],BBX3;QF*RTDR01'
MMV;QA?-=C7]S[A5,,4NPG90Y;H7A=9H:>DJV_B&BY=6Y))$GM(WM_P 0_D Z
MIW_6^@+_ *WT#E;[-[^P_P"L?Y![-[^P_P"L?Y .J5_UOH"_ZWT#E;[-[^P_
MZQ_D'LWO[#_K'^0#JE?];Z O^M] Y6^S>_L/^L?Y![-[^P_ZQ_D ZI7_ %OH
M"_ZWT#E;[-[^P_ZQ_D'LWO[#_K'^0#JE?];Z O\ K?0.5OLWO[#_ *Q_D'LW
MO[#_ *Q_D ZI7_6^@+_K?0.5OLWO[#_K'^0>S>_L/^L?Y .J5_UOH"_ZWT#E
M;[-[^P_ZQ_D'LWO[#_K'^0#JE?\ 6^@+_K?0.5OLWO[#_K'^0>S>_L/^L?Y
M.J5_UOH"_P"M] Y6^S>_L/\ K'^0>S>_L/\ K'^0#JEOXP-5O;?0.5A]6[/?
MVC_K'^0B75N=/9VC_K'^0#JAW6XN<-(B*YF.64/U;1MQYMMW!/5H6HB4OLA?
M1*^T]PWXP S!T3F"HZ'JFD9@TI3B2-V&TNZ:/C+;M,!E<S,N,"N?&)=_&)DV
M(!,(*$0 2J%%/\H2_P#G$*TH44_RA+_YQ!FIN56O;![8/:@D-U4P
M                                @KO3\PB(*[T_, HDE)79&.V\:16B
M([;Q19+^,8_SI%;+< B
M  \(K8PX7ZI^H4^F2+L0CXRO6/OC/P=SXI^H?!3%SE*"_65ZQK\9U5P !EH
M                                       %)J;\3N?&3ZQ5A2:F_$[G
MQD^L7$U4(7:PCXI#U+</"#OJ$?%(?0)NF   *
M                                                      )3*PF
M!@;,/?AC1G[QSUD,XP)&4(Q^[3ZA@W,.7_?*C"_\QSUD,YP1?[&Q^[3Z@'N
M  "5(F$J0%$K;\EIE_#.?X3&.,I/]24J_B8K_-,9'K;\EIE_#.?X3&.,I/\
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M Q;JFH:.AW5HV&E#B5&7R$8^A"KK-'( ]0
M                                           !(LK\0G$+7 :B]5"(
MBRE55?\ \G_&0X*J/=8OE'>GJHVS*95!?N?\8X*JW )0
M                $Y'W-MQ^L9KRRYGJSRXUS#SZ01;RY8MQ)1<'I=RM.[Y+
M#"9;[&5Q,2CL9$>P]X#])F7O,%1.8"B(2JJ6F+3CKC9:]C2[I"MQ[-^\942>
M@FQJN/SE98<S5:9=JUAY[(HYU<O6XDHN#-?<NIW<>ZP[OY?<P-%8^T3"U12<
MR:<<<;+7,:7=-JX]^W?<!EBY%;:%R.XDO>UQ,6\P$5"B_P#ZA_\ G(*TH47_
M /4/_P Y 359$Q;A*)BW 8B  "@
M   ""N]/S"(@KO3\P"AR?\91W_**W[4423_C*._Y16_:@)@
M                            !,'A&?@[GQ3]0^"F/Q2W\97K'WQGX.Y\
M4_4/@IC\4M_&5ZQ6%6  !L
M  %)J;\3N?&3ZQ5A2:F_$[GQD^L!]\'^#M_%+U#V/>0\8/\ !V_BEZA['O(!
M$
M                       !@7,/^65%?O7?60SG!?@C/[I'J&#,P_Y945^]
M=]9#.<%^",_ND>H![@   E2)A*D!1*V_):9?PSG^$QCC*3_4E*OXF*_S3&1Z
MV_):9?PSG^$QCC*3_4E*OXF*_P TP89D  !L
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MS$$17.YVN=MHZ$).^T(=/0  1L
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MH?\ YR"M*XA1?_U#_P#.0$U61,6X2B8MP&(@  H
M                @KO3\PB(*[T_, H<G_&4=_RBM^U%$D_XRCO^45OVH"8
M                                         3!X1GX.Y\4_4/@IC\4M
M_&5ZQ]\9^#N?%/U#X*8_%+?QE>L5A5@  ;
M              !2:F_$[GQD^L584FIOQ.Y\9/K ??!_@[?Q2]0]CWD/&#_!
MV_BEZA['O(!$
M                                  !@7,/^65%?O7?60SG!?@C/[I'J
M&#,P_P"65%?O7?60SG!?@C/[I'J >X   )4B82I 42MOR6F7\,Y_A,8XRD_U
M)2K^)BO\TQD>MOR6F7\,Y_A,8XRD_P!24J_B8K_-,&&9   ;
M
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M3&Y"$DG=N$UBO<N,04G98MOD B<  %
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MEN/E'K:^P]I& BH47_\ 4/\ \Y!6E<0HO_ZA_P#G( K(F+<)1,6X!$
M                                  05WI^81$%=Z?F 4.3_ (RCO^45
MOVHHDG_&4=_RBM^U 3
M"8/",_!W/BGZA\%,?BEOXRO6/OC/P=SXI^H?!3'XI;^,KUBL*L  #8
M                                 F@*34WXG<^,GUBK"DU-^)W/C)]8
MH^^#_!V_BEZA['O(>,'^#M_%+U#V/>0)@1W$1*D3 H
M
M # N8?\ +*BOWKOK(9S@OP1G]TCU#!F8?\LJ*_>N^LAG."_!&?W2/4 ]P
M2I$PE2 HE;?DM,OX9S_"8QQE)_J2E7\3%?YIC(];?DM,OX9S_"8QQE)_J2E7
M\3%?YI@PS(  #8
M                     "%RY0N7* B  )@\(S\'<^*?J'P4Q^*6_C*]8^Z,
M.T,OXICX:7_%+?QE>L5A5.Z#NA, -H;>,1     2   $   (   0   @  !
M  "   $$#*XAH^43 *)='RB)%;C$0
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M"(@KO3\P"AR?\91W_**W[4423_C*._Y16_:@)@
M               0N7*%RY0$0 !,'A&?@[GQ3]0^"F/Q2W\97K'W1AVAE_%,
M?#2_XI;^,KUBL*L  #8                                       F@
M*34WXG<^,GUBK"DU-^)W/C)]8H^Z$_!D?%(>Y[R'A"?@R/BD/<]Y F()$P@1
M6$04
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M&RLS]R?J'P4UW$I;3R*5ZQ9K.[BK@)=,@TTB-7$P"732&FD"I@$NFD--(%3
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M<GZ,A> !V19_8VMO')^C(.QM;>.3]&0O  [(L_L;6WCD_1D'8VMO')^C(7@
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MM,OX9S_"8QQE)_J2E7\3%?YIC(];?DM,OX9S_"8QQE)_J2E7\3%?YI@PS(
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MG80#T,",N4?(N92U$2F"7,(9,0K<R;J26?\ RWN/>Z0'I<+E82EL0(&H]'>
M&9$?F#22>TC$ID=K;S/Z1@'-1F;F67*%DT7 4)$U"<V>)I:65*+5=T17V$?*
M V 4LDV*VWD$=))63RBBTE/EU%3<#/78=3)QC*73;46U%R([?2*LG24D[E;R
M<@"<U$5SOYS$--.EH:5[BSL1\5Z(PHE:)K6\X*70;AZ*7#0:KF9V]8K-*U+)
MJODC%04]%E%0$66DRNUKD KA&1"(\R,A.1\0"(               )@\(S\'
M<^*?J%/IC\4M_&5ZQ4(S\'<^*?J'P4Q^*6_C*]8K"K   V
M
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MK;OH >H  "50HO\ ^H?_ )R"M*%%_P#U#_\ .0$U61,6X2B8MP&(@  H
M                                 @KO3\PB(*[T_, H<G_&4=_RBM^U
M%$D_XRCO^45OVH"8                                          3!
MX1GX.Y\4_4*?3'XI;^,KUBH1GX.Y\4_4/@IC\4M_&5ZQ6%6  !L
M                               %)J;\3N?&3ZQ5A2:F_$[GQD^L!]\'
M^#M_%+U#V/>0\8/\';^*7J'L>\@$0
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MB"%D:;VVB4R-2+&>T118^Z+< ]                           $#*Y"(
M-0>JA(464NJ#7_Y/^,<%U*(QWJZJ/_X2ZHN?@?\ &0X*;-R2 0
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MY16_:BB2?\91W_**W[4!,
M   )@\(S\'<^*?J'P4Q^*6_C*]8^^,_!W/BGZA\%,?BEOXRO6*PJP  -@
M                                     I-3?B=SXR?6*L*34WXG<^,G
MU@/O@_P=OXI>H>Q[R'C!_@[?Q2]0]CWD B
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M5N :237.+C?CKB#-I5A)6L-1<CE3BFR?<U;NM,KEN5M+:0N/*]G/Q3B\8(O
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M>_=).QG] QSF!)*,D,8WI:)%+V+D1>0A\'4O;EEPEJ#;T;.O;;[_ +X8#<8
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M!]*N(47_ /4/_P Y!6CXA1?_ -0__.0$U61,6X2B8MP&(@  H
M                          @KO3\PB(*[T_, H<G_ !E'?\HK?M11)/\
MC*._Y16_:@)@                                         !,'A&?@
M[GQ3]0^"F/Q2W\97K'WQGX.Y\4_4/@IC\4M_&5ZQ6%6  !L
M                           %)J;\3N?&3ZQ5A2:F_$[GQD^L!]\'^#M_
M%+U#V/>0\8/\';^*7J'L>\@$0
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M5&_\)E4?^S_C(<$CWCO;U4;_ ,)E4?\ L_XR'!(]X
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MA$05WI^8!0Y/^,H[_E%;]J*))_QE'?\ **W[4!,
M                     )@\(S\'<^*?J'P4Q^*6_C*]8^^,_!W/BGZA\%,?
MBEOXRO6*PJP  -@                                        I-3?B
M=SXR?6*L*34WXG<^,GU@/O@_P=OXI>H>Q[R'C!_@[?Q2]0]CWD B
M
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MJH2&:81[EM!)+F(?0 4   H  !0  "@  %   *   4   H  !0  "@  %
M*   4   H  !0  #-'A&?@[GQ3]0^"F/Q2W\97K'WQGX.Y\4Q\%,?BEOXRO6
M-7QG<580,KB(#-:>9HN8B:;%L$V\@O;>842: G(K"(!0  "@  %   *   4
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M   4!!7>GYA$05WI^844.3_C*._Y16_:BB2?\91W_**W[4!,  )0  "@  %
M  *   4   H  !0  "@  %   *   4   H  !FCPC/P=SXI^H?!3'XI;^,KU
MC[XS\'<^*8^"F/Q2W\97K&KXSN*L  ,UH  "@  %   *   4   H  !0  "@
M  %   *   4   H  @H*(BDU-^)W/C)]8JJ12JF_$[GQD^L5-??!_@[?Q2]0
M]CWD/&#_  =OXI>H>Q[R$W3$0  S5   H  !0  "@  %   *   4   H  !0
M  "@  %   *   4   H  !0  "@  %   *   4   H  !0  "@  %   *
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MF7\,Y_A,8XRD_P!24J_B8K_-,9'K;\EIE_#.?X3&.,I/]24J_B8K_-,&&9
M ;2W._\ J/FC9C 2U).3"/AX9L]RGG4H+Z3'T$1W_P!1H1U66*F$/AM)VX"/
MB(1;SAMFMEU2#*ZR+B,!O%PKI91DDJEE9WW%UXWM^D5%F(8=1KF'VW&SVDI*
MB,N<AR6I'J<,[J#!-C$QG&F:,QW6YQ:4FIP]J2TK=]Y!EWJ:N/\ 7E?R&M:!
MK::.1ZJ:;4Q"OJWVLHC/Z &_KM4TTPLVWJ@EK:D[TJBVR,OD,QZPD_D<<9-P
M4Z@8E?N6HA"CYB,<7:1P)G&9+-/4U*/XA3*3P[,0?<H=<42KW/<1[!?6,^5W
M'/)$RG%C#;$R832 AW$JBDN:2B;3<BM91GOV@.N;L0U#H-U]UMIM/?*6HB(O
ME,4Y56TLFY*J65;/_6-_:-0U9@&L><ELTK9IU<+,3A-&*2A9DI*BV7N7*9#2
M?*1D_3F,D,TJ2>8T14H6R^K0AW8M5R[LRXU$ [.0,ZD\R,TP$V@XE1;R9?0L
MRYC'T+?:80IV(6EMLMZU*L0U3RKY.(++_.XV<RW$UVHRB='6-&\:R*WE-1V%
MN]41S$3"AJ(/#&@XM3E4SUM9()D[K:2G:J]MVP!N3"3:5S S*7S&&B33OU+J
M5V\]CV#W4LDITC58BWF.;?4@9C.8N5UHN=1L5$Q.L:-1/O*791J.]KGL'1><
M&KL7&*T=I0SAD=]W<F ]&)O*XI\X>%F<*ZZGOFT/)4HO.1'<?49F9V)5C'+O
M)E-YK%YRJNA8F9Q:D)B-C:WE*3N/B,[$-YZMS58)T172<.*CJQ$)/E$9E#K;
M,BL17/NMVX!E[9I7O8>$9,I=+[''3"&AB5L3K74HOYKF,"2;/5EGG]7-4/+Z
M\2J;/KT&VEL*0E2B_6/8->.JL3B(@Y/0\9+9@^P3D22E:EY2"4G33O,CY '0
M=#S;B26VX2DJ+N3([D/.(BF(1LWHI]ME!;UN*)*><QJ[(,[F7;#6G9'2U8UX
M3,QZV90I),J<(E&DMZBV"]\?)S0N(V7F:S55<G*9!'M)44V90:C;*^\B3M 9
MF*;RM4-UZB90IPQ?[TGDFCI7L/6$C82-;)Z#BV8AL]RFG"47.0Y^P\NIFFLA
M4[9H;$6*JR#;)1HFBDK:69ZP[[SOLW#PR39H<+<'LNTK>Q3K)UEUYQZRE$M]
M>QP]Y%<R =#EN)01J4=DEO,?-#3651BU-P<RA7UM]\AMY*E)\Y$>P8_P\QNP
MSQPHZ,GV']3-QL!UNX3CA)T5-EHF5S2>T:EY<9A@QA35^(U:,8W1=1+0X2XN
M'7#.$4&KNK$5SV[>0!OZ:KGOV<8BDS/9N(AS1PJZI3+X_'J:2:N*X<X($^EJ
M ,H,S-1GLM8BN6VPZ$3'$.D912QUE-9NU"RLVB>)UP]'N;7(R(_( N5*B)1E
M?=] BD[[>+B&MLLZH/E7G,V;D,+B"9Q3SAM()4(M*341V[X]F\9FJ?$VC:,H
MIVOY_.VT2-A"7%139:9$D]VX!=6F5[<9"*5$9V)0P9+<ZN7.;04NF$%7C3S4
MV<4U"V:/26HCL9&6\MHS="O)BF&HAH_O;J26D^4C*Y /I
M          !,P?/&_@SGQ3'P4O\ BAOXRO6/OCOP9SXICX*7_%#?QE>L:C*K
M@ "-
M                                                     @9V 6Y5
ML?"RO41D6O0;0>T[#Y2Q.HY*"-4TML*_<&/@Q:OV!49[B^T81([$1)/88#/_
M &T*,\:?V##MH49XT_L&,   S_VT*,\:?V##MH49XT_L&,   S_VT*,\:?V#
M#MH49XT_L&,   S_ -M"C/&G]@P[:%&>-/[!C   ,_\ ;0HSQI_8,.VA1GC3
M^P8P  #/_;0HSQI_8,.VA1GC3^P8P  #/_;0HSQI_8,.VA1GC3^P8P  #/\
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ME;2R-*BO<A.9&1WY1A_#[$!4 IN4S9S38/8ETS[S[1EQMUMQM*T.$M*BN1D
M]C.Q 6X2WN(I 3                                 (6VW$0 3<J5 ]
MI"DU,7_9#A_K)]8JXI-3?B=SXR?6+A7WP?X.W\4O4/8]Y#QA/P9'Q2'J9V4&
MXN(EY@N5]XE)2N,A+W*N,!/I%NL(F9<0E(K"32(CM<K@/2Z=Y@2B5L$I&9%=
M5A#3N?<@/2Y"&D5MXD+1TMXAW!F9$HC >FD1;;[Q$E$8\UDFQ$9[!#31K"2D
M[D8#UO<+D)#41;S(A U<@">YEO$3-)'M$BG$I+NUI+SF)=-*MQW\P#UV$%R$
MBCMN$NL2DM)Q1)+E,[ /79<K!RCQ0ZE=S0XE1>0[B<C/8 G(R/;R!>^XQYZ1
M$D["73(BL2RN7%?: ]C,@+:0\](K[A#2.^\!ZZ0:0E-1<:BYP(SM<C 1OR;0
MW>02&M1^00,TD5U'<!ZF9"!'?>6\2&M-NY41WY#$4'I;N,!Z
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M*O93UA,V5N&MO3)6PUF9;2\@V209[;)V<0#U
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MI$9$?&!<F[E(65AIBY06+DD345"3YJ90#FU)EW*D^=)[2%Z(5<C5>Y'N >@
M
M                     "P\6_Q H81XB&;L6_Q H81/<0"
M
M
M       ">^ MJMH!NVD (,V[F@S+;W*>09'P^K]4 \B43)9FR>Q+AGN&.;[2
M,RV\H$9H([&>P]E@&T;+R'B-UIPE)41&5A.2C(B,T[#WC$&'U?*EZVY5-'#7
M#*V(=,^\^T9=;<0MM*T+):%;=(C >IGL MPE$4@)@
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M0THB-23,BXO(-I<)*]@L1:*@)]".I6I;2=8DCO8R*P"^#.P%M$HBD!,
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M$"1@?,/^65%?O7?60SG!?@C/[I'J&#,P_P"65%?O7?60SG!?@C/[I'J!I[@
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MHN,1-)\1B8+6.YF \C:61]PJQ<9";0N7<[#Y1/;Y0O?R@(&D$IL)@
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M^PXKB<8LXCH3+IG-5DOL>@DF36_9=.P]XW@(R616.Y /0
M
M       !8>+?X@4,(GN(9NQ;_$"AA$]Q (
M
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M9]R6T[F8#(^)N/S]$3V,I]RBW9@PRGNWKGHJ*VW986'4>*$@Q%R^3N+D$I3
M0\.XV1,IW$9N;?I'U57FGI:K96Y*,/Z?>G$YF"#92T["*;T;[#/24GRCVEF"
MLYIG+9&TRN$M-XDSBGTEM.VGIVYA8P^]RO([#G++#SR5%:+T2::V[C6K1O\
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MLKC,4JG))!TY(X222QHDP\(TEI)%LW$17^@55')OY 'H
M                             "8/",_!W/BGZA3Z8+_LE'QE>L5",_!G
M/BF/@IC\4M_&5ZQIA4STK;A*9*'I\@B(V\4M'HW7M/E$RF[D9*.Y"?Y; 6SB
ML E3<M@*OR"< 'F:-(Q&VB6P3@ \R1Q[Q-HB8 'GHFG<!)49#T !XZLR*Q?+
MY0T%Z-M*_+Y1Z:)!:VX!(E!GO$309#T$+V 2:L3)21"-R$0
M
M          !8>+?X@4,(GN(9NQ;_ ! H81XB 0
M
M
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MLQ$D6$X /)2;EL$Z$Z)"8
M        $P>$9^#N?%/U#X*8_%+?QE>L??&?@[GQ3]0^"F/Q2W\97K%858
M&P
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MLST"#K6$][,] @&K_6D5[V=Z!AUI%>]G>@8V@ZUA/>S/0(.M83WLST" :O\
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M#K6$][,] @ZUA/>S/0(!J_UI%>]G>@8=:17O9WH&-H.M83WLST"#K6$][,]
M@&K_ %I%>]G>@8=:17O9WH&-H.M83WLST"#K6$][,] @&K_6D5[V=Z!AUI%>
M]G>@8V@ZUA/>S/0(.M83WLST" :O]:17O9WH&'6D5[V=Z!C:#K6$][,] @ZU
MA/>S/0(!J_UI%>]G>@8=:17O9WH&-H.M83WLST"#K6$][,] @&K_ %I%>]G>
M@8=:17O9WH&-H.M83WLST"#K6$][,] @&K_6D5[V=Z!AUI%>]G>@8V@ZUA/>
MS/0(.M83WLST" :P=:Q?O9WH&!PL9[U=Z!C9_K6$][-= A!4-"$D[0S6[W!
M-8.MHE2C23#IFC]0Q$X6*(SO"N[/U#&PTHAV'8V,2IAKN3+VA"KE"09__:M;
M?U" :P]:17O9WH&'6D5[V=Z!C:#K2$][,] @ZUA/>S/0(!J_UI%>]G>@8=:1
M7O9WH&-H.M83WLST"#K6$][,] @&K_6D5[V=Z!AUI%>]G>@8V@ZUA/>S/0(.
MM83WLST" :O]:17O9WH&'6D5[V=Z!C:#K6$][,] @ZUA/>S/0(!J_P!:17O9
MWH&'6D5[V=Z!C:#K6$][,] @ZUA/>S/0(!J_UI%>]G>@8=:17O9WH&-H.M83
MWLST"#K6$][,] @&K_6D5[V=Z!AUI%>]G>@8V@ZUA/>S/0(.M83WLST" :O]
M:17O9WH&'6D5[V=Z!C:#K6$][,] @ZUA/>S/0(!J_P!:17O9WH&'6D5[V=Z!
MC:#K6$][,] @ZUA/>S/0(!J_UI%>]G>@8=:17O9WH&-H.M83WLST"#K6$][,
M] @&K_6D5[V=Z!AUI%>]G>@8V@ZUA/>S/0(.M83WLST" :O]:17O9WH&'6D5
M[V=Z!C:#K6$][,] @ZUA/>S/0(!J_P!:17O9WH&!PD7OZV=Z!C:#K6#][-=
MA*<)"'_]JUT"$S:-8NM(LTD:8=WH&)V8",B31J85PU*.W>F-E8F#AM0O0AVK
MDDS[PA3J:AH5V5M1!PS>GI*]J7**+2P^P^;@$)FDS1I.JVI2HN]&1BN5FT)V
M<O((DDDGW*;$>\$DHCM:Q>L!.16$0
M      !- 4FIOQ.Y\9/K%6%)J;\3N?&3ZQ1]\%^#H^*7J'N/""_!T?%+U#W
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M_(%K@/E<EL*\HM=#M+2G<2D$9$/I2E*")"4D1%Q%L$P
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M*,DZR;C$:I2-6J]N/?N&4?)>]]Q#EEU*TD]MW$DC29'U\5R_YU#;#-!G6DV
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M40T]D<1KX*+02VG+6N7F%1)1;RVD,:Y>R6K""G+E910J/40R25C5OM;>0#T
M  ! ]PB('N 6G7<U5)89J8ZC3U?%<6FG&W0(B.3:6CL_I!7<6[=@#.__ ,N,
M(7(R,RXP&5NW?_P/_JAV[_\ @?\ U1BBWZOTA;]7Z0&5^W?_ ,#_ .J';O\
M^!_]48HM^K](6_5^D!E?MW_\#_ZH=N__ ('_ -48HM^K](6_5^D!E?MW_P#
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MC<]UK"/=7(P&4^W;8_Q+_P!03=N__@O_ %!BG;[H-ON@&5NW?_P/_JAV[_\
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M4Q^*6_C*]8^^,_!W/BGZA\%,?BEOXRO6*PJP  -@
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M; Q+;[#R26A:%$HC(_*0^HB 1
M &!<P_Y945^]=]9#.<%^",_ND>H8,S#_ )945^]=]9#.<%^",_ND>H![@
ME2)A*D!1*V_):9?PSG^$QCC*3_4E*OXF*_S3&1ZV_):9?PSG^$QCC*3_ %)2
MK^)BO\TP89D  !M+OV#G]U7/7]K&4%#G]]UAZ!_K:96^D= =$C.Y[QJ#U1#
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M>U542ZLJ<SNS,'4&@T<1[#/;L%1J[)F=39DX',"S6?6O62C/K#K?2TNYT>^
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M6>E^L ]@     !8>+?X@4,(\1#-V+?X@4,(GN(!
M
M                !$CL(  ](:)>A7TQ#*S2I!W2DN,9HH#$!J;MIELS<)$4
MDK),_;#"9D96XS'I"ONPKJ7F'32HCO8N,!M(A9*N=Q%)DK:1BP*"KUB<0Z8"
M9+)$2@B)*C/OA?:%$K;:RN0![                                "8/
M",_!W/BGZA\%,?BEOXRO6/OC/P=SXI^H?!3'XI;^,KUBL*L  #8
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M\!#1$#2)P >:T\@(38AZ"![ $C;9H(^,"29G<QZ"'R@($5Q,
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MB;Z6H%90AW5?9:Q%<MMANWB-F4P?PIDLKG];U+UA!3<B.$<-I2M.]K;"W;R
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M0R>IY6Q.))'M1<)$I);;C:B,C(!:^+7X@4,(GN(9NQ;_ ! H81/<0"
M
M                                  ![//Q 6T]%7?<1AM+=NXQ$NZ+0
M3NY0$\)$.P[QO-.&A:#+87&,^T'-YI-Y2ER9,&A2"(DN'[;Y!CR@J 7-W6X^
M9LFF%0=TH/VXS-#PZ(9DF&DDE*2(BL0#W
M     $P>$9^#N?%/U#X*8_%+?QE>L??&?@[GQ3]0^"F/Q2W\97K%858  &P
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MEA2S;(T),_UMHC;>ZKLQV U(8A0^'M35!!E4L6K198ZU)Q5[>Z(M@T[SB37
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MYMHF:KV^D!DS%K\0*&$3W$,W8M?B!7R#")[B 0
M
M              #?M/>&_8>X-^T@+:=BW@!=T=M':7%RB_: P_=F[J)E-&S3
M#7N@C]L(T'0+LW>1-)DV:89!W01EWPS*Q#MPS:6VD$DDE:Q (PT,W",DTTDD
MDDK$1$/5%]MQ,                                  )@\(S\'<^*?J'
MP4Q^*6_C*]8^^,_!W/BGZA\%,?BEOXRO6*PJP  -@
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M"-JV*4M1N+5YU*VF+S3?0M:Q":W$6\-G)L 2H383*3<3  DM83$5BM81
M                              $H  !0  #-'A&?@Z_BF*?3!?\ 9*/C
M*]8J$7MAU_%,?!3'XI1\97K&JSN14C;([[!'0\GTB:^[:&^VT1IYJ:TC,^43
M&B^P1,]I"8!);9<026T>@A:P"4DJ$= A,(6N D-!GM(0U>G;2'INW!L,!*>D
M16(0)&D6T>@A:X"715RB&BHC'H(6/E 0(N,1$0 2FG9L$II5?>)RMQ!MY0$M
MK; )&CM$X //160C91B< 'D2%$8F)*B,3?*(@)"29"-CY!, "30T4V(A T:2
M>Z$Y6XA$!)HDHK&&B2=PF/R 7E 2DFY".CL$;[;!?;8!+H$?%80T#+<)[WW&
M&[> DT>YN1"!I7:Q&/3R!OVD8"0D;-I7$33Y!. #S6D]'8(H(R2)P >>@=K<
MHAJS([CU !YZ%S.XB2=$C$W&8$>RY@)";VB;0(3  \R:(RVB*D:2;"< 'GJS
M(1)&P3@ \TI,A,?F$P@97 2*1I'<3:)$6X3  D 3@ \R1LVB8DV(1+8(@)-%
M7*&BH3@ DT2T0T2T1. "12;F0)18B$QGO SW@)23Y -/D$X //1416$;$1;2
M$WRA?;8!9F)4!%3.4]90B--Q>XAC+M9UB96*5Z1<NF0S-/B(HB&L6TS,59O:
M173M(B 8#[6-9^*O[9!VL:S\5?VR&P( -?NUC6?BK^V0=K&L_%7]LAL" #7[
MM8UGXJ_MD':QK/Q5_;(; @ U^[6-9^*O[9!VL:S\5?VR&P( -?NUC6?BK^V0
M=K&L_%7]LAL" #7[M8UGXJ_MD':QK/Q5_;(; @ U^[6-9^*O[9!VL:S\5?VR
M&P( -?NUC6?BK^V0=K&L_%7]LAL" #7[M8UGXJ_MD':QK/Q5_;(; @ U^[6-
M9^*O[9!VL:S\5?VR&P( -?NUC6?BK^V0=K&L_%7]LAL" #7[M8UGXJ_MD':Q
MK/Q5_;(; @)1K\6&-9\<J_MD':QK/Q5_;(; B!A1K^>&59;+2W;\8AXGA[51
M1)0I2[[Y\<AL(=]I%Q"B[.$!VW_R%&&^UC6?BK^V0=K&L_%7]LAG\K<@F :_
M=K&L_%7]L@[6-9^*O[9#8$ &OW:QK/Q5_;(.UC6?BK^V0V! !K]VL:S\5?VR
M#M8UGXJ_MD-@0 :_=K&L_%7]L@[6-9^*O[9#8$ &OW:QK/Q5_;(.UC6?BK^V
M0V! !K]VL:S\5?VR#M8UGXJ_MD-@0 :_=K&L_%7]L@[6-9^*O[9#8$ &OW:Q
MK/Q5_;(.UC6?BK^V0V! !K]VL:S\5?VR#M8UGXJ_MD-@0 :_=K&L_%7]L@[6
M-9^*O[9#8$ &OW:QK/Q5_;(.UC6?BK^V0V! 2C7[M8UGXJ_MD':QK/Q5_;(;
M @%&OW:QK/Q5_;(.UC6?'*O[9#8$2J/N3\PHUY:P]JIYQQEN7;6K7[LA[]K*
MLCWRW^V0S))B,IE'6XS2*WMM>P# !895BD[E+?[9"O4CA7,5QG7%00^I:;,C
M2U>^G\HS!?89F8)TMA'M\H#SAH9N%92TTDDI25B(B'JB_&)@
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MS(G7*3JWL89W-*-0:_68P-574?L596IS@]/.RA;='[VE%QV9*Y6V7\H&1_S
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M $I46\P(B(]HFW%M SL B
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M !)J6?!(Z)!J6?!(Z)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G
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MEFW]$CHD&I9\$CHD!F5M]@(R+C 0U3)';5(M\4@U3!';5(Z)":W<"&Q2='C
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MZ)1V7UG^R:1+U>BJV_C&54,-$1?>4)^0AJUU,<S/)Q19)*WX1_F#:JU[*/B
M0U+/@D=$@U+/@D=$A. "34L^"1T2#4L^"1T2$X )-2SX)'1(-2SX)'1(3@ D
MU+/@D=$@U+/@D=$A. "34L^"1T2#4L^"1T2$X )-2SX)'1(-2SX)'1(3@ DU
M+/@D=$@U+/@D=$A. "34L^"1T2#4L^"1T2$X )-2SX)'1(-2SX)'1(3@ DU+
M/@D=$@U+/@D=$A. #SU+5R^](Z)"DU.RTF5K-+:2[I/%Y162W"DU,1%*7#/W
M2?6+B:^V$99)A'WI!]R7$0]=2WX)'1(20?\ 0(/]4A[\6P-3$NI9\$CHD&I9
M\$CHD)P&<:2:EGP2.B0:EGP2.B0G 42:EGP2.B0:EGP2.B0G !)J6?!(Z)!J
M6?!(Z)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6
M?!(Z)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?
M!(Z)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!
M(Z)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(
MZ)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z
M)"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z)
M"< $FI9\$CHD&I9\$CHD)P 2:EGP2.B0:EGP2.B0G !)J6?!(Z)!J6?!(Z)"
M< & LQ#;95E1FBA)??'-Q>4AG6!+_8X?]VGU#!V8<KUE1G[QS_09R@MD&Q^[
M3Z@'N   "5(F$J0%$K;\EIE_#.?X3&.,I/\ 4E*OXF*_S3&1ZV_):9?PSG^$
MQCC*3_4E*OXF*_S3!AF0  &TAWOOV 1=T9VV")D9'<MXU\S?YJ596Z5AZF*E
M.S77%_O>OU=K'R@-@B45KDK9R"76%L*]C5N&!LIV:JF<TE#E5$OA42J:-?A<
MNUFF;%SL6WCN+,S?Y\:7RMQ<!*&Y*B?36-,R7#$]JS;MRF VM)5RN1W(-.]C
M25R/Z!C3+WC"K''"V4XD.2;L5V3)1]:ZS3T+';>,D&1+[Y/\@'J2K\=A!:B+
MRB!E?9N$%&I);"N ]+GOX@OM\@DXM#C$I[.XOM >ER.]PVG8R$AJ)5K&)KGM
M(@ CV\AF(&=C2A1;_*-=<W.;-65Z!DT<JD2G935W5VU^KT.Z(O\ 49DPYK$J
M_H^6U7UIUKU^T3A,Z6EHW+=<!=%]_(0$JY7(QYZ7<F=[&0QEF,QE/ 3"B;8F
M=@^RG8PD'UKK-#3TCMOX@&4"/>9G<1(R4FXPQE>S!*S'X;0>(94[V'ZY-1=;
M:W66LJV\9D.Y*+9>V_R )[D>TA$CN5R'EI%?0+CW")'MMQ'N >FV_D$+\=]@
MEV:.A<2'X.^T!Z7+?N,Q#8DRV[]Q#YXN,AX&'<BHMY+33974I6XB&"L4LUU/
M8>5I2%)P+$%-&*G6\E46F,010VARE?C 9^-22(S5LL%](M(B%&D=32.I6U*E
M4PAXG5I2I>J<)1%<O(*NG2N97L1[@'J
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M_P )E4?^S_C(<$CWCO;U4;_PF51_[/\ C(<$CW@
M
M
M         ._W4Q?_  ;45_\ N/\ ,&U0U5ZF+_X-J*__ ''^8-J@
M                          %)J;\3N?&3ZQ5A2:F_$[GQD^L7$U]\'^#M
M_%+U#V/>0\8/\';^*7J'L>\@TQ$  9Q0  4
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MOY1Y,L)AVM!EI#*>)*$D1%\A#U+:?(9 /4
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M14] M0D%#)T4(0DBV"LIVD1GO KF6^X7/CW\1 )P     !J)U4;_ ,)E4?\
ML_XR'!(]X[V]5&_\)E4?^S_C(<$CW@
M
M
M._W4Q?\ P;45_P#N/\P;5#57J8O_ (-J*_\ W'^8-J@
M                 %)J;\3N?&3ZQ5A2:F_$[GQD^L!]\'^#M_%+U#V/>0\8
M/\';^*7J'L>\@$0
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M&*<(]0N.3JSXC[M5P'2BQ%Q"*0,1+8 B
M                     #ST23L(-62=I"?S@ ET;]\(&@R[T3W(R$0'GH&)
MM A, #S-(F2FVT3                            #43JHW_A,JC_V?\9#
M@D>\=[>JC?\ A,JC_P!G_&0X)'O
M
M                                                          =_
MNIB_^#:BO_W'^8-JAJKU,7_P;45_^X_S!M4
M          I-3?B=SXR?6*L*34WXG<^,GU@/O@_P=OXI>H>Q[R'C!_@[?Q2]
M0]CWD B
M                              P+F'_+*BOWKOK(9S@OP1G]TCU#!F8?
M\LJ*_>N^LAG."_!&?W2/4 ]P   2I$PE2 HE;?DM,OX9S_"8QQE)_J2E7\3%
M?YIC(];?DM,OX9S_  F,<92?ZDI5_$Q7^:8,,R   VE,[G8MY#4/JD%51TNP
MHA*5@%_?IU&,)T2.VD274W&WAD7,-).J4P*42VCJBBR4J EL8G7I+<>DXDB
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MK:["-:5^,R05Q=);;GN/E%@X&P3LNPMD,(LS690C9G<K;TD+]21([U.TP'H
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MYS_[FX Y5^QBYR?S8?WQL/8Q<Y/YL/[XV.JGLG63?\Y_]S<#V3K)O^<_^YN
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M #G_ -S<#V3K)O\ G/\ [FX Y5^QBYR?S8?WQL/8Q<Y/YL/[XV.JGLG63?\
M.?\ W-P/9.LF_P"<_P#N;@#E7[&+G)_-A_?&P]C%SD_FP_OC8ZJ>R=9-_P Y
M_P#<W ]DZR;_ )S_ .YN .5?L8N<G\V']\;#V,7.3^;#^^-CJI[)UDW_ #G_
M -S<#V3K)O\ G/\ [FX Y5^QBYR?S8?WQL/8Q<Y/YL/[XV.JGLG63?\ .?\
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MM+R#/]SMOO81,C]J>\2ITK[=GD >@
M  *34WXG<^,GUBK"DU-^)W/C)]8#[X/\';^*7J'L>\AXP?X.W\4O4/8]Y (@
M
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M\8X*'N(=Z^JB_P#A+J?_ -G_ !C@F>X@
M             ".P
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M8^^,_!W/BGZA\%,?BEOXRO6 JP
M         *34WXG<^,GUBK"DU-^)W/C)]8#[X/\ !V_BEZA['O(>,'^#M_%+
MU#V/>0"(
M                              # N8?\LJ*_>N^LAG."_!&?W2/4,&9A
M_P LJ*_>N^LAG."_!&?W2/4 ]P   2I$PE2 HE;?DM,OX9S_  F,<92?ZDI5
M_$Q7^:8R/6WY+3+^&<_PF,<92?ZDI5_$Q7^:8,,R"50F$J@;>:D&>D:UZ23X
MAH57\JE,XS_2.7S:%9B&%FY=#J24G^C\HWU-:>7N2WD.<68>D:TK7.U*I)1%
M9<%I@]IZN/)@GC+[W[DP&9L]V&^'<#@5,:AA82$E<QESL.J%?AB)M>D;A;"T
M;&=Q@K,)-)K467[#"85&TI42XZ2%DYM[DG$D5[^09L:R38EU?'036-6.CE7R
M2%63AR_K'4$HR.Y7,CY2%H]4<IMN74+2%/TY$%+2:=2RPZE-]7W:2([<8#8Z
M9X4883'"I3$RD4M0A<I)9N$VA!I435[W(N4:SY,<2':$P1K2(F<<Y$2.2+>1
M /.*/NC4M1$1&?EL0NB592LQE0TU!P,\S/.1<FBX=HW8(I62#-LTEW.D1WW;
M!9N;*C87!G!N19=L(Y6<3.*C>);#2%V4^IMPEKN9[K[><!B>"HZ:46]2N<B)
M9>A9A$1SR)E<S/20IS5MF?R&-Z<RDT8FN6N;35I]+R(B#9<TBVD=R(_]1JU7
M9YMJIP5<PQC<KZ6I2F';4;A35NZ301*TK;]Y7%<H.O)C4^2*=TU4Y*:G<F0;
M48PM5U-D:S))7\Q +PR:E@W]S]*SJ8Y&49I1&O4]JM.VF?+MW"V,OLHDL;FZ
MJJ=80..(I6%4UU^2",FEF:-FC?9OY!\64O)3@-B-@A+*KJNG(YZ9Q:WS6ZB8
MNH29DL['HD=A<^7&9.8+9C*GP$-XER5TVNPA&W91$2=)9&K>KY0&Z]S*^EMO
MN%/G\PETME$6_,XU$*SJE$MQ9V(B,C&!,3,>,P=)UK%2&C,O*JCE3:DDW,>R
M26M,CWGHF,8YB*^K:O*APUPTJZ3KI9JJ775S&&2_IV-HR4DM(@%.PWG6'\HK
MFIJ>JI#<QIJK5:J63.*AM&RBN2MJBN6T^4;*Y?\ !"68(4Z]*)7-UQL)$+-Y
MHE&9Z!*4:MES\HP_GS@Z3D670H-"&&9BRY!)@3:(DN&9.)N96VC8#!UZ:16'
M<CBIYI*C50C9*-6RY:)6^@!>,7$(A8=V*65B;0I9GR$17',_&*AHC-;6-?5:
MA#BF*)=AWI)%)4=E6.[MB+XHWDS+8AHPQP=G]3*<)"T-:AO;M-3G<E])C2G+
MQ$9N:"PT=D4HR[=FX6:F^M<>J9(;-]#AF972>W82@&X66/%.&K_!"558]$)4
MY#M.,Q%SVI)GN=I?\HQY.LVF*E03:9-8'X(G6<HEMR<F!3 F"*U[[#W[2,86
MR<3:J*#JFOL)\5:9<I@XMI3D) &_K2:TDJ4O1,M^\>&!^)N+V&DHG4CPNPT@
M:MI:,?>;@YD_-FH19&:U$LS;6>EL,^/D 9_RW8H8F8NS>/JVJ9RF1PL!?KJF
M]%+APUKEM<X]UQYU9FZJN85;,J1P)PM57K\G,BCW"B^MTM7+98SV*^0>6 N$
MTXHN@JMK&;1K*JBJ2%=<BF6'DN$P9)58B-)VW&*3U/#K#M9QQO$V<V*,B.NS
M5;6J+6JT=*^W< R#@7F=1BC.(NBZSIQ5*U; &1/RM;FLM?=9>X]G(*+B9G!A
M,.<3U85\$G8Z8.[(0T+/[ZJU['8M@QYB0LCSQ8?JIQ*$[8GLCJ;>#[G3M_J*
M\W#0\5G/<.(AVGK$6U:".WWOR@/ME&<>L9+7TIHS&?"15&P\\4I,!&G&:\G2
M+E(MV\A<&9Z:T,W,Z/.J*1<G2HEPU0BT1:F=3<R.^S>+#S^L,F_1)ZI*%)BM
MCA%M3W:14,UZC6YANE*+]PBRK^1(#*N,V.\NP;I^5HAI24QFLS904NEYNZ!N
MF1%W.EY-@QU)<V^(DEJ*6RW&[!9=%RV<*M"1J8WKG3Y#LG=O(??F/POI+%=-
M*29=8IINL89@E26,4WIDE6B1J[D]AC"6(-0XY8++E*L>9:W7M-L/MLIF)Z#!
MMD:B2DR26WD ?=U0;%#&"2M2UJE:"=.3F\RMB:MQI)UUU),BT-Y7W#:'+W6V
M)]94NT]B-AL=)K:AV=0DXLGS?+1+NMF[E&#L]<3#Q6%U-1D,C5L.N0KC=]R"
M-:#L-KZ/63M+RITC)1G!L[2^(0"M@                         F#PC/P
M=SXIBG4T1G*6[>Z5ZQ4(PBZW6?ZICX*8+_LE%C]LKUC6,,(9O<J7W4U*0U-J
MJHY$<->SI,ZR]SON&HL+U'"HX/5H9S&3)M#9D9(2RXE._D)0Z?7XSWCPC'H>
M':4Y&/-M,EO6XLDI+Y3$;:U/9(J1GN!<NPAKJ:KGL3*D**&F;A*):%*.]]]Q
M@^7]2PGKSD- 5#CI&32G6'#5V,5#J22D7N2=*XW_ &IM*G(?KQ$TA%,)WN)>
M2:"\ZKV'K"1D)'-ZZ!C&8AM6Y32R4GG(!ANI<LM,QN CV!%(K3)9<MHFVW"3
MIZL[W,_+<PRXY<RP#PE+#%50]ENX>2<5JM#OS,]WDN,UZ-CO?S@HC(B-)?(
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M)E4?^S_C(<$CW@
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MW/BGZA\%,?BEOXRO6/OC/P=SXI^H?!3'XI;^,KUBL*L  #8
M                           *34WXG<^,GUBK"DU-^)W/C)]8#[X/\';^
M*7J'L>\AXP?X.W\4O4/8]Y (@
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MEW2",=%J%4ZY2$F<=,U.*@F#4>[VA +A
M                     !J)U4;_ ,)E4?\ L_XR'!(]X[V]5&_\)E4?^S_C
M(<$CW@
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M_!W/BGZA\%,?BEOXRO6/OC/P=SXI^H?!3'XI;^,KUBL*L  #8
M                             *34WXG<^,GUBK"DU-^)W/C)]8#[X/\
M!V_BEZA['O(>,'^#M_%+U#V/>0"(
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MMK$,I9>,GM:'E4FF">*LL3*HV.(R29F3EC)9F1[/D&])[3O;=N M*VD96MQ
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M*(SM;>6P9)ZHG@/B?C7A]+))A7(NR$5"'?5ZPD:-C(RW^8;B>VOH^<1V'8R
M<HJ>I+JJ%.43#T%*:?.#@V$:E+A/,GHH/8?T#.N37(O/<-:K>Q@Q?F!S&K(@
MR<;2XFYL*/8K;N/>-Z#/;?<0\W$DLM'CL9$8#G-G-46-6:S#[!^6-:QZ4ON.
M/+3W1(V$HK\1;AT0DL(J7RF#@5'<V&&VS/S)(O\ 08VI_+Q0DCQ2F6+90!.S
MZ8&D]<I1F:+%;9?<,J(,B*Q;3 >@
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M3%SC_FO_ +X@!JM:Q:5A"QD6X;5'U,?.18KX8_WQ \_8T<W^OU)X9]UR==H
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MW\97K'WQGX.Y\4_4/@IC\4M_&5ZP858  &P
M               4FIOQ.Y\9/K%6%)J;\3N?&3ZP'WP?X.W\4O4/8]Y#Q@_P
M=OXI>H>Q[R 1
M                                   8%S#_ )945^]=]9#.<%^",_ND
M>H8,S#_EE17[UWUD,YP7X(S^Z1Z@'N   "4CMO$P\W#,MP"A5T\VU24S==<)
M*"AG+F9V]J8PYE9KRE97@[+(..FS++J8F*NDU%?^E,9LJ&1P%42=^2S9DW(=
M].BXV2C*Y><AB^3Y3\'Y5"=:E(GSLI2M(HI9%<SONN":O[MG43X]8Z1!VSJ)
M\>L=(A:/W+^#_B&(^=N?:'W+^#_B&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+1
M^Y?P?\0Q'SMS[0^Y?P?\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_B&
M(^=N?:'W+^#_ (AB/G;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_ !#$?.W/
MM#[E_!_Q#$?.W/M J[NV=1/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/^
M(8CYVY]H%7=VSJ)\>L=(@[9U$^/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W/M
M J[NV=1/CUCI$';.HGQZQTB%H_<OX/\ B&(^=N?:'W+^#_B&(^=N?:!5W=LZ
MB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0^Y?P?\ $,1\[<^T"KN[9U$^/6.D
M0=LZB?'K'2(6C]R_@_XAB/G;GVA]R_@_XAB/G;GV@5=W;.HGQZQTB#MG43X]
M8Z1"T?N7\'_$,1\[<^T/N7\'_$,1\[<^T"KN[9U$^/6.D0=LZB?'K'2(6C]R
M_@_XAB/G;GVA]R_@_P"(8CYVY]H%7=VSJ)\>L=(@[9U$^/6.D0M'[E_!_P 0
MQ'SMS[0^Y?P?\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_B&(^=N?:'
MW+^#_B&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0^Y?P?\0Q
M'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_ (AB/G;GVA]R_@_XAB/G;GV@
M5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_$,1\[<^T/N7\'_ !#$?.W/M J[NV=1
M/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/^(8CYVY]H%7=VSJ)\>L=(@[
M9U$^/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W/M J[NV=1/CUCI$';.HGQZQT
MB%H_<OX/^(8CYVY]H?<OX/\ B&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+1^Y?
MP?\ $,1\[<^T/N7\'_$,1\[<^T"KN[9U$^/6.D0=LZB?'K'2(6C]R_@_XAB/
MG;GVA]R_@_XAB/G;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_$,1\[<^T/N7
M\'_$,1\[<^T"KO[9E$^/8?I$';-HGQ[#](A:'W+^#_B&(^=N?:('E@P>\11'
MSMS[05=<7B319P[A%/(?81^W+[1\-.XCT:U*VT*GD/?25[<N44%66#!XR-!R
M"([K_P!6Y]HEA\K6#K+9-ID$01%_ZMS[087EVSJ)\>L=(@[9U$^/6.D0M'[E
M_!_Q#$?.W/M#[E_!_P 0Q'SMS[06KN[9U$^/6.D0=LZB?'K'2(6C]R_@_P"(
M8CYVY]H?<OX/^(8CYVY]H+5W=LZB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0
M^Y?P?\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_ (AB/G;GVA]R_@_X
MAB/G;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_$,1\[<^T/N7\'_ !#$?.W/
MM J[NV=1/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/^(8CYVY]H%7=VSJ
M)\>L=(@[9U$>/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W/M J[NV=1'CUCI$'
M;.HGQZQTB%H_<OX/^(8CYVY]H?<OX/\ B&(^=N?:!5W]LRBO'D/TR#MF45X\
MA^F0M#[E[!WQ!$?.W/M#[E[!WQ!$?.W/M JZU8E47X_A^D0BC$JBRV]GX?I$
M+3^Y?P>\0Q'SMS[0^Y?P>\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_
M (AB/G;GVA]R_@_XAB/G;GV@5=W;.HCQZQTB#MG43X]8Z1"T?N7\'_$,1\[<
M^T/N7\'_ !#$?.W/M J[NV=1/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX
M/^(8CYVY]H%7=VSJ(\>L=(@[9U$>/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W
M/M J[NV=1'CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/\ B&(^=N?:!5W=
MLZB/'K'2(.V=1/CUCI$+1^Y?P?\ $,1\[<^T/N7\'_$,1\[<^T"KN[9U$^/6
M.D0=LZB/'K'2(6C]R_@_XAB/G;GVA]R_@_XAB/G;GV@5=_;,HKQY#],A!6)E
M%>.X?IE]HM'[E[!WQ!$?.W/M#[E[!WQ!$?.W/M JZ^V51-[]GF.D0G+$RB+[
M)[#](A:/W,&#WB&(^=N?:'W,&#WB&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+1
M^Y?P?\0Q'SMS[0^Y?P?\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_B&
M(^=N?:'W+^#_ (AB/G;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_ !#$?.W/
MM#[E_!_Q#$?.W/M J[NV=1/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/^
M(8CYVY]H%7=VSJ)\>L=(@[9U$^/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W/M
M J[NV=1/CUCI$';.HGQZQTB%H_<OX/\ B&(^=N?:'W+^#_B&(^=N?:!5W=LZ
MB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0^Y?P?\ $,1\[<^T"KN[9U$^/6.D
M0=LZB?'K'2(6C]R_@_XAB/G;GVA]R_@_XAB/G;GV@5=W;.HGQZQTB#MG43X]
M8Z1"T?N7\'_$,1\[<^T/N7\'_$,1\[<^T"KN[9U$^/6.D0=LZB?'K'2(6C]R
M_@_XAB/G;GVA]R_@_P"(8CYVY]H%7=VSJ)\>L=(@[9U$^/6.D0M'[E_!_P 0
MQ'SMS[0^Y?P?\0Q'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_B&(^=N?:'
MW+^#_B&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0^Y?P?\0Q
M'SMS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_ (AB/G;GVA]R_@_XAB/G;GV@
M5=YXF43X]A^D0'B91-OQ[#](A:'W,&#WB&(^=N?:'W,&#YE^(HCYVY]H%5>=
M8C4>M^'M.X?89^W(55.)5%)T?^VX?<7MR%GO96L'75)-4@B-G_JW/M$Y98,'
MN.0Q'SMS[0*N_MG43X]8Z1!VSJ)\>L=(A:/W+^#_ (AB/G;GVA]R_@_XAB/G
M;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_$,1\[<^T/N7\'_ !#$?.W/M J[
MNV=1/CUCI$';.HGQZQTB%H_<OX/^(8CYVY]H?<OX/^(8CYVY]H%7=VSJ)\>L
M=(@[9U$^/6.D0M'[E_!_Q#$?.W/M#[E_!_Q#$?.W/M J[NV=1/CUCI$';.HG
MQZQTB%H_<OX/^(8CYVY]H?<OX/\ B&(^=N?:!5W=LZB?'K'2(.V=1/CUCI$+
M1^Y?P?\ $,1\[<^T/N7\'_$,1\[<^T"KN[9U$^/6.D0=LZB?'K'2(6C]R_@_
MXAB/G;GVA]R_@_XAB/G;GV@5=W;.HGQZQTB#MG43X]8Z1"T?N7\'_$,1\[<^
MT/N7\'_$,1\[<^T"KN[9U$^/6.D0=LZB?'K'2(6C]R_@_P"(8CYVY]H?<OX/
M^(8CYVY]H%7=VSJ)\>L=(@[9U$^/6.D0M'[E_!_Q#$?.W/M#[E_!_P 0Q'SM
MS[0*N[MG43X]8Z1!VSJ)\>L=(A:/W+^#_B&(^=N?:'W+^#_B&(^=N?:!5W=L
MZB?'K'2(.V=1/CUCI$+1^Y?P?\0Q'SMS[0^Y?P?\0Q'SMS[0*N_MF45X\A^F
M0=LRBO'D/TR%H?<O8.^((CYVY]H?<O8.^((CYVY]H%7=VRZ*-7X\A^F0HQ8B
MT84[)SLXQ;XY"DGE?P>([]@(CYVY]HD/*S@WK-;P?B+_ ,6Y]H%7GVRZ*O\
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M@N06(2G8!-<N4+D)+>41)) )M(KB&D5[!HE>X@9%< TD@DRN(&DE;1%.B96
M37+E CN($DBV\0E<)1[2 1TRO8Q-=.\>?](5RXA%!F96 3W(+D%B"Q %R"Y!
M8@L0!<@N06(+$ 7(+D%B"Q %R$#41"-B$#(N4 -9$!*2HKCR)6@5C*XG+O;V
M 3:16#2(R$AIV;Q%"2,K7 3W(+ERA8A(NP";33N(1,R+:/(F]%.TQ,1D2+F
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M0E,B 1N1;A'2$A;-XFW[B 1N07(+$%B +D%R"Q!8@"Y!<@L06( N07(+$%B
M+D%R"Q!8@$-+R!I>01,B$JBXC 1)9&!K(A*LDI(001+W@)B66D9")*(QYE8E
M&8G01'<!,2B,0-1;C$=$2+L8";32!+(Q(6B>P1(DD GTBY1 E$)#26C<$I[F
MX#TN07(>1&0FN0";32&D7$)#)'*863R@)S41".D7*/,S20F21 )KD%R"Q!8@
M"Y!<@L06( N07(+$%B +D%R"Q!8@"Y!<@L06( N07(+$%B +D%R"Q!8@"Y!<
M@L06( N07(+$%B +D%R"Q!8@$+D97$%)UFP36(]P7(@$EBM83)$;7$0
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MQ>J#$N@(J!J".BHYR5+-#<2_#J94MLU&2=AD7%86?U1]1(EE()0=CZ\3_F)
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M6T:77(6,=2XHU%I]RON2OM'1# RLX_$#"Z355'DXB)BVB)PUH-*C,ME['NN
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M>8A96<V EL-@+4,1#P,,VXM;&DM#*24?=EO,BN8N+*X6C@G($ME<B0JVW?M
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M)3L-2XA"2^DQJ/E@R_-\$Y=BK6=31<ZG4*Q%*@EFXM"6KD9'=-['LY1C_ K
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MB+G%F81XA0>*-!2NLH)K5)C4&1IO?166Q1<]Q>17,S+BY 'H
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M[2X[#*3S#44@VG&4*1NLHB,C^0PA(.#@4DS!PC,.CB0T@DIYB ?4
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MCW6\3@ DT/((V/D$P )#MQ"!I5N'H(6/E 2VMW/$!HMMWB< 'GH&(Z!<9"<
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MVXA-\HB ET1*9'N$_P H%L 2:LQ,2;"8
/                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914402807552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">vTv Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3916571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3980 Premier Dr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">High Point<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">841-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTVT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914403171104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,571<span></span>
</td>
<td class="nump">$ 9,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Current deposits</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">42,958<span></span>
</td>
<td class="nump">10,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,164<span></span>
</td>
<td class="nump">11,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,226<span></span>
</td>
<td class="nump">10,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,424<span></span>
</td>
<td class="nump">10,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">18,669<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,251<span></span>
</td>
<td class="nump">29,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">311,060<span></span>
</td>
<td class="nump">256,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(296,084)<span></span>
</td>
<td class="num">(281,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) attributable to vTv Therapeutics Inc.</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="num">(24,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">17,913<span></span>
</td>
<td class="num">(24,680)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">43,164<span></span>
</td>
<td class="nump">11,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantyLiability', window );">Warrant liability, related party</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantyLiability', window );">Warrant liability, related party</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WarrantyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WarrantyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914400932608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 20, 2023</div></th>
<th class="th"><div>May 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,612,257<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">577,349<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401895584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - Unaudited - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,224,000<span></span>
</td>
<td class="nump">2,824,000<span></span>
</td>
<td class="nump">9,312,000<span></span>
</td>
<td class="nump">11,457,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,282,000<span></span>
</td>
<td class="nump">2,544,000<span></span>
</td>
<td class="nump">10,976,000<span></span>
</td>
<td class="nump">9,338,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,506,000<span></span>
</td>
<td class="nump">5,368,000<span></span>
</td>
<td class="nump">20,288,000<span></span>
</td>
<td class="nump">20,795,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,506,000)<span></span>
</td>
<td class="num">(5,368,000)<span></span>
</td>
<td class="num">(19,288,000)<span></span>
</td>
<td class="num">(20,795,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">504,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">1,136,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,840,000)<span></span>
</td>
<td class="num">(8,540,000)<span></span>
</td>
<td class="num">(18,168,000)<span></span>
</td>
<td class="num">(21,525,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,840,000)<span></span>
</td>
<td class="num">(8,540,000)<span></span>
</td>
<td class="num">(18,268,000)<span></span>
</td>
<td class="num">(21,525,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,057,000)<span></span>
</td>
<td class="num">(1,886,000)<span></span>
</td>
<td class="num">(3,440,000)<span></span>
</td>
<td class="num">(4,753,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,783,000)<span></span>
</td>
<td class="num">(6,654,000)<span></span>
</td>
<td class="num">(14,828,000)<span></span>
</td>
<td class="num">(16,772,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,783,000)<span></span>
</td>
<td class="num">(6,654,000)<span></span>
</td>
<td class="num">(14,828,000)<span></span>
</td>
<td class="num">(16,772,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,000<span></span>
</td>
<td class="num">(3,640,000)<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="num">(1,514,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">$ 341,000<span></span>
</td>
<td class="num">$ (173,000)<span></span>
</td>
<td class="nump">$ 406,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.70)<span></span>
</td>
<td class="num">$ (8.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.70)<span></span>
</td>
<td class="num">$ (8.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,456,307<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="nump">5,498,479<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,456,307<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="nump">5,498,479<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914396623696">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th"><div>Class B Common Stock</div></th>
<th class="th" colspan="2">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th" colspan="2">
<div>Common Stock </div>
<div>Class B Common Stock</div>
</th>
<th class="th" colspan="2"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total vTv Therapeutics Inc Stockholders&#8217; Equity (Deficit)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,104)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 254,757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (265,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">255,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">255,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">255,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,131<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net loss attributable to redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of redeemable noncontrolling interest to permanent equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,260<span></span>
</td>
<td class="num">(5,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,260<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">256,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281,042)<span></span>
</td>
<td class="num">$ (24,680)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,828)<span></span>
</td>
<td class="num">(14,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of redeemable noncontrolling interest to permanent equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,260<span></span>
</td>
<td class="num">(5,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A common stock and prefunded warrants, net offering costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,884<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock and pre-funded warrants, net offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 50,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares', window );">Issuance of Class A Common Stock under ATM offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOffering', window );">Issuance of Class A Common Stock under ATM offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">311,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296,084)<span></span>
</td>
<td class="nump">15,008<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,857<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">307,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291,301)<span></span>
</td>
<td class="nump">16,475<span></span>
</td>
<td class="nump">3,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,783)<span></span>
</td>
<td class="num">(4,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">853<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares', window );">Issuance of Class A Common Stock under ATM offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IssuanceOfClassACommonStockUnderATMOffering', window );">Issuance of Class A Common Stock under ATM offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
<td class="nump">2,612,257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 311,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (296,084)<span></span>
</td>
<td class="nump">$ 15,008<span></span>
</td>
<td class="nump">$ 2,905<span></span>
</td>
</tr>
<tr><td colspan="15"></td></tr>
<tr><td colspan="15"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)</span></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ChangeInRedemptionValueOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Redemption Value Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ChangeInRedemptionValueOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IssuanceOfClassACommonStockUnderATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Class A Common Stock under ATM offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IssuanceOfClassACommonStockUnderATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Class A Common Stock Under A T M Offering Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914391485952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="num">$ (18,268)<span></span>
</td>
<td class="num">$ (21,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 promissory note early redemption</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Non-cash interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment of investments in Anteris Bio, Inc</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(140)<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,016)<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,482)<span></span>
</td>
<td class="num">(16,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs</a></td>
<td class="nump">50,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of Class A common stock, net of offering costs</a></td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ProceedsFromSaleOfCommonStock', window );">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from debt issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">52,607<span></span>
</td>
<td class="nump">12,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">32,125<span></span>
</td>
<td class="num">(3,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, beginning of period</a></td>
<td class="nump">9,446<span></span>
</td>
<td class="nump">12,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, end of period</a></td>
<td class="nump">41,571<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital', window );">Reclassification of noncontrolling interest to additional paid-in capital</a></td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">173<span></span>
</td>
<td class="num">(406)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">$ (157)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Reclassification to Additional Paid-in-Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404443936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $28.9 million of cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various holders own non-voting interests in vTv LLC, representing a 18.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to 81.9% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#8217;s Class B common stock, par value $0.01 (&#8220;Class B common stock&#8221;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#8220;Letter Agreement&#8221; and collectively, the &#8220;Letter Agreements&#8221;). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#8220;CinRx Purchase Agreement&#8221;). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (&#8220;TD Cowen&#8221;) (&#8220;TD Cowen Sales Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2024, the Company had an accumulated deficit of $296.1&#160;million and has generated net losses in each year of its existence. As of September&#160;30, 2024, the Company&#8217;s liquidity sources included cash and cash equivalents of $41.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional accredited investors (the &#8220;Private Placement Investors&#8221;), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the &#8220;Private Placement&#8221;) (i) an aggregate of 464,377 shares (the &#8220;Private Placement Shares&#8221;) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the &#8220;Private Placement Pre-Funded Warrants&#8221;) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the &#8220;Private Placement Warrant Shares&#8221;) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.</span></div>On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404446048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2024, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) for the three and nine months ended September&#160;30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2023, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2024, the results of operations for the three and nine months ended September&#160;30, 2024 and 2023 and cash flows for the nine months ended September&#160;30, 2024 and 2023. The December&#160;31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One collaboration partner represented 100% of the revenue earned during the nine months ended September&#160;30, 2024. The Company did not have any revenue during the nine months ended September&#160;30, 2023 or during the three months ended September&#160;30, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company has no investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, the FASB issued ASU 2023-09: &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (&#8220;ASU 2023-09&#8221;). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404289072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company&#8217;s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The Company may combine the results of each party&#8217;s clinical trials to seek FDA approval in the United States for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#8220;G42 Healthcare&#8221;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FDA Approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least ten years after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#8217;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables&#8220; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 310&#8221;) and was initially measured at its fair value of $11.9 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newsoara License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#8220;Newsoara&#8221;) (the &#8220;Newsoara License Agreement&#8221;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s phosphodiesterase type 4 inhibitors (&#8220;PDE4&#8221;) program, including the compound </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#8220;Newsoara License Territory&#8221;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#8217;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#8220;First Newsoara Amendment&#8221;). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the &#8220;Second Newsoara Amendment&#8221;) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the &#8220;Upfront Fees&#8221;) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0&#160;million. If the Company receives the Upfront Fees, $20.0&#160;million of revenue will be recognized at a point in time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue for this performance obligation has been fully recognized as of September&#160;30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the nine months ended September&#160;30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and nine months ended September&#160;30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404295952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a four-year period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. As of September&#160;30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $4.7 million, which is expected to be recognized over a weighted average period of 2.5 years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2024 and 2023 was $14.85 and $30.59 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2024 was de minimis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company&#8217;s Board of Directors, effective on the closing of the Private Placement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the nine months ended September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,247&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.53&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,153)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.75&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,800&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.20&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,200&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.73&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914400905184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin</span>. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914400895312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease included an option to renew for a five-year term as well as an option to terminate after three years, neither of which was recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September&#160;30, 2024 and December&#160;31, 2023, the weighted average incremental borrowing rate for the operating lease held by the Company was 9.5%. At September&#160;30, 2024 and December&#160;31, 2023, the weighted average remaining lease terms for the operating lease held by the Company were 1.2 years and 1.9 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating lease as of September&#160;30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2024 and 2023 was $0.2 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401100688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text">Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 18.1% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;) governance rights such that directors designated by M&amp;F no longer comprised a majority of the Company&#8217;s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company&#8217;s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December&#160;31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,783)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,828)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,236)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404277648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">Stockholders&#8217; Equity (Deficit)<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Certificate of Incorporation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company&#8217;s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company&#8217;s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company&#8217;s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Pre-funded Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued pre-funded warrants to purchase an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,853,997</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of the Company&#8217;s Class A common stock at a price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.80</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.01</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.99%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the number of shares of the Company&#8217;s common </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.99%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by providing at least 61 days&#8217; prior notice to the Company. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were pre-funded warrants to purchase an aggregate o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f 3,970,587 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company&#8217;s common stock that remained available for exercise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company&#8217;s Condensed Consolidated Statements of Operations.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the &#8220;Transaction Date&#8221;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#8220;CinPax&#8221;) and CinRx-Pharma, LLC (&#8220;CinRx&#8221;), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company&#8217;s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the &#8220;CinRx Warrants&#8221;). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#8220;FDA Approval&#8221;) to market and distribute the pharmaceutical product containing the Company&#8217;s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#8220;CinRx MSA&#8221;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company&#8217;s board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we entered into a sales agreement (the &#8220;TD Cowen Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#8220;TD Cowen ATM Offering&#8221;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. </span></div>During the three and nine months ended September&#160;30, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914501483712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of September&#160;30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately 46.7% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&amp;F governance rights that now entitles M&amp;F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404193344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company&#8217;s income tax provision for the nine months ended September&#160;30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September&#160;30, 2024 and 2023. The Company did not record an income tax provision for the nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2024, is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404429856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,440)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,783)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,456,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,498,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.19)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.70)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.04)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended September&#160;30, 2024.</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,595&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,359&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401058608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the nine months ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclass</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability </span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2024 and December&#160;31, 2023, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.13% - 124.70%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.42%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.96% - 89.61%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.55%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64% - 4.85%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01% - 4.87%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2024, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401101184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events through November 12, 2024, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914495290016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="num">$ (4,783)<span></span>
</td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (14,828)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404299760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914497260944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2024, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (Deficit) for the three and nine months ended September&#160;30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2023, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2024, the results of operations for the three and nine months ended September&#160;30, 2024 and 2023 and cash flows for the nine months ended September&#160;30, 2024 and 2023. The December&#160;31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One collaboration partner represented 100% of the revenue earned during the nine months ended September&#160;30, 2024. The Company did not have any revenue during the nine months ended September&#160;30, 2023 or during the three months ended September&#160;30, 2024 and 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company has no investments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the </span></div>Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In December 2023, the FASB issued ASU 2023-09: &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (&#8220;ASU 2023-09&#8221;). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401027360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Award Activity for the Period</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2024:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,247&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.53&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,153)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.75&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,800&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.20&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2024</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,200&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.73&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Expense Related to Grants of Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914497258592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities for Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating lease as of September&#160;30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404399968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">Summary of Net Income Attributable to Vtv Therapeutics Inc</a></td>
<td class="text">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,783)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,828)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,972)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,236)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4M<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914400938816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(*)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,440)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,783)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,456,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,498,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.88)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.19)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.70)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.04)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The shares underlying the pre-funded warrants to purchase shares of the Company&#8217;s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended September&#160;30, 2024.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,349&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,595&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,359&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(*)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(*) Adjusted retroactively for reverse stock split</span></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914496869488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summarizes the Conclusions Reached Regarding Fair Value Measurements</a></td>
<td class="text">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the nine months ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclass</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability </span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2024 and December&#160;31, 2023, were:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.13% - 124.70%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.42%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.96% - 89.61%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.55%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64% - 4.85%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01% - 4.87%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2024, were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914405852800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 05, 2024</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,571<span></span>
</td>
<td class="nump">$ 41,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296,084)<span></span>
</td>
<td class="num">(296,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (281,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EntityPublicFloatThreshold', window );">Entity public float, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat', window );">Percent of public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares', window );">Private placement, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares', window );">Private placement pre-funded warrants, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">179,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Private Placement | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,853,997<span></span>
</td>
<td class="nump">3,970,587<span></span>
</td>
<td class="nump">3,970,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | TD Cowen Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterestByParent', window );">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EntityPublicFloatThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity Public Float, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EntityPublicFloatThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914399626016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vtvt_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vtvt_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914405635888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue', window );">Collaborative arrangement, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash', window );">Collaborate arrangement, contingent consideration transferred, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid', window );">Discount on note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Receivables, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod', window );">Royalties receivable, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceivedTerm', window );">License fee received, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeePriceIncrease', window );">License fee price increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Newsoara Biopharma Co Ltd | License And Technology Transfer Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue recognized from change in estimated transaction prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | JDRF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones', window );">Maximum funding percentage of research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate Arrangement, Contingent Consideration Transferred, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborateArrangementContingentConsiderationTransferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Note Receivable, Discount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementNoteReceivableDiscountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Receivable, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Price Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceivedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Received, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceivedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum funding percentage of research and development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CognaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CognaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_NewsoaraBiopharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_NewsoaraBiopharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_JDRFInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_JDRFInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914405709472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - Stock Option - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Non-qualified stock option awards vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested share-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized share-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.85<span></span>
</td>
<td class="nump">$ 30.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock', window );">Modified common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount', window );">Expense reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ShareBasedPaymentArrangementExpenseReductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Expense Reduction, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ShareBasedPaymentArrangementExpenseReductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914403330112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Beginning balance (in shares) | shares</a></td>
<td class="nump">249,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">447,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(5,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Ending balance (in shares) | shares</a></td>
<td class="nump">691,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">237,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">551,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, weighted average remaining contractual term</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 77.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">13.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">18.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">36.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">75.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914403200240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914402739456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2007 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 1 Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">50.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Other Indication | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember', window );">Sales-based Milestones Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914404392496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseTerminationPeriod', window );">Lessee, operating lease, termination period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining operating lease term</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914403315776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remaining three months)</a></td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OperatingLeasesImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401409776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interest, equity, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock', window );">Number of days used to determine exchange value based on weighted average price of Class A common stock</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Noncontrolling interest ownership percentage</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period used to determine exchange value based on weighted average price of Class A common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest exchange agreement stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914401101872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">$ (4,783)<span></span>
</td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (14,828)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent', window );">(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances</a></td>
<td class="num">(1,972)<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">7,592<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet', window );">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</a></td>
<td class="num">$ (6,755)<span></span>
</td>
<td class="num">$ (5,062)<span></span>
</td>
<td class="num">$ (7,236)<span></span>
</td>
<td class="num">$ (12,560)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4M<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914396508896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 20, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 22, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2024 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockAndPreferredStockSharesAuthorized', window );">Capital stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EntityPublicFloatThreshold', window );">Entity public float, threshold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat', window );">Percent of public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember', window );">Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights', window );">Percent of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares', window );">Private placement, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares', window );">Private placement pre-funded warrants, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivableTerm', window );">Sale of stock, consideration, receivables, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember', window );">CinRx Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncreaseInCommonStockSharesAuthorized', window );">Increase in shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="nump">179,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Private Placement | Private Placement Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,853,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,587<span></span>
</td>
<td class="nump">3,970,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | TD Cowen Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="nump">179,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | CinRx Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percent of Securities Called by Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and preferred stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Par or Stated Value of Private Placement, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EntityPublicFloatThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity Public Float, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EntityPublicFloatThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncreaseInCommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncreaseInCommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration, Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_PrivatePlacementPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtvt_TDCowenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914400722480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail) - Related Party - MacAndrews &amp; Forbes Incorporated<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OwnershipPercentageOfMajorityOwner', window );">Ownership percentage of majority owner</a></td>
<td class="nump">46.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Share held by related party (in shares)</a></td>
<td class="nump">577,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Share held by related party (in shares)</a></td>
<td class="nump">912,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OwnershipPercentageOfMajorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of majority owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OwnershipPercentageOfMajorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914402193536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember', window );">M&amp;F TTP Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914396349392">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,840)<span></span>
</td>
<td class="num">$ (8,540)<span></span>
</td>
<td class="num">$ (18,268)<span></span>
</td>
<td class="num">$ (21,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,783)<span></span>
</td>
<td class="num">(6,654)<span></span>
</td>
<td class="num">(14,828)<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,783)<span></span>
</td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (14,828)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,456,307<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="nump">5,498,479<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,456,307<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
<td class="nump">5,498,479<span></span>
</td>
<td class="nump">2,084,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.70)<span></span>
</td>
<td class="num">$ (8.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.70)<span></span>
</td>
<td class="num">$ (8.04)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914405774832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">1,344,537<span></span>
</td>
<td class="nump">896,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">577,349<span></span>
</td>
<td class="nump">577,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">691,593<span></span>
</td>
<td class="nump">238,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">75,595<span></span>
</td>
<td class="nump">80,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914396706480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(406)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass', window );">Reclass</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass', window );">Reclass</a></td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass', window );">Reclass</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Warrant liability, related party | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities:</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of assets and liabilities measured on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45914399736000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember', window );">CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life of options in years</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.9513<span></span>
</td>
<td class="nump">0.7996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0364<span></span>
</td>
<td class="nump">0.0401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">1.2470<span></span>
</td>
<td class="nump">0.8961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0485<span></span>
</td>
<td class="nump">0.0487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">1.0942<span></span>
</td>
<td class="nump">0.8155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0379<span></span>
</td>
<td class="nump">0.0415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_LetterAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_LetterAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULM5I1<YLX$/XK&K?3:6>:&$F
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MC.61$9@"R/M+2L5+1YT9ZD.H]Q]02P,$%     @ 8(5L61W1:'C:!@  1"8
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ME04M2[;.5$\&2D .Y\-!2 1 ,%1;&:G:GC95(S:7C9]D(YSO),0I\;>/CC^
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MED!I*926H6B\?EN_D:7W&QTW6VS)II!F*6<D+N7H@_?6$]1>!*4%.YIV*>=
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M6JYGV^)^E]#")\KJ'!'3$9?V%%>@JO=, =PWH&H-+K9^(Q[L[RILJ&,%2IM
M:3Z4%D!I(90606DQE)9 :2F4EJ%HO+!;\XNM=R]\^^\J;(4U@3@C:R1V1U O
M#)3F0VD!E!9":1&4%D-I2<>6E'9,EZ%*QTNK=:_8>O<*;N9=L;V-8N8=>M 5
ME.9#:0&4%D)I$9060VE)IW:4=DJ5H4K&:ZLUJMCZO6V^\Y2ZO'&-:DI=3J6<
M4H<:2Z"T $H+H;0(2HNAM 1*2Z&T[%#CY13GM(811V_AZ//K(T=V8A#)5WNM
M#]BWPX+2?"@M@-)"*"WJ5%<Q-&8"I:6=KB!#Q>3ET]HP'+T-(ZRJS7:&CW54
M5TW795PV,EJRKJMJ)E&,?#4S6.2;S6K&%/:0EV6^JJN?C15[0"MN;FC9=&33
MHJJYN76E^I!KY]=0V@1*\Z&TP)&M*[8S'(V$H4\(C1I!:3&4ED!I*926H6B\
MGEM/AZ/W='35\TD'02M%K'!UF-)4]+6^E+W5"75_0&F!(SL%Q-4R:, (2HL5
MQ6_J4^BE$FC0M%LCRE!!>2FU9@U';]902>GJ44K;]06C45!I7'Z*6]T<Z@*A
M9U5!:1,HS8?2 D=VN)#AV#%-46E0\P>4%D-I"9260FD9BL;KMC5_.'KSQQ&Z
M56I5889P//&7M/JR]-8@DN9#:<&.QBUFB_)#!HS4%4#$)T"H*01*2SLUH0P5
MDY=+:_9P]&:/O2MM/58"')57P':E42'4^0&E^5!: *6%4%H$I<506@*EI5!:
M=K"1\P)L/2P.>I,6I5%8'Z7WV!)J7G$46YIXQ++<H>!45"14.A6[ L..P AZ
MO3&4ED!I*926H6B\=EJ;B/,M>Z2H=2*OTK-G"2(-[*"V$"C-A]("1[%%BB?*
MZ.!F)Y'BOMJ$F.*Z8PPM?**(>F*-/5.<'4U5U>Z:INC-4"2SQN:^[_C6<^'H
M/1?'M%-YO5M<Z=TE\?8GF>C+U;OA0?T24%H(I4506@RE)5!:"J5E*!JOL]9_
MX>C]%T<=8J*6'W1/$"AM J7Y4%K@R,O\EF-;(WEDIO #*$=F4+\%E)9 :2F4
MEJ%HG!+=UI?A]CQ.J)/J7-5A-HXMM)UK?>R^<H+2?"@MV-&XP9FX\*M((P[.
M%/?5-H=#1T@70PN?***RP1FQ37$_9$5"XCE#<4%(=15CSU(/SMS6 ^$^KLG^
M,S\B<:$V!RAM J7Y4%H I8506@2EQ5!: J6E4%J&HO'";LT0KMX,\>T_(G$5
MVU,X0^ET+'TY>JL4:G> T@(H+832(B@MAM*2;@TI[98L0Y6-UU7KC'#USH@^
MGEM77KH?N9)^H$X&*,V'T@(H+832HBY5%4-#)E!:VN4",E1(7CNM.\&%NQ,.
MN8KT$7N/.*&.!BC-A]("5UZ>5[J*H%$C*"V&TA(H+872,A2-UVUKDW#U-@F0
MJ\A5[.4@NXKT9>FM0:A1 DH+7,46&:+\H.X'=06(KB)HS 1*2SLUH0P5DY=+
M:VIP]:8&A*O(E=?N3X@I3B1?ZTO26RS0?3:@M !*"Z&T"$J+H;0$2DNAM.Q@
M(^<%V#HCW#[.B*-=1?HHO<>64%.%JUBK5[J*% F5KJ*NP+ C,()>;PRE)5!:
M"J5E*!JOG=:MX<+=&JYLQ5"YBO2!>PL :NZ T@+%#9%<18HTTL*5G$3I*H(6
M/E%$5;N*5-6N<!6I;L9>5Y';N!VX3[QVU=4[<* !^=-X]>_7QN7L?YNJIC.C
MI&RHE4_K^3U=?#5NBI)]<D_+BNY^#EBM%_/Z,<MB4;2;5B17X?87@=LQW$/.
MQG$L8[59U,9-62R-^HZR]\)>%XI=+ SVL4\_EYN\_&I8PT?]&*\^4FHD14V-
MX6N58$^K.TKKZ[S.+\Z7M+RE5W2QJ(QIL5G5S5U\\2DKQ0V[+>3L'1F<2I\'
MY.Q7U><A.?M-]7E$SMZK/K]TQV<IJQ?%7SSS+&65POYRVA;UXGR=W](X+V_G
MJ\I8T!M6;//-D/47Y?SV[OE-7:S?#LC ^%S4=;'<OKRC.7N,;!*PO]\4[![M
MWC0!'HKRR_;67/P?4$L#!!0    ( &"%;%G/!S96^08  +X@   8    >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&ULS5IA;]LV$/TKA%<,+1#7(BG+=I882-QU
M*[!V0=)NGVF)CKE*HDK*3O/O=Y04R9(H.AD\;%]B23Z>W]WQ^!ZI7#Q(]55O
M.<_1]R1.]>5HF^?9^62BPRU/F'XK,Y["-QNI$I;#K;J?Z$QQ%A6#DGA"/"^8
M)$RDH^5%\>Q&+2_D+H]%RF\4TKLD8>KQFL?RX7*$1T\/;L7]-C</)LN+C-WS
M.YY_R6X4W$UJ+Y%(>*J%3)'BF\O1%3Y?T9D94%C\(?B#/KA&)I2UE%_-S8?H
M<N091#SF86Y<,/C8\Q6/8^,)<'RKG([JWS0##Z^?O+\O@H=@UDSSE8S_%%&^
MO1S-1RCB&[:+\UOY\"NO IH:?Z&,=?$7/52VW@B%.YW+I!H,"!*1EI_L>Y6(
M@P'@QSZ 5 -(=X _,(!6 V@1:(FL".L=R]GR0LD'I(PU>#,716Z*T1"-2$T9
M[W(%WPH8ER]7,HV@*#Q"<*5E+"*6P\U=#A]0K5PCN4$KIK?H/51<HS'ZDK)=
M)(P17-^]0Z]?O4&OD$C1YZW<:99&^F*2 S+C?Q)6**Y+%&0 Q0)]E&F^U>AG
M0!.UQT\@HCHL\A36-7$ZO./96T2],T0\XEOPK)X_G#K@T#K+M/!'A[)L$K@I
M$KA1,D'0A8KE(KTOI['(!=?GMK25;GV[6]/BYSIC(;\<00]KKO9\M/SQ!QQX
M/]EB/I&S5@;\.@.^R_OR$ZQ(L=0:K3FL/1RE,@VAY$K&L4F#2',./YK;<E Z
M#@K'9E7:+\=X3H+YQ61_&)W%C. IF=9F+=S3&O?46;FKZ"]HPK(3<@D+%Z .
M10P!/"\@,\B8AF8&[$R?0:<\N_S34Y;_1,Y::0SJ- ;.\K_CX#04K%BZ^??,
M+#FV@$LOTX,B!K-.G9TF+7"S&MS,">XW4\:B+W_Q"<K@0F@MU2/4-.>(,Q4_
M0N$CGF0&O@WVK(?)ZZ#N6U!,[;#G->RYNZ5D.BZF53W7!$S!Q)K7^5& ?8LQ
M]CP[PD6-<.%$>+=EBH\-RT8(D)FJ'YT!BQX.O*"D ]9BA&<#G8Z]A@H])]S5
MEJ7WW#3HA@F%]BS><4-_(MWS:@VP4IMW-+D6DS'U?'\ \0%Y8R?B#TD&2 VR
M#DX3Q)69%D*C:R'/T(<TM&+'Q['W37SB#R6;--")FQ*+9!= F=8<((-T0+%@
M:Q$/+XB5TQ.MB*?RUDY!(PJPDW&75V$H=Z98L#1RL6?KV-H1E9=V:_J],O6M
M\&Q@A<$-:V,W;=\H#C,L>FK8LD@RWW(%XE0I,_'*ZEF!^Y99'W1Q]XV"8&AV
M-:R-G6RV_+V Z( V[?WJO"LH+#8#ZR%N:!"[>; N><8>3;V+?+(P5#O>)-D*
MN$][8]_#O6SVS0B9#<%N"!*[&;),YT%S6B'V.6Z,#_17A=#%E6UX#1'B(TSX
M'(%EA6QA/>+Y\R[?V.QP@(>$!VX($B]>M#'8B)2!OCRN#+&3>5^\$)[(6WNO
MUA O<1/OC9(AYU&5 \WB@G97,?0ONC+*(0'- %OA\&O1+X!AO-F9G2)Z8$HQ
MZ*>S0F3#(+G9 .E!_D*I[:U/^EP\]2CMSE.+V< \)0U=$S==/S_.E\33YV?B
M![0;CHOHV^$T%$Z<_-@)QVCGFT8[?[)I9[B,B_,%V!4YRPS?A["38FNI2L68
M,96G7%D30(YJ&(L))AX=RD##X,3-X.T,1'P-&ESK';2PE<E)GZ-[2/LFTR 8
MP-G0.''3^"VP^..33#2[FIJ K# MO(T7N(O4QNYX8$4D#7,3-W/7:SGLP_;"
M]/CZT;HL6I'W*7M* J^[A;288:#)Q0#VAMV)F]T-=MB#*0X['O0ZXN75&\-(
M14AF\2HN^+<=Z+UX:$=!^BQ.29]*+69C.C_0,>TP&K8G;K;_+',6#R,^0VM^
M+]+4E .F$U"MD)$UC#[5+WR_*UDL5AB"'9KSC2@@;E%P- INI*P3?Y_U?3R=
M]1JA;S8G=*@*C30@;FE0;^^/* %R4B5P*F_M8])&"=#G;L$/2*/>B+_@T)!:
M=MP$^YW2V:PP]@;VY;0A>NHF^EL>&E83&Q&6]#4,WE =BR)AS&"^FMW6N%@O
M,@'SUQI:G\K-(M<-[=F$3QO"IV["OZW8^P;(^-$*[:3;\U-Y:T=[<&;O/K3_
M;X]^Z6F/_O^-LW_:Z _JUA]#)VM/\MV:@+Z^.#S0J.*RB!#?&^ .VH@0>D2$
MR%0=G>LG/9P_E;=VP(URH<'_>:X[9=6+4WDB;^U4-NJ)NM73/YKK,\L[KFE7
MMEJLNDOZY.!-<,+5??&"7*/BT*E\>UH_K5_"7Q6OGCO/K_'YJGR5WK@IW^Q_
M9 K4GT8QWX!+[^T,9JXJ7Y:7-[G,BO?-:YGG,BDNMYQ%7!D#^'XC80-2W9@?
MJ/]E8?DW4$L#!!0    ( &"%;%F!V!0[=0L  ) ?   8    >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULK5E;;QLW%OXKA)IV'4"1)?G>) 9L)VFS2%HC3M.'
MQ3Y0,Y3$S0PY)3F6W5^_WSGD7"1+:@KTQ=8,R7/YSIWS:F7=5[]4*HB'LC#^
M]6 90O7CX:'/EJJ4?F0K9; RMZZ4 8]N<>@KIV3.A\KB<#H>GQZ64IO!Y2M^
M=^LN7]DZ%-JH6R=\79;2/5ZKPJY>#R:#YL4GO5@&>G%X^:J2"W6GPF_5K</3
M84LEUZ4R7ELCG)J_'EQ-?KP^IOV\X8M6*]_[+4B3F;5?Z>%]_GHP)H%4H;)
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MG^(CU45?M55N;:*C37MD&4&7MMCL )3[P0U44\13;_"4>)07D]$]N>]M@?&
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MP9;\<ZEDKAQMP/K<VM \$(/V(_SE_P%02P,$%     @ 8(5L6;H^V]DR$0
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MMJ-F.=2R;F2%@+:_DC:U2%7U(U7\V1#<EP^7!5J:I-QI<+=+*U'Y$X.J:?1
M)3YG%G$"QL\#$O</\A9I)Y[TF0I&8DH=XE!SK1Z_B4CI-E^WBB/'WV#T8850
MX^E"(9$I15VBU?@3!=TD,0P;:BZQ'\3D*3 ]NV##-W2+R4MW\(ZO9"P[/3W
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M/ZZ;<:*?<I.N8KEL]$3U)PXUR<OD??M-R\E.8]>U'<[#-!66]_Q2ISF%XW^
MM%(7+*^>?4N.90T-@\@8830.I %/C',^OA6JZ<V.'*OEA)O>6LBORP"L=G3/
M\5I4NV_NC]SYVS0)6&YR>S[-6WCX,IF=[L,/Q,&^U^1/BG_=@"9@S?^&@]^&
MZ:/\0X?QV_&?B5S(OXZ8'I=_8_(C#PF":LT*2T^/O__V2&:_^8_H-OQO)98N
M1M?Q1VKWC*<'\#N]))O_H W&?SSS\O\!4$L#!!0    ( &"%;%FQ^C_X*1(
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M_X?3)D2T5<2O2%/?R2':UT8$2AW%/"=[Y"]KE9*U+%9!I5):<2^S2M7V>^[
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MEA;@^Z5!I8P?Z(#FQYEO_PM02P,$%     @ 8(5L67 -7_7S"    1D  !D
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MT7G@4@'1;DX2&*'J-)+O)^N.W$>)(WZ<?CE'+0,@G\/ID01G2I9FG+"VE?/
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M<1V0KPM"8_"\ >LSYV+[P JZ_WI<_Q]02P,$%     @ 8(5L61PALBNX!
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M)*]#(Q6=%^B"0'Y-Q?S9DZ,7DS>/\#T>^!X_AO[=<ORXM?A4D;AR=2/M5NB
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M:03H_48(?=P8 ]V'U.PK4$L#!!0    ( &"%;%DT.;(3LP(   @&   9
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M+5;-C?J[>/-=\H&J'4-N<MBBJC].L#!5<]=O7HRLW/UZ(PW>UMVPP,\C4%8
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M965T<R]S:&5E=#(Y+GAM;+5438_3,!#]*Z,@(9"@2=-VRY8T4ML%48G55JV
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MTCPHS8?2*)060&D,2@M1-%U9M>GJ;*VN__N=H [T<64HS872/"C-A](HE!9
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M5/K,!&YO21+8H*F#"\TBHCA]% /%<_/%O^8*SP_F=H<G-A#Z!?Q_P[DZ#72
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M'M@/U="OY\JO\O4O!N\IWV8XT>6PP:.LBTOLAKP>PNL;R2H]9=XQB3.K7J9
M$^ *@,\WC,G'&W5 ^U-(\ 502P,$%     @ 8(5L6>AC1)L" P  6@L  !D
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MY+AK&ROZZL:*GXF[HSF'MEB@FH%J)JI9J&;W#Q3W+X-N-^?0W@E4\U#-1[4
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MO?)][G[)E&XYF;*<%@W7T9J1BBJ?2XMVE<ER,9(DL9]+A1O5>N:ANCPL-'U
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M@)85*5I3*\NJ6J/C]5SEEF8Y"EK]'AGXR\T2K8/X8(F]JL2>M<1[)I\_306
M+DZ!QE=(4 7O$HT5>=]Y=@16(Z%?D= _>='T79+I"*Q&)@Z,J0N.*IL2?DLW
M0=C9THU]&!\M<\.[XO?UF@E;L@GHM?#*()Z\2SIVZ'VGVQ5:G0AC3S$Y>?E@
MIQ;8%5J=4&."L=46'BZ@-7Q[4S_;VCF&,<7&F6*[C[QE*4NR1&NEV;'=@-+=
M")W/=&<JONQ9Q>3(<9;,',._8F-@<?OTQ>34#KM"JQ-J##&V6L3#Q;2&QU'=
MQ;5QN"VIQL!NOV_Z5KT$8T.QW8<:M>RV:_LIQI'E+ L_AH'%QL'BWNDKQJD7
M=H56)]2X86SUAX<KIM\D!.W?HFW%- =& 6Y6##$6E-@MZ"U]<==?[,_:>WOM
M&*Z5&-=*\,FKA3AUOZ[0ZH1N;,[:=V</54L)7Q,!;I&HNR66IKB@U>MW=HG%
MV$UBMYM&+([:B_UY>\_O,:PJ,5:51*<O&*<.UQ5:G5#C<(E]C_9@P;2;NT:O
MO:V878'='8HQGI+8/>5C\?N<'OOY$@2=@:,^XW3CU!5:G2+C64GW]&7CU.:Z
M0JL3:FPNL>_4'BR;7E.?"?K1]G9T4Z!N-+C=WB$;8RR)W5@VR,95QW&Z?>H*
MK?X3J#&O87#RT@F=>EY7:'5"C><-[3NUATJGA/_?%YIN?TLZ.P(CO"T=?^.=
MB?R%E5LJ9BR5*(:I3@Q:7=VZQ/H=D/6)XHOB-8HGKA1/BL,YT F(/$#?GW*N
MWD[R-S.J-W%&_P%02P,$%     @ 8(5L6>X,W:A1 P  CA4   T   !X;"]S
M='EL97,N>&ULW5A13]LP$/XK41@32!-IFC5M1EMIJX0T:9N0X&%OR&V<UI)C
M9X[+6GX]OCA-T^)#P,-HEPIBW^?O[KOSI3$,2[WF]&9!J?96.1?ER%]H77P)
M@G*VH#DI+V1!A4$RJ7*BS53-@[)0E*0ED'(>=#N=.,@)$_YX*);Y5:Y+;R:7
M0H_\06/R[.U[.O+#^+/O67<3F=*1?W?V\<]2ZLL/GKV??#HYZ=R=7^[;SRK@
MW ^<3GLO<'K1P?T:#',=[[K>+#\UOAKN*4;N.\A;)DH;O"B=9[+!'"?.9%JI
M(,1^QUV%-A4M83]$R+ML2P_J+AH/,RFVS13YUF#\DYQZ]X2/_ GA;*H8L#*2
M,[ZVYBX89I)+Y6G3Q29@");RP<*AG4&#UWYR)J2J8ML(]O>T7KX';&8@D''>
M".SZUC >%D1KJL25F52+*^,3R*O'M^O"*)PKL@Z[/7]+J&XFR%2JE*HF3.AO
M3.,AIQG(46R^@+N610"@UC(W@Y21N12DTK!AU /C=D8YOX&G_W>VXWN5M7:N
MVG31#(V@>FC=V GX;WNSOMMN>V_RZQ7L7NIO2Y..J.;0X/1:T8RMJODJ:P1@
MWD/<.RD*OO[*V5SDU";_XH#C(=GPO(54[,%$@U:9&0-5OG=/E6:SMN6O(L4M
M7>E-.ZTR7'/W"#7_VSK/J:"*\+9HT_N'7.4W*X[Z[R6Y^E;9%^S46+_2#UUD
M[QA$QL<@\BAZ<G#X(J/D\#761\8#%]E_MV_VUX@,#U)D4!_76F?"G1-A8_7@
MY#WR?\%)GF^#>M,EXYJ)>K9@:4K%DX.A<:_)U/RQN>/?K$]I1I9<WS;@R-^.
M?]*4+?.D674-A:A7;<<_(+TP;H[])A83*5W1=%)/U7Q:#3TS,%'K"PC[R%5U
MN1&,8S$W A@6!U. <2P+B_,_Y3- \[$8IFW@1 8H9X!R+,N%3*H/%L?-2<SE
MSC1)HBB.L8I.)DX%$ZQN<0P_;F^8-F!@<2#2ZVJ-[S;>(<_W ;:GSW4(EBG>
MB5BF>*T!<=<-&$GBWFTL#C"P7<!Z!^*[XT!/N3E1!+N*:<.>8!Q)$@R!7G3W
M:!PCU8GAX]X?["F)HB1Q(X"Y%401AL#3B".8 M" (5%4O0?WWD?!YCT5;/\#
M.WX$4$L#!!0    ( &"%;%F7BKL<P    !,"   +    7W)E;',O+G)E;'.=
MDKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<
M'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X9
M9K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.5
M6QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,
M<6*T_C6"R0_L?@!02P,$%     @ 8(5L64KT'2HG!   2!X   \   !X;"]W
M;W)K8F]O:RYX;6S%F=]OVS80@/\50B_K'CQ;/Y*V05T@K9LM0)89<9#7@9;.
M-A&*=$DJ:?K7[RC'"[7$A[T<_&2+DJA/1_(^DOKT:-W]TMI[\:/5QD^S30C;
ML_'8UQMHI?_-;L'@F95UK0QXZ-9COW4@&[\!"*T>%Y/)Z;B5RF2?/^WKFKMQ
M>F #U$%9@X6QX$[!HW\Y'P_%@_)JJ;0*3].L_Z\A$ZTRJE4_H9EFDTSXC7W\
MPSKUTYH@]:)V5NMIEN].W($+JGY5O(B0MW+I^Y(@ES<20:;9Z00K7"GG0W]%
M7[]$Q@? BW='7; 72@=P,QG@=V>[K3+K6 V^Q3AYC3X.^]]=$,_<_PFC7:U4
M#3-;=RV8L(NC QT!C=^HK<^$D2U,LZ_V 5Q\'WS 9;-[MX!02:3<F<(3[K+I
M\3A13 /&0R/PG[=:-<C1B"]22U.#2" + K(X(N3?10)9$I#E42 7$0=O32 K
M K(Z(N0@DB<$Y,DQ(<L$\I2 /.6%G(&OG=K&<F%7XDOGE0'OA32Q8_H$\CT!
M^9X7<M&UK71/$7"AUD;A;=($<5[7MC-!)9 ?",@/W,VMM5Q:UY\1YVL'<;R$
M-(0?";J/S"'<2 <C;-&^.[98D^\O2M/WA,K?$^[HM:T*?<#ZOH=#)J#7P-0*
MTA#FI&28+7,%&+\!#663G%DGU];4&*4XK\!(B4N#<P+P(<6C/)(SBV01;'V_
ML;H!YW\1W[YW.(<2[V: MZOP:TI)B21G-LE-+(1F-)<.\6Z=Q''1SPD'S4Q9
M)&?6R"6V<@OB5OX8=CU*&CFS-:ZQWBN+FMB"$WUJ2<DH4^3,JKB0RHD[J3N(
MMKA0!J=62FH<'3ZXKDTQ*5?DS+)8=$L/WSN\2'Q[^(\E<DH3.;,GYO))/'@Q
M!]??'B?/,^5K;7TW:.2"DD7!+ ML3(5I)0[7)J:^<X?C=OU*MP7EBH+9%>2<
M93!%+<@E";-$#LT+Q#M<<.I!BU,R*9AELC/O,Y1/[5%0]BB8[7% P7O.%)-2
M2,&LD-?I^LU(4D8IF(U"YNWA<*'T4C#KA5PN#3$IO13L>J&23[KT+"C9%,RR
M.;1D$B-QWC3INJZD=%,RZ^9@CGR-21FGY#;.8<S8'U),RCCEL8P3,8>[8.0V
M&/L^&+$@%:,4DS)0R6R@9S'N>F(\V^?,757#Y7U)&:AD-M"_F NLK.ETG^7_
ME*%S"#T094E9J.1>UQSP^7-X4TS*0B6SA0YC]HD_Q:0L5');B-P!2#?E2\I"
M);.%#F\!].V>[GA3%JK8%STO^P!OC/<4D[)0Q6RA-^::(W$#V%]KI57:-RO*
M0A7WYME;F"_)*<6D+%0Q6XB>%J<3N8K\',-L(1JS2C$I"U6]A<;[+Y<-9@H#
MS34^PF-Y+74]=R+^[/9>JY.X5;+JM/Z*97^9*RN;_8?0_4?<S_\ 4$L#!!0
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M&^IM!'H;ZFT$>AOJ;01Z6V>SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
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MN\:U*INC/^O^I<T_ 5!+ 0(4 Q0    ( &"%;%D'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " !@A6Q9'=%H>-H&  !$)@  &
M    @(&P&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M8(5L689_:&V:$   'M$  !@              ("!P!\  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &"%;%G/!S96^08  +X@   8
M          " @9 P  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " !@A6Q9@=@4.W4+  "0'P  &               @(&_-P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 8(5L6;H^V]DR$0  2#,
M !@              ("!:D,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( &"%;%FQ^C_X*1(  !\Y   8              " @=)4  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !@A6Q9T]U@YR &
M   Q#P  &0              @($Q9P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( &"%;%F^E5&,$@0   ,)   9              "
M@8AM  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 8(5L
M6;[Y"F2\!   [PH  !D              ("!T7$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " !@A6Q9?.]TU'8&  "]$   &0
M        @('$=@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( &"%;%GXR^NJ^PT  *@I   9              " @7%]  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 8(5L67 -7_7S"    1D
M !D              ("!HXL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " !@A6Q9'"&R*[@$   2"P  &0              @('-E
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &"%;%GA9/I&
M?P4  .4-   9              " @;R9  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ 8(5L64FCGHM0!P  #!8  !D
M ("!<I\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !@
MA6Q9/LSGZ7H"  "1!0  &0              @('YI@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &"%;%GX?#N?E@(  -X'   9
M          " @:JI  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ 8(5L60!ZCZM# @  B@8  !D              ("!=ZP  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !@A6Q9*O%T8241  !$
M-0  &0              @('QK@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( &"%;%EOZ> AY ,  %0)   9              " @4W
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 8(5L630Y
MLA.S @  " 8  !D              ("!:,0  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " !@A6Q96;Q1CB(#  !7!P  &0
M    @(%2QP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M &"%;%G8WP@_2P4  'P-   9              " @:O*  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ 8(5L6:GO<H-@!0  S \  !D
M             ("!+=   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " !@A6Q9Q6'H<>P+   EG   &0              @('$U0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &"%;%E.I"R45@(
M (\%   9              " @>?A  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ 8(5L63_D!(DT#   ^I0  !D              ("!
M=.0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !@A6Q9
M"RSMB4P$   E$P  &0              @('?\   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &"%;%D358.1VP,   \.   9
M      " @6+U  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ 8(5L6<J@+5BS P  %A$  !D              ("!=/D  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !@A6Q9Z&-$FP(#  !:"P
M&0              @(%>_0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( &"%;%F$MIFA*P,  &\+   9              " @9<  0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 8(5L63:B&OG'
M @  YP<  !D              ("!^0,! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " !@A6Q9Q(KHF@($  ##$P  &0
M@('W!@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &"%
M;%FD<GB??0,  .D*   9              " @3 + 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ 8(5L63#E8D,)%   '% ! !D
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M=#0S+GAM;%!+ 0(4 Q0    ( &"%;%E W$214 D  .!=   9
M  " @7@R 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M8(5L60LSOJ/\!   E2,  !D              ("!_SL! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " !@A6Q9[@S=J%$#  ".%0  #0
M            @ $R00$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &"%;%F7
MBKL<P    !,"   +              "  :Y$ 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( &"%;%E*]!TJ)P0  $@>   /              "  9=% 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !@A6Q9N#;$W*D!   N&P  &@
M        @ 'K20$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !@A6Q94]DK*;(!  !3&P  $P              @ ',2P$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     -0 U &H.  "O30$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>236</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NoncontrollingInterest</Role>
      <ShortName>Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Noncontrolling Interest (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NoncontrollingInterestTables</Role>
      <ShortName>Noncontrolling Interest (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NoncontrollingInterest</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossperShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Description of Business and Basis of Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail</Role>
      <ShortName>Description of Business and Basis of Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail</Role>
      <ShortName>Noncontrolling Interest - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail</Role>
      <ShortName>Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail</Role>
      <ShortName>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtvt-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vtvt-20240930.htm">vtvt-20240930.htm</File>
    <File>vtvt-20240930.xsd</File>
    <File>vtvt-20240930_cal.xml</File>
    <File>vtvt-20240930_def.xml</File>
    <File>vtvt-20240930_lab.xml</File>
    <File>vtvt-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtvt-20240930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="556">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtvt-20240930.htm": {
   "nsprefix": "vtvt",
   "nsuri": "http://vtvtherapeutics.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "vtvt-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "vtvt-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vtvt-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtvt-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vtvt-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtvt-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 195,
   "keyCustom": 41,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 23,
   "hidden": {
    "total": 9,
    "http://vtvtherapeutics.com/20240930": 2,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 209,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 505,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 556,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://vtvtherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations - Unaudited",
     "shortName": "Condensed Consolidated Statements of Operations - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
     "longName": "9952154 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited",
     "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation",
     "longName": "9952156 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreements",
     "longName": "9952158 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation",
     "longName": "9952159 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies",
     "longName": "9952160 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://vtvtherapeutics.com/role/Leases",
     "longName": "9952161 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://vtvtherapeutics.com/role/NoncontrollingInterest",
     "longName": "9952162 - Disclosure - Noncontrolling Interest",
     "shortName": "Noncontrolling Interest",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquityDeficit",
     "longName": "9952163 - Disclosure - Stockholders' Equity (Deficit)",
     "shortName": "Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions",
     "longName": "9952164 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxes",
     "longName": "9952165 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShare",
     "longName": "9952166 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments",
     "longName": "9952167 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://vtvtherapeutics.com/role/SubsequentEvents",
     "longName": "9952168 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables",
     "longName": "9954472 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://vtvtherapeutics.com/role/LeasesTables",
     "longName": "9954473 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestTables",
     "longName": "9954474 - Disclosure - Noncontrolling Interest (Tables)",
     "shortName": "Noncontrolling Interest (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareTables",
     "longName": "9954475 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables",
     "longName": "9954476 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
     "longName": "9954477 - Disclosure - Description of Business and Basis of Presentation (Detail)",
     "shortName": "Description of Business and Basis of Presentation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
     "longName": "9954479 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "longName": "9954480 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail",
     "longName": "9954481 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail",
     "longName": "9954482 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "longName": "9954483 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-130",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954484 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail",
     "longName": "9954485 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail",
     "longName": "9954486 - Disclosure - Noncontrolling Interest - Additional Information (Detail)",
     "shortName": "Noncontrolling Interest - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail",
     "longName": "9954487 - Disclosure - Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "shortName": "Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
     "longName": "9954488 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "shortName": "Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "9954489 - Disclosure - Related-Party Transactions - Additional Information (Detail)",
     "shortName": "Related-Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-155",
      "name": "vtvt:OwnershipPercentageOfMajorityOwner",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "vtvt:OwnershipPercentageOfMajorityOwner",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "9954490 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "vtvt:PercentageOfAmountOfCashSavings",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
     "longName": "9954491 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
     "longName": "9954492 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
     "longName": "9954493 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
     "longName": "9954494 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)",
     "shortName": "Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-207",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and financing receivable, after allowance for credit loss",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r798",
      "r799",
      "r800",
      "r801",
      "r830",
      "r884"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r307"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r719",
      "r751"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r712",
      "r722",
      "r754"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r747",
      "r755",
      "r759",
      "r767"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r341"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r126",
      "r143",
      "r183",
      "r187",
      "r194",
      "r195",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r370",
      "r374",
      "r409",
      "r479",
      "r566",
      "r640",
      "r641",
      "r670",
      "r690",
      "r821",
      "r822",
      "r844"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r130",
      "r143",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r370",
      "r374",
      "r409",
      "r670",
      "r821",
      "r822",
      "r844"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r78"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r125",
      "r633"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total cash and cash equivalents, beginning of period",
        "periodEndLabel": "Total cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r140"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r74"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ChangeInRedemptionValueOfNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ChangeInRedemptionValueOfNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in redemption value of noncontrolling interest",
        "label": "Change In Redemption Value Of Noncontrolling Interest",
        "documentation": "Change In Redemption Value Of Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "vtvt_CinRxInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CinRxInvestmentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx Investment",
        "label": "CinRx Investment [Member]",
        "documentation": "CinRx Investment"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CinRxWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CinRxWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx Warrants",
        "label": "CinRx Warrants [Member]",
        "documentation": "CinRx Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r127",
      "r128",
      "r129",
      "r143",
      "r168",
      "r169",
      "r176",
      "r178",
      "r185",
      "r186",
      "r231",
      "r252",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r265",
      "r266",
      "r269",
      "r272",
      "r279",
      "r409",
      "r519",
      "r520",
      "r521",
      "r522",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r554",
      "r575",
      "r598",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r777",
      "r794",
      "r802"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r185",
      "r265",
      "r266",
      "r267",
      "r269",
      "r272",
      "r277",
      "r279",
      "r519",
      "r520",
      "r521",
      "r522",
      "r646",
      "r777",
      "r794"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "vtvt_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of securities called by warrants",
        "label": "Class of Warrant or Right, Percent of Securities Called by Warrants or Rights",
        "documentation": "Class of Warrant or Right, Percent of Securities Called by Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "vtvt_CognaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CognaMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cogna",
        "label": "Cogna [Member]",
        "documentation": "Cogna"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CollaborateArrangementContingentConsiderationTransferredCash",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash",
        "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash",
        "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, contingent consideration",
        "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value",
        "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r111",
      "r118"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CollaborativeArrangementNoteReceivableDiscountPaid",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount on note receivable",
        "label": "Collaborative Arrangement, Note Receivable, Discount Paid",
        "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties receivable, period",
        "label": "Collaborative Arrangement, Royalties Receivable, Period",
        "documentation": "Collaborative Arrangement, Royalties Receivable, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r97",
      "r481",
      "r553"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r246",
      "r247",
      "r626",
      "r815",
      "r817"
     ]
    },
    "vtvt_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Common Stock",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Common Stock",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "vtvt_CommonStockAndPreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CommonStockAndPreferredStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital stock, shares authorized (in shares)",
        "label": "Common Stock And Preferred Stock Shares Authorized",
        "documentation": "Common stock and preferred stock shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r798",
      "r799",
      "r801",
      "r830",
      "r883",
      "r884"
     ]
    },
    "vtvt_CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement pre-funded warrants, shares (in shares)",
        "label": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares",
        "documentation": "Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CommonStockParOrStatedValueOfPrivatePlacementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "CommonStockParOrStatedValueOfPrivatePlacementShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement, shares (in shares)",
        "label": "Common Stock, Par or Stated Value of Private Placement, Shares",
        "documentation": "Common Stock, Par or Stated Value of Private Placement, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r554"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62",
      "r554",
      "r572",
      "r884",
      "r885"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r482",
      "r670"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r48",
      "r49",
      "r198",
      "r625"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r48",
      "r49",
      "r198",
      "r514",
      "r625"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r48",
      "r49",
      "r198",
      "r625",
      "r779"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r113"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r48",
      "r49",
      "r198"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r48",
      "r49",
      "r198",
      "r625"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r370",
      "r371",
      "r374",
      "r375",
      "r436",
      "r627",
      "r820",
      "r823",
      "r824"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r370",
      "r371",
      "r374",
      "r375",
      "r436",
      "r627",
      "r820",
      "r823",
      "r824"
     ]
    },
    "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances",
        "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent",
        "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net",
        "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r47"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]",
        "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from change in estimated transaction prices",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r294"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r294"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r261",
      "r267",
      "r434",
      "r455",
      "r478",
      "r634",
      "r636"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r198"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r25"
     ]
    },
    "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developmental and Regulatory Milestone Payment",
        "label": "Developmental And Regulatory Milestone Payment [Member]",
        "documentation": "Developmental and regulatory milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r309",
      "r337",
      "r338",
      "r340",
      "r654"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r168",
      "r176",
      "r177",
      "r178",
      "r182",
      "r364",
      "r367",
      "r385",
      "r386",
      "r474",
      "r494",
      "r637"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r168",
      "r176",
      "r177",
      "r178",
      "r182",
      "r364",
      "r367",
      "r385",
      "r386",
      "r474",
      "r494",
      "r637"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r179",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "verboseLabel": "Common stock options granted under the Plan",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "vtvt_EntityPublicFloatThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "EntityPublicFloatThreshold",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity public float, threshold",
        "label": "Entity Public Float, Threshold",
        "documentation": "Entity Public Float, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r120",
      "r133",
      "r134",
      "r135",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r184",
      "r232",
      "r233",
      "r242",
      "r281",
      "r354",
      "r355",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r427",
      "r492",
      "r508",
      "r509",
      "r510",
      "r530",
      "r598"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of investments in Anteris Bio, Inc",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r719",
      "r751"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r706",
      "r716",
      "r748"
     ]
    },
    "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock",
        "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]",
        "documentation": "Exchange of redeemable non controlling interest to class A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrants",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r662"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r662"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r662"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r400",
      "r401",
      "r403",
      "r442",
      "r443",
      "r444",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652",
      "r659",
      "r662"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r659",
      "r835",
      "r838"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r473",
      "r659",
      "r663"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r297",
      "r302",
      "r389",
      "r401",
      "r442",
      "r650",
      "r651",
      "r652",
      "r659"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r297",
      "r302",
      "r389",
      "r390",
      "r401",
      "r443",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652",
      "r659"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r389",
      "r390",
      "r391",
      "r392",
      "r401",
      "r444",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652",
      "r659",
      "r662"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r659",
      "r835",
      "r838"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases / Issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "vtvt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclass",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclass"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales / Repurchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales",
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r402"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r400",
      "r401",
      "r403",
      "r442",
      "r443",
      "r444",
      "r644",
      "r645",
      "r650",
      "r651",
      "r652",
      "r659",
      "r662"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r838"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Change in fair value included in earnings",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r402"
     ]
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "documentation": "Fair value of assets and liabilities measured on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]",
        "documentation": "Fair value of assets and liabilities measured on recurring basis table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r263",
      "r277",
      "r382",
      "r408",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r493",
      "r643",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r810",
      "r811",
      "r812",
      "r813",
      "r831",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r755"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement",
        "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]",
        "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_G42InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "G42InvestmentsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G42 Investments",
        "label": "G42 Investments [Member]",
        "documentation": "G42 Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from G42 promissory note early redemption",
        "verboseLabel": "Gain (loss) on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r26",
      "r27"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r578"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r101",
      "r105",
      "r476",
      "r488",
      "r639",
      "r640",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r394",
      "r397",
      "r402",
      "r505",
      "r507",
      "r583",
      "r630",
      "r661",
      "r854"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r394",
      "r397",
      "r402",
      "r505",
      "r507",
      "r583",
      "r630",
      "r661",
      "r854"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356",
      "r358",
      "r359",
      "r360",
      "r524",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r116",
      "r162",
      "r163",
      "r183",
      "r192",
      "r195",
      "r347",
      "r348",
      "r357",
      "r496",
      "r656"
     ]
    },
    "vtvt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IncreaseInCommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "IncreaseInCommonStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in shares authorized (in shares)",
        "label": "Increase In Common Stock Shares Authorized",
        "documentation": "Increase in common stock shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r747",
      "r755",
      "r759",
      "r767"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r771"
     ]
    },
    "us-gaap_InterestExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Operating",
        "documentation": "Amount of interest expense classified as operating."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r475",
      "r791"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r576",
      "r616",
      "r617",
      "r640",
      "r687",
      "r688",
      "r790",
      "r886"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r190",
      "r195",
      "r640",
      "r792"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share held by related party (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r607",
      "r613",
      "r615",
      "r681"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r515",
      "r516",
      "r517",
      "r518",
      "r608",
      "r609"
     ]
    },
    "vtvt_IssuanceOfClassACommonStockUnderATMOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "IssuanceOfClassACommonStockUnderATMOffering",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Common Stock under ATM offering",
        "label": "Issuance of Class A Common Stock under ATM offering",
        "documentation": "Issuance of Class A Common Stock under ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IssuanceOfClassACommonStockUnderATMOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "IssuanceOfClassACommonStockUnderATMOfferingShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Common Stock under ATM offering (in shares)",
        "label": "Issuance Of Class A Common Stock Under A T M Offering Shares",
        "documentation": "Issuance Of Class A Common Stock Under A T M Offering Shares"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_JDRFInternationalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "JDRFInternationalMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JDRF",
        "label": "J D R F International [Member]",
        "documentation": "JDRF international."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining three months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "vtvt_LesseeOperatingLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, termination period",
        "label": "Lessee, Operating Lease, Termination Period",
        "documentation": "Lessee, Operating Lease, Termination Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "vtvt_LetterAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LetterAgreementWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter Agreement Warrants",
        "label": "Letter Agreement Warrants [Member]",
        "documentation": "Letter agreement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r143",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r371",
      "r374",
      "r375",
      "r409",
      "r552",
      "r638",
      "r690",
      "r821",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r99",
      "r485",
      "r670",
      "r795",
      "r814",
      "r840"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (Deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r124",
      "r143",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r371",
      "r374",
      "r375",
      "r409",
      "r670",
      "r821",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r832"
     ]
    },
    "vtvt_LicenseAndTechnologyTransferServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LicenseAndTechnologyTransferServicesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Technology Transfer Services",
        "label": "License And Technology Transfer Services [Member]",
        "documentation": "License and technology transfer services."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseFeePriceIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LicenseFeePriceIncrease",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee price increase",
        "label": "License Fee Price Increase",
        "documentation": "License Fee Price Increase"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LicenseFeeReceived",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee received",
        "label": "License Fee Received",
        "documentation": "License Fee Received"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseFeeReceivedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "LicenseFeeReceivedTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee received, term",
        "label": "License Fee Received, Term",
        "documentation": "License Fee Received, Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MFTTPHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "MFTTPHoldingsLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M&amp;F TTP Holdings LLC",
        "label": "M F T T P Holdings L L C [Member]",
        "documentation": "M&amp;F TTP Holdings LLC."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MacAndrewsAndForbesIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "MacAndrewsAndForbesIncorporatedMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MacAndrews &amp; Forbes Incorporated",
        "label": "Mac Andrews And Forbes Incorporated [Member]",
        "documentation": "MacAndrews and Forbes Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r649",
      "r673",
      "r676",
      "r826",
      "r853",
      "r855",
      "r856",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding percentage of research and development milestones",
        "label": "Maximum Funding Percentage Of Research And Development Milestones",
        "documentation": "Maximum funding percentage of research and development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r304",
      "r342",
      "r392",
      "r471",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r606",
      "r610",
      "r611",
      "r612",
      "r614",
      "r628",
      "r629",
      "r642",
      "r646",
      "r653",
      "r662",
      "r663",
      "r667",
      "r668",
      "r674",
      "r825",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r662"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r662"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r304",
      "r342",
      "r392",
      "r471",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r606",
      "r610",
      "r611",
      "r612",
      "r614",
      "r628",
      "r629",
      "r642",
      "r646",
      "r653",
      "r662",
      "r663",
      "r667",
      "r674",
      "r825",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r98",
      "r143",
      "r231",
      "r252",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r409",
      "r484",
      "r556"
     ]
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestChangeInRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in redemption value of noncontrolling interest",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r36",
      "r84",
      "r85"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r66",
      "r69"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r649",
      "r673",
      "r676",
      "r826",
      "r853",
      "r855",
      "r856",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to vTv Therapeutics Inc.",
        "terseLabel": "Net loss attributable to vTv Therapeutics Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r76",
      "r102",
      "r122",
      "r131",
      "r132",
      "r135",
      "r143",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r174",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r364",
      "r367",
      "r386",
      "r409",
      "r491",
      "r574",
      "r596",
      "r597",
      "r688",
      "r821"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r93",
      "r131",
      "r132",
      "r159",
      "r162",
      "r163",
      "r490",
      "r789"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders",
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r155",
      "r156",
      "r157",
      "r158",
      "r165",
      "r166",
      "r175",
      "r178",
      "r367"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r178"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to vTv Therapeutics Inc.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NewsoaraBiopharmaCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "NewsoaraBiopharmaCoLtdMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newsoara Biopharma Co Ltd",
        "label": "Newsoara Biopharma Co Ltd [Member]",
        "documentation": "Newsoara Biopharma Co Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r713",
      "r723",
      "r747",
      "r755"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Abstract]",
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r281",
      "r798",
      "r799",
      "r800",
      "r801",
      "r884"
     ]
    },
    "vtvt_NoncontrollingInterestReclassificationToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "NoncontrollingInterestReclassificationToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of noncontrolling interest to additional paid-in capital",
        "label": "Noncontrolling Interest, Reclassification to Additional Paid-in-Capital",
        "documentation": "Noncontrolling Interest, Reclassification to Additional Paid-in-Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "vtvt_NotesReceivableDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "NotesReceivableDiscountRate",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Notes Receivable, Discount Rate",
        "documentation": "Notes Receivable, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NovoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "NovoLicenseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novo License Agreement",
        "label": "Novo License Agreement [Member]",
        "documentation": "Novo license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Customer",
        "label": "One Customer [Member]",
        "documentation": "One Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r639",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r669"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r669"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining operating lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r669"
     ]
    },
    "vtvt_OperatingLeasesImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OperatingLeasesImputedInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Operating Leases Imputed Interest",
        "documentation": "Operating leases imputed interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OtherIndicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OtherIndicationMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Indication",
        "label": "Other Indication [Member]",
        "documentation": "Other indication."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r711",
      "r721",
      "r753"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r714",
      "r724",
      "r756"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r714",
      "r724",
      "r756"
     ]
    },
    "vtvt_OwnershipPercentageOfMajorityOwner": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "OwnershipPercentageOfMajorityOwner",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage of majority owner",
        "label": "Ownership Percentage Of Majority Owner",
        "documentation": "Ownership percentage of majority owner."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total vTv Therapeutics Inc Stockholders\u2019 Equity (Deficit)",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "vtvt_PercentageOfAmountOfCashSavings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PercentageOfAmountOfCashSavings",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of cash savings percentage",
        "label": "Percentage Of Amount Of Cash Savings",
        "documentation": "Percentage of amount of cash savings."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PercentageOfNonVotingEconomicInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PercentageOfNonVotingEconomicInterest",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC",
        "verboseLabel": "Noncontrolling interest ownership percentage",
        "label": "Percentage Of Non Voting Economic Interest",
        "documentation": "Percentage of non voting economic interest."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PercentageOfNonVotingEconomicInterestByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PercentageOfNonVotingEconomicInterestByParent",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC",
        "label": "Percentage Of Non Voting Economic Interest By Parent",
        "documentation": "Percentage of non voting economic interest by parent."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock",
        "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock",
        "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and regulatory milestone payments",
        "label": "Potential Development And Regulatory Milestone Payments Receivable",
        "documentation": "Potential development and regulatory milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PotentialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PotentialMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment",
        "label": "Potential Milestone Payment",
        "documentation": "Potential milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par or stated value per share (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r265"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r554"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PrivatePlacementPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "PrivatePlacementPreFundedWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Pre-Funded Warrants",
        "label": "Private Placement Pre-Funded Warrants [Member]",
        "documentation": "Private Placement Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collection of notes receivable",
        "label": "Proceeds from Collection of Notes Receivable",
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Class A common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt issuance",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "vtvt_ProceedsFromSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ProceedsFromSaleOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner",
        "label": "Proceeds From Sale Of Common Stock",
        "documentation": "Proceeds From Sale Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r472",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r632",
      "r648",
      "r672",
      "r674",
      "r675",
      "r677",
      "r678",
      "r818",
      "r819",
      "r826",
      "r853",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r472",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r632",
      "r648",
      "r672",
      "r674",
      "r675",
      "r677",
      "r678",
      "r818",
      "r819",
      "r826",
      "r853",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before noncontrolling interest",
        "terseLabel": "Net loss before noncontrolling interest",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r131",
      "r132",
      "r138",
      "r143",
      "r153",
      "r159",
      "r162",
      "r163",
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r364",
      "r367",
      "r369",
      "r372",
      "r373",
      "r386",
      "r409",
      "r476",
      "r489",
      "r529",
      "r574",
      "r596",
      "r597",
      "r657",
      "r658",
      "r689",
      "r789",
      "r821"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r426",
      "r477",
      "r487",
      "r670"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r296",
      "r304",
      "r332",
      "r333",
      "r334",
      "r342",
      "r392",
      "r445",
      "r454",
      "r471",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r606",
      "r610",
      "r611",
      "r612",
      "r614",
      "r628",
      "r629",
      "r642",
      "r646",
      "r653",
      "r662",
      "r663",
      "r667",
      "r668",
      "r674",
      "r681",
      "r816",
      "r825",
      "r835",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r296",
      "r304",
      "r332",
      "r333",
      "r334",
      "r342",
      "r392",
      "r445",
      "r454",
      "r471",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r606",
      "r610",
      "r611",
      "r612",
      "r614",
      "r628",
      "r629",
      "r642",
      "r646",
      "r653",
      "r662",
      "r663",
      "r667",
      "r668",
      "r674",
      "r681",
      "r816",
      "r825",
      "r835",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_ReceivablesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, fair value disclosure",
        "label": "Receivables, Fair Value Disclosure",
        "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r832",
      "r833",
      "r837",
      "r839"
     ]
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of redeemable noncontrolling interest to permanent equity",
        "verboseLabel": "Reclassification of redeemable noncontrolling interest to permanent equity",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r95"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r706",
      "r716",
      "r748"
     ]
    },
    "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio",
        "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio",
        "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable noncontrolling interest",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r84",
      "r85"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable noncontrolling interest, equity, fair value",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r84",
      "r85"
     ]
    },
    "vtvt_RedeemableNoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "RedeemableNoncontrollingInterestsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Noncontrolling Interest",
        "label": "Redeemable Noncontrolling Interests [Member]",
        "documentation": "Redeemable noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r303",
      "r431",
      "r432",
      "r480",
      "r486",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r571",
      "r573",
      "r605"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r431",
      "r432",
      "r433",
      "r434",
      "r480",
      "r486",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r571",
      "r573",
      "r605"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r579",
      "r580",
      "r583"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r303",
      "r431",
      "r432",
      "r480",
      "r486",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r571",
      "r573",
      "r605",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r432",
      "r435",
      "r525",
      "r526",
      "r527",
      "r581",
      "r582",
      "r583",
      "r602",
      "r604"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r261",
      "r267",
      "r434",
      "r455",
      "r478",
      "r635",
      "r636"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r828"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r828"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r630",
      "r640",
      "r852"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r707",
      "r717",
      "r749"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r715",
      "r725",
      "r757"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Retained earnings (accumulated deficit)",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r89",
      "r483",
      "r511",
      "r512",
      "r523",
      "r555",
      "r670"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r232",
      "r233",
      "r242",
      "r354",
      "r355",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r376",
      "r378",
      "r379",
      "r381",
      "r384",
      "r416",
      "r419",
      "r508",
      "r510",
      "r530",
      "r884"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue recognized",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r829"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r183",
      "r188",
      "r189",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r292",
      "r293",
      "r472"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r631"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "vtvt_SaleOfStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SaleOfStockAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "documentation": "Aggregate offering price."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockConsiderationReceivableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SaleOfStockConsiderationReceivableTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration, receivables, payment term",
        "label": "Sale Of Stock, Consideration, Receivable, Term",
        "documentation": "Sale Of Stock, Consideration, Receivable, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction, gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of public float",
        "label": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float",
        "documentation": "Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SalesBasedMilestonesPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SalesBasedMilestonesPaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based Milestones Payment",
        "label": "Sales Based Milestones Payment [Member]",
        "documentation": "Sales-based milestones payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r778"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "vtvt_ScheduleOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ScheduleOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Line Items]",
        "label": "Schedule Of Earnings Per Share [Line Items]",
        "documentation": "Schedule Of Earnings Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ScheduleOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ScheduleOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Table]",
        "label": "Schedule Of Earnings Per Share [Table]",
        "documentation": "Schedule Of Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r579",
      "r580",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Award Activity for the Period",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r82",
      "r87",
      "r88",
      "r89",
      "r127",
      "r128",
      "r129",
      "r185",
      "r265",
      "r266",
      "r267",
      "r269",
      "r272",
      "r277",
      "r279",
      "r519",
      "r520",
      "r521",
      "r522",
      "r646",
      "r777",
      "r794"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "vtvt_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Modified common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Modified Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, Beginning balance (in shares)",
        "periodEndLabel": "Awards outstanding, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)",
        "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "vtvt_ShareBasedPaymentArrangementExpenseReductionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "ShareBasedPaymentArrangementExpenseReductionAmount",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense reduction",
        "label": "Share-Based Payment Arrangement, Expense Reduction, Amount",
        "documentation": "Share-Based Payment Arrangement, Expense Reduction, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated vesting (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r141"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r127",
      "r128",
      "r129",
      "r143",
      "r168",
      "r169",
      "r176",
      "r178",
      "r185",
      "r186",
      "r231",
      "r252",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r265",
      "r266",
      "r269",
      "r272",
      "r279",
      "r409",
      "r519",
      "r520",
      "r521",
      "r522",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r554",
      "r575",
      "r598",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r777",
      "r794",
      "r802"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62",
      "r65",
      "r66",
      "r120",
      "r133",
      "r134",
      "r135",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r184",
      "r232",
      "r233",
      "r242",
      "r281",
      "r354",
      "r355",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r427",
      "r492",
      "r508",
      "r509",
      "r510",
      "r530",
      "r598"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r184",
      "r419",
      "r472",
      "r515",
      "r541",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r577",
      "r578",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r682"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r184",
      "r199",
      "r419",
      "r472",
      "r515",
      "r541",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r577",
      "r578",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r598",
      "r682"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r710",
      "r720",
      "r752"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock and prefunded warrants, net offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r62",
      "r89",
      "r519",
      "r598",
      "r619"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock and pre-funded warrants, net offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r62",
      "r89",
      "r530",
      "r598",
      "r619",
      "r689"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit) attributable to vTv Therapeutics Inc.",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r80",
      "r556",
      "r572",
      "r599",
      "r600",
      "r670",
      "r690",
      "r795",
      "r814",
      "r840",
      "r884"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r45",
      "r120",
      "r121",
      "r134",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r232",
      "r233",
      "r242",
      "r281",
      "r354",
      "r355",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r410",
      "r411",
      "r415",
      "r417",
      "r427",
      "r509",
      "r510",
      "r528",
      "r556",
      "r572",
      "r599",
      "r600",
      "r623",
      "r689",
      "r795",
      "r814",
      "r840",
      "r884"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r142",
      "r264",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r281",
      "r383",
      "r601",
      "r603",
      "r624"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_TDCowenSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "TDCowenSalesAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TD Cowen Sales Agreement",
        "label": "TD Cowen Sales Agreement [Member]",
        "documentation": "TD Cowen Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityNetIncome",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to redeemable noncontrolling interest",
        "label": "Temporary Equity, Net Income",
        "documentation": "The portion of net income or loss attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r263",
      "r277",
      "r382",
      "r408",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r493",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r671",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r810",
      "r811",
      "r812",
      "r813",
      "r831",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "vtvt_TypeOneDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "TypeOneDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 1 Diabetes",
        "label": "Type One Diabetes [Member]",
        "documentation": "Type 1 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_TypeTwoDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "TypeTwoDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 2 Diabetes",
        "label": "Type Two Diabetes [Member]",
        "documentation": "Type 2 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Unaudited Interim Financial Information Policy [Policy Text Block]",
        "documentation": "Unaudited interim financial information policy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r110",
      "r112",
      "r114",
      "r115"
     ]
    },
    "vtvt_VTvLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "VTvLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessandBasisofPresentationDetail",
      "http://vtvtherapeutics.com/role/NoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vTv Therapeutics LLC",
        "label": "V Tv L L C [Member]",
        "documentation": "vTv LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock warrants",
        "terseLabel": "Warrant liability, related party",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, fair value",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inputs utilized in the valuation of warrants",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants, term",
        "terseLabel": "Expected life of options in years",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "vtvt_WarrantyLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20240930",
     "localname": "WarrantyLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, related party",
        "label": "Warranty Liability",
        "documentation": "Warranty Liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r454",
      "r628",
      "r629",
      "r662",
      "r846",
      "r848",
      "r851"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r178"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(3)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001641489-24-000075-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641489-24-000075-xbrl.zip
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M/RB2B&2"S'-8%&?&F($EX3N7J!)B._?BW0(.3QZY=(?@J[#[%]% 7\Y2QY^
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M.'<$>,Z.*12Y-/X#$_P82Q]SJ@]0B[A=]MC$_H\I' )+IQDI*"FRN'/9?2\
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MDOY8,L:G!)PD\(&^T5=JNR-\]NI]A.[0<>X:J=P%6$J#L0/YK2IW88_28.Q
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MH1@)2!#Z$TKM5'K_2_T%,LV989D[5RV=:-X/FMAYZQYHV>X&*:6E9G=D ^"
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MD7P>*H!A. 0*\@?$HP/7!L 7U=I* P29;HA?/XW=Q\VV3UZ)94<!H4N&BL?
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MX;DFC^!*P95%:FB-2PVMLHKA>JLA%+00!4(4[$<4+/01XD(48/G<:J>YV#M
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M9!;Z2W$A9-B)D8Y<YF;W0L8(&2-D#),Q7(H83+EK53O*XJDT(6/RY&Z=,;3
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ME7P7B=3DJ!Q=2C8Z1TQ94(KZ83BIE8VH_O)9BHXB4%/R*. 5T?!*[3%B%*[
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M&I6>IK>J[?;61\(YI-C3(JLT7R!+9_5%HF+:>8:F%C5Q$\A&$$PY".9H%)#
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M7Z=?8S:KFPS4HKT$R+PYJJ=J]&W#N<=IR>D-;= K(.UI-XVW4K;G[X&XF7R
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MOBG-1FR66B?&HQ*G0TT3-_.=!O>D6Z8,<?AIO9]&_[^0E8$_I0[;8)#.9%6
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M87V 6%-AW?98-]@-UJV3ZABA9+<!EFRMTSJ4_A\54NT6J88OQ,JZS;.K0<8
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M!W@3_#, A9RV3'0RD[LG8K-@N_CS^%X !F(V$]P; D3.0J!$(HV<1M>B6/-
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M6S-6&L\ 5-$OE#Y#\),]" .-1PFJS+)W<I-*7\UIO?01>_",+VR/%6Y#%".
MY7B"<4ZRF+@/V1> AVC3@TZV!(,7, -'S I$:/@N!$*AIFUHW"-/"^H9&L&Q
M"9/KT!(V(#20L&YGQ+%.U=V9B$+-HI=?R8'TC--/R2Z: %U?2#MKY/F^]T3&
M/;) A>H)M ;9-'.LA.L&&42N\CJ778T+VK^F8L9Q1IIH+(GA.@Q ?(=M F,=
MFVHM.D 5(^T4Q+&S-]5]^4UUT4A,VU*I#_Y2MZ[#W5UTU"XUXI!!N3L&[EU2
MG!<"3+<'U;)RC<:@O1[8:QF-04E4$E0*=]A]A1WV<8?I1OFTPQIR)^R>"LQI
M]EQ/J;_;J>>?51#PBQTN??@OQ1,R=/9!V0Z@!\D/Y2E=MA+3>HQ";HG VJ.9
M1';V:N51&J']233]' [JK6:G;,_/0;?>;PYVT^JQ56\,6MNT>CR)CEN$5N<1
M0V9E_\'#=H5;C=\]T72[$TV;6U&74LC@I3,O8 D%;.-F\M%%9>-_2!2EDN5Z
MP[.KSJYZ:E4-$-:B\6[5ZN!%<?_]4GR%%>^>Q.Q1<+/7#,SO8\5POW]:E9^'
MCOJ]:LS02Z,^,OJ[)R^>-3UQ?PCG\M_"][(HH7EV13IPZ]=*$+PF-?0K0? J
MU(!J=!EZ:.V,'BKI4(8>!I5T> UZ^.@M_3+DT*[$PQZZ8V >) 4;*R%1EBAR
MXZZ:(NZ\M^*;[3K7".!-:*)3B8A]=8QAWZS*(-I&9&Q1JWJ2=%-6F&011A>;
MM.^X]++JM;D11N UOL&D'<IP<"G+(DB-;SAQ<7*^*WF22'C[Q&#])*&:10H8
MD4SW$UC?D7]8DH&ONWW@./\-I_C-0YG^D17]JQJ*5>T.]B)5<^1I%N?H@Q#=
M]5B&0^Q?<(S)!3>))(&Q%_"(4,PH4"F542;!V ZFUH02!%3:P1R'T'%4UQ+Q
M(709R3R8ND-I5.6* +)+ +)Q$>?!9J3_]P=;M?O8\*7#LZM&/2TV<VL0UBH2
M7R_'O]<\S1S_?ND<_R_NW,,\(:7>%/7!&#32B?Z#1CK1_ZLWET6.5)'U2>NC
M&V3^\_H9;RW; >-0N$JB84*P'%$1K<Q\_?!C/,5AW$;)+I77RIPQ]=CCW:/U
M^YQ3NQ>L"'$:B2B;@SGH9^8[<@41YS#:]^)F G?Z#P]?\@%^[SVXXY0^;&0X
M#H"\FH-ZND7S7[">T,0-9:M0=PPXU.?/[RQO&08A,$3\OC@QZQR,5XL0?WC!
M-0D9\//%OY:N+]M6!-2;PN'4>2PR_A>F$#-H\*,(L-3 !3._K;=44.$AIN!0
M:63NF)I._6QI>_S8=?PQ^(==]C*:[9AFT8C=QG?AP(E0R,)=O(M@J"Y"'5V?
M_!;W 0^"W [@Y=^1KM+)B[ 377X@;[(17210F3<7J7N\A%4NL?YR9 <NU1!0
M'CZ)P/.HB@L /K%=WP+B_%,8JCJEY&4!S8YU+EDL_6!ISPN(XX+*RK(S_ C@
MYUS)@ 7<]CTBU(,PKQK0[:)FTN 8F 70N/^,-R,!Q[G0MH.,A"MB$ 5XP\$"
M-+N@)O\"?N0"?W$"6; :KQP(&$6%.@6#(]ZL1<-N1=D,=OR/4ZKK.;_#;^^\
M]VHU!:Y_X'NHY];-/)'>^@U6!N*FNWA'%T%(DYGBZMC/$5ZT,8R39.B7\(CU
MZ,W@SW3V\0)?M?KR)P0&V08G?>&O>%E52YKU6]+T$L"J6M)4+6E,%>Y8E;4;
ML\U*G[4.;(&!#&>N*N-0/T-N!<ST$9G/MYD]9M4#F)D]'X/8X8J,3\"D NR<
M\IT[9T0ZBCWCPK@O_VD_+'[]:-W=?;/^YLVX-]C=DT=ZT;GLIB(?THU4[K%]
M";Y(-_*@9AOA%$2C YK/&%Z)K#4  )/-.GK6+YI[ULP##NM3/:CO!EPA9_]!
M1H%FUPGA^M:S?2Q;M=[KY=.JF*_UE5RE#Q]Y8$$]$9C*+[B43PE(K8PA#R?E
M C!Y2@6LB O%"ABVQS#[HW&E'T&%&I4]T<WQ7>+6$H?%G&QO>3_-! !BYD(0
M>F8 @]JRV*BS+V=AZ9X-W6+;.J8&CC/40-!VP^>/H':1W,\PO >=LZMN/>UT
MTK7^*9N"E#BMO:UQL5XFW<@B52EG =,FU#T/4  X%#PI:.M*^#^(?__;)@]*
M("E-7Q "'C$5_D5N+,+JM_:,:.!V*@2WI<G;G<V8 :^=RW84"]"8;/J#]W *
MM8+ CM -Y67=A(GG6#;L.U3/N_)>I;(]A=>P$GW>O* *8Q=0&JLR#4Q9S)8!
M-A!</BS9529LZB85_#+S@H"*C -O[-)7FH?F(A18&*T+Z7G33(-?I%O2@/;,
M*! @"EB(%E1!5U0EM\:A56TU 2EFW)3:"GY3BA7LA!&\LWW_&3Z]IGZ-6=R@
M>W;5RS#5<[QNQT@)[TB<!(JQI$S%ISG8#E-WD>F->)JZ,Y$@F)!*OA'O5_DR
ML%P=: !AC_P.^R$$BL^%/IR)H8WM4:1CV? -2<\%M8IABR:?,.'7<EFR=U !
M8"F*=<\EF^0JI@H;P\CR':SSSRF\\?D&(.7<+D>!Z[C 4+[9V.?S1H%/(]YD
M @P[ +.2-_!5A!F^Q(R>NH.,GKJH27#='9T7.7>P?""C#^AI+J@ZW .#TPY#
MWQTM0]7-"F_@+FI3%8#V-:XSE!'N$VRKD2\CWFSFK.R5;E/RZB6 8$G5&VQ-
ME:D![#3K_6Y_5S6 _?:PU%+YG[>'W6I3K[ZI3O'+5R0B%$XE&:8>RXBHL[?C
M=>+'@U7A%R*FCS+D1RGH%M<B61_B,3^KW:CE)N7\'.#YBOK\FM#9!HO2CQT%
MF% [WQ9#CO?H[9_WZ-6MKT?TVP_&C,7KAVF-::])2* J6V@=KZG-*G\7.L)
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M1R89*\;?>FXF2[ 'CRU9="D&%]QO@S)JDJT[U&;=<)6U)*.7 ?!-WAT[[]/
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M_3XW[.\TC-H794KME-0%#5ODP^IG?*H"7 6X"G!'\=119V>L#L>0!#!<0=5
ML6IG!SM0+-5C)SY-K+6_X6%<#Z*=S<\UBWR!H,%C$/WY&%-XFQ?GK9PLWC+7
M>FHM*;..>*3IG)GS1]O) :3QB((A*C*"\6>I.:*]1N_L:I">(7JT59(5[I\N
M[G>VPWTS17GB_A#.Y;^%[V711/_LBM(D6K]6A%$1QN$31O>U"&-0$49%&$=$
M&*EQ[=MJ2\,#TI9V.J^KO9>4\$WMMVTJ6D^-AK..>$HTW-\Q#3<;9U?;EYT=
M3H5^A?NGB_N#5U+LFLV=*785852$\?*$,7PMPFA5A%$1QO$01K^Q:VVI?4#:
MTH[B6/3>5O<P+)[LD"]UEMFP!X+,F$T6L/^<(\IV"9I3XA/-7?.)SME5L[6K
MMH>[N*X#=2=61%H1Z;I$VGHM+;>[:[]^1< 5 5<$W-\R6V-] NY5!%P1<$7
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M1< 5 >^<@'==2MCJGH*:7"9'^O!F0?\$TZ#;]6%C1S.<5R^U9GIP-9SY%6F
M3O31&#*J9@@ZUC*@D7A38;V= 6.YO!U/O1G.<%X0/\3)E_C @^>(6=WZ\&,A
MQI@U\.AAJ'Y&,SH#'$X(GWD\T7GJ!J'G4\:O\53.:-;8J&3O48Y??L#QG3A;
M=1X:(PJ%Y;O!GY<37\"_<.!A\LV_UV_A.9\&]#U;SZZ8P:4M_4<:-@T<$B<N
MVB$/> ;(XIYX;".<-&.0\@D@<:F<X4V37%YS3&GA<=^Y\^\_$"OFGC7SYO>
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M-M7.JIV=4#F79BA515=5T56E*+](2'5%XT<=1_U"7GV!WH%_NN'4[ /!;2!
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M'K[SA;&4*QV"]8RAKQDDB#P%V9X[7Q)O*D>4_)$[=X#SO6GU]S&VMT7QO*D
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MZS2?DH=,O<A[ $2'"_#&?UH>\%QZZL$+0D0YW +<O.LY=0N!YKO!GY<3)!/
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MNJ\@HH&-):VX7*N- K'!]=Q1!I@K@HQP+#SPU9O[,9/M'^KE=V(\G;O_6HJ
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M@PC5B<22#"4+G<SS<<&N+MYUS>+=OA\ZH>L#L2:ZC'<1QK[U!9C-"6 9_UZ
M3;4TFZJJ-K>F:G/VZ:RN0.ITS[Y:C1J;%]/__MJ^;'\Y^WIVV95ZQHUUVKDY
M^7YST[FZM-J7I_#_]L6_;CHWUM6Y==ZY;%^>=-H7ULG5Y6FGJZZY/KOY?M&E
M2ZZ^G5VW\8>;>2-,JPN[$R=#O'+BL45R_5K<.C&NU3J/8M"J/>LBBG[@Y[RE
MPK/B:J^T27KB1^HVX,[!(CNAA4="Z@!(*B.0F@L?/V2S%ZZQ07#YB?5'YL3
M]((Q@&D4Q2E:)@"FH57?V_V#-!?JI]%GR.T&$G*Y%+/N?7@0ZZ-#X6"'9*4*
M]P40-HH\+.VEZE\K<.ZQ(X<\$!LU=;R>VF7@8VX3FV2L3R2-_G';&@4._D=K
MVG!7DF3#D?H9)+?OLB\=-8">"'S1![V]':0#4A7N!7]Y)[1. 'KQ UO"_AYL
MIV4C@ =JSX!/R&Z,-TMM02H70\>C0'& )T+N?=@%VH>Q+T)7*(T=R /0)A[C
M'N#>(*"H+UP*%[I"/ACN-DXOC47HP3YU!PK0,'RY=VV ]K,4]!'0?NY$$(UT
MXQ4)V3X81E&<KUA! _?IC$9Q-(I]M!R($W-[%#]VLR%Z3UPACP2>0<8&M<G!
MV#NJ29[?[\,M>"[PB #0J!]'0WA$!!!&12E+DCP"/AOD->O<7",_W'4R> JH
M6(B&L=\#O46V;Z&'XYL1MHEJR3/U6MAG=$]P$$$B[DD5I*7XB(2$[KQEY**-
MO4_?@!:L3L>VK@ALG9Q:I/^G \NUZFW;0D>Z6C+=7/]$[\DA.! .\1SYZ+(;
M^&+Y3#QU?C\N$0'>9NMNFBY_KRE.5H:\"A@&K2, 71$S;2*R14GBD_2,&:-S
M#%+'2P$JU6+&MGJ8Z2&2!%Z$-N8MTC+AEW&-9#/P#DFQHXB(&/9P&T?WZ0"N
MQJV@F\\7A=^!R_X0Z>S?S56A!AYGMR:N8WH&W,CJ..)APL8 &>B4N4&W8HL>
MD?J<L#$'! &?S:\),[D75%I@KXXKJ<T%.= #R*,(]/L^8N#80GL$X):Y Z1U
MB0X.7.#Z(V)G"AWD3Y(XI[XGFIC\,A'BQ]25.:><_('8Q=37Q&R]J:^'SGCR
M*S[8R2_5,4W]P)QY^H8X^JML'<F@;(OW?C#U9++1U'=PZ(D/(M8AA@NHDFA9
M@ @0@K1!*TEZ:)!#T)'4K"_P+3.F$(WL*$N )(%.4.2E"L,U[V3C+T=X%C:*
M+D1XY\=1B)AB$^+ R^X'/AYZS,S*=ZF]6*0$%MT_1'.W<&E/C",DK$RRO2BP
MK7&460P<PCTX!9>8=48>1!^9M/0H/B+7%(<BM[@I#">$'[[E%C0#0%/!@(-M
M$SNA5\6*(%'()I']T#N!S\+%U!<K0T$1@KF%OV@'V8/BW93HL$60+X[VM*%E
MS7]K=HXY9BA&\2IIP1,-@MJ!"522V:$3(.J!I':4LI2-Z&&/ G"4P6TNK (9
MC7F;U!&2)TC)G!4H.?G@&FSR7UA^'Q#[OL#D>P+;C<$2[AP@!O:5LM@EUEY[
MLG/O: [GWK)T?>DQNKH3\9TO[M>_%=J?4BVS7/B-Y N<_:VP1@,'#MH5&86$
M2);AQOL1Z#HRH  XF%*ZI4B=7@2(2M0#*!(X0\"1" PBT(W8E0W8.X3G#V%E
MB"-^3.T-=Y$STK/A;H/-^4/@V7=".I E+P64]5EW^U,JP>2M#B,>PV*-_)'
M_>&U?1]X#D!WEUHO6\D06>0P"L R #S56\5W ;O0GTG0NQC"0T*#-UT!#PE
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MD+N3YK]R^G;=VL&W2ZS6+]>X;7W7=J/^L0 SX*\>6%&HCWD*4G"RXB=8*@F
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M>-+N=NLLWO"-K&$8:6LKKE$LE>@H,1=.7BED!9ES(2<+%HYXIQ>@_4?A;<
MR1_1LQ,PV&$7K7UK>/O!NT!NV;2&PRCX<&'+C&6Z"MDI2['D/9WVA9QY6'S5
M.Y9Z[XI?B]IMS9:92;AN.'"?DVSQN4[(Z;J K$D4DC"MM_9R+LSH-FD97876
M?V? KQL'9JS5H% CE600!9ZFCPJQRA%+!A=MF0>J\,N@5;M8Q4O!2CAMPCR
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M&US?G%@7J5?+4Z?W&RKETV8?.#L#0+TL1A[,F(2L @I ,5!1#58"I$+SU??
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M6+;)5>;IJ;E42%"#OE48%KA64*,6;A74%H0:?/MZ\FO56<X#.5@O(<?6"A&
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MQ4E5K9QB09\G:O]E_] (4^<J')Q7C]?$RH "0BQY@M1*:-$FT92YGA,@R#[
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MD=:L<TZ3M4U>A?4)DS<,,[30I*.>(BZ.@AKYXF4%@VQ^B[0$RKO/1H$,&?>
M+_9]#@!IT-)S>X64#>7QD]Y&7_;ZFNK-[(?X8DHD!?M$!@DP!L)@-5:?$.A%
M0;SJ%9B05D"=A*GY2!]^$JI@44<4^GSJG+T<8B]B)<!49_ \.<L3*86<5:Q\
MQD8XT8&G.SC<MH)7\U?FW6KGJB=<DIJ[.ALYY-19L!<D+\%[R/7G1?<A;SAR
M70H\:( F5*;)F,QI)'Z"F=&3+98+8.NI*#=2 O,\&:''A.>,<LSXO!.TG63T
MP\;K,,4Y4\[K])XB.<,([3P1C3BQ9(*#WL':B!KRL]L UM8MDAW&HYC@3!0E
MBQ1D!D>?L1L4AFE)0JM4+C.KPNFA,<K-#'Z &!E$D5>2+R7I,A;J+(%&)O$>
MUB-71TR/"MAX"6S-4K^.-.'XDR<M>8XJ(\WD33M5IV8=EJM95]C*CZMX<G;#
MJ>AD:@/3]L ,1J^0@:@JFY';-\B'$;KD65FP9JP44%7B,I4K5RE5MB,/$%%L
M'5^-I!G[Z+,5\_,;XD^[N1XRR?9Q0%(>$/'DC >B-/B'^ :]G(F2<[AT#KQF
M%NMGJ9_DB:<=5>]]$AE]''.Y?*U*NC>"HB=3<0V<5>U/"!B%II9FSH2J;Y>C
M2REW,B(!3%&^/N@H<)V,ZS*I*F^;RI'@I Q4)9"ADW"6"L28V8)LVS)Q@[W8
M"M<0*_\4H-H#3VESC9%NY\8H:.9\G43QB%B!]07WSZ6!G=R@F+GWE49.K9 H
MSV/"=8V@T ZP9H@8F-KX;;YQV5[<U+Y+ ?0E RE-M@LEL*-T^!QAS@;Y-'#J
M"N4_\7<3%[>QY1,9<.I*@+>:G> *6[=73+'H33V^G:%+$[8UQ/P,N.HR&E*1
MIBPV*UVFOEQ>,L2I4JP=ZI_8/5T.+_5(]@-3ZDN@$E48PT 'O+^OW:5WW*5:
M9-@,L@:0QE1EY!&%"KX<[51 !.2IRA?AQD78L-C6SF8$PZTH3[8N/4!%ZS+G
M2BH.:#ARHZ-""C47T1)?T.-49/]]FG^F,W8]9ZR:*_-C.-=("UM\OKP1_M1Y
MWQ)&UB!-1Q\_?$!()<*MP7(9Z*X,=RKS5UVO\AXIA<AA16B^S+\7H-9?_]&+
M/_Q:Y2_,RE]HODC^0G.ORE_8ROR%Y>@#W]K774QY)=94_V1==7\[N[8ZE^=7
MUU_;W<[5Y12]/\P,YL7R9EE,9OUB,/69,9B+LR_M"PZ^G)UV+K_,&WU98=W^
MSUP Y2D-+(5(G2X$\@)QRRW_T&1&^?KT %[SX)$ WE27EO7 G?9,Y,&,'>N\
M?=*]NMX O$$'-F53J#(2JAKC.06@)[U1QO_KU),6]F5DYJ.#W(\RG5$>2=_5
MBRWR%16Z><GR>#-X>&,F&7Z_O#[[TKGIGEV?G5HW[8NS&^OJW#K[XWNG^R_4
MY[]?=[J=,PZS?[\YPQ\EP]\ JKV,PI*DBQ?!G/W2AA3KASFS$S5/S\[;WR^Z
M-];W;U>7@"J7G:MK V,V%3OF1H#'6DRLIT2?G9'SM7-Y!ASD_ P8AY&GNV:)
M6\\\],?:(:SGH;=F'OKCME0)$.;H+[C$'6,&#F@JO=9NW>K*P:O?L(![G;96
MCMRG'&V@MF'4(VHBSL#:V,RDG1"S>W5FDW3T8O1!Z-2,B-,O$NL?_L^/</TE
M=DOP7?;V_4ROT:_@[M;WWUFA,X2="]?[B !'>-?;<=SV(GBY=QXXM^\L]L,#
MX?U,/_;]G\(#J 2)>$?4V-\].,0ZF/G? Z3]]%<!-W?XAG]\*+SRU\G/")"G
MKZH;#\-TWD4=++3_)[_F\-VO6/J/'O<YML\-3<,4)R39E$&!_9YE7:FJL,2.
M"-H2&&4QF!P)Y02H3GHT3SS/<\/ISD[J)WU.0'  S2A&<R=TOWXS6-RW#"K>
M<=^K,E)I=<%R=TTR5_.5C<93-6F-/5D4M$HK*8%RW5TX( 3.1TXM&W]:>_EP
M,%,^G/W/;YW/G>XSM$'8%]?8:F]Z#.;Q+G70&R7BH_KC$]B@@%7CCWY(JZ2;
M%&BE"[X%;Z"NC,#TY%OHA?RS="8?']4:]7WT)Z<Q_-]3+Y:NYAKL^D/)]_!#
MHU[ZTUYMT>_W]PX6NF/6HHX.:O7#YH./^D";Y(T"*/&4_M^[YKL)@^5C8_33
MJA?/!]%S"IK1Z*7Q\.@Q-"3?_]G/@=_S4[+9+FE0F\:XU'ML<WNX-0FDQ6#
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M#"YP5M&C87!]W67+\F %Q>M_?1#&E8\Z_N()?W;9"EIRQ:8M$EQX&7P#410
MZ"WNX DR3V[&S1AENF]+/K#I$"_(3$P-# @LK4QNMM_V@_-2%2U-[EB_L,64
M<K>"L<$-7G?ZDK&IWAK78Z,[*GH1O@#?VGSJ6/]#X;^3TD<YW6Q:\=6UF=<9
M/'1'(]#3'>N01Q;VR1J<MNX3P3=2L]^N\=LPN\%NT/.$Q9@M;STQ?:0.6I/8
M46B[@6H#:VTVW)VQ^8,4\EX$4!_2U6NT2$HR/<KM.TAB9ESAU:<%W;$QW\:Z
M1WQ[G3:*3U.13URJTD>9%\'_ _:LKIPRU]F XRY7$A6)J= I76],7?ZGEI1<
M P@?.JZ=/MG?30+%Y() _49'T:*Z#<Y;Z"5;74R@I6?Y0W:7G645SFD5^NG7
MP?S^_KH\C%ANTXA887!S+9Z8B_.:C$]PEUM12K([HZK;U//X'/RDYU!+/P%G
MNO5AE;+#@-40[%4F;X*M&PTB2"BTR\N=#-$4]UV%0%4'9P^&-^HZ#H+77P6>
M(/D,RYB8<LL8!U>DWN5XG@4J;,O4JT5P3?AF)B=<FF%Z*BP#Q;J>=D4[S%E6
M1[4ASE^+5XWL=Q>!?BV=,[/:-CNDD/D+]U 0O@<O2(QAZ1J#TE'> C98K-#\
M"I1-K7U\=H'GHN</(<*\=015@PGT%IZI*+2VC*2I9J80>J#/?.I/D\V/@;AB
MCZ!].*V!PR:F58&\)L-M>WD2%U2?#,/#4MWR-T%+ _1:+)H3B7===NU+):;,
M*P_T<AHV(B:OUN_&X*TVFY>.TGXYOG/G$%?HZ+'G>]:$2A9G&!U\^V3LTM1;
MIW,&7][#Y.NFVI5COET9C7"7+^Q)"NK1*RYFL!!.0?M[99=W0SE-(\SZ]TW_
M5D>:+@W*2.46%39OA#&_G*;]SN"BN6T;888>'.7:+S5IA-+1X'5MO?<G'#$.
M3C!"]/;(O#D\-B!2AT,C3$Z%+IBV<SO\P: ^LQC,:';731VM!,FR..Y?AU5S
M2^**R4!Q5 ]WFG$U[$,L7U+N+J'96:!7+^U-+U:8;XUUB_@%2K4$7.2X$(S'
MF8Q.SW0N5Y+_;55*4[.(Q,QZ1N+/X%3HNW68-G:_I,@E^F)!'<R2DF$3O/E?
MV[E*..TH6(V(-C ?9XSLA(&;8+7M+V/56+<(5\M;QJ(UHM#NO*;KSPP[73NR
MJ@Z8-ZUA6=!\-P6P&EX;'Q.]87/FB%F8]O39& \G"6_QP!V(/:%C>G2A(]#$
M 8O+Q1LQ;3SBNL!WY\*PT;_O:X1\I7U#[0N+6EBHQ7I JN+?9Y)12(T[>(X_
M!C3&L#A8W(1E,_80"JY42J;DJT72)'1F?=O-@[#YB&LRXXF2[0IYZ9IZ1M/$
MCO@N&=O7^4%GBNM7A7ZISJJIN4;J.I/.RKTII457,UUS*JVID4R=TOF^/+^N
MSZ<Q6;;4[IK,8Y7LK4#8" ._B+FH5UXMHVB$2?BXZT(H38=,F>H^!8T;8\C@
M250W)*=Q(PSIXAL(=Q P! <'#5LV^8T;84C)S&W<JZE&^](;-'&8OSHMFQ.#
M+$53*T#W3$K&EJ^ZP=R-!QL+ADI&1>H73P/S](S?X\#=;2PR=$:*>?^!N/U6
M^%XMDTVLF@K^R@U'=].9'YW>+3LA9B)KJKF?GRW]C@?F9ZDW7*YS?CI!9 [^
ME\_46V'=B'G=I']D:1SP1)LE<^;AJXY]5+#0=;;$?4=+P\SW6+5#AR 'WY$?
MB!N(,'"^8Y'FNN*OH]VN^XWQ\02&1@>TI^.@4!*^4U+I58QMRVE"%3EUK#9X
MXTI^FX /++I/+K/Q=Z^XS6$X!V<M\4M/3O@L\H^0)#K*T!U5/N/Y R0WMD9]
MS=W^<[++;MC2SF_<B,DIJC+>N2F_#DY;=GPU$?CN=7&T4I'ZI=]@2RD7'#P/
MML?JV5J/R4L?Y<69JCL*C\]VO3Y.9_%AP^0<XC5U'&9?+:)SMF'+DF.\&S-N
MQ.'&TD,)J%WIYDQ5\I=?'1ZH!<[JL2=,"V^%-V1XMY[P9GHSV7#(JR)Q(^:Q
M>'5);QH\T/_">%1Z/2K./ZJ0-F-S(:U@4+^&F(3*R2.=0\17/&B-=,TP+W6)
M6&F).]NN.27MA]O!H/<OX>#^E32^T%?4NA%#*M7-QOI3?MN7KC=%UQMU1Y^I
MYV(?]](_&U=87C>1-<?=BE4U'^^N0OK2",87Q<#$)273U<W4E<[A;2V0L/4Q
M\D"F^F?#2N'=C&=SL%_3#J-C;,ZW,5Z3NLWG&U>3KZX82N;I""VXW&?Y&K]5
M@\(:9'@W0>'RNBMQ3=V:OF<*$O6XH%3MK6@#42-6/)VH5S,GM^F/-4)?R"1A
M%I_23S_]#U!+ P04    " !@A6Q9Q0ENI^ 4  #+OP  %0   '9T=G0M,C R
M-# Y,S!?8V%L+GAM;.5=6W,;MY)^SZ_0>E\7,>Z7U$E.^;KE*B=VV<[)V2=6
M VA8W$-QM.10MO;7;X.D9-TL4R0HC;VI%&62PYD/W1_Z C2 O_W]\]'DX 1G
M\W$W_?61^)D_.L!IZO)X^O'71W]^>,G\H[__]M-/?_LWQO[Y]-WK@^==6ASA
MM#]X-D/H,1]\&O>'!_TA'OS5S?XU/H&#MQ/H2S<[8NRWY<^>=<>GL_''P_Y
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M14'N%%9W2K)8^WEY4TS$T+R3R \WV*J/)3 0%0<:;+4#HC\&6SV(OQT&6SU
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M>CRO;8[.9GCENJ9XS@N"9R'0^9W(AK<J@_1*%%-2#&P(@?7!?!3OY\%(&\#
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MMW?O7JW[4'JO$E<<9#:JEI&3]<QJ'4@,O#B4.>?=/)ZKGWHX]Z6?8*<MI#)
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M=8',1(C9\'KD"Y3<)89Q%POZWH$8MY_]S&VF)I0T3CCZB%]O^HLW(:Y>C%U
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M/\Z69=R?IBNW\-67*M2WDS?SQ?@T+&C-5X3;O5DC)M"19!.9\)Z#0FDA*AV
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MNF5ZCKK2'Q_1-\>WD7)5AVP=.W:.5]?S]"XL<'&A2>+)VP*BD,]!Z\H0K;'
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MSSH= &@* P#8Y_^2)_ , * /!0 :Q_Z2]Q>?N%EY6/TIB_3B(;:S P ^%0$
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MIGU-3G-/-<$"JREG8-]6B>&?A9)R6U6/EONEVUTF[(\)QI1(/T6]J.AON8M
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M)#ZH=?I4Z=#:X2(C=XOV&0^/(T_>#=Z4^W1U*GA?>V$]#8<>%5E?FQ:;OOG
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MKU.U15S5&TYL]L;65-9H:> :&.8GT>+;@N^6XE/6B9 ]ILRY$C+)2&VW#+M
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M$EC"K>8T:(14A,78XOA6S<+0U_:D$"YDUB#NQ< !U^4[0O_HQ>B_!1C349H
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MGQ(MR6OV/.@Q)VT?X/&QY%3+0X*6!6$*4(0K":S6 (^Y'^L=<K@$1A(V>!D
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MO%_ &9R:](?)5'KJ\:J7I,>7#?1?L@](.;BCVUB X7^AZ^Y*F@XV-G7@$?P
MXC1:#'C4!=XT&B=X?+-#6Q*N<^<D=]S1ZW.42MA#O[:Z7**"1Q#XEZW-2S#\
MX"7UP\AI8I#1%'X W,[[QZ\5^1N_W;RCYEESP+#@1,$U9496_5)3-< @\8"4
M$H[NW*#FJF<X(*Q4*_4X"B%&"GHMF2S47+AO76M9B$ML"Y7>MVWO]+<6PON
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M2%/Z<CMG6+ASR:E>9K\-L\YETE)OAGBOV=DG-W&@[RZJZQE/4_'&4.$>6?F
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MKKK\UM5M>[N L,3I#V4TSR,%BW&Z-RHG!7:8 QJY1YJ(7@CB\=BI_":@"7P
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M-R G?V" C;V"*A:AOEG(X=LF92'3^%7P!72?OXM-#9BMEBH6%>WLSMTKC-"
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M5LM7C&Q-.1/4&0,)&T757&.,Y7-(]C"FZC1E!1"UZTI!!&>X61#H^^93=O)
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M8%#&\2_/\$2'0&&G&OK?U0R_%0DHN'_C%O@)&#W.[ > ?B(++7M^.67H%L#
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M/&%OX62Y7CZGG(@8C0OP0;UC3G2#_)E:V2"=[=99$I881]$6@1/"=K8M0/T
MZ<S8BJ\YPD7FO="/12$)#B8N'NDI8[!'*A]"08*\]",MB>DX]9G"\VB%D09<
MO[K5>=T2M<)&]KMV!HQ,N>=T] 3@U9$P#1M_UELF.K6;9#R90% CQ-03\"R:
M_>DDKF7O*FJ"&L]"I/@0F7J_G<+7][!Y'\WO(;^A5R@1/E'*3&;!4P:K<9U"
MD>$5^1U6OAE,!$OLRUQ(/PK,<>N8G=,6*]C]KEINF3.Z:[2F>U!1H77)0U;9
MM @.4+HWD!I]\H"I*J_>M>T:(R4ZPM_2<YZ+CY$;J&=S^.S5,^65"CI9[>@Z
M&DM_)Y&*L!,B7%%19'7K98E&AI^;9W..TUO= DXC]H0&KF5?"YVX3,7234B+
M!SS$EX>AXUNG5S+OF0S$?8KL)Z221L6YIP@7CV6D3\V:\NJR(6YV(I)G_YL:
M%L9(U5U:T&>=])Y]RF#&VX9D#X*]XOP5HU.1\H&M<T>^U+C97 Y=.^D4JP?6
ML9G676FHQ#>RXI_5=@V14,'YMQ[CB>+%7]N9JCDX3''8BK.SU'3)'">ZXH)I
M%M2:8(=2#T]TB:>2L%;5\AR2SYL,(@4ET]O&K$0UB7P9%*T4[ZN6L\69C%>^
M=/MH/SBA76T=**XP6./ZV5^]W-CN01.R@@__&[>H@-=$7%8!OGS:CJGRI'M$
M;K::3_&G9R+=;>*,8(]0T9SN?**M9G_G&&T2MY  VL_Q]8:L_0 -,P*.^K+"
M U4:54X7O6CC"15U>3MYY,&M%F-D-?(1/'5PTU%=(4VMTY9@85&;K&G%V3=1
M;DC#U\;+]X[53M83PK6R03#)LIXNF[!(NJH:JKW<Z!RO0+-B=FIH)FL_5P:=
M[-E,0:=KK:>$_K@&E"";9<I,]'Y3SGPQM!+Z6J!*[TLE:,O D*XB_1S+EPOX
M:.X>N8M(Y7/!E9J7L-A<K8#"Z09[TLBOS_S;3[X())C8^#-%,FY*QK3T%7]L
M)Z7XHAN+-Q8'3$_5V$F]AZ98A@UNDE>I>C6U] Q5U6> O&%9/+9W*"MMO8F<
M_37-7=8-Z?$OAIM"2O?=<A7'89A"?DN:]U]2Z_2*NXH^D'>P+SS!?S@BXOQ9
M<K]7!;& L"U<2HPS9L3A5VFP]@YJ#@6RKS['63VGV\8R)=-RT";=7<97F5'-
MA#DQ+S&%("\DHN:G;+!(18V>KQ_4$G0MFZ-UL*&5+SNPUE<#;$+X(]S7DH"3
M0\C%ES' YX!9(52% 7>G*=X=H=WT:6U\I5$G,(E/B+HTKX(N2>+TDF@MG&EH
M[6 WMAME,:36NZ"U^,BO%K]2CQ]6Z7,!-/%ISECX0G3,2!O(CD+B/^'RSM!@
M,=MH;<P&<2YO.?JNW^H,"ARA(<ZD8F0L217/="H-<?&QQG9P\#I_"SA"V][6
M;$..IW)T>6I\_$E:51>96BW+PDT<7*!>_7QC>,!F:D"1;A6?]IQ>6L=HKJV7
M&#2-&M,YXTO7& (*2/;WM]C8VZ^3.G$@$)4"8;%CJ;:AO1+4=YNRN2TF!7GV
MSS^'+Z/JMKKR4'IXNMAI/:!MG2],O>_$%SK/'4)PE0=B^T)!N?OYHSGA#B2(
M"M>@/KHU,GY\?%UI=O;GW%!9T+3[,HB3(*+ HWO.2E+Z'VL^6 A_[;?'<+VP
M_6L,<,S=Y*='GOK4-]0=IO1S].N E_)%^#_7U/Z)%S9D3AI#HQ!G;.=_L??>
M<5$M6]HP""(H2$8: :6AR4T&"0("3>@F2<XB.><D((C$)N<F@Y)S;)H<)(<&
M)4=!<D8!!034#_3<,^?>N3/OS)WY?I/._J-Z4UV[JIY5:ZVG5E53FV*0D)C,
M;ZC!#/W>*HEU@>IJ$J*Z)IC9%##V^RQF_6EA>KO*XT0#,)>5?1DR;3>N*9?-
M:5>T:5]<()27OJH$$MXGL%(T)=1SRF[X,K!3('L9-%QOX#OQ5C/WP$XTJ >K
M18N.^$@RK23(=/F6]'M=MZ"^$KLSV08 0-M/X5_L) O_@V4/,1X?X]*_W#T5
M.Q5_,W>:MTW;VQP2<>_#WH7J%T*3A4? ?[&.?]/%Q6'T X.]L&*A:8<N_4,;
MML6)W!=\0/*+05:VD_*S/@M!SC> ;Z.BCT3;?S]IL&X5.7AJ(=YA0FW&=!:7
M^(*4_+M51+2>K[Q"6[#+!2-WC^J+(A:M@ZO?[G.A_3 (_*YI4&*6P@D@DGK$
M>UA5N_=)B1=;"2,8VAJ)VQHQQ6*=7E(>\4)3K!R(^6E*R]KI<_7;'J7)-4 "
M*R9(B;,:,+DNNXF'__61K!PRXB63=^BM5EY28+<+IN#_&]UO$5U6H5I1^#'H
M'N!JSG-!\S;,]_4GM7MA>J<#7R)-"*W&Z]>K"XO,,U]*5ZXP-GDT0GG:1OFC
MV728V9$37VBT.NT'\[V.FU0FSZC*\MW;: ]J!1KFW[HO84$!5.H>HVR4D0T[
M$Q)=S5291DB-:Q=#G)/L+"S^0?+F-M#4L',Y4[%\ >(2PD\DMU]P^>OQ K:H
MLO%,34M !D,?5P&:I?T(#$VW@V4-6>ETTZ_RH+1!N&9HBOV^!_X8AY]_HD0M
M)F>(%-&G+08Z) ,<#F_V$Y)/9<71"-7YAAB-SRW#EV6!E%U/58A(F_8 -^&;
MSWBH7;MIH?-H7/ME:"P_=28!U"U4/K*((4V[#UG176G', :>AHIT33KYFRG8
ML":[\%ISZI>E@1?VYWG"H?)6,)7ZL"XL A,.3:Y%RDU&9JNN*F9[S&S[ZQV\
MS4*Q#FP.\U*:K[T2CTZ#JEB+N"=9+91XUN/RPH)52&*]XQR<WLT!,M]?2/0.
M/ )3<W<*Z^%MGK)2Q23ED^AA1%*\D_7. BP.<W1*Q!*GS \ZP:??]AG?=7!A
MT_-(P*G>P&+B,(\#IKJ15SP=>'30]'KR;,AN7-;FP![P/3)_ J9&<N:ZS-^-
M/:#[ &S'1DS^_:4^_247]>'7T1Z!V]DC##OCN]G%4Q]O\.W0)^=(E?/Q(<64
MN%]5+^2"M$#Z.M :XCLXX[KC>72%T@Q1&[[T-#R:._M$K8N/"7@'"]2, ]Z$
MA='6%!>4E##%6/-SDQ/!P*2BY_C#*W3FG2PLZ*Y6:8RPTMS0N$8E1K355BQS
MU()BIW$$:G^Q669=UOXI56WRPT@Y[N'PF#Z:0I&[_ 5I,#ISAI'"OH$Y5U^)
MB()O"EO=#I#BU KN5* #9<_+1]+4PG')SO2S,G$BK*OZ)L\C(J+.!\?OI^F>
M-/A->=JKQ5]'.#2L;K<PY-5(R&X+:7AO1N!Q;&LV*(]LQJI1MES.\)KSTDVM
MJ33#NRR<P;>F4;8TV&R(-]=DDYX2N Y\5[",J(>9W 0<I2F9A_+U*E WL.Q=
MR#8911B&BRH6&2CKM>@9&7CMD1)3Y*BKZE@IV2A\5VE"S$K;3#^"[]6M8A9]
MM>GCYW[Y!5:RG?W*0$LMY7U#0"$?E8#V,>TW_X*T](3^FH>J]9O6$5M;S87C
M^3DD,Z7[%OV'!!GT^Q'P@+#)>GRZX!1;Z0<!+84'5+D:>K=1D77&-!(Y"O4H
M3YQ:Q3-$#8*1>/>=]GMR92B]5FZ1,]UX-</"NE;])C#LNP3-W<Q8Q.@\%H[9
M&"L?HZ$5<ZJ70C^D1V%.8%TE6$:6V'NO:G_!Y*;R689:OYDA7V&EQYUE%EQH
M\9!RAS795YJ//OF^:G>;(:8W*O?L@K$,>";BBPTQC'.8#GCI,]352$$0!47&
M )VD[0,".$PS2/<,*OY*P8NUZAYE*&,71*\!XU]VRW__XB<MCOR!$3B0\P/#
MXL)4D,&[U]NK</%4H5C\^$6/E+]L\S_@E__!"[?\FFE2##;TY@C'1NM[))^M
M66[&7%=70BKJLXSZX+XAF^V+LM=6UJKZ.V7@#J9L/F_$6/-QYM 4)G[;T^L.
MT;6Y(!;8((U;G3[8NU%T@+3'0S0MY)ES-P+&RZ$.X?.7QAV+YT?%1T2\VT>4
M'<\UOD%05ZOHN&0GQ\H]U75^BAIU<@J.NE3UE?=&:?CAGK9K&%6(@[L W(O7
MAW[P?['3?UEL_..RXX<?&#<<EI,*O6D/:;E>!-0=R(^+1GMB_,N5_)NN]H:0
MB^KL-J^/I<$N_A?$6>_IQ[G,_SD!8IQ@8&"R0CK4_;(U_^XJ(X_HO[1MA0N8
M?HEL4CBF*0670KI@:O@LV@.ME2G VWHXD4S46IS$VOJFY0[:ZV\U.FHSD6$\
M 7Z1>CQ?NZ"U5/TTH:-CBJB+5ZP:XAH-A58)4JX<MV7552?O9*M$EEG!!LY/
M\#<0$:=&ZT]-!M+"@H5]\S2W;'H\UA;<E\G367,K'3B>88+#"T$Q1*K)ENI"
M9.>56Z[[2\0?>5J/J&;SJW543$IIF49.X^9;K5>Z2T+,:4QAFCNVTUB"*S@>
M(EHFZ04WPL)WQA72)[YLZ%MN[M*W1@]P[+XUK\X:#"*^I2(M'\^?)IMWXSJ8
MR55]JWB*[4!W19)W1%/><GY:;8+/5G**$"?2VO6QN?7Y#)6'<_3S%J!%EFUW
MD[8QMD91F,+<.(Q: UF>1GSX$<A%0SOXG5E#NTY24F-"D:C8:'I\J^YF06V!
M@WBRZ?!J5#=RT(D0H8-YB\W?_-HU<O;J#CSD:Q$\!FECDF%ZW428\<I['3ZX
MN>96F6QC/^\/C$=4D6GVA9 :]L2(QLC@G(%7H:$N,NP#]%J3:]4]+^@B$SNH
M88CEH>MLY6;@/*(QQL_]#"6;60##82$Y5]*&OAX%U7(2ZPB_A#@WRV5>F+J>
MD$"N;:]J#9DW9\A8!$^4#]0KWD<QKS9S%,3^]7G[@\ES=]I].A+-42 55AKU
M^K*_DP' =[!+*%$Y%^K.(B!*DS1?EA84?RN%?6UMLCG^T<H1L09#YK/EQR,U
MMZ5+6N ?7\D.8+V:C@PG$R ;5.$OM[B.>7,I3K4&FC%\O'SO>7%U_'A"VRVK
MC;-]/(6R=4UI.Q[HDTGJF>U,!#]Z]5,B-ON27 X0+TDGZ!V0KTB7R>;CQPCS
MTN .<UHL_*Q48_V3"H80[+R!U F&4'^&>XS?P1]XGA@<F7'W"B_GY9APG;'*
MI& 5V7%S4$5D-62.-GCB](+TWCHY4:ZWXIC?HN7&<0@;A?K(WQY_G@@ILHE\
M)!!O&RXW? QNNA5AA@XV=V[L+F8LE&$:(B7GSU<<LMEF>#5AHM$4=X0QOS>%
M&ELA L7%.S\>82\W?T#I-$:[HXVP)A>!C.V,6-]0U52)!>C)^QY2[!E% -YT
M/S1.44MV$K8/CFUG@=BWE3Q)A.\9&]2E8&P&G9<M,O=.V(LM!1&J2ZK4@B23
M=4JMD=I/WUGD^SH5S!@.1?&V1-10MQCOFK@4S>1!@U/HY( @2T#LC(@03JGY
ML$;R,2\3H[&#ZMT:V6RMZ<1X*[".9[COH /FK+F!U&[>>F)N" E,.?DX%%GZ
M/%!*!R28$:J-B0BQV76.9$&NZ]V.5TD!M8B"X>\/"73SJUZ(3^\Q1W4K<*6S
MJB@:*'5*W%6L@"(!6QZR=4X8VYAE+"H@V3;'T)(!OBG0U\[,E4AQ536W0$+=
M\<^#;/+E17H&!HEULF&35"O2YH/"R4%P<I_K(<S"D9O:N77X)PNS.WQ;-,?W
M?)PQ)_RK:,^S*"-1\]'#[/@4>V'I@HD(EN]J5.I.:2B:8_N9>L,B0[=LK'=_
MU[E=+?"=BF21?9/ZD"].5G>0N'/ON<6'_>=J7PC]DR]4%WNT2C7)C5CCG;BP
MK @8J9AZF#!(2%SEB&2]DU./"<[_HRN??]65F[W(!XA18EHEJRSO2IS<+X_'
MGN=/W&@[N^O:YZB^9W<NYQO%:^C_ \.5EKQWR<.\Z<Z,XK6=LB>9%9"/31&6
MC5ZA5'*\>^^-Q4\]CC 'VFG4CXE^8-C]P-!ZP?67NQ\87-0EF!/*1H3'BU]>
M'!'^]HDY4/E/I2_+_*\NWC3/;E*<V0'P]6ZM^&ZT"R1^<;%_UO;5;\VLW/T6
M8)]N@F>;GKRM_&/)#XSDT\'"\KC(':7W3<K?[UVT.R_T4'!?5DG4)KKXJZW!
MH_?__1#^]RO^2TQ8VT!B\G,/^Q\8(5?%2\5 VN#6SB*B#&GG<*?C6W?9[0#D
MY_<N>B=V@?,#IXMMWVDN15YY0T,T4'SNQ<0/#/3O-S=8V]W4IJ6^U7TSO.C\
M[;/=N?3_1E&/GT79Y. 3-A]7B%O?SWG*JF5N@T@MU8(B,Y:>O(_^;@R553$B
MCMF3*:%RC;'>CYW^MBI;%X$3N/:1LQ8E/AF#K.7F<+.K7R+]:'G"K'0TU^3X
MD4+[L%?:;#@L*$;NU:Q^MUWN"A I4D#>MEKY>5!3VU(?-0KN8^G3-(Q2(8;(
M4K$7*-0YS/,*:^2:ZT7XX0$=_S6_1OKHGV\C==][_OMJC%0/X2?W[RQ>(54?
M[RO@[@-!<LED_P$WBOG2A?"KF;3OET4=_(WKI_3BC;*%3]%_V#__M<&$N8^!
M<4T]-+ ($U+6!LHW_/FBAQ46\?&$DM/DBB,%4Z^Y0UVS"]ZL)>XHGOAO4%A;
MZ*_#$TR)>.KA6%8"]O.F?/3%*2]KR5UDH%6,Z2'.(/6<_//*O?QMYVUZ3DZB
M11<8"D#S53;0E9K!Y59@9+#=N@$T3TX7"N4YHKSMM;3NQM,6*GAMF';]MM",
M-]R,778PW:Y#R]%=V57O67#Q&*7=(^-UVSQG=*V<\1*+H+:_8P[^O"H9!&*Q
MZ"GGVEK1)Z9E$YH6/Q!-^.Y"OGA4!7661B_.C9\15$\7G/R G<4 4U%J< :X
M.FHH=^RW_MW>+$(\O5A,GC=8JC1.M3-413_Q!)G;&_7TTW9A/P=/?U7O+2JW
M5&-KNV)A0/4^ $Q"S[O6@G85J!@4(-2J'>=@4$>^U7_[82(7+5,KG>UKU['5
MI0_.=E*-]0HI6]WK[5^$/5YA=.=EV*^NBR&,O^$$R^P^NZFC,U9EZ4O+'<=/
MI6S%#$>6/W$*X?T6?B/HZXOTMEL4ELFR]U-#@")4Y>XB+A$M091,(<^8&#1$
M0N+<!E^1>0A$K@E*H\XY'G*[8'(-4K]:,IM.! JE$5F/FE%-W(_S:)USF,>*
M:]#I+#T=<TT8+GC3*#>?H ')>8#8,;5FRSAF<Z \KWXIULW>:KXV2W_GZ01K
M9!;8(,86C23+@::Z(X8VND1N04?C;E)($<J/<8%N8>)D4*303\<=A9,T#](2
M+&L87#?02"@V9G*\.6;,PI%*P+2&^D2]6FJ-PW,^@?N$P1B;MTQM)!P63VE'
M%0.QFT;%>LH,&V^HB^";N1&(*!F]O]_M<Y?/B=FUUGU'E9>-=E3,\)5M,..'
MVQ0FV*'%[BWY.LD2?'&2L#.V*OO]< <B9.5;1B'O#L"R-8PJ!,+GK&P2_;"@
M;!VDCW-[.R6;QRHI6>BM"6)$0$%LFTAK@KB(T:PFQI3ZM?$W3 .S,RI9V+ :
M\5TL3C=B LL4*L)')Y$ORRRM38A9IK:LBW7G;:M9A#FJRY(X.+DJ'=-8ZUG\
MK9,K"*W<Y)5L99(KCH/8$_3DC6CWUK&@9YF/OWE$"5;@[B6$/&&<+'$8'>7\
M0OGBSC;+NC)W8U.,_(PSA8&F93ZQJ3>9>7Q+^/#K\73!P2BRI8>'%JJ/D3\P
MM!7,=YCH:2>+=#O!<X3#+*=MB0JW>Z&E^!LD10SH%;/M,:,.-[D1\7C?#U3G
M,6&WQ?%YWMZ#$[3?,R^(A$#JXSDVT9$R\6<RE4_=C!>>VC2B;**?Q338Q!5,
M*K3GQ9O!H%1A4XH5E2$Z6V>JT@IR.OD,[W"-]3N]\F? N=#:4B[T#CW -DM]
M>%)EG#M]9"(^W*DP#P732@15WGCHG-VHH?-=TA(>LI! ,H[0/$;$E0:T^2!-
M+WY@*+ZV3'_[F-Q-JH"0U>R$0(6*T0H<^, ]9: <5V7BP-A.1!9(DEW%D$VR
M-=N507OBOJ33?=%J]$187B=A68,K-(=H:L+GT[O<1=_16:PG+G%%O@_-*(SX
M.E/"<OJ)=L',9HQ>'=#$;Y+M_9EV7/8A@R[J=F9""ODV+$;'6<%..2 KFK[P
M0:?&4[L U]MDJKC9S#/<4C"B>"C7]M!HU<?9U^'6I?YKP=59;2IO+0E,727[
M[<OJ\U#Q/-_4=S$+4@AB>B9/V^#316QVFYX< 6&F0SF2-/22 ZMLHDI J,D"
M8YDB(M[)\DQ1ZC6?^=V1:1^%[)C<U=WVP<>SJ>\D8>OQ; # 1V[;I6$#KAR\
M8KP,#8A:BPE76FD2U7XM;+*PSE9TKMWT?;!IF@,I0ZG[ZCP=ZEB,^U9<8K9L
M_8W7 "=<JE)W;KJ4?;DG<^3(&Z_O,8=0QD+,2V+A>5;S3YD:KO?)SR]:1H9]
MH'?>($GM"X?-=361NM$N$XF2-&0N8PJET(3#NQ2.8YT(19C'[ TZ3$;!'YAX
M@6QPJCCI7% #8#/4-2;G':80>\2>W0=KX,K\0Q3*BPD9[1&CE#T"5-FKHR24
M%(%',Z0@AE6$87,*[0H8UYY^BFC3XUQ.+A@]V95_ 7A2]3@"S&QQ^_MX-T^*
M4WD72F99KA^VX*M2:J2+R=A0<3,J%N=GBCOK2&*3^JEPB^A7BM<.+;?IR,F5
M^)D^8OJKPACIV*GKS:S"$*J?Z;4_'_UO_*C='!R&G+-\^7!RSUH8@K.C]Z50
M_"O\.H7S0H0Z #$(V"-'(",99&N,;,D\YXKT/JTG%AAET1YHVO5\EDM8?G '
M@'%<=1TN_\<&&?\G9^!:?H4T]C2S"O5):4\%R<KY*=8IJ+#KW_^!L7&_S":U
MY4OH!IFBP+FHC[%GNY; ?#NJ</^^?6W=1_@&W36G:EY1:Z&^&WEP=DD#ER?D
M-$""GRDF___<#,'$X<\7';^4Y7Z!+E^*#7'3>Z*;#U._Q436L=P<(4[)Z*90
M0#**">PS>3WKMM!?)(5?JF"IA#')SA]U\G]RQB-32463)^34JW2E#E=:DLA@
M^&&'S5N-[,SB0-[,P;9"^SP[0Z*Z>DS6RW>ZX4:GHJ!_8IT'B<%H_6#"S6*6
MZA'26!)(:@^*HI8&B.76E+2H,GK="R->_TJ_ GZF?DK7%/]*ZGC\0\_47>&_
M4NP/#%/\2RJC]W^EI'[_!8_2\2FQ\',_4=_H42Y5_S)D>[XMU*=:K*4G)(]P
M$CU\=I$=%L'T8?-J8WEE-<BM15+L-/-S_47 =,:E7:6_Y!:&=*(S+-L6<G(E
MA7_JTLW_%M[O?_6C;X3@59ID#A^I?V!(I+\6OV9R OU"],83[E13RCP*ROU^
MMG$O(=C%7^1-]8NO<G_U%L!_W][\-1QWG-$B3;;,I5 7^FC5B.NO#(N!LSO)
M:ZEZ@8'T5<VUM*%Z:SP "T]$[#Z54$9>L4W4J9:B(K$GG]K'M'Z5$U:^Z;$7
M"3<FE-0:EKNUKY4!NJ6R*2/!-B0!+^V^83LH>ZRQW0JXP7U.P8*O;8'E-$S@
MI#*2;X8I6$5B[ K;%B7;50R>'-"5(BG4I&*(NVM4K1@VQP?K6"QD#J.R4QG<
M!G3A\VP0F><$.BF1:"%1<Q'M^BKQ+,])\/HV-Y^9,J-8-E3]-WAI'Y-Z/K2.
M)"*%"]8F^13YL/%\Q>TI,!<.%1XD,HH-T_!_72CP0%[;<71Y8+Y0%+R"\V9<
MVS"@(2H[-\4K4V'6+P,\/K0$K!V$?5:;GU%Z\>IVTL.CQT-%ITDQ<U8+>85Q
MTH?)O?4U3VKH7S/&IYJ_\A<\=37 'MMT@O@:<[\\2M2=Y T=(@U(>+[G7*NI
MZ^-Z!EN7DXX87&.+>;4\K&SUD/?-Z5G\+>.<5ZQDR-EE($V8T[+KV]9]37/I
M'BR.I4G@LATT"8<-+C"7-KY?7RU)@43* QT'/7?! :Q+I9,YJ2.5:JP#F"1?
ML_MESAFV!!/L3J0K>RI48;YW@'8L2F6<<0DP73(K7LTZJ_F@'C76[W>8;@"D
M0-,-VX^]KN>YL;2(?;3Z7M9N6Z2><+BPX[YQN&>WEZTB-]J6>D).PB-ZAS\H
MQR8K(82;V9-1CTU8S9 U:RCO66EGHU)75Q-1H, ^8H\<<+\'O8Q@T7HFFK"Q
M7>SOG+2-0Q2LQ%T-@\^I(NTU9ZH8L4R35,8*O<NF1)-(/II(=-]/D%UOZ9U.
MNHM*>1A@I2>WKPD\BM+OLTAA3QF5?JSQQ0T*T*^?7=3O)AH)A39[\"%>>HC<
M[N*<Q>+6CA<8*),EQZ2Y"^")%YXCZ&["ST_(I]B/W,UN[<)8%,JP@ Z\7@R+
M+%P; L7QLS=NX91ERL\;/3=$\V$_N?6V1($Y2S"YR":2_DF]BV)Y"VD5,RK2
MM;#Z:Y)VZ8V'BNKO-QM3AFZ<+?%:\"7L)PX)EW$8I 5]TQ3G3EZUV]QJ?LVE
M$G47ZE8-91C"<PQE? 'R,Q=6:ND2&C:D8V,Q%68BIR]JU-,+M4S?1^V)!E6:
M*O"EC!^E"M^TT):/Y4@I32P/D<]= O;6-(*#^1<-)QO8[8& B9I7"7'J00"
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M2#)7'95]R<[FK0<46@)S_'I-2N<$=<S,!I[=Z?0,)TWOP!P^RX0=;V0 0$9
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MOTQA':*\][**.&H@W5N+G&(L3%E_^CCC6WG4@FB.=27IC;4&GVP*IYK-POX
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M;.]XW?V@I,%#3V[?^Y'%IF<@F<X/C&IIKH.#[7F07K(/E?3"HA6^@>*'YO*
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M&<>_T1M\Z5)X/:0/\WJ?/2*2XB#.%=G$D&<W0E]U@#=6XZF--J9&R2RK)5N
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MPP'+YJ.B\'#;I5=_N+&OM5IL1_9'4=7/)W946^FSG13/'OVC(U?.XCE2.-3
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M<8+UCX6 2^M8UAN-:B7(80LW*YJ3S'UOEI''W'H?LK?$R.=Y3?5PZU-,]!N
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M>.\<CYV?CGS,=J)$F+H1X0N'TLK0U.KVQ$/1C<21_O*&+]4_\BOC\Q?0QCP
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M.S[WQ3XGCDB'&MA(Z#4F*UD6>"/SXBRWDG,4^ADB'[AV!]^2"SYGR:9!HT;
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M!E;"RR_:I@_S)7'-MA3O4AM6'G1_&P_&=($^6OATF6AC8=G_=?U"EI*Z)?:
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M4TD3BUT]93 1(N)Y::+&GG\)GY%M2#2]5*#K3-I>PRWINR((0G91.^&_E"L
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MUJG>4WJE)*[FJJK-=$S918>,_@;@(KG]E[]?4H. 8"L@CE_1)I9BTJ5PW#=
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M3CBMS@4J=1ALM"6(:JG&JP2? %EE]L__(DPHX,=N> >(X$!K\$H$YX4=XS<
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M79[\61(7$Y)OW_U)#!I6G(AAS<:YH%A7 _32D /W=^#*KJW&P=E,V'B/,P"
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M](TA^AV,NDU.RXAWM_"?][$_$CNR@9'![]%G-4%F7MD-5_%T[!]$FX@\99U
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MR]6)*NQ?MY'%X7]D7_Q*N!*.OY7DT<VUGQZOVU7C9@4B"7P6+JZL;:G86:/
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MH\;XRI_9HO72-?3G<TC'%F+>LE;]"-&^VS_6L2HKIK"Z^3A%B=ZJCTXO?TJ
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M>J0_EH4#H3]6B-'Q?D,WR0UCOC*C_@Y@*;]4)OY;7=H_A^LY^)/KY<,[RP"
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MQ'CX!!RV"X$T8=(9YF3'E@0&6P7Z)([!.(WO/;JV)"P @.0G.KGRCZ$=VB/
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M0BA>VEQ%.FJ_](CRBW73P5PO?3SO7&.HBPQ6<S[D\Y5W*JPT?'GD#O&6-6
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M]K]#/?Y7D%[I66KR2RPMMW6;T0[EW(]?8HWN/- &,3(?XDT?NT@)!91E:^=
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M_?VJ;%=0S-J6RAQ[GUA?8Y==?"2LPDGR.ECCU/AR43;12&E<S7$1 H#$GI_
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MGO&(6<>5;P%D/RH>.FJLQ&-JJPIGQ%+GSK/TE5+@<X1J7J$8U4> ZN4_T5H
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M75F73V@ 6-&*I\X]Q9F?:*BG4[G6C1=T'S^DE 8KGFS7O.K")M,NMGK:&=C
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MEBDPL\FE"G?>G:AK/ 2\T'*JM7J $Z(M9#(G;[T#(J*AID8M.+;ZOK<[UNJ
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M14QT!,U!C99YC7)]-<^BGJMZ)*</T@E1O:AKMAV3;/L671R/].&MB']$0MQ
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M.?%WDDVN&;,$K-<Z$$:&:H_3YY/8ZI^)(Y8&99)I8XS[#MQ]_D!;>O?/T98
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M<%VL)^%K@ ]L^5$3"(4>>R\!5:_MJ8-]CT^YN--Y%Q;9'U2SF=VLVN_3CJ-
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M)Z1@@4S9:@7@H12+RGX^[NK\2L[<]:C41VK:WXB");\1!6W+@R++,N=4L'R
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M.XH5S<)#?CH@[^SV$J_".)-'B,J#+>F#?75OXZSEY7@WF'QL)SPABJ[F4Z9
M$6CQPJ4V\WA'IWR1I+ETH:"QS>4I\(9)B)1.(M>:K%SQ6PD!5B+ <%:$+3G5
MB9)HT ^F+F@E#?\U1*_)R7T8?@W1)1;6A,TB0!$Q,;N9;.NMU#@_E^4BQP[O
M!R+8Z]1Q1\SW?>TN13:-Z9Q1)V9N,;L7%1E135;..X7CU@^D4C5,Q:UH9^5!
M*Z?"'UM.!<F<VRSX+=\[+_0:"/GZ#G(Q(;1C^,UTO-=GSKQ]*+M_HC$5'CB&
M)%G9O=R[]))3D5 >W-C S% ]6:&OEA>VG>9Y]*JTKL[HU01PD]^4871#N#X
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M#]'-L78:.V@8#.%V(R:@@%FFKC_IBB]3Z)@0"^9X1!_6D\Z[Z6$X06BKJ4M
M#>*"K8XE*2H=;@IZ3G/[%8TKLJH=!S8VETUT^Q^U?[OOX)SY:RYT_;T88[*"
M*^UQPV$?9)..:]G/9G ./+YFE*%M?!^JLD]RH!B6L)/S? \X*;?Z=<P"#!V5
MFP2\]&=M&G>8: L8BWFT2+6X*6TGO1.2UIN32+)/HJ_2!NU6W]:IN5B+%#'Y
M"#YWU%-WXDH3D;;1;V*W>LO"E]ECR5]J9^;:@,7\WN^ <>XX194>^4R=^6'I
M? %[H<H"6A4W;*\&MU3\H$8(750>/EB:9*,.&%FVMOZ:3W4O0F(-4+CM>BV[
MPE%4D_^,PU#Y+8NQZLTM]G".0_TSZ:% YA+&)/'%A>>"_?;XO]QL=6+ _O/U
MI[R5$WO?L&"\Q4/J;,)6(9ERO8(?W)!>"AN<B*G]8;>(3X\:2\JV=.1I HK'
MEGX9EVZJZODTZ07<(7RAZ'[C4P[N%."LL0JH>-$-IA'0V%R\R/S<4M&@#I4V
M&G6#<S _% TF,>:5^Y"X<6/G,[O1BEF4VHZ55%D/^'9%5D6LKK*&T,'3NBEV
MTOSV-:45_'2B;.3KF(QR.*#6C9\]_&,3>['M,74-#[5W59EJ75=HVBO^$^=%
M]I99ASGVY7D[V,8A<YA[XFN_WO%-#H79Z5'11CH3R&)IE16> J! >.5-%&97
M9)F*M#885]0?[+P(6VN?Q#-K"'(2W- ,>2O:_]$; T_QK8KK*-ZWA>\V(D-,
M^V\H#XTV$JU.,,6KBXU$Q'>NRGB>GT1V;74&KI2,'G"!K IEK 196(UTA<$B
MK\ DGK&@Q"V&R1XA>]TG: YTQ%8QU9^ZR?;B:V<PJU3XN<_I5Y7#PUZ44QU_
M1O_4!Q.%PZLE$N9&I0^,E96K%/>G'ZWDE+/-GO3(9\7D)K>GXABKM958LZ[G
M<N$WY#RNMQ)CF=55$ ]U)TD#R#62[JE <$>UO4\_4^$]H*Q_]1K8K6E6;GDT
MR.TR3RL X-.H@K#3QT8%^E*"%KYTS']^$59\,"5"<U GN*K^/IW$5#I#T=KA
M_"4^#R27YY<W"4CZ4%(M^WNN,]*!8FDS=QV4H$]1A2;NLY_P94JVFQ5W1,(=
MM"1@TI:E+>Y!L]1ZRIN8FH<AAJ>I-W:37',<@,F![%EC@]E9V9>E1S'*!\OF
MP#Y.D;[E0X:4PJ@K%RZ(V,2TUT*+[X)#EO@TG>T]\A#2">'PS%[) EC;7(Q(
M27[1EN'U&2TTD:Y]:'^+@#9.G36&Q9+$KC7F8!7@V-4=1RU"\>:/+YWRXE9+
M.YB!P=@Y.^C_R>^:__K::KP)^Q[>*G[*Q%=BM8EF.K.F!'-SC[P.ZK^Q.T/9
M IWG" +R8M>PWWKB-?C$ ]/%8&&R&_=MM_#'!J1<)XN:X\!LR95/60GPUUG9
MYL!L"9 !D/P"Y9J;X+\L\8^SF/_N8"V9+_^_72V5W#UH!$'_EF^,OR(N</?]
M]>[>Q^ [^C<19ODG 2.^O3\(MP8%-*^E]S!8<%FE^Y@P<D63GDXSF:>H;F<B
MPI\#PHD:XQ,0PX*?2^;[O:TIJ<TM"H5,_=6[^&2ATQN,8]9E!E(GTOV3, [L
MV<8$I(DB%.V%>7F&6 '*;GJ,&PP"D8&$H_'DH].)&7/6%!B(K_I XF2SD_S
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M?K>=V'W(;P@TSJ64VNMROV%J%].F"O,.YH^K8_72%UNG<1,)5L+I2M"H69X
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M]%>VWIZMLSVFC,]!S0@;6SZ@)BZY$APZ-/O+B*QE=OTYI]1_A37(Q R=X=R
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MBO]&/?'T94<YO&-6%2C,LJMGU2\_W30L_H"^/B;!2ND@Z3K(#_&^U_QN2?3
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MFP9PU43(O8;&RF]7S7P3>1FI*R#+U/T+IR&!ME=55MN7I'R](9XM.,#36HO
M 88/X:<=7QK,H?*T:.\Q%"GI:1$OA6@8L:][K0UE5A<FSK)/C(F^"BGEUR5>
M.0-_H1=76;T3V9@)D!:L,(R7V9>1K_J1,A8FDD]N%1P\8"4+41RD>Y,BQ5Z0
M6W"E.?V0)/P!)_O^XU,1\U('^Y[9^!!SN8DX0556AYL!+*'GE'_:(_/^-1T9
M1(%U28BRO)5*JMPG)2A7'Q:@CWU0*B57601ENFF7SAK]"3] *@@U[$;)2[_@
M=S2<C?S$-&=KS?&%[YX6CVG:/9MB/L0DB[:_VON:AT5S:H9^\GOQ]LX-([[H
M$4IV:8M.89^V5&."W'F01J0&YXL3J'S5V8/GZ#=1DS+I\J*=_<B%W*_O99I"
M.[GQ%"$3ZE6<#=/N-U,/C/UAF(-[EBF*;*>"-LB @XN@QB)?U B/[H[]K=J[
MC] G<8$KC#53N36JJ^+HX]C@X0_>J>U^!% J: ?2<[O8KJD?WQBC:V5TI>SX
M7OLI@]L$/6BRD#[,@RQ+&?4P>MM (\-X3MDP;;[CLB:XL"H;'1$<:'D/Q.3-
MUL_BAP^![CVAXO?F\9+A74T([2$8$/BV=0NI)L[M'$J+F$M>2![7$P^#_.2U
M&("7,6LI2PE;CL^DGI&J\FXKQ^(EZY_1P.-I0TJ9WX )J4*SH="H, ?UW9K)
M+)77BC5,T)3Q6<LCDE=&779#NGU=TW51>1-*IU>&LCPJS<$@IP79CR^)E 9N
M)#/UKQ\Z& <==2('04574?'C4@-/,#&CC;H[^DY+TK6F$0VH>SKC+WMJO'T4
M"R;7)6?JPC&CYD[<G0?;KH7<UNK(4$"A<H\I$EMB]B@):IRSJ@H>,&=2J1,O
M4 !S%WCK/PA[+B!<-/0!I,J>62_A#K6*G'!@7%5\!&(8Y[D:D-H>K'3EJTGN
M?=ZXQK=[NC"[5F/#P?\N<6'+!SWC0XUZTE OOS'PH?+;@KZO>T1):BO;R_!T
M/6^90IJ;6PX]_J"A(O\"^(S%537X7$]%M1<['LEJ17E\@6/%-; YR(MAL<_E
M_4&4IVK+'=EDD$RJF66>+LB0=D2S8* ?F=IR9GU95^SP2"=NHFCS\$YV]9A3
M>3(-!2;:93 JCJ5&^53!/H72JE7#CF.CH1_!Z'.J3SB0E>L9W2B$-##*FGMA
MM;MB*[M+V^F+KVDWK5VGQ;;#S/W-(-%TM,61DGLR;?/MX/5F?G=WYFIF&B:<
M<BG:^;2&\"IK7LT7'[*FJ/H.F*H281_D#5;C4J0BS8.F"6:OV<?4IRNOFEE#
MD_6C;-)*1"Z=>8.MBQCIPG\;?R80( L+&[@U.%#HHZ5.0YD]K8U\K3_\+EHE
M_ 1JR.)"?T:=\=3@S6B8\ "PVOW^;3_#2<4!"7C!K&-BL<OW'[]US?^W:'F)
ME6J-C0D40R42>H:\GD;F#8;6V3DEY,-W+@+/S;@<)AY7RZEE-?D0)/&'L6M]
M8XJ$MF,=!1PB1IOK!IV[1S.<W(?$[MIR=3J1A>_"XF>RT\LG\F#W#ZR=J&VI
MLF#&FI$,49B8R=JZCT=8 CP1BU9SD\V3[\$MY<09!?IC+ ?$L#HK6UN"WI.@
M)@L/\;1RK$6%.$OW95U4C\IS0Y@SD4/B.UL+T6^F\-3#;:P<B_!++>K:<66E
MKBU!D\]0!?%?.&R?%T:5>#](QWC*9!#95D,HJBFS6WP[X5"( ,NT@%%C6.!V
MB9+%.>2MEF#N(R&[.X(-X8@DC2?-(8U!W^2(BV:<F9H.[ 3+O6^D*%U<)Y/:
M:+.>+;6_+KD"3T0@LQE7K+*9D&GDCLI2V'#EJ#D6*--IPKF'O_7&)9I9)5Y=
M[_*%NSP);UQ>0176("U3W'Q=KH_YD;MU*00"9]F+MDU?8]4Y35:;NHW6OAKJ
MDM+T#"6-W3S[ECY<"5G;CW ZT%+,0D[.^D0FJ;U+!-PE7QMNF#M#1"QH$'Y]
M_$;(/OBEDO8+\RF)!30@H;)B@GE<@ 81[WO19I>C%459^Z:C1<N6V/)RP.N.
M_8[\"507R*XW$RA%QYZP.S(]T_JDS)HZ0X0M[93'\3-M@@)DKLSI^&%7%E3(
M4Z9CE4MD8*\2^*GVB'92FFBM0D.X_Z<MQ_J ^2,7)6U@PD"2NU(4/\WC\7=T
M4)18UQK#T[5N#P"%IN';@K-,2K0@>$RO?KDE3#C-)I^_$=7E6_$L928$,0CD
MR= @(55?$?%7:-Z;5[#FBC-;T);0WYR8P4X1"9911WIM7%E6ETSLT%XE*!L5
MU"Q'4$S11!-SJ%\K&Z##E^RN\D!L^Z9/"&M1KY8M=4!QX2BGOH+5S4,\F4D_
MC+K"OF<]J_FR6:&-GJ!O1*Z'&DDXM3.EQ_W[E1MI&B#V\::G 9#UUAZQLE)\
M'JOCS\"X3C:4)<BM,CTGWCD9)$H*&UUG,(BN *::Y_A2*&FD)][%@4H/*!+9
MO/9C:HVV>Q!/!O\A-NM34J!3!%(>$42E-AG#<<N<@7/*?1%_#$!L6J_3X/0G
M(3K.<MX\Y9(TY 5R^[%BU*?M&7G_7?$UP\MW%XB.(=W.1EF2%\-3X#0YH7%H
MRHP&FK4@AZ7=:9/YX2'L;I7>@ZII UZC(AA8<8(OTDA8>"&M8-#71[1-CZ/<
M;)2!]-/X@G[9(0NE+<\TZ=H&5 E8\&121M9==)_&GYZ/BAK^F>-H0:KCVU)G
M+0W!RE JDQ(*._SU*%9OF%LXA'_ZCG2IFG'7:*EPE"&<0[(QM]!= ) \#/H8
MXSQB8GTP))+SO8K7*:-,FVQ3!C;RF9=V97(092/(Y )WM[\H2G0^1;:'2*GI
M^\GW^"LY]X8Y?$WV>I;]#3^9 BA<OD<_^+!KA65;L.^]QVSMR_X I4Q8+E 3
MW?-XV-8/O5/M N*-=NJ7M26WB([:'+\L.+D"Q@)I)ZT#G[<F$)@\L6$5]WU5
MSCX70KXF@%R87<^OON1.1MC(.C/-UZSQ?VWFG9HBDOE4![K+&QZJO:>"OO$$
M,[0./V,:9\8>4[[7\4R>H261%5W5J/F%4YEH[R7I\O+YVQS_B0]%5\XN6SB0
M%(OC>-YV9?;"L5OC3*5^"'I@^T(&D*._<=Z'OJ=)IS%Q>)JNWPQ.^IR*D15\
MK"%*PR'M5# GF68@(N,C'K*Z'?()4.T91JG[M./Y8XX0:_%7\S+6[T* E$='
M1OXZ/WN1(??32PLQH3K28EK<I%8WB%>QGP5)HP.'WPE.6V=B4<BWF\1Z0*UJ
M/P2P@]%'7/1;VO(HQF'Q=MS%9+>AP,LR>0M/ICE6SR0F.%>N'$('XXGT68!X
MW=4P[RIF42S)::\O."F+$'=*=*V8LDO?\T\S'1 @K6LW>IBE_M22A= B_R0]
M%UFLQ0QMJ)T87[24,'U"7&1]UEP!OTUBMCD3HNK-X&8_%A!KSU4I[[B =5X"
M^W$ISOA(\)7<J(K)='%<X64$MGA]_DQL,T_2,/VF :&1O+?)B-TK&-APSFQY
M)_[B3Q#FP*I#]PL'/UG^Y^AYGYO"C[BS4XV/W].T7^_^PHD)OQ/_\C_? /_?
MT Y^:%']PL&;U/OMPO["X756GS(I>OJ3J.3]+QSX3[.Y=_\A(2X4_9&L\3!I
MA\+\;U=49*;_O +O!  '-U,=Y^Z_/$O<-QY_^=CK\!^K +;^FRJ N/M_VWD@
M4_$15&3:*?R3C'J-_?DDLNP\]?VQLI7?_)&A]?6?7=EQX*0;J.+'R*A?./SM
M858X.$ZT=Z><S %"7HQA;I7AID"VEK#?_O\-[8,IJ^O@XM=1\A>1N.6>ZSKR
M"=OC2I&D$<\^R^NH%^6;L]B$&,)F/5;W8_3U^^6FA!;#!50='%$,SG UL'N/
M$7,UJYK,WA%QR9B^:'C#:)#VGG"$)LNF.KW3'(;<CT5.1DX7/ >3H]R.U4">
MWD-^BW)!I>3=,L5S!A5I=1EVK.%Z;(A4QN>ZJ["4@$@+E9G-<Q<%YZ SDS:V
M+N;!H)>Q.2*72F)=^(%,TEI5ZDI:"37%I /(55);]\:L07."W7#2LE<<VZXO
MM)&D1&0L\_RY1TZ98\SNO0LY"19.@F&=!/FWF.'2Y(>"3#QY,=93/$2AW'CC
M9XF4P22NO$2Q@S\=X-*/>1DJE5N/4;J8P8!).$"X7(-FX<0'3C B#>$SLKBA
MTQ*(K,V+R9A('W8LA3Z9LM3!4NZ%\HYJ,E$TQF0\-$_P,>\F)2LPOM1V8&J]
M#N/=?#HYL9NSYN6CUI;;!W4VLE<B4%T3)VO]H(,SIUR[":/B>__(T3>J%/;)
MLS$[!E"# !EP?/3YZ"?[EG?8Q '"%ZGEX,@-O\>2TI<EF,< S.TPV&,Z:"D
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M04G$I3@_T"BVN #MJ*TLO&@@6!<Q:C=)X/'\?!;&>]T3.PBI97=G@!>M$MA
M0=]*QFV;^R""=]=^\EI876C.+=^A@K85>VKF1\[OKN,>#OQVLO20(QDYDBN'
M1=SA B4"LA50$,URJWB(N+ABGVDBO>!Z8S"*SB_?+$$FB\YPFEJ+5[BAR$W7
ME@@Z6%A:PA$QGT3:$],W:3U@W6#1(/93YPA_X0%U;[ &?TRZN!4BU:O_ _3#
M3B+E\/IM 2U?G78CCL@L77X*-C<R_3X?Y$ZDKR*((;BU<I\OWY>W?< # /<G
M6S]_H_01@'.BB']GQ\%5H;+L6^E2[GCM>W94R7%%1BH_&LKKNM.WGT5/%RMI
M*Z'5%.Q+FTG2=@O]Q=Q(TSA5<$7:7G\HYJS890VWFEHMN9RT7;\XG_<RSN$6
MZ'@<5F;05'9!!%-X-5.-O";J2:O5:OJ9R-88PNK9,C]@;[1%.8*S>9G3 YTX
ML3K2;/(N"P.S@BJ-Y>37-9+CS<ZWE2TJW+Z"J[2=]2!LZ29E$'9W;82D9(;]
M/O;*,95@YX)E,,82'+9J9V'0AW0,UOA0 :3).LL^=5FCLF';6"8XC+JE]_2]
M_7X_']O8CHRC=NP#P_F6+K"6"UEL8=>\3%],18\<"S0MD28E\@BGN+\@P5W8
MDC32T:^(\:$*-NOLMP/X]L68I_[(IH6HB^R'^2XG(QB.U+Q@0FI4QY-_;O;^
MG$7\UST_*K_C[;^4@M+X:PD6=LSGO]:"J@Z+.U6'$YCCJVK-F++%:QJC+1#A
M\ZJG"".U2\+"2'(@'H,5E@45!"7C/5H7KJKPT'1Y#8WUV8YK[Q:(GS&G/?#L
M6%T88UYL97:!O+"*J5%!(A>2N&W-7TD!L#&GXD=[0=2%+U0W&Y+8@B-CI>,,
M7&7);)<YHU8GVRX\\<A.90%2YH[[64+AY(9A.0(8/9=K[!+W4+85 CUT5X"_
MI""UD4JYKM* CIN_$+!H8R3W;(?3 "_??0>LHL>;P9&/1MC8IXK()5/\V!4]
MQ!G_61+[@+>K96Q@2^A^;7A4A.*"<X?*B7;*R<=/5H_J;36N*=JWHXFJ57X0
MOU9^5A+L/(]8>L8#!1\[,32FC)F\WJ)<TEOJG]K%[G\)\^FI+'Y+%"N$8NLZ
M58G2+R!S469,&$NWV$6,M6(IRF^CDF.%(^#4N8H6%9X[I5%EFRQK=S9/&(DI
M/D03?=_.DQ:F>H.,84%YGXAR+\V_SS/=YONL;9*-TCRO?>MYDHNI)<('E"F2
MZC)5%UC]1!=%5;E'"([.=;YJ5K]]W^J8G#5-^#V9]"IY_Y3F\;F['RVH RSE
MJ5%H\51XQJ)E64<@Q7K3BX%7*J-B[.1XF.4N2T!'I.(8Y"DR_,4.89ZF;WZ;
MHN8M07%P6CFA"#&M.'<Z<I8>$]7]8:/*DFO#S%HX2)C'.RP!8;RC99<941<[
M\>S^OAG/$&UGWR.%;1\I+;C*5E)599,B=IR?;=(42O(>'1!Y+))/LCGS^EFD
M5IP6";K GGZDI[;^D]1%OS [C4!R^G023Z_LW%7S%"'N9.Z;.!=,-W7Q_=,'
M<:KEY_'-.FV>>5U&4NRW =Q!3/^7UFNQ$ZCH?0&KK +6XR!\3]?E^[2$S6/B
M?7TR][+?1&+N*^.(#3-9%<W+M/TSXML:(B7+Y\JES\]>]T@'R[?XU)?&_L()
M'<C_A6-[;24$]/^G5/^=[=[KIM2/YX)Y'V]Z+T(<PDI/^5Y_=Y9]?15_C#?U
M'U,1J*B<9XW&Y.B7_?V*Y,/?W[$PKMT[%WU-WBH]\R/A?M!_:7K_2K$;;O!/
MFM'OJ;TTT)\%A:9=?RK=,$\O(R:>KF3^PL&/@2-SMA5UKI7U+HH((4]P;MLK
M[WMSKPN0E$KJR"M5Y9$F!YDN%VO$L,K$S<F@M.#U8;)#_$FE6K>02G;;45S(
M$GPG"Z\M[MZ"584@9PFZOMRM!<'D@02$HA;.6P.0<]$L39Q+']]^0EO,U]5'
M(^CP2'@#BGHJ@ZNBDY/9I2LQ+F,"KMP]5O-UQ<F9QV06E5!GQ?_\*;C?JE<L
M-34R](Z8H6:#,ZEO07ET@X0F+H)BBJ<=F?:Z6D5U/GGFQR^<GV-!WSNI[8?L
M1B>QZ"+8RU2#TKE-Y"QJ::]11DY$IUT$IF0-X:@1:AIN_?CB4T,)C2>5MA_^
M0S=":8B7#]>[!-D?E5*X&UGL!7?R!68,^#)E!(>8565\'.N:QY<$LXMZAP@1
M8]4 CZ8P?:<BTD%)$ _],"53-9'2:"P%8^6QZ-N382A!_<;AB QHDK%3,HU4
M*0:;,".LI[7&6647GLH4%:W5+T4NUQ@] ,V*CAAIXY77N@1L1U/R@9L3%9<L
M,N)AMO=7"CZ]!9!&["95G?.JEA:Q*^^O*JM ^<+?6BV$5[=8R2X]9EN^M(@N
MLG/PJ?)LJ4AEDZ/58+P/I:*B.8QST]"G"*=>S(J12[%XE/MMYJ57YW9_27*=
M8_ZI,E[WYH_'5:!R4+I"GHT;Y/Y6M-_#&-Y^H7R]A G_!\\X$7YAB'XQ;9G-
MNV?#FQ;:\YR0\3'-9.>,0?.87F4K46Y^Y"P:4Q3II4&8QEX;$0,?AUX@;:39
M++AE7YBWXE,(5A ]Y+]F9*S'T#9IRGE#[0KNB1^UIFT?DWRO9(A[QRMPV=AO
MI:RX]AAN2VPW#I<S/G2FDT3%;&@V-*L+2VDCO][9(?\!XC2@C1E94*P&[-(D
MD; (60H6F6]Z2BI.<4<P:]G,J<OY>R_'9]K'0:I93?RK;CQITVP<E")V@W,C
M8@4_S18Z9P1IE I?YS_P>P<XQ6,%*2"'R(.#8GUK82JSS8\3L#%?TU^Y#G9U
MXA>Y"T]>$DW)51>23'^?F[('&%7DR5EC.]:[9LJK+8E,YYZ3>O'IW"+-$J14
MM-8;&Y_9'WW7(]%M]&'C-<^,LVCY!E@W=_5A.V;V.6U)B !7+'N-MFV/U>WU
M[=>M=Z-][5V22A-VK:I5Q8(54ZP<Y:KVZGV=:!2;RZM>LYPX->G@JSP2JQMV
M2%?B'?#5:QW9E+'%C,:8$U:HVJ9Y]%\U(';?](<,1L JVDQ?#->)^;MNBL86
M=+Q2R^=;"GI3-D)KA,T;S],6G2.FLX$1-E>T"3SG ?!>A YEF@B_Z!1@35&:
M-':^5_W ;VL,PK_[_)TIO28^;6JGKU? K=D\"6G*$?1Z%C(8AF:^Q -WV0E[
MTWT-BS&AKF#7WNAM9B0BV)CG)G=J4C(G;)ZB2\L4-,D,@_FI=LM(P?>8IXNN
MA-J<7*C57BI)]MMT551V"!0&0H 4W>,P%_]XI+X0W9W=Y@=6O-$0 R2SC0^G
M*_3!*5#A0 O3YO>?F+!4,>:GTR/.9T7LF+''%H;S>W]>+0QZU>:0=XND5RL:
MG@^<QEH2R6\GF1MUE+P#I48SOH5-<&B<B(S#.$OZ52E1GZ19QRLXP1=6;Y,K
MS= >QW92X; RIZ%Y?LK(1=9-JDI^2V+R%6!D0Z9N>A[>+0%#?%"-"VG<V>)7
M/M/.\&_]R0)$PKE05HXX;D$D\EMBRLV"E&#WK,K Q49<:G3Q2ZW9[":#]P;H
MJ;EMR.)1S!&428,MZJ<&7QH-8.'%T$1 <YLC VA]'DML!CR?[R3&[&H.R]\M
M&9\VJEB&$Z69YUN'K9Q@ZNP47YT] 7)ZIRPQD\W'HV+P*C9#0/*IZ?L9Y5'U
MN\_O+4UO^RT;5,S).QZZ4"R,;#S?#\^W\LQS^-!U1IW.[5*L9I!GO[JZ($BA
MR+^HR)D&O\_.,<:DAEUZ%<1]+5:@&)J_,5DMYS6JSZ^R@W$NM*C;Y=NT/SKQ
M3>S43[^S3=Q)+H4(@)=.&PY\6$DCQ*#RC(Q>!5M".&F3F[=P2[VLWBSD;= R
M(8+2&P6C454EWCG2+'(K#=X'2B,2+L4\9/+J^A(ZP'TB]5K#R,^/(Z2BFY@F
M(&J?+.V^(G>+"D/9H)-D<$*C>-T:9L[$W<=.7/Q<A"+F3V:45/AU__A)N/LP
M+/V0(FR_]J A3+P[TZ^3B]3B%C,I:VL,>]2IV[*_P%;IV>I1:BN(+!5_LI(!
MSA,QW2'S)&5N;QF0/#A]*T^1^1:XM5PL$CJQ_U-2.&VY:>'6,T@KUE>F:%7)
M>=_(<@0T*2TM_'#[!&:-MQK?)^M!O494"P@]KY-(F_ 4E_X\02/2#XC=1F89
MY.0$?J&1V/BP$BBYZ:!(&''>-0@9VW]!V/?C#5O#&0V<! QAKB&87C+*>P/[
M3#Y-KV#A4/K!88&\Z2$FR]=DLF7!C(=SCWE!AE8//']$J!1R\:Z]Q2<J)KB3
M(TWKF9DV-/#[MB3P.LS_!V%5GI3W@4;02:-16]RZA3&3:/;*L0#XC>^4-.0Q
M<;V2O[T72][%4[?'QH,!H2Y&^1N!(I3X-4966EP%YPL&P ^)WR;*1<;$)M!P
M@H6"TO77[#BGX]R;M+I+8I5R-K5Z'EW,'N Q 1^C%^+X4-YQ*'62^8Q\(RX?
M5PR1C)&YQ3HI._"5&0LSLTK?[KW+9N<N$'\B  VJ@_7PI&\JX5LUI(P Y"<O
M2[.!NY,,A?+^%*--BPUXFLQ-<;WU,:$$7?E,HJ2!B9R.(&!*W*FL?XQOM-#%
MVW,:HGLTD3I4EH:I3Z4>G<JU,K<VM!3=9MI*]RYIZ; PH(T%M;SER"D!>2FG
M,P0P1WQN[P:F#.PY)D:ET8">:>QMX&XSNC.N(W0.X!1LB%O.G(OL,U8@C86#
MPJIZ%!M-F6W=!O4!Y>$.895X*A6<]/5,E[)>6;ANR>>"LOGH 3,P(QLR'\II
M^R1USW_>>T45,?S%]FC:YJ@8LV*AKLJ_45&0Q+E/OKW:7.2VBHHIYYC9KT&V
M ^A&OZ5C7->?4!$G^COWL# W4HY9F-M U/7'GG"@B(L#DE!I:8Y>-K$%WN+A
M&U1UX_:-I3]P]]RY.ZB82.T3*9<8C^MX44V'G77_CFFJB307/Q,@8^+AS1&6
M+8:]F7SM+&;975$AU<-#>KG$?OFZB/>.3K\E&I@4P1&L1R*4TE@>'BG)7>A>
M,+!NQF$H\\J_X]K*ORO,MBNKXX[#1_^&>Y4I8X!-*Q^ ZB^<)_AM_\Y 2LI;
MX%8T7G0:=E*Y_Q#/98/:6K'R77ZH#Y\ VAOHB1<)LQDKOUK+'N^D_X5SV=/K
M H\G92=D+?QLK.>A6I7T@L9QU9/(\)DH90>U ;V64180HT:&!5#]PK%K#1(V
MW;7XRGIL?G-8=<;GD711]?-\9KNXQB/I]<CK'\]NSXKT?_SZ_"HC2%COG^)Y
M_2_>_V?P+&V?Q"V6^_S"V:%C,.F)<\/?Q^[9+N90&;_S,IT5[J__^NPJ(SC5
M6#,FAWPA7]36YWD'U[VG-S%.ZX%.SS\(WIWL&9'?_'BU9EGZH7]:Y:/P+YR%
M!1*K'99?.+^#BGT7G W3ZNC,G.'P'SV=,]TC:IN=?U"S?Z/^POE?W/]_XL9F
MOO\K;L^(WC_@/I1 CZ@,Q33;_L+Q<+O'/K=M9WOW%(W]/K(M=[33Y<10_%O@
MA%]?5\]>6UJ6D.ZC3=3,\YD83%B=W :6=^,(TD6*&H6]9,;AHDT&,Q]G*6\G
M!_;(P?=-;_CF7E_V= 7$O%I__ MGD*CPXTUU]<*">-<<A-S*[10$$+&PO/U0
MSMZ+@TFG!;TDM8<=_W",VV9J227\/(/D(#;\;_^P]W70/9R &*/UGW_$GZ&'
MQ_VUX.-E.OJ?.(]P_ZYJ_M2-_=<SKU\Y^9SCN-W[VS,Q_YM.5B]_P6U[_#_R
MUG=/P1X1"(@)S4RTZXH=J?0IY#B$<DQBA&;KR1G@=.Y>8-XOG'<&V7MD];SG
M[!XMN;7<A07O]8D)_WYO\;]-0O0:1^CVO[%2M<E_F<3!=YS/"U$K;^U#+NR+
MV&C/#&:V)C\:OP^? 'VSY]G M(0\7]C[< 8 /W?P[T*/?UC,?L'P'V92_F^<
MQ?+DOY2-N7UK\Q]2+^UIX=<U>1_]#LK#/(*O 3F+S).W%W!P[J#)\#5O1<("
ME90__J6H5H_F:S2[WE^*:O6=UJ]C!L]MGW=8/K)FO40DOR:C^&D?0MB'\\36
MS)DG^8<3$[6HD)#VR]H0,@,NP;X>?B8#,&>:PU118&[&I!YWH0</XUL^5\$&
M0*A'LB;U&VW1>[R^+$GF#;(M-KKS2Z@G)(_R]:*[N,A31!\=9O90\$A)S$4-
MR+U))]@X(G"ALS9XZ1NGP\/G5E\YD*OEL,,M%U<F\SN:B:(DMGG.SJHIVV;>
M<GAN$+IE_PQQS5R.K:/<L4\$$+9&ZQ^'"7&#+ (BM/:K@R,Y,1A!%WM?S LK
MYNI$KE&SSS,M95XC5OJ]JZ58_M]J;;O]6D_^PV/">]I47'R'W%("!O*.CS1
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MD9\%-MA,R2*F8X7#*ET8FUSXRRO432QCX=&H55&[5%,$UA]GDSSS:??ZG-?
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MCL@?D_; BV*[C8'<1A>)"V5U;AW,XP>-SP H[!N S0<.#2M>G[B+R^+WH8:
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MC47NA6>JKTM@M(3E8ZU>LR<P8T/'FB>6<3!F6EO-NO9RL800X(,$OY07@]:
MHL&?S;VF<K,R7Q#IDP+DG%6-_,;][+$+(W?Z@2B%]\!!#S!CW=_^'%P(#S]>
M]]SIUIS$NLZKS7MC^J<P,=E&'DA4C'5W3>,=V#E7"GB8FG:CCB$J?;%#(F<
M\&2:G\VG6GR OUV..80Z>),3G#7PE.QR:S/(;!=9]4)[+)>)_/'CAM,F$F=
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M2M/%)\0FA.)"L$2,QDM9PLJ0)N_0WK58/E+G<6T--UZM,Y0V(H!-8Q"H='(
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M%^5ZSL#3I_\DVV4X[2J9K@IGS5&W]!JD$!L,N&EWK8$[R@QCJ-F>&1\B65R
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M!+JJTC/L6<2 60%QOWG?R#=?9B-%\&564E'MGJRX<,_/$T:V"6=$QI,S]AT
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M7M\&(8 ?=S)(*WIC5&S*5)K\[*D6F<&VNY5LPBC&88JA4S3HF:R;3?!8?/]
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M)5#SA4CL\F8GAF)Y:=/4H>/C5LKF>"4G_ER/74%$HM<3TS2*_5CL.4RC ,,
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M'M-A\O@5VT3\U=.?T[+6<F:8 <>,KO-TX,QVP6= ?/_*S^1UPQ( 6=USP_]
MTDNM;HH[:2]_7LN5;_@7J0AK77F%EDLY1KE]KFP?+!>4"B?2C1T8AS&%0>Q3
MF,0A@EX:AR%-$Y_04*L"X#Q\IKY4K!&1<E9N4 &DQD7&@KZVV(@= $6-CWY3
M0EL;HV9'SLAN/577=&\3C&Y!2I;6,"_ =A.V"(*KS2;\T=N$!DN+A0)VV&6K
M3N!,;.8M$[##NH,J 4O+&C;26%49S9;K*GMA6V#7W\AR31F5_<ZDXEY7[<S
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ML!11\7HK[#[AOHL/B_(Q>^Z4VS7G C/AWS<%TN5G5FWK8BCQ/1(P)-SF@,+
M25*8(DXA]8. .SR-O3#0"CU.B>W4Z8)M5%]X80*J$%*2/S%P655%AH6A+8]P
M.9"Q>@'WCZQ STP8YZ24SVE&)2?=4<68Y?>R3YH1S3[:,MVY+$$E$  -ZJ#&
M'6R1OP -^F"#?Z\'6TM"/>>B(>*BWO@I*K%FY;NMT.BDN,X;.)V#[0=AU5F
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MY6XH!VI$PE]RQ0E"(W&"(.;"('7CA&#D4U_KEF\0VN2ZOPE"U,!W1'XTI=6
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M\X6^S6G>B7V?L8QI%MTFN'Z+BIOB2R7O3^M& UVURL+W'8<%"8,H#663HRB
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M([\OF)$<3JG8*Y7<RY?.7IV3XRS:N16=3%?.0*JF;**1Z\K9SCCI1'-ZV=H
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M$^Z'/J,9XB$6"(LD16D6!BB)*8X#G 4,UNQABN#LWN29)KA:J?YF$.K9$YO
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MZ2SG9X[)8I8!=FK!Y?+ 1L39RP8;^YQ)F+.$:<GV@;D/11]N(9'*4EL'C 0
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MZG4O-:(^\XZQQTYC/G8,.5N.>K,#...#4=9PL.;$#F:Z]V&[GH#-Y%8)C!_
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M2VDG)$NQ'WLHP2Q!.,QBE/B^/%^E+F$NCYA/*43'M:C.?J*JOW<=,N4/ S:
M\["U -33>^NP (]-YQ"Y<EH>G-^[/ZU6 QA);VL\LQ;-98<H0V X&G4,>MC
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M_)OBQ'EI+K.?>=4FY37I>9N:[7YS4?WN6:CU3AGV 819AZ-ZWKL6NY:)+A%
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M#,T=KNTX5$T:=CPV ZWHCLN=RMV7VUX.\+$2UE[2N"%["^B!L>,>]=LCU&\
MJ)MT&+(!/Z"QT,*OP:R?T% )JMWK* Z48+M)KTN'GFAH8JNAMT7,1OL'V:"S
M7-L@BZCL=0NRN:YIT? OW_EJU?>?H#3%GH@2Q*D;(!RG<O-Q4X)$D)'8#0@+
M?6"GCN'R<^\G;15M0]&T+<<>&N.F_G(9@88;(IY!@? I*2ZH#MY;;N'2X%.B
M'-<%G_R4J1JIJ=/5<]/22^FG/%/>J&R^ZO6FE(<VXD<Q\=P$!4&4R9,=RU!"
M?8K\+/82E_M1)K0BA9KTEE&T/1:NVAP3IPDF-8PXBA.H_HW#J*N0UL QTM"+
M<#%07"UI+]#D\?475FTM88]U7>^Q2Z;V-?OSN[[\WPL8Q3%%'LM"A#WY4Y)$
M*1(I$0$1J4\3T.W],8F95;P]\K\S<+1&4-&+ 5TF*TQC._%Z:>>:X7=*&*M#
M_/8(O,$4OU,"GA[C=_*3\&OY^XI=5]6G@MWGZY564.3XJ9E5J*&A?[-^(-&X
MKEPF#$Q'[BO2#)DZN#UB^4O.-F3EC,L)NB\_+9+1Y?C!4HO=A)\687CM?>83
M,!VHJ_6#RODO5SE3":+-+I?SNLF-$GXB4LX$B@+>#/3#B)" (T9XD(C(CQ-?
MJX9UC,C<^\^ K-/3G4JDTD=H7+MLR0W=BPQ$UE8O'9G&MB3Y_& [DG_;J=OH
MTHLHGHYPO0IJ?=:TREPNJ.SCO0KD/) ,L]CS, H\ZB&<IABEC$?()Z%+@Y0E
M*8YAI>3#Y>=.YNB).;\WY#2U[@P4>B<_<P%AFJ8OFT&I]RD1K-5S[RV^<-'V
M*<&.*[-/?LK@/NT7^IVSS4I-#B%5(<\?=5_^T'ZC:(ACXA(?"3>5'A8/*"(X
M]I&;Q2FE4>)QHC6.4(?8W*K645<W,CW]79$.3/^TL!O71MN( '5S:3  %TH6
M03&[++H0'-A5D*:TH]<\4VLL=X6C*<W>]8SN,X:5'WT'V$&"PL>*_WO#"_K:
M51\E;BC/\C1&(5.M)"(_E$>(-$%N2A.:>E&"/:W[& #-F8W=,+MF2QE8$J(!
MG-Z!PS(<,$MW$HD9*KD 0MJJ'-&@N&P5B3X$1Q4E@$=-7/B-NN!])M7Z]2MY
MXHUSF@99F@2A/-5$68)PX&.4\2Q$(7$QB7D0N!CKN^_'!&9WW7<D'473P&T_
M@8J.RWZ9K%!W'2@FT%4_+\M%;OJ)91=TT<\+M>^>CWS.T#7/'XM<Y)04ZZ[/
MBIJ!4JYR*EW_7?&2+RC/<"10'&:IBIPQE&*5BQ=Z\D^.DS0&#3G7(SNW?[%Y
M>B+5J\HP&O#C[!AR>HZ /KX>IIJ^OW6D@'['.#)S=88#26TKC*!'=-GP @B(
MH[ #[&F3< 19\;JIIOF2RY_69<'KKJRFN]S,/"*\*,1('LWEULT(4T-$8Q0P
M'/#,Y4GB:@U;T",WM\E0]+M2KAT'?2$1Q/N>Q$TG&&$3#:!94*2==V> ,$F"
MG48$$I&PB8QA3&+P57G:(?3<<F$K+U5;T/%PQ.0J"P8D="7:#TEH/P5/9+O)
MUZ_7%2=-JI67> 33*$ IHX$T9ZH?C!LP1#$G;N0S^5OMV3'#A>=V/E0"EJ(%
MS#[;DWW<)%TB$=#%T!,&E#)VBG.CW+"]A19+ CO%_C#;Z^2_7SPJ[6935:J5
M1*;&1-#U0X(]/W,#Z9<GF4 X"3R4QL1% 96;?4J))SQ0D^CSI.96EY::L[(Q
M*NT0);V#OQW988JU-R*MQ^#WGJ[%\_VT</9GHQT2>JNY:&<$'IF)=NX)>'K8
MI[8;YGW%>B_@KBKIUW)]S<KG-8?W/=5><&:%[?AP^J2LK7^J^@0KECC;R,<=
MR9G3L::?@J:/VKAJSP883,L-L)JA!PP8"*-T-WTJBV7"@04?)LG!'[[P$JXI
M#:X_\Q>^\OK:?Y+$'A8"B0#[" MY#D[#,$8\%'[*0Q8QG!A=OAW3FMEJ_#^;
M4GVY[ZJ<RN][TV:\F5'VA53_XNNZ:0'RB4G3FU.R<J[K6OWRIX9!QP/V4QU#
M5.]$8 DGF+'8#4J]:JO^Y<F@ V"&M' -$6W?Q9V@]#9W<.=%/GOW-O*(02SO
ML]2"HN8?.?_&*9=ZP![<,"!N'$GW-G6EJN/$D]ZNU/PHBG D$A8%KJL=O#M>
M?V;U[@@Z@G.GZD@"(E(G\- (RETF)?2\W@HHB3G?K @(B+%=)JA94 TD,"R2
M=EZ<T=#9B<>6BY6=YWDO.#;R,=/*+LE;L6ZKQE3?D'>O[WA!OS_)?;/-M ^\
M(,)^*L\$TGA@*J3=H!YMQJ=SX9'495I1,EV"LU_=#\BW76^VY*'57Q/(Z1T%
M;.(!C+V-0&&]H:NNF-9JQB;(+5Q!IB?\<3V9YG.&W2.;4W 7DGB02ATE8>0C
MS_>Q] 6R !%!?,0]'"0)8T+^Z\.Z7).5GJ+OK0[2ZBT-[:_RO7K$H5V8BS24
M@3T9][#04UUC"6%ZVI+91O$L-BX\Q;^M+H-[:R_;$O"46$?]^TY^Z,*BF%MQ
M0^KO'U?E'_4V1(R3&'LLINK27$BU8@E*5%P]QFY&@BR1VVIF5")S@MC<5^;;
MHI)2.(JXTU#7"2O#<=-305MHP#3R B#,RVU&)+1=?'.*U-N4XHP(?;8P9^P9
MP[R86]&T!^A'4'5]/-4!7&7)W_/JZ2$E-,:$>"@,/#7-0-TKNUZ !"$DHSR.
M@T1KN@B Y@(9,NH+WLTHHD-&KCHO7+%27_6I$(ZD\@1,%-& 5L-5MP\8T"*0
MMF2EFTETLX_5CHLKYWX6B( )-7:A,L^JL0 9/,E&7_C)3!N-I99-M]&7[2CG
M!O"HX3%)E16].VR'/.BY\.YU]Y$NXZ<907?;#+VO/_S)*YK730>Y31-L%Q$6
M/!48"5<>L#"-&2(,^XAY*?&2-$B]* *=K6QS.+.%[L@Z?$>W&1;7#(FKH2.O
MK;\>S2/<6X(.M/*#CO-#9H>-0YSL]71G>L7RE=,Q?>4,V+YR6L8M'AKGPM36
M2=,Z?\L>3^>"]^A,.QLADX-P6V0A]XFQ7/3/><$_R8-X_>!SU0HPBE&:JH"2
MQPC*B!\B-TC#"&<T<+%61T 3XG,?C;MZD]O)>A/G=\63TS %RJ$&@JUS1IX/
M0J 9_>'0@QR?YT/1\!R]JWVJ!VB2'9K/'5/6,M7-(!@_30/77/!8;2;M_OG:
M< UXAOO[[COTJ1!E]=1\DW9?\R 3\E#L!X@D888P$0RE/$I0E(7RC01QPGRM
M'( I0C-;WYZT,Z!M8"DFX1JWJ39!@-E/<_E!>?0ZPAGEU8\NO%B>O8YXP[Q[
MK<]?F*+7WDI<%VR0,MQ5Y;-;Y8UOJDH:#/F!KV51]7^5I[^\5L\W3-US^KW(
M_[WA]7WKN/<9K810(6(W1MP/&,*91U":T42YS)S'3/XR,^NT,2?7,YN274Z<
M<S04I\VBW7+H[%@T3!><]>WJ.=L_W#N#63ZSU]5U#7)FJ6]>%%';&9.S\OPV
MN9=+O(:S69R+$'^;Z.O/\H/K^E/1CJO[.\\?OZ\YNW[A%7GDS3^^)VN^1>(A
M<SD7)/502#T7X2 +4*K227 2NI@EF"21UGW8&_$_\[[3TW=(RX#SJ#AP5+M.
M1R@C]](8.>G3E5V,M_F ?$#%=S<U<YYYU<9Y%P[S0K\'RP2!9WR[;Q<B;H52
MQ0RM6%?.]FO32=9^Q%&R.;N]\<>)(QN^EA\DR@SE_C\J!FWX:FQ'J$W9,-L$
M;]??>:6Z].?MZ-8F3S>+8^)[7/E%*4;8%PP1@5VY77D)"1(_(RYHQO4I(G-?
M!"J2SH F;$\X"8N>X;Y46)AU/9+3>I[RF#R6S-))$HO:CC$A#Q5\]+-F6J@F
MU3SQ>_+G^[RFJU*=CG=^;.8*QL,P1:[K,7ENI"G*HI"@-(H(#P+L1@*4+SE&
M;&:M;$D[DC8T9#"*D)YBVI(;IJ [D9T=W9DZB^E(:$EE1TDMJKHZ0A^JL-8S
MAAU$N/1X^>USDR]4/'Z6OB[O?=_7;KNOWV_X/SBI/LHOS8,@+HU9$B)&F.K\
MR0(D]U^.8LX\[ 4Q3R@H" EE8&:5E]^<!-A=!(J@GOK/B0O,)+2<*+>FX\5I
MF+ERMNQ<J9&O&9=^4"Y]',61HUBRV*/$$ Q;G4N@Y)?M9V((SE&7$]-US"S/
M8;_R;>$ R]*(8(Q1[+JIM# X09DT+2@*1<A%YC-,",3"G",TLR4YU?S>L,[B
M+%1ZIL0& #"3828[V"Q,"69)_<^2653-IX0]5.?)SYNI[5>^;H\CG\MZ5^P3
MX]!S0RI4)D*&,/8X2IBZGW0)CK(,IUD"ZD-RDLK,"OMU\Z1,7UD!VXN=1D1/
M-2^6$Z:7DIS3G?!_4A3_XEROUU6>;=;-_9K<Q>_(;(W&1F6UI*JG:2RJIZ-B
M'BKI^(<--]9_;U2'P5W]8I:FH4K@)&&$<,($2JA0<[Y2DGAI+/=44"/ _>7G
MWD0;8N8;YSX4FMNEL8# 35);-OC&>%($6]OA_N++;H(G!3O:^DY_RDR=OO$U
MR0O.^OWTFM+-TV:EYO*]YR*G^?I!N"*.4\]'.')CA%F<H#0)7*EGB> IC2E+
M02TVIDG.K'8#@@YK*<(43P.T+/08I7&,LC@*I7$*U!P#EZ(X2GB"$QRD C^\
M\"HKWP:V(6EMX'H6'-Z?@'\BQU@";WPUP-2S;'8!@EF[+3);W^"GX;?L_10R
M8!NH+ZPENZA!<%%;J0_ H?T$/&E0AB(=$M44A3SR6_&U+'XK5;3A@Q2J?,KI
M)S55A=?KAS14D48W0&[ "<)>(FTJC7Q$7.9CD6&<4:UK!'V2,]O4'0\J*Z0H
M"_32L.'PC@\G[QA1__YR_^+<?Y?^R#/?K'-:.W\K5ZQ1F\^?;U1&@?J _!%0
M4Z&'>X+C6(2JN9PTP-*3DWM91J((>5'JTRQ1^URL9Y;G0=[(+$O*DN1:+K!2
MB.^ _J.0+_)[_JRR<3H^K2,Z;IOG00EFFP=?S5OA2 :<E@.G9\'I>; .#J!P
MQSI(9N4Z1WKLG--C6^4Z(,%'BW3T5EJN- <DV5Y!#NQ)P]9Z*U+7755]/^PR
M(=@- P_%"<T0#H1 )"0!\M/(PR3"/(E \[*/2<R\"S4$FS%;BB2P8=XQ'GKG
MSLNDA-FR?0%GF%5Y7AA;K>^."2S;[.ZL@$?M[<Y_TM37KJ7C1+]?%_*@^<)7
MY7.3;K9+1KM1N[CTZ>]+:0!4&<_'LFH27.IWK_>29I/X1+U '@_E$28+(@]A
M-^&(9(P@1B,1^7$D@A345<(*5S/K=<]C4T,QX'*8MMKT:&D8;2*]+:M-8^V6
MV2M',0OU36V\,5WW=>'W /5P;;T"ZTEQ5I&SYB[;X&EAC]HBC,=.M\W%3>UO
MX^3?J:FF]Y)P+<GM5=1&$24>IP2EB4L19O(D1/PX1D%(8\RQEY) P$SK.,'9
MK68;?6KH.P,&#*J1M3'4-7;VD(':L8M ,3!.>I):LSL3Y!8V*7K"'UL+S><L
MW/++GU8;UO0YJ)KB@,&=\7W9%,(QSI^:)C5[@9:MEX^Y)STCST<9<07"Q NE
MV6 ,^2PD.!59FB:@.TB[[,V=5\#7SDKRZ9"#N_:C&)^4Y'S,8(GWI&>:W@Y]
MF"$[RG908U,Z;IV.W:,$B#V.G8/ X608[+*D"&M8SI%-<3ES;Y>&80W8T?P-
M>U3,C/;/O)#&9"4/D-?L*2_RNFD\_\(__*GJNOB#QP4-:!BB*""JGY>;H#2F
MD7SO(4DQ<TF<@ YO$_1F-JL=]<;;(GOT829T"C4]FV@1"YB1&\*P3]KI:-LS
M5II"6K(^4]06-2>:HA_:!]W'#*LAJT=2Y/_3W%^HMJ_E*F=M^6;![N1WIK_;
MN!4?\X(4-">K;9/M7:9B@ E)A$@1"7&,<!A0E/@91YQ&-$GBS",$%-.VPM7,
MQF/(8]NZ>,ME-WIQQZ<*)F\Y=7:L&F>EV7EM>G9I\9<!LUY+O0=X&:E-W&S5
MG5KA:=E"59LP'E6V6ET</L'WOF+75?6+Z@+3-(JY?GR\?B'YZOIIK3NS=V2)
MN5/\'A\K_JCZ3C0$U:%4?PKOF.3C=LFBT#!+TT_8W0O&[WAP3N#A7#^I!H]V
M9NQJ"&TT57=LW<7FZ&H(-YR<J_-QN#I^^/?Z]?J/BM77[)]U-\U54PU//#JS
M^G7)WTTG#?GE8__<U)#&#^?DG5:^"T6%*=U9*2W.JYT0RDBI3JVWF#*-"#-4
MHK&/&;H3>Z6?!ZU<5.FYLH;?I(GLDF\> BYB$?L4^7Z8("S<!&6^=!^\.&0)
MCF(B JUVM*8,S*RC1SV^\H*V#0OE^3,KJZK\0^THDF5@R $,M.99?T;X@,?Z
MPU+QH[Y7/3N.XN?*Z3BR>'XWQ,+641U*?ME3N2$X1P=PTW4,LL9_+<B&Y7+Y
M)EB:/VV/](-VODT?[M?VO[MV*RGA*2%NAI@7"82]6)6E9A[*,E\$J2N2!&O%
M-RYC8V9;M>7+Z1@;N,H#U@#YN^: CUNKY6"$V2Q-!-O1!J_.[]V?.IUQ;((+
M2)A>!&2S).H=V'D'MMB"G0_ ;B8?O-I*I+X8D-'D:O/5ETNXOAB!O23LRU>S
M<5#=]BAYR))$I"SRD,]#BG 6>BB->(I($ @_2*A+!:@+P1DZ,YOR+G2UZR"[
M4M2=U:XC\26GS1U:)H=*(PPN/#MN:<YU.CP2:I9#X([*&Y[UCD0=/](=?]PX
MG4B-=+VKRI><<?;N]==:&8W.7A2/UW2=OS1?[0>/1VGDAR'RN/P/#B,7$8(]
M%*;2GZ2AGV(!FF*N3QJDUO 1YRH;A:I1P\\=*ZJ+L.C9<,B6#W &D"ZT>@H_
M#V P&Z"P:L8RWPVP^DDQ(D\'?W&VO#C7TZB9I.0  ;"7;J-+>.E4&B @)])D
MH"O X[]-E/'7@E6KU\=!;%G_,N;L K/[;E+ U:OZ/N_(ZL>!S\L]'0VV(C),
MMQN2SDF9K5ZX3(IF%!D^O^IB\>%)P891XND/&]9&EL6+_*8WMZM-_==7\L3[
M(LDH2@,BC^&9B&.$N8A0YD44N2GCH9^Q(!*P(LGSM&;6S!WE;47AE:.H PLG
M1\#2VY0M00#3U+/2SU%5.2V@K?+*$4K+UEE.BWQ4<*GQ"'SDX/43+YB*X7Q<
MD<>'F'+7B^($T5@YT4F6HLSW(I00/Y)G;T'22"M7_VCEN1,:>EJ.(J8_07!?
M^G%UO$@FX#:I)PYH(.!)UHTF .ZOM-C(OY,"#&?\G?X 7"4^%&OI]7[CCTW&
M9K%6>O9 TI1R/W:1\+!T37WFH@2[ <+2+<TRGPB6:$U$.D=@[I2#AJ2SHPG8
MR<YB,JTOETH*4QN@D"#U&9/$2(M.+KB8,HV),]2IT<\9N&GLGTTQQ!TOO_)2
M#9WY6.RN-W1=M;%%YMYHMFDL7;T0NOMPZWR5_[\W+^IC6:Z+4C<U8!H9#6?.
M%BC G0J&A^5A$MJ"F[E[HRLOY_+I"+CG]FD]8#B(4!T\KY^?*T[SYM5^4_?^
M]2_7WW[1S[K37FQF96Z[Q P9<%H.G)\D#S5T-M\D-'KNGE548-H\!8C%S#VP
MM+;&RDW26W80G*[X1Z/;M!\T'O-4J5N@][S]\Y,T(4_/946JUS:Q\UNY6GTL
M*Q5B>G#=.!)IDB _PQ["7J1ZX%(/97'BIC'C881!=Z\0XDO8B._E2B)7_Y?3
MY[0>UPV?JA1V?E=\.AVCP$(AT O0LRQSP0HS,CT7SD\]'W]1/2VWK/0@:X)G
M,GD*C(*]253ZI)>>3 4&Y<2D*O@:-@91&+2D"%R/A3YBPE5#(UV!TH 2Q-,H
MC4E XBQ-8.VG+V,(HFQF/5#/M:$H3C='O60(QA*-)W[D1A,_5%>)'ZJ+Q']2
MUXAYND0LU15B>_MW8J8WY$)\\='JNSG8#FDZ>>YF9 ,OQ<'3S"T)#8R?-!?B
M,PT"UY#(_![\K49H:PAU= =N?13US:9>2Y6N;A2O1=/707E@];\Z3]^G+O-)
M&B+N^@'"+"(H"4F,A"_<2)XY(M<'%4=-T)O[)KRC#KSXGL!(;]NW*#E,,WO"
MSAYE1Y&>(0RB*::M:_ ):LM>A>N)?G0=KOF889QSD]7\WQNY\(>7O<X;(6.A
MR[U,*C5-$>8N16D69,A-W4 P/TI\ NIF=X[0W&&-+5FGI6O<T.0L4IK13@OR
M X.<)J+#XYH3<MD*9YXCLVP4<T+8H^#EU.?-E':[NW\JGC?K^K/JI.MWNXWK
M,T_EIB'JQ9Y47KD9ITD0(D*2,':I%_@Q:#+]"*VY53=_+'*14W5D;%H .[<2
MS>JE\2Y;;J0GJOAQ?. 5QAB >NIL"1:81N_.S%<= %=.!\ ,6[6&B):4>XS2
MHOJM(?*ABNL\8K@UDQ7O,^ V:CWY%S7CMOY4UQN563YHB2L/XI3Z<10C[F.Y
M9_.4(C5?#@5I&@@WPZX7:GG$)L3GM@,-7:<N5\SY*2^<NOD[]-(2 J;FCCX3
M1,!=7G(QS%QM.&E^T<+6,M-</.S8L;C]&X!@ZT@ (;WL,<$ E*.C@\D:%QXG
MOG!2;]KF'_7VEW_+>:5:]K]VN=QQ$L0T2 +$><813C/I&(A4^OU10'D8XX!E
M($L#HKY<5&Y+N&G1]_7Z-\,3AA:FP#.';:1,3R''(,V0-&\DM>V#B1;MMSFJ
M0& Y>W@!+0(/T7_CM'SAU>NM^%!5*E%+]4U9E8KD9\V1$;K+S/>][ZFKS572
M+PM>;NI5U_A+;K%[B8 [SBP/E(#B8!3XUB*P6!0<(NXP) YZ[H(TP79'?K^I
M5%=T7N4E:]3G*_^C^9?Z@8;<2]TL0K'P!<*)QU :2<<\%B0*$Q;*?P;5BFE1
MG7FK5$2(?'5*&]IQ=-<.+9^>Y'>_;K+KU([P7'$D-H72#JDDZG)">JP%5\-?
M!5>,RT=JW7: ,,PUS_"VD00>WANDNB-ZRX#3<G#5^_F2B_8#%HN_05+;S$><
MI+E\3J(N#"?S$K4?-BW.N69,?GWJ.ZDE9/7_YL\W)>,/&&-?))@BQE1A3I@&
MB @W1+$;T\SW6$:Q#RO1.45F9OO1U;!TE*^<EK8CB3N*.K1BYR10XS; GO@P
MI3>5W*",9TRP"XIY3BZ[<$G/F&C'A3VCGS;;^M4TNELQZ+3<#'GT,^(FJJ:4
M1GZ$<!SY* F3" 5NF)($QZ$7$,A6?Y+*W-?@Y4JR4'8#-@:TV_D;@[^W8?GU
M=U(X>P_!-O332.IMX!?C ]/=RZ&Q/O9R% %+F_=I&HMNUJ-B'F[.XQ\V/.K3
M[YQM5%#NP]/SJGSE_!=>O>24-V&Y=Z3F;.@!7J^:5]=4L2M'Y+'(_X>S]I!P
MHPZ]NZ*W$+.817& XB!A"&/.4!)%&&6QSQ,<QF'B@ZH*9N-T]KOZIR?2^M=[
MOG0W1\;I9S:NRS:1;# !^_99?1+J2,SV1C6=CQ_A/0$=%L49:EAS[LCK\>3?
M[EVQQA[>D.=<[K>*S:NN[8WS^WUS?VNU/'(Q0&WY0K/QN:S_-#?<1S[7[ 1-
M0IMU/VY%)5XV1Q?-S.,3C\YL80<4G?=<+O"4%UV\4O[ZO_4SCT])K1._O4A@
M:+AV3%9KQ[ )N0S#K\?K+1AM/2O,?G#U_,<,.I]_YFOYBJX?*]XL^?<N6MCE
MY(C437S/]]OJ)9RR$!%* L1CXF&NYCM&6DE-TZ1F5L"6MK,E[O34 6VUQZ$:
MUT*[ , 4\JSLT[E+4!  _<.M@6'6([P#A6Q!Z>/DMMJ!:\DWVO)[?(7EVGIK
M2;+7NEOO"3-W<'#JK:\+]K4LR.XW@]R,_BL9BXR1,,7("U1>IIMZ*.5Q@OR0
M^83+_TL8:"XMD/[_ST)&4/3U'+(9,5T^S&0]$<,0'4L^$Y3ZHIZ0(32'_HWI
M,O#;I:Y+ZJOG9_?Y>L4?"/:2,& 421,5(.P)%R6"9"@2),X$PZXGM,S3J<5G
MMCT-#14*\OR?LK_TG7;/-]*?!F/ZWN@2$6&F "H=Z);HG!A&=T-'BRUV(W1.
MC.$]T-G/&+<&WJ_&>O>J@LZ-(QR0*,P(3U!*,C4QCKHH"]T,"2PU*L4I90$%
MM@8^1VOV;?VH)%!1!C<&/@N5WKYL"0#H'GQ2=NOW-QK"V6L*?);2TDV!IT0^
MT11X\A%3359)2\TU0EL]GV:>FY'81<1-5"D%BU'FJLK'T,L"CZ>IB%.8^NX3
MF%UG!TE8+Z,%]GIXZ.JHN910Q6P$[ H>^G*H)A/'IE:>%L>:*AXLO[#^G1;N
M6.G.?,X@P-<W3?I4#%9M*QJN-^OO9:5B\P\X\[,PX!1%,95><H13E/@N0:$@
MKG#C*$V$UM:I3W)F;=PV =L6+CED2QM>S@2 4B,0:!T@F")OL?FDG->=4O>E
M2SL>K(,#"!!:!\DL4#C\(NWEV1Y]JVQ%#D&"CT80]59:+I((DFPOH@A[TNQ
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ME=1^MS?RZH^J0:J_(H% ).$49DP(B+C\@3W&(!$^C9%($0\"$S]GRL#,WNU
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MH:@8 3\:3B[J/AEEU3JC_JA9:^/NQ0Q[D3=1MYF_J;FK<^,N5,LJA7):L]@
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MDQ: 06((@3G4J0D^KBV[$3KDLT/'[J+M!!M?9F$R'U>AK/$=/%->%PO($_'
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M%+7UMO5TRDUIZR2!HLVE\D$4TH&=N<+730=0FV)](?J9E;7AG@C@36W':H5
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MG I@=:(0S2=12FOCOA?!P_JQ/0%[*]5U,R=O/Y:C]\K53K52\U*?!6IS;UW
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MFEXO(+O B JG-VP6O@.FACS'VFGV$:CL(.:!P;(JG:S5&6%R=GX#[Z607%M
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M84^2AYG%T0MNGU+?O<+[S0\*^\9S7&[<BQ]>\,A'Q6<;,A)7H:9\,>T@EI3
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MQGMV \+#*&_0T=WKY(F[)4>.<.5M]=6E2WS^&D%T7DST6=XL+*=)C42(Q>K
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M5_5/6.M6R%B<%_N?AN/:<XV/5,XN284@<LB@?&)D-I(C[U04GXSTAK4NMAR
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M,!HY$*0GP1O!7[1CW5>@_-A494\T<L,FKV0KV+%2U^/+\"3WJ#7*E%ILN16
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MCS]WR.4N^W->3O1P*:ZYU-TY,_H4V5< HAU9G=!#SEE0P$67 E K4['3$(/
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MK.%> 1T-$W H*"<0L:1KH;3#$Y4]K<FBYN=O8C/*M0*O;G_BK=9!!BXD4-[
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M,XOR*L#F]CZS7&"2I^PYSP%A*%V(Q$!,,4. =-I[2ZBP^E#2>(Y;]^X6<+"
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MBQY%^27834K5ZG,@-7;2GJQ4>Y4H[?/$I=R/A5XV;SU'45M#E0W*#LN\.2:
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MR&<^#VM^AB_53OP7<G\!4$L#!!0    ( &"%;%GFLW@,EP<   ,H   8
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M=N$'%S&W]'1;2'!K0F;(T=(\-/G,W<WJM[I&VG775_\!4$L! A0#%     @
M8(5L6:&6W5Z*(0$ ?:,. !$              ( !     '9T=G0M,C R-# Y
M,S N:'1M4$L! A0#%     @ 8(5L6:8Z\]F"$   ZZ8  !$
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M2P$"% ,4    " !@A6Q96YT@01K=  "OK @ %0              @ %IX00
M=G1V="TR,#(T,#DS,%]L86(N>&UL4$L! A0#%     @ 8(5L613>YHDCA0
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MQE,& '9T=G0M,C R-# Y,S!X97AX,S(Q+FAT;5!+ 0(4 Q0    ( &"%;%D
MPU/AE 0  ,42   8              "  :A8!@!V='9T+3(P,C0P.3,P>&5X
>>#,R,BYH=&U02P4&      L "P#D @  <ET&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>vtvt-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtvt="http://vtvtherapeutics.com/20240930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtvt-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:NewsoaraBiopharmaCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-20</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-20</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-11-20</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:PrivatePlacementPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-22</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtvt:TDCowenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-20</startDate>
            <endDate>2023-11-20</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-20</startDate>
            <endDate>2023-11-20</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001641489</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat contextRef="c-96" decimals="3" id="f-374" unitRef="number">0.333</vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat>
    <vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones contextRef="c-115" decimals="2" id="f-416" unitRef="number">0.5</vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-151" decimals="3" id="f-548" unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-152" decimals="3" id="f-549" unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37524</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">vTv Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-3916571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3980 Premier Dr</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">High Point</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">27265</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">841-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Class A common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">VTVT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-25" unitRef="shares">2612257</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-26" unitRef="shares">577349</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">41571000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-33" unitRef="usd">9446000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">242000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-35" unitRef="usd">102000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">1060000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-37" unitRef="usd">1044000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">85000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">65000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">42958000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">10657000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">156000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">244000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">43164000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">11018000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">6226000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">10242000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">181000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">169000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">191000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">6424000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">10619000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">32000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">169000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <vtvt:WarrantyLiability contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">82000</vtvt:WarrantyLiability>
    <vtvt:WarrantyLiability contextRef="c-7" decimals="-3" id="f-63" unitRef="usd">110000</vtvt:WarrantyLiability>
    <vtvt:WarrantyLiability contextRef="c-8" decimals="-3" id="f-64" unitRef="usd">44000</vtvt:WarrantyLiability>
    <vtvt:WarrantyLiability contextRef="c-9" decimals="-3" id="f-65" unitRef="usd">0</vtvt:WarrantyLiability>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">25251000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">29567000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-68" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-69" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">6131000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-72"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-10" decimals="INF" id="f-74" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-11" decimals="INF" id="f-75" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-11" decimals="INF" id="f-76" unitRef="shares">2612257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-77" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-3" id="f-78" unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-10" decimals="-3" id="f-79" unitRef="usd">21000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-13" decimals="INF" id="f-82" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-12" decimals="INF" id="f-83" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-12" decimals="INF" id="f-84" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-13" decimals="INF" id="f-85" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-12" decimals="-3" id="f-86" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-13" decimals="-3" id="f-87" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">311060000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">256335000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">-296084000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">-281042000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">15008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">-24680000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">2905000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">17913000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">-24680000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">43164000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">11018000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-101" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-104" unitRef="usd">3224000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-105" unitRef="usd">2824000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">9312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-107" unitRef="usd">11457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-108" unitRef="usd">3282000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-109" unitRef="usd">2544000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">10976000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-111" unitRef="usd">9338000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-112" unitRef="usd">6506000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-113" unitRef="usd">5368000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">20288000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-16" decimals="-3" id="f-115" unitRef="usd">20795000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-116" unitRef="usd">-6506000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-117" unitRef="usd">-5368000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-19288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-119" unitRef="usd">-20795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-120" unitRef="usd">85000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-121" unitRef="usd">-3640000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-19" decimals="-3" id="f-122" unitRef="usd">157000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-20" decimals="-3" id="f-123" unitRef="usd">-1514000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-21" decimals="-3" id="f-124" unitRef="usd">77000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-125" unitRef="usd">341000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-23" decimals="-3" id="f-126" unitRef="usd">-173000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-24" decimals="-3" id="f-127" unitRef="usd">406000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-128" unitRef="usd">504000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-3" id="f-129" unitRef="usd">131000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">1136000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-3" id="f-131" unitRef="usd">384000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseOperating contextRef="c-14" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-15" decimals="-3" id="f-133" unitRef="usd">4000</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:InterestExpenseOperating>
    <us-gaap:InterestExpenseOperating contextRef="c-16" decimals="-3" id="f-135" unitRef="usd">6000</us-gaap:InterestExpenseOperating>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-136" unitRef="usd">-5840000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-137" unitRef="usd">-8540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-18168000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-139" unitRef="usd">-21525000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-141" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-143" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-144" unitRef="usd">-5840000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-145" unitRef="usd">-8540000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-18268000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-147" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-148" unitRef="usd">-1057000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-149" unitRef="usd">-1886000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-3440000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-151" unitRef="usd">-4753000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-152" unitRef="usd">-4783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-14828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-155" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">-4783000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-14828000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-159" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-2.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-2.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-8.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-8.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-168" unitRef="shares">5456307</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-169" unitRef="shares">5456307</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-170" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-171" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-172" unitRef="shares">5498479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-173" unitRef="shares">5498479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-174" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-175" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-29" decimals="0" id="f-176" unitRef="shares">2432857</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-177" unitRef="usd">24000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="0" id="f-178" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-179" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-180" unitRef="usd">307746000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-181" unitRef="usd">-291301000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-182" unitRef="usd">16475000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-183" unitRef="usd">3962000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-184" unitRef="usd">20437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-185" unitRef="usd">-4783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-186" unitRef="usd">-4783000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-187" unitRef="usd">-4783000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-188" unitRef="usd">853000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-189" unitRef="usd">853000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-190" unitRef="usd">853000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares
      contextRef="c-39"
      decimals="INF"
      id="f-191"
      unitRef="shares">179400</vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-39" decimals="-3" id="f-192" unitRef="usd">2000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-38" decimals="-3" id="f-193" unitRef="usd">2461000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-37" decimals="-3" id="f-194" unitRef="usd">2463000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">2463000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-196" unitRef="usd">-1057000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-197" unitRef="usd">-1057000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="0" id="f-198" unitRef="shares">2612257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-199" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="0" id="f-200" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-201" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-202" unitRef="usd">311060000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-203" unitRef="usd">-296084000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-204" unitRef="usd">15008000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-205" unitRef="usd">2905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-206" unitRef="usd">17913000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-47" decimals="-3" id="f-207" unitRef="usd">18879000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-48" decimals="0" id="f-208" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-209" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-49" decimals="0" id="f-210" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-211" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-212" unitRef="usd">255499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-213" unitRef="usd">-280809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-214" unitRef="usd">-25283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-215" unitRef="usd">-1886000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-54" decimals="-3" id="f-216" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-217" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-55" decimals="-3" id="f-218" unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-219" unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-53" decimals="-3" id="f-220" unitRef="usd">-6271000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-221" unitRef="usd">6271000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-222" unitRef="usd">6271000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-56" decimals="-3" id="f-223" unitRef="usd">10722000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-57" decimals="0" id="f-224" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-225" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-58" decimals="0" id="f-226" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-227" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-228" unitRef="usd">255932000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-229" unitRef="usd">-281192000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-230" unitRef="usd">-25233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-62" decimals="-3" id="f-231" unitRef="usd">6131000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-63" decimals="0" id="f-232" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-233" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-64" decimals="0" id="f-234" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-235" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-236" unitRef="usd">256335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-237" unitRef="usd">-281042000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-238" unitRef="usd">-24680000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-3" id="f-239" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-240" unitRef="usd">-24680000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-69" decimals="-3" id="f-241" unitRef="usd">-14828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-70" decimals="-3" id="f-242" unitRef="usd">-14828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">-14828000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-71" decimals="-3" id="f-244" unitRef="usd">-1085000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-71" decimals="-3" id="f-245" unitRef="usd">214000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-69" decimals="-3" id="f-246" unitRef="usd">-214000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-70" decimals="-3" id="f-247" unitRef="usd">-214000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">-214000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c-71" decimals="-3" id="f-249" unitRef="usd">-5260000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c-72" decimals="-3" id="f-250" unitRef="usd">5260000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">5260000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-73" decimals="-3" id="f-252" unitRef="usd">1932000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-70" decimals="-3" id="f-253" unitRef="usd">1932000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">1932000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-74" decimals="0" id="f-255" unitRef="shares">347884</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-74" decimals="-3" id="f-256" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-75" decimals="-3" id="f-257" unitRef="usd">50332000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-70" decimals="-3" id="f-258" unitRef="usd">50335000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">50335000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares
      contextRef="c-74"
      decimals="INF"
      id="f-260"
      unitRef="shares">179400</vtvt:IssuanceOfClassACommonStockUnderATMOfferingShares>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-74" decimals="-3" id="f-261" unitRef="usd">2000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-73" decimals="-3" id="f-262" unitRef="usd">2461000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-70" decimals="-3" id="f-263" unitRef="usd">2463000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <vtvt:IssuanceOfClassACommonStockUnderATMOffering contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">2463000</vtvt:IssuanceOfClassACommonStockUnderATMOffering>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-72" decimals="-3" id="f-265" unitRef="usd">-2355000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-2355000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-76" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="0" id="f-268" unitRef="shares">2612257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-269" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="0" id="f-270" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-271" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-272" unitRef="usd">311060000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-273" unitRef="usd">-296084000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-274" unitRef="usd">15008000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-275" unitRef="usd">2905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">17913000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-77" decimals="-3" id="f-277" unitRef="usd">16579000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-78" decimals="0" id="f-278" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-3" id="f-279" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-79" decimals="0" id="f-280" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-3" id="f-281" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="-3" id="f-282" unitRef="usd">254757000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="-3" id="f-283" unitRef="usd">-265524000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-3" id="f-284" unitRef="usd">-10740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-83" decimals="-3" id="f-285" unitRef="usd">-4753000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-84" decimals="-3" id="f-286" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-287" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-85" decimals="-3" id="f-288" unitRef="usd">1175000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-289" unitRef="usd">1175000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-83" decimals="-3" id="f-290" unitRef="usd">-1104000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-84" decimals="-3" id="f-291" unitRef="usd">1104000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <vtvt:ChangeInRedemptionValueOfNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-292" unitRef="usd">1104000</vtvt:ChangeInRedemptionValueOfNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-56" decimals="-3" id="f-293" unitRef="usd">10722000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-57" decimals="0" id="f-294" unitRef="shares">2084973</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-295" unitRef="usd">21000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-58" decimals="0" id="f-296" unitRef="shares">577349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-297" unitRef="usd">6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-298" unitRef="usd">255932000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-299" unitRef="usd">-281192000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-300" unitRef="usd">-25233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-18268000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-302" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">67000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-3" id="f-304" unitRef="usd">67000</us-gaap:Depreciation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-306" unitRef="usd">-313000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeOperating contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-16" decimals="-3" id="f-308" unitRef="usd">100000</us-gaap:InterestIncomeOperating>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">1932000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-16" decimals="-3" id="f-310" unitRef="usd">1175000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-16" decimals="-3" id="f-312" unitRef="usd">3044000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-16" decimals="-3" id="f-314" unitRef="usd">4245000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-23" decimals="-3" id="f-315" unitRef="usd">173000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-24" decimals="-3" id="f-316" unitRef="usd">-406000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-19" decimals="-3" id="f-317" unitRef="usd">-157000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-20" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">140000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-16" decimals="-3" id="f-320" unitRef="usd">-173000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">36000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-16" decimals="-3" id="f-322" unitRef="usd">-665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-88000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-16" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">-4016000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-16" decimals="-3" id="f-326" unitRef="usd">2270000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">-125000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-16" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">-20482000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-330" unitRef="usd">-16167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">50335000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c-16" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">2463000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-16" decimals="-3" id="f-334" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vtvt:ProceedsFromSaleOfCommonStock contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">0</vtvt:ProceedsFromSaleOfCommonStock>
    <vtvt:ProceedsFromSaleOfCommonStock contextRef="c-16" decimals="-3" id="f-336" unitRef="usd">12030000</vtvt:ProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-16" decimals="-3" id="f-338" unitRef="usd">566000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">191000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-16" decimals="-3" id="f-340" unitRef="usd">317000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">52607000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-342" unitRef="usd">12279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">32125000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-344" unitRef="usd">-3888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-345" unitRef="usd">9446000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-82" decimals="-3" id="f-346" unitRef="usd">12126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-347" unitRef="usd">41571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-61" decimals="-3" id="f-348" unitRef="usd">8238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">-214000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-16" decimals="-3" id="f-350" unitRef="usd">-1104000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">5260000</vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital>
    <vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital contextRef="c-16" decimals="-3" id="f-352" unitRef="usd">0</vtvt:NoncontrollingInterestReclassificationToAdditionalPaidInCapital>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-353">Description of Business and Basis of Presentation &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. (the &#x201c;Company,&#x201d; the &#x201c;Registrant,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#x201c;vTv LLC&#x201d;), the Company&#x2019;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that vTv LLC is a variable-interest entity (&#x201c;VIE&#x201d;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#x2019;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#x2019;s results pursuant to Accounting Standards Codification Topic 810, &#x201c;Consolidation&#x201d; in its Condensed Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $28.9 million of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various holders own non-voting interests in vTv LLC, representing a 18.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#x2019;s interest to 81.9% of vTv LLC&#x2019;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (&#x201c;vTv Units&#x201d;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#x2019;s Class B common stock, par value $0.01 (&#x201c;Class B common stock&#x201d;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#x201c;Lenders&#x201d;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#x201c;M&amp;amp;F Group&#x201d;), a related party and an affiliate of MacAndrews &amp;amp; Forbes Incorporated (together with its affiliates &#x201c;MacAndrews&#x201d;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#x201c;Letter Agreement&#x201d; and collectively, the &#x201c;Letter Agreements&#x201d;). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#x201c;G42 Investments&#x201d;) (the &#x201c;G42 Purchase &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement&#x201d;),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#x201c;CinRx Purchase Agreement&#x201d;). In addition vTv Therapeutics Inc. also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (&#x201c;TD Cowen&#x201d;) (&#x201c;TD Cowen Sales Agreement&#x201d;). v&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2024, the Company had an accumulated deficit of $296.1&#160;million and has generated net losses in each year of its existence. As of September&#160;30, 2024, the Company&#x2019;s liquidity sources included cash and cash equivalents of $41.6 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2024, we entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain institutional accredited investors (the &#x201c;Private Placement Investors&#x201d;), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the &#x201c;Private Placement&#x201d;) (i) an aggregate of 464,377 shares (the &#x201c;Private Placement Shares&#x201d;) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the &#x201c;Private Placement Pre-Funded Warrants&#x201d;) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the &#x201c;Private Placement Warrant Shares&#x201d;) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.&lt;/span&gt;&lt;/div&gt;On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#x201c;TD Cowen ATM Offering&#x201d;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-86" decimals="-5" id="f-354" unitRef="usd">28900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtvt:PercentageOfNonVotingEconomicInterest contextRef="c-87" decimals="3" id="f-355" unitRef="number">0.181</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:PercentageOfNonVotingEconomicInterestByParent contextRef="c-87" decimals="3" id="f-356" unitRef="number">0.819</vtvt:PercentageOfNonVotingEconomicInterestByParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-88"
      decimals="INF"
      id="f-357"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-358" unitRef="usd">-296100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-359" unitRef="usd">41600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-89"
      decimals="INF"
      id="f-360"
      unitRef="shares">464377</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-90"
      decimals="2"
      id="f-361"
      unitRef="usdPerShare">11.81</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-91"
      decimals="INF"
      id="f-362"
      unitRef="shares">3853997</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-91"
      decimals="2"
      id="f-363"
      unitRef="usdPerShare">11.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-90"
      decimals="2"
      id="f-364"
      unitRef="usdPerShare">11.81</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-92"
      decimals="2"
      id="f-365"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-93" decimals="-5" id="f-366" unitRef="usd">51000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares
      contextRef="c-94"
      decimals="INF"
      id="f-367"
      unitRef="shares">116493</vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares
      contextRef="c-94"
      decimals="INF"
      id="f-368"
      unitRef="shares">116590</vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares>
    <vtvt:SaleOfStockAggregateOfferingPrice contextRef="c-95" decimals="-5" id="f-369" unitRef="usd">50000000.0</vtvt:SaleOfStockAggregateOfferingPrice>
    <vtvt:EntityPublicFloatThreshold contextRef="c-96" decimals="-5" id="f-370" unitRef="usd">75000000.0</vtvt:EntityPublicFloatThreshold>
    <vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat contextRef="c-96" decimals="3" id="f-371" unitRef="rate">0.030</vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-372"
      unitRef="shares">179400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-97" decimals="-5" id="f-373" unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-375">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2024, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Equity (Deficit) for the three and nine months ended September&#160;30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2023, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September&#160;30, 2024, the results of operations for the three and nine months ended September&#160;30, 2024 and 2023 and cash flows for the nine months ended September&#160;30, 2024 and 2023. The December&#160;31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One collaboration partner represented 100% of the revenue earned during the nine months ended September&#160;30, 2024. The Company did not have any revenue during the nine months ended September&#160;30, 2023 or during the three months ended September&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024, the Company has no investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (ASU 2023-07)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In December 2023, the FASB issued ASU 2023-09: &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; (&#x201c;ASU 2023-09&#x201d;). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2024, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2024 and 2023, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Equity (Deficit) for the three and nine months ended September&#160;30, 2024 and 2023 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2023, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September&#160;30, 2024, the results of operations for the three and nine months ended September&#160;30, 2024 and 2023 and cash flows for the nine months ended September&#160;30, 2024 and 2023. The December&#160;31, 2023 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-377">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-378">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One collaboration partner represented 100% of the revenue earned during the nine months ended September&#160;30, 2024. The Company did not have any revenue during the nine months ended September&#160;30, 2023 or during the three months ended September&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-98"
      decimals="INF"
      id="f-379"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-381">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024, the Company has no investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the &lt;/span&gt;&lt;/div&gt;Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-383">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-384">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (ASU 2023-07)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company is currently assessing the impact the adoption of ASU 2023-07 will have on its Consolidated Financial Statement and disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In December 2023, the FASB issued ASU 2023-09: &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; (&#x201c;ASU 2023-09&#x201d;). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, and we expect considerable changes to our income tax disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-385">Collaboration Agreements&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Purchase Agreement and Cogna Collaborative and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#x201c;G42 Investments&#x201d;), entered into a Common Stock Purchase Agreement (the &#x201c;G42 Purchase Agreement&#x201d;), pursuant to which the Company sold to G42 Investments 259,657 shares of the Company&#x2019;s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#x201c;G42 Promissory Note&#x201d;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval in the U.S. for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#x201c;Cogna Agreement&#x201d;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#x201c;Cogna&#x201d;), which requires Cogna to work with the Company in performing clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as jointly creating a global development plan to develop, market, and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in certain countries in the Middle East, Africa, and Central Asia (the &#x201c;Partner Territory&#x201d;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory, but will not have access to the various intellectual property (&#x201c;IP&#x201d;) related to the license and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;needed to conduct the trials. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Cogna Agreement, Cogna has the right to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for commercial sale under terms to be agreed upon by the parties at a later date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company will conduct its clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of the Partner Territory at its own cost. The Company may combine the results of each party&#x2019;s clinical trials to seek FDA approval in the United States for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#x201c;G42 Healthcare&#x201d;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The G42 Purchase Agreement also provides for, following the receipt of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company&#x2019;s Class A common stock (the &#x201c;Milestone Shares&#x201d;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#x201c;Milestone Cash Payment&#x201d;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; FDA Approval will be granted or as to the timing thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a period of at least ten years after the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#x2019;s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#x201c;JDC&#x201d;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2024, the clinical trials had not commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#x2019;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#x2019;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resulting in a loss of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and was recognized as a component of other income, net in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The G42 Promissory Note receivable was classified and accounted for under ASC 310 &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&#x201c; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 310&#x201d;) and was initially measured at its fair value of $11.9 million. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Newsoara License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license agreement with Newsoara Biopharma Co., Ltd., (&#x201c;Newsoara&#x201d;) (the &#x201c;Newsoara License Agreement&#x201d;) under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company&#x2019;s phosphodiesterase type 4 inhibitors (&#x201c;PDE4&#x201d;) program, including the compound &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the &#x201c;Newsoara License Territory&#x201d;). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company&#x2019;s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the &#x201c;First Newsoara Amendment&#x201d;). On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the &#x201c;Second Newsoara Amendment&#x201d;) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the &#x201c;Upfront Fees&#x201d;) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$76.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0&#160;million. If the Company receives the Upfront Fees, $20.0&#160;million of revenue will be recognized at a point in time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has fully allocated the transaction price to the license and the technology transfer services which represents a single performance obligation because they were not capable of being distinct on their own. The Company recognized revenue for this performance obligation using the straight-line method over the transfer service period. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue for this performance obligation has been fully recognized as of September&#160;30, 2024. In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the nine months ended September&#160;30, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the three and nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-99" decimals="0" id="f-386" unitRef="shares">259657</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-100"
      decimals="2"
      id="f-387"
      unitRef="usdPerShare">96.40</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-101" decimals="-5" id="f-388" unitRef="usd">25000000.0</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-99" decimals="-5" id="f-389" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-102" decimals="-5" id="f-390" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-103" decimals="-5" id="f-391" unitRef="usd">12000000.0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-104" decimals="4" id="f-392" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-103" decimals="-5" id="f-393" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue contextRef="c-102" decimals="-5" id="f-394" unitRef="usd">30000000.0</vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue>
    <vtvt:CollaborateArrangementContingentConsiderationTransferredCash contextRef="c-101" decimals="-5" id="f-395" unitRef="usd">30000000.0</vtvt:CollaborateArrangementContingentConsiderationTransferredCash>
    <vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod contextRef="c-105" id="f-396">P10Y</vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-106" decimals="-5" id="f-397" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:CollaborativeArrangementNoteReceivableDiscountPaid contextRef="c-107" decimals="-5" id="f-398" unitRef="usd">600000</vtvt:CollaborativeArrangementNoteReceivableDiscountPaid>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-107" decimals="-5" id="f-399" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-108" decimals="-5" id="f-400" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-5" id="f-401" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-5" id="f-402" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-109" decimals="-5" id="f-403" unitRef="usd">12000000.0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-110" decimals="4" id="f-404" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-109" decimals="-5" id="f-405" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-106" decimals="-5" id="f-406" unitRef="usd">11900000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-106" decimals="-5" id="f-407" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:LicenseFeeReceived contextRef="c-111" decimals="-5" id="f-408" unitRef="usd">20000000.0</vtvt:LicenseFeeReceived>
    <vtvt:LicenseFeeReceivedTerm contextRef="c-111" id="f-409">P1Y</vtvt:LicenseFeeReceivedTerm>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable contextRef="c-111" decimals="-5" id="f-410" unitRef="usd">76500000</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <vtvt:LicenseFeePriceIncrease contextRef="c-111" decimals="-5" id="f-411" unitRef="usd">20000000</vtvt:LicenseFeePriceIncrease>
    <vtvt:LicenseFeeReceived contextRef="c-111" decimals="-5" id="f-412" unitRef="usd">20000000</vtvt:LicenseFeeReceived>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice contextRef="c-112" decimals="-5" id="f-413" unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-113" decimals="-5" id="f-414" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-5" id="f-415" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-417">Share-Based Compensation&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued non-qualified stock option awards to management, other key employees, consultants, and non-employee directors and these options ratably vest over a four-year period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. As of September&#160;30, 2024, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $4.7 million, which is expected to be recognized over a weighted average period of 2.5 years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2024 and 2023 was $14.85 and $30.59 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2024 was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company&#x2019;s Board of Directors, effective on the closing of the Private Placement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-116" id="f-418">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-117" id="f-419">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-116" id="f-420">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-118" decimals="-5" id="f-421" unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-116" id="f-422">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">14.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-119"
      decimals="2"
      id="f-424"
      unitRef="usdPerShare">30.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock
      contextRef="c-120"
      decimals="INF"
      id="f-425"
      unitRef="shares">14340</vtvt:ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c-121"
      decimals="INF"
      id="f-426"
      unitRef="shares">7590</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <vtvt:ShareBasedPaymentArrangementExpenseReductionAmount contextRef="c-116" decimals="-5" id="f-427" unitRef="usd">100000</vtvt:ShareBasedPaymentArrangementExpenseReductionAmount>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="0" id="f-429" unitRef="shares">249247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-430"
      unitRef="usdPerShare">77.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="0" id="f-431" unitRef="shares">447499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">13.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="0" id="f-433" unitRef="shares">5153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-434"
      unitRef="usdPerShare">18.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="0" id="f-435" unitRef="shares">691593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-436"
      unitRef="usdPerShare">36.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="0" id="f-437" unitRef="shares">237800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-438"
      unitRef="usdPerShare">75.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-439">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="0" id="f-440" unitRef="shares">551200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-441"
      unitRef="usdPerShare">41.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-442">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-443">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-444" unitRef="usd">228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-445" unitRef="usd">113000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-446" unitRef="usd">511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-447" unitRef="usd">316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="-3" id="f-448" unitRef="usd">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-449" unitRef="usd">320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-3" id="f-450" unitRef="usd">1421000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-3" id="f-451" unitRef="usd">859000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-452" unitRef="usd">853000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-453" unitRef="usd">433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-454" unitRef="usd">1932000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-3" id="f-455" unitRef="usd">1175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-456">Commitments and Contingencies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novo Nordisk&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2007, the Company entered into an Agreement (the &#x201c;Novo License Agreement&#x201d;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#x201c;Novo Nordisk&#x201d;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#x2019;s GKA program, including rights to preclinical and clinical compounds such as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; cadisegliatin&lt;/span&gt;. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vtvt:PotentialMilestonePayment contextRef="c-130" decimals="-5" id="f-457" unitRef="usd">9000000.0</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-131" decimals="-5" id="f-458" unitRef="usd">50500000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-132" decimals="-5" id="f-459" unitRef="usd">115000000.0</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-133" decimals="-5" id="f-460" unitRef="usd">75000000.0</vtvt:PotentialMilestonePayment>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-461">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease included an option to renew for a five-year term as well as an option to terminate after three years, neither of which was recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each of September&#160;30, 2024 and December&#160;31, 2023, the weighted average incremental borrowing rate for the operating lease held by the Company was 9.5%. At September&#160;30, 2024 and December&#160;31, 2023, the weighted average remaining lease terms for the operating lease held by the Company were 1.2 years and 1.9 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating lease as of September&#160;30, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2024 and 2023 was $0.2 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-462">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtvt:LesseeOperatingLeaseTerminationPeriod contextRef="c-4" id="f-463">P3Y</vtvt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-464" unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-465" unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-466">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-467">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-468">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating lease as of September&#160;30, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-4" decimals="-3" id="f-469" unitRef="usd">48000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-470" unitRef="usd">177000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-4" decimals="-3" id="f-474" unitRef="usd">0</vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">225000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <vtvt:OperatingLeasesImputedInterest contextRef="c-4" decimals="-3" id="f-476" unitRef="usd">12000</vtvt:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-477" unitRef="usd">213000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-478" unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-16" decimals="-5" id="f-479" unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c-1" id="f-480">Noncontrolling Interest&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 18.1% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2024 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&amp;amp;F TTP Holdings Two LLC (&#x201c;M&amp;amp;F&#x201d;) governance rights such that directors designated by M&amp;amp;F no longer comprised a majority of the Company&#x2019;s Board of Directors (see Note 9). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company&#x2019;s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Condensed Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December&#160;31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <vtvt:PercentageOfNonVotingEconomicInterest contextRef="c-87" decimals="3" id="f-481" unitRef="number">0.181</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio contextRef="c-134" decimals="0" id="f-482" unitRef="number">1</vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio>
    <vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock contextRef="c-27" id="f-483">P20D</vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-135" decimals="-5" id="f-484" unitRef="usd">5300000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-5" decimals="-5" id="f-485" unitRef="usd">6100000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock contextRef="c-1" id="f-486">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease)/Increase in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-487" unitRef="usd">-4783000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-488" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-489" unitRef="usd">-14828000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-490" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-14" decimals="-3" id="f-491" unitRef="usd">-1972000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-15" decimals="-3" id="f-492" unitRef="usd">1592000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-1" decimals="-3" id="f-493" unitRef="usd">7592000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-16" decimals="-3" id="f-494" unitRef="usd">4212000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-14" decimals="-3" id="f-495" unitRef="usd">-6755000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-15" decimals="-3" id="f-496" unitRef="usd">-5062000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-1" decimals="-3" id="f-497" unitRef="usd">-7236000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-16" decimals="-3" id="f-498" unitRef="usd">-12560000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-499">Stockholders&#x2019; Equity (Deficit)&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company&#x2019;s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company&#x2019;s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company&#x2019;s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock and Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,853,997&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of the Company&#x2019;s Class A common stock at a price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.80&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.01&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.99%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the number of shares of the Company&#x2019;s common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.99%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by providing at least 61 days&#x2019; prior notice to the Company. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were pre-funded warrants to purchase an aggregate o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f 3,970,587 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of the Company&#x2019;s common stock that remained available for exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-funded warrants were classified as a component of permanent equity in the Company's Condensed Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Investments Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the &#x201c;G42 Promissory Note&#x201d;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income, net in the Company&#x2019;s Condensed Consolidated Statements of Operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CinPax and CinRx Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 22, 2022 (the &#x201c;Transaction Date&#x201d;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#x201c;CinPax&#x201d;) and CinRx-Pharma, LLC (&#x201c;CinRx&#x201d;), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company&#x2019;s Class A common stock at a price per share of approximately $96.40, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the &#x201c;CinRx Warrants&#x201d;). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 12)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#x201c;FDA Approval&#x201d;) to market and distribute the pharmaceutical product containing the Company&#x2019;s proprietary candidate, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Product&#x201d;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#x201c;CinRx MSA&#x201d;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 9)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company&#x2019;s board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2024, we entered into a sales agreement (the &#x201c;TD Cowen Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;TD Cowen&#x201d;), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the &#x201c;TD Cowen ATM Offering&#x201d;). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. &lt;/span&gt;&lt;/div&gt;During the three and nine months ended September&#160;30, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtvt:IncreaseInCommonStockSharesAuthorized
      contextRef="c-136"
      decimals="INF"
      id="f-500"
      unitRef="shares">100000000</vtvt:IncreaseInCommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-137"
      decimals="INF"
      id="f-501"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:IncreaseInCommonStockSharesAuthorized
      contextRef="c-136"
      decimals="INF"
      id="f-502"
      unitRef="shares">100000000</vtvt:IncreaseInCommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-503"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-138"
      decimals="INF"
      id="f-504"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-505" unitRef="shares">250000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-506"
      unitRef="shares">350000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-140"
      decimals="INF"
      id="f-507"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-141"
      decimals="INF"
      id="f-508"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-140"
      decimals="INF"
      id="f-509"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-141"
      decimals="INF"
      id="f-510"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-142"
      decimals="INF"
      id="f-511"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-142"
      decimals="INF"
      id="f-512"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-89"
      decimals="INF"
      id="f-513"
      unitRef="shares">464377</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-90"
      decimals="2"
      id="f-514"
      unitRef="usdPerShare">11.81</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-91"
      decimals="INF"
      id="f-515"
      unitRef="shares">3853997</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-91"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">11.80</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-92"
      decimals="2"
      id="f-517"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights contextRef="c-143" decimals="4" id="f-518" unitRef="number">0.0999</vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights>
    <vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights contextRef="c-144" decimals="4" id="f-519" unitRef="number">0.1999</vtvt:ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-145"
      decimals="INF"
      id="f-520"
      unitRef="shares">3970587</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares
      contextRef="c-94"
      decimals="INF"
      id="f-521"
      unitRef="shares">116493</vtvt:CommonStockParOrStatedValueOfPrivatePlacementShares>
    <vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares
      contextRef="c-94"
      decimals="INF"
      id="f-522"
      unitRef="shares">116590</vtvt:CommonStockParOrStatedValueOfPrivatePlacementPreFundedWarrantsShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-99" decimals="0" id="f-523" unitRef="shares">259657</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-100"
      decimals="2"
      id="f-524"
      unitRef="usdPerShare">96.40</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-99" decimals="-5" id="f-525" unitRef="usd">25000000.0</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-99" decimals="-5" id="f-526" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-100" decimals="-5" id="f-527" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:SaleOfStockConsiderationReceivableTerm contextRef="c-99" id="f-528">P1Y</vtvt:SaleOfStockConsiderationReceivableTerm>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-103" decimals="-5" id="f-529" unitRef="usd">12000000.0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-104" decimals="4" id="f-530" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-103" decimals="-5" id="f-531" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-146" decimals="0" id="f-532" unitRef="shares">103864</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-147"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">96.40</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-146" decimals="-5" id="f-534" unitRef="usd">10000000.0</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-146" decimals="-5" id="f-535" unitRef="usd">6000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-147" decimals="-5" id="f-536" unitRef="usd">4000000.0</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-148"
      decimals="INF"
      id="f-537"
      unitRef="shares">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-148"
      decimals="2"
      id="f-538"
      unitRef="usdPerShare">28.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-148" decimals="-5" id="f-539" unitRef="usd">400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-147" id="f-540">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <vtvt:SaleOfStockAggregateOfferingPrice contextRef="c-95" decimals="-5" id="f-541" unitRef="usd">50000000.0</vtvt:SaleOfStockAggregateOfferingPrice>
    <vtvt:EntityPublicFloatThreshold contextRef="c-96" decimals="-5" id="f-542" unitRef="usd">75000000.0</vtvt:EntityPublicFloatThreshold>
    <vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat contextRef="c-96" decimals="3" id="f-543" unitRef="rate">0.030</vtvt:SaleOfStockMaximumSecuritiesToBeSoldPercentOfPublicFloat>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-149" decimals="0" id="f-544" unitRef="shares">179400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-150" decimals="0" id="f-545" unitRef="shares">179400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-150" decimals="-5" id="f-546" unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-149" decimals="-5" id="f-547" unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-550">Related-Party Transactions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MacAndrews &amp;amp; Forbes Incorporated&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacAndrews directly or indirectly controls 577,108 shares of Class B common stock. Further, as of September&#160;30, 2024, MacAndrews directly or indirectly holds 912,982 shares of the Company&#x2019;s Class A common stock. As a result, MacAndrews&#x2019; holdings represent approximately 46.7% of the combined voting power of the Company&#x2019;s outstanding common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letter Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#x201c;Letter Agreement Warrants&#x201d;) to purchase additional shares of the Company&#x2019;s Class A common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#x2019;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#x2019;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#x2019;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and MacAndrews are party to a tax receivable agreement (the &#x201c;Tax Receivable Agreement&#x201d;), which provides for the payment by the Company to M&amp;amp;F TTP Holdings Two LLC (&#x201c;M&amp;amp;F&#x201d;), as successor in interest to vTv Therapeutics Holdings, LLC (&#x201c;vTv Therapeutics Holdings&#x201d;), and M&amp;amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#x2019;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investor Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an investor rights agreement with M&amp;amp;F, as successor in interest to vTv Therapeutics Holdings (the &#x201c;Investor Rights Agreement&#x201d;). The Investor Rights Agreement provides M&amp;amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&amp;amp;F governance rights that now entitles M&amp;amp;F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="c-153" decimals="0" id="f-551" unitRef="shares">577108</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="c-154" decimals="0" id="f-552" unitRef="shares">912982</us-gaap:InvestmentOwnedBalanceShares>
    <vtvt:OwnershipPercentageOfMajorityOwner contextRef="c-155" decimals="3" id="f-553" unitRef="number">0.467</vtvt:OwnershipPercentageOfMajorityOwner>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-155" decimals="2" id="f-554" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-555">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income taxes as well as state taxes. The Company&#x2019;s income tax provision for the nine months ended September&#160;30, 2024 was $0.1 million representing foreign withholding taxes accrued in connection with revenue recorded under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September&#160;30, 2024 and 2023. The Company did not record an income tax provision for the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#x2019;s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2024, is due to the valuation allowance against the Company&#x2019;s expected net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-556" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="INF" id="f-557" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="INF" id="f-558" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-559" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-156" decimals="2" id="f-560" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-561">Net Loss per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,456,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,498,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(*) Adjusted retroactively for reverse stock split&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The shares underlying the pre-funded warrants to purchase shares of the Company&#x2019;s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(*) Adjusted retroactively for reverse stock split&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-562">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,456,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,498,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(*) Adjusted retroactively for reverse stock split&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;The shares underlying the pre-funded warrants to purchase shares of the Company&#x2019;s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-563" unitRef="usd">-5840000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-564" unitRef="usd">-8540000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">-18268000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-566" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-567" unitRef="usd">-1057000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-568" unitRef="usd">-1886000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-569" unitRef="usd">-3440000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-570" unitRef="usd">-4753000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-571" unitRef="usd">-4783000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-572" unitRef="usd">-4783000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-573" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-15" decimals="-3" id="f-574" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-575" unitRef="usd">-14828000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-576" unitRef="usd">-14828000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-577" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-16" decimals="-3" id="f-578" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-579" unitRef="shares">5456307</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-580" unitRef="shares">5456307</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-581" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-582" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-583" unitRef="shares">5498479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-584" unitRef="shares">5498479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="0" id="f-585" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="0" id="f-586" unitRef="shares">2084973</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-588"
      unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-590"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">-2.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">-2.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">-8.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-594"
      unitRef="usdPerShare">-8.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-595">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(*) Adjusted retroactively for reverse stock split&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;___________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-157" decimals="0" id="f-596" unitRef="shares">577349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-158" decimals="0" id="f-597" unitRef="shares">577349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-159" decimals="0" id="f-598" unitRef="shares">691593</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-160" decimals="0" id="f-599" unitRef="shares">238636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-161" decimals="0" id="f-600" unitRef="shares">75595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-162" decimals="0" id="f-601" unitRef="shares">80359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-602" unitRef="shares">1344537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="0" id="f-603" unitRef="shares">896344</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-604">Fair Value of Financial Instruments&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the nine months ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2024. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income (expense), related party in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#x2019;s current capitalization. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2024 and December&#160;31, 2023, were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.13% - 124.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.96% - 89.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.55%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64% - 4.85%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01% - 4.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2024, were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.&lt;/span&gt;&lt;/div&gt;Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#x2019;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-605">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the nine months ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-163" decimals="-3" id="f-606" unitRef="usd">82000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-164" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-165" decimals="-3" id="f-608" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-166" decimals="-3" id="f-609" unitRef="usd">82000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-167" decimals="-3" id="f-610" unitRef="usd">44000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-168" decimals="-3" id="f-611" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-169" decimals="-3" id="f-612" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-170" decimals="-3" id="f-613" unitRef="usd">44000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-171" decimals="-3" id="f-614" unitRef="usd">126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-172" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-173" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-174" decimals="-3" id="f-617" unitRef="usd">126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-175" decimals="-3" id="f-618" unitRef="usd">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-176" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-177" decimals="-3" id="f-620" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-178" decimals="-3" id="f-621" unitRef="usd">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-175" decimals="-3" id="f-622" unitRef="usd">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-179" decimals="-3" id="f-623" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-180" decimals="-3" id="f-624" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-181" decimals="-3" id="f-625" unitRef="usd">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-182" decimals="-3" id="f-626" unitRef="usd">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-183" decimals="-3" id="f-627" unitRef="usd">173000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-183" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-183" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass contextRef="c-183" decimals="-3" id="f-630" unitRef="usd">-201000</vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-184" decimals="-3" id="f-631" unitRef="usd">82000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-185" decimals="-3" id="f-632" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-186" decimals="-3" id="f-633" unitRef="usd">-157000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-186" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-186" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass contextRef="c-186" decimals="-3" id="f-636" unitRef="usd">201000</vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-187" decimals="-3" id="f-637" unitRef="usd">44000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-188" decimals="-3" id="f-638" unitRef="usd">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-189" decimals="-3" id="f-639" unitRef="usd">16000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-189" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-189" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass contextRef="c-189" decimals="-3" id="f-642" unitRef="usd">0</vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-190" decimals="-3" id="f-643" unitRef="usd">126000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-191" decimals="-3" id="f-644" unitRef="usd">684000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-192" decimals="-3" id="f-645" unitRef="usd">-406000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-192" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-192" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass contextRef="c-192" decimals="-3" id="f-648" unitRef="usd">0</vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-193" decimals="-3" id="f-649" unitRef="usd">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-191" decimals="-3" id="f-650" unitRef="usd">684000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-192" decimals="-3" id="f-651" unitRef="usd">-406000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-192" decimals="-3" id="f-652" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-192" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass contextRef="c-192" decimals="-3" id="f-654" unitRef="usd">0</vtvt:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclass>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-193" decimals="-3" id="f-655" unitRef="usd">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-656">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2024 and December&#160;31, 2023, were:&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.13% - 124.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.96% - 89.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.55%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64% - 4.85%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01% - 4.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2024, were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-194" decimals="4" id="f-657" unitRef="number">0.9513</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-195" decimals="4" id="f-658" unitRef="number">1.2470</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-196" decimals="4" id="f-659" unitRef="number">1.0942</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-197" decimals="4" id="f-660" unitRef="number">0.7996</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-198" decimals="4" id="f-661" unitRef="number">0.8961</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-199" decimals="4" id="f-662" unitRef="number">0.8155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-200" decimals="4" id="f-663" unitRef="number">0.0364</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-201" decimals="4" id="f-664" unitRef="number">0.0485</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-202" decimals="4" id="f-665" unitRef="number">0.0379</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-203" decimals="4" id="f-666" unitRef="number">0.0401</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-204" decimals="4" id="f-667" unitRef="number">0.0487</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-205" decimals="4" id="f-668" unitRef="number">0.0415</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-206" decimals="4" id="f-669" unitRef="number">0.982</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-207" id="f-670">P2Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-208" decimals="4" id="f-671" unitRef="number">0.036</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-209" decimals="4" id="f-672" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-673">Subsequent Events&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated subsequent events through November 12, 2024, and determined that there have been no events that have occurred that would require adjustments to our disclosures or the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-14" id="f-674">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-14" id="f-675">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-14" id="f-676">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-14" id="f-677">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-174"
          xlink:label="f-174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-173"
          xlink:label="f-173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-169"
          xlink:label="f-169"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-168"
          xlink:label="f-168"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-171"
          xlink:label="f-171"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-165"
          xlink:label="f-165"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-164"
          xlink:label="f-164"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-163"
          xlink:label="f-163"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-161"
          xlink:label="f-161"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-160"
          xlink:label="f-160"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-166"
          xlink:label="f-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-170"
          xlink:label="f-170"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-175"
          xlink:label="f-175"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-162"
          xlink:label="f-162"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-167"
          xlink:label="f-167"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-172"
          xlink:label="f-172"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:6pt;text-align:justify"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-174"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-173"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-169"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-168"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-171"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-165"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-164"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-163"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-161"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-160"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-166"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-170"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-175"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-162"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-167"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-172"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-244"
          xlink:label="f-244"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:6pt;text-align:justify"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-244"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-208"
          xlink:label="f-208"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-225"
          xlink:label="f-225"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-212"
          xlink:label="f-212"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-209"
          xlink:label="f-209"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-211"
          xlink:label="f-211"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-218"
          xlink:label="f-218"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-224"
          xlink:label="f-224"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-210"
          xlink:label="f-210"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-228"
          xlink:label="f-228"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-227"
          xlink:label="f-227"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-226"
          xlink:label="f-226"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="margin-top:6pt;text-align:justify"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*) Adjusted retroactively for reverse stock split</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-208"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-225"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-212"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-209"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-211"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-218"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-224"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-210"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-228"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-227"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-226"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
